0001713210 true P2Y P2Y 0001713210 2022-01-01 2022-12-31 0001713210 2022-12-31 0001713210 2021-12-31 0001713210 2021-01-01 2021-12-31 0001713210 us-gaap:CommonStockMember 2020-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001713210 us-gaap:RetainedEarningsMember 2020-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2020-12-31 0001713210 2020-12-31 0001713210 us-gaap:CommonStockMember 2021-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001713210 us-gaap:RetainedEarningsMember 2021-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2021-12-31 0001713210 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001713210 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001713210 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001713210 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001713210 us-gaap:CommonStockMember 2022-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001713210 us-gaap:RetainedEarningsMember 2022-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001713210 us-gaap:NoncontrollingInterestMember 2022-12-31 0001713210 AATP:AgapeATPInternationalHoldingLimitedMember 2022-12-31 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember 2020-05-07 2020-05-08 0001713210 AATP:SubsidiaryCompanyTwoMember 2020-05-08 0001713210 AATP:SubsidiaryCompanyFiveMember 2021-11-11 0001713210 AATP:SubsidiaryCompanyMember 2022-01-01 2022-12-31 0001713210 AATP:SubsidiaryCompanyMember 2022-12-31 0001713210 AATP:SubsidiaryCompanyOneMember 2022-01-01 2022-12-31 0001713210 AATP:SubsidiaryCompanyOneMember 2022-12-31 0001713210 AATP:SubsidiaryCompanyTwoMember 2022-01-01 2022-12-31 0001713210 AATP:SubsidiaryCompanyTwoMember 2022-12-31 0001713210 AATP:SubsidiaryCompanyThreeMember 2022-01-01 2022-12-31 0001713210 AATP:SubsidiaryCompanyFourMember 2022-01-01 2022-12-31 0001713210 AATP:SubsidiaryCompanyFourMember 2022-12-31 0001713210 AATP:SubsidiaryCompanyFiveMember 2022-01-01 2022-12-31 0001713210 AATP:SubsidiaryCompanyFiveMember 2022-12-31 0001713210 AATP:HealthAndWellnessServicesMember 2022-01-01 2022-12-31 0001713210 AATP:HealthAndWellnessServicesMember 2021-01-01 2021-12-31 0001713210 us-gaap:ShippingAndHandlingMember 2022-01-01 2022-12-31 0001713210 us-gaap:ShippingAndHandlingMember 2021-01-01 2021-12-31 0001713210 AATP:SocialSecurityOrganizationMember 2022-01-01 2022-12-31 0001713210 AATP:EmployeesProvidentFundMember srt:MinimumMember 2022-01-01 2022-12-31 0001713210 AATP:EmployeesProvidentFundMember srt:MaximumMember 2022-01-01 2022-12-31 0001713210 AATP:EmploymentInsuranceSystemMember 2022-01-01 2022-12-31 0001713210 AATP:HumanResourceDevelopmentFundMember 2022-01-01 2022-12-31 0001713210 us-gaap:ComputerEquipmentMember srt:MinimumMember 2022-01-01 2022-12-31 0001713210 us-gaap:ComputerEquipmentMember srt:MaximumMember 2022-01-01 2022-12-31 0001713210 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2022-01-01 2022-12-31 0001713210 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2022-01-01 2022-12-31 0001713210 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001713210 us-gaap:VehiclesMember 2022-01-01 2022-12-31 0001713210 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-01-01 2022-12-31 0001713210 AATP:SurvivorSelectMember 2022-01-01 2022-12-31 0001713210 AATP:SurvivorSelectMember 2021-01-01 2021-12-31 0001713210 AATP:EnergizedMineralConcentrateMember 2022-01-01 2022-12-31 0001713210 AATP:EnergizedMineralConcentrateMember 2021-01-01 2021-12-31 0001713210 AATP:IonizedCalMagMember 2022-01-01 2022-12-31 0001713210 AATP:IonizedCalMagMember 2021-01-01 2021-12-31 0001713210 AATP:OmegaBlendMember 2022-01-01 2022-12-31 0001713210 AATP:OmegaBlendMember 2021-01-01 2021-12-31 0001713210 AATP:BetaMaxxMember 2022-01-01 2022-12-31 0001713210 AATP:BetaMaxxMember 2021-01-01 2021-12-31 0001713210 AATP:VegeFruitFiberMember 2022-01-01 2022-12-31 0001713210 AATP:VegeFruitFiberMember 2021-01-01 2021-12-31 0001713210 AATP:IronMember 2022-01-01 2022-12-31 0001713210 AATP:IronMember 2021-01-01 2021-12-31 0001713210 AATP:YoungFormulaMember 2022-01-01 2022-12-31 0001713210 AATP:YoungFormulaMember 2021-01-01 2021-12-31 0001713210 AATP:OrganicYouthCarCleansingBarMember 2022-01-01 2022-12-31 0001713210 AATP:OrganicYouthCarCleansingBarMember 2021-01-01 2021-12-31 0001713210 AATP:ATPRMITOPlusMember 2022-01-01 2022-12-31 0001713210 AATP:ATPRMITOPlusMember 2021-01-01 2021-12-31 0001713210 AATP:LipomaskMember 2022-01-01 2022-12-31 0001713210 AATP:LipomaskMember 2021-01-01 2021-12-31 0001713210 AATP:EnergetiqueMember 2022-01-01 2022-12-31 0001713210 AATP:EnergetiqueMember 2021-01-01 2021-12-31 0001713210 AATP:TrimPlusMember 2022-01-01 2022-12-31 0001713210 AATP:TrimPlusMember 2021-01-01 2021-12-31 0001713210 AATP:ProductHealthTherapiesMember 2022-01-01 2022-12-31 0001713210 AATP:ProductHealthTherapiesMember 2021-01-01 2021-12-31 0001713210 AATP:OthersMember 2022-01-01 2022-12-31 0001713210 AATP:OthersMember 2021-01-01 2021-12-31 0001713210 us-gaap:ProductMember 2022-01-01 2022-12-31 0001713210 us-gaap:ProductMember 2021-01-01 2021-12-31 0001713210 AATP:PeriodEndMYRMember 2022-12-31 0001713210 AATP:PeriodEndMYRMember 2021-12-31 0001713210 AATP:PeriodEndHKDMember 2022-12-31 0001713210 AATP:PeriodEndHKDMember 2021-12-31 0001713210 AATP:PeriodAverageMYRMember 2022-01-01 2022-12-31 0001713210 AATP:PeriodAverageMYRMember 2021-01-01 2021-12-31 0001713210 AATP:PeriodAverageHKDMember 2022-01-01 2022-12-31 0001713210 AATP:PeriodAverageHKDMember 2021-01-01 2021-12-31 0001713210 AATP:SubsidiaryCompanyThreeMember 2022-12-31 0001713210 us-gaap:VariableIncomeInterestRateMember 2022-12-31 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-12-31 0001713210 us-gaap:VariableIncomeInterestRateMember 2022-01-01 2022-12-31 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-01-01 2021-12-31 0001713210 srt:MinimumMember 2022-12-31 0001713210 srt:MaximumMember 2022-12-31 0001713210 AATP:ComputerAndOfficeEquipmentMember 2022-12-31 0001713210 AATP:ComputerAndOfficeEquipmentMember 2021-12-31 0001713210 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001713210 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001713210 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001713210 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001713210 AATP:VehicleMember 2022-12-31 0001713210 AATP:VehicleMember 2021-12-31 0001713210 AATP:GreenproCapitalCorpMember 2018-05-17 0001713210 AATP:GreenproCapitalCorpMember 2018-07-30 0001713210 AATP:GreenproCapitalCorpMember 2018-10-16 0001713210 2022-07-18 2022-07-19 0001713210 AATP:GreenproCapitalCorpMember 2022-12-31 0001713210 AATP:GreenproCapitalCorpMember 2022-07-19 0001713210 AATP:DSwissIncMember 2020-11-03 0001713210 AATP:DSwissIncMember 2020-12-09 0001713210 AATP:SEATechVenturesCorpMember 2021-09-27 0001713210 AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 us-gaap:CommonStockMember AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-05-18 2023-03-09 0001713210 AATP:PhoenixPlusCorpMember 2022-12-31 0001713210 AATP:PhoenixPlusCorpMember 2021-12-31 0001713210 AATP:TH3TechnologySdnBhdMember 2022-01-01 2022-12-31 0001713210 AATP:TH3TechnologySdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:TH3TechnologySdnBhdMember 2022-12-31 0001713210 AATP:TH3TechnologySdnBhdMember 2021-12-31 0001713210 AATP:DSYBeautySdnBhdMember 2022-01-01 2022-12-31 0001713210 AATP:DSYBeautySdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:DSYBeautySdnBhdMember 2022-12-31 0001713210 AATP:DSYBeautySdnBhdMember 2021-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2022-01-01 2022-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2021-01-01 2021-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2022-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2021-12-31 0001713210 AATP:HostastaySdnBhdMember 2022-01-01 2022-12-31 0001713210 AATP:HostastaySdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:HostastaySdnBhdMember 2022-12-31 0001713210 AATP:HostastaySdnBhdMember 2021-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2022-01-01 2022-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2022-12-31 0001713210 AATP:CTANutriceuticalsSdnBhdMember 2021-12-31 0001713210 AATP:CTANutriceuticalsAsiaSdnBhdOneMember 2022-01-01 2022-12-31 0001713210 AATP:CTANutriceuticalsAsiaSdnBhdOneMember 2021-01-01 2021-12-31 0001713210 AATP:CTANutriceuticalsAsiaSdnBhdOneMember 2022-12-31 0001713210 AATP:CTANutriceuticalsAsiaSdnBhdOneMember 2021-12-31 0001713210 AATP:DSYBeautySdnBhdOneMember 2022-01-01 2022-12-31 0001713210 AATP:DSYBeautySdnBhdOneMember 2021-01-01 2021-12-31 0001713210 AATP:DSYBeautySdnBhdOneMember 2022-12-31 0001713210 AATP:DSYBeautySdnBhdOneMember 2021-12-31 0001713210 AATP:HowKokChoongMember 2022-01-01 2022-12-31 0001713210 AATP:HowKokChoongMember 2021-01-01 2021-12-31 0001713210 AATP:HowKokChoongMember 2022-12-31 0001713210 AATP:HowKokChoongMember 2021-12-31 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2022-01-01 2022-12-31 0001713210 AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember 2021-01-01 2021-12-31 0001713210 AATP:HostastaySdnBhdHostastayMember 2021-01-01 2021-12-31 0001713210 AATP:HostastaySdnBhdHostastayMember 2022-01-01 2022-12-31 0001713210 AATP:CTANutriceuticalsAsiaSdnBhdMember 2022-01-01 2022-12-31 0001713210 AATP:CTANutriceuticalsAsiaSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2022-01-01 2022-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:HowKokChoongMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001713210 AATP:HowKokChoongMember srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0001713210 AATP:RedboyPictureSdnBhdMember 2022-01-01 2022-12-31 0001713210 AATP:RedboyPictureSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2022-01-01 2022-12-31 0001713210 AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember 2021-01-01 2021-12-31 0001713210 AATP:ShareForfeitureAgreementsMember AATP:HowKokChoongTalentLimitedMember 2021-01-01 2021-12-31 0001713210 AATP:ShareForfeitureAgreementsMember AATP:HowKokChoongTalentLimitedMember AATP:ShareholdersMember 2021-01-01 2021-12-31 0001713210 AATP:ShareForfeitureAgreementsMember AATP:HKCHoldingsSdnBhdMember 2021-01-01 2021-12-31 0001713210 AATP:ShareForfeitureAgreementsMember 2021-01-01 2021-12-31 0001713210 AATP:ShareForfeitureAgreementsMember AATP:HowKokChoongTalentLimitedMember 2022-01-01 2022-12-31 0001713210 AATP:ShareForfeitureAgreementsMember 2022-01-01 2022-12-31 0001713210 country:MY 2022-01-01 2022-12-31 0001713210 country:MY 2021-01-01 2021-12-31 0001713210 country:HK 2022-01-01 2022-12-31 0001713210 country:HK 2021-01-01 2021-12-31 0001713210 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-12-31 0001713210 us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0001713210 country:US 2022-12-31 0001713210 country:US 2021-12-31 0001713210 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001713210 AATP:LabuanMember 2018-12-28 2019-01-02 0001713210 country:MY 2022-12-31 0001713210 country:MY 2021-12-31 0001713210 AATP:TwoThousandTwentyEightMember 2022-12-31 0001713210 AATP:TwoThousandTwentyNineMember 2022-12-31 0001713210 AATP:TwoThousandThirtyMember 2022-12-31 0001713210 AATP:AATPLBASLSEAAndWATPMember 2022-01-01 2022-12-31 0001713210 AATP:AATPHKMember 2021-01-01 2021-12-31 0001713210 AATP:AATPLBASLSEAWATPAndDSYMember 2021-01-01 2021-12-31 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001713210 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember AATP:FiveIndividualCustomersMember 2022-01-01 2022-12-31 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001713210 AATP:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001713210 AATP:VendorThreeMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001713210 AATP:VendorOneMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0001713210 AATP:VendorTwoMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0001713210 AATP:DSwissIncMember 2021-01-01 2021-12-31 0001713210 AATP:DSwissIncMember 2021-12-31 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember AATP:VendorOneMember AATP:DSwissIncMember 2022-01-01 2022-12-31 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember AATP:VendorOneMember AATP:DSwissIncMember 2021-01-01 2021-12-31 0001713210 AATP:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001713210 AATP:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001713210 AATP:VendorThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001713210 AATP:VendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember AATP:OneVendorMember 2022-01-01 2022-12-31 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember AATP:OneSalesDistributorMember 2022-01-01 2022-12-31 0001713210 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember AATP:OneSalesDistributorMember 2021-01-01 2021-12-31 0001713210 AATP:AgapeSuperiorLivingMember 2020-04-01 0001713210 2021-05-30 2021-05-31 0001713210 AATP:TrainingCenterMember 2021-05-30 2021-05-31 0001713210 2021-05-31 0001713210 AATP:AgapeSuperiorLivingMember 2021-05-31 0001713210 2021-10-01 0001713210 2021-11-01 0001713210 AATP:AgapeSuperiorLivingMember 2022-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:MYR

 

As filed with the U.S. Securities and Exchange Commission on April 14, 2023.

 

Registration No. 333-239951

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM S-1/A

Amendment No. 5

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

 

 

 

AGAPE ATP CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Nevada   8000   36-4838886

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(IRS Employer

Identification No.)

 

1705 – 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia,

Taman Desa, Kuala Lumpur, Malaysia (Postal Code: 58100).

(Address of principal executive offices, including zip code)

 

Registrant’s phone number, including area code

+(60) 192230099

 

 

 

How Kok Choong

Chief Executive Officer

1645 Village Center Circle, Suite 17

Las Vegas, Nevada

United States, 89134

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:

 

Lawrence S. Venick, Esq.

Loeb & Loeb LLP

2206-19 Jardine House

1 Connaught Place Central,

Hong Kong SAR

Tel: +852.3923.1111

 

Louis Taubman, Esq.

Guillaume de Sampigny, Esq.

Hunter Taubman Fischer & Li LLC

950 Third Avenue, 19th Floor

New York, NY 10022

Tel: 212-530-2210

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: [X]

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐   Accelerated Filer ☐
Non-accelerated Filer  (Do not check if a smaller reporting company) Smaller Reporting Company
   

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 
 

 

EXPLANATORY NOTE

 

This Registration Statement contains two prospectuses, as set forth below.

 

Public Offering Prospectus. A prospectus to be used for the public offering of 600,000 shares of common stock of the Registrant (the “Public Offering Prospectus”) through the underwriter named on the cover page of the Public Offering Prospectus.
   
Resale Prospectus. A prospectus to be used for the resale by the selling stockholders set forth therein of 30,269,516 shares of common stock of the Registrant (the “Resale Prospectus”).

 

The Resale Prospectus is substantively identical to the Public Offering Prospectus, except for the following principal points:

 

they contain different outside and inside front covers and back covers;
   
they contain different Offering sections in the Prospectus Summary section beginning on page 3;
   
they contain different Use of Proceeds sections on page 22;
   
a Selling Stockholder section is included in the Resale Prospectus;
   
a Selling Stockholder Plan of Distribution is inserted; and
   
the Legal Matters section in the Resale Prospectus on page 88 deletes the reference to counsel for the underwriter.

 

The Registrant has included in this Registration Statement a set of alternate pages after the back cover page of the Public Offering Prospectus (the “Alternate Pages”) to reflect the foregoing differences in the Resale Prospectus as compared to the Public Offering Prospectus. The Public Offering Prospectus will exclude the Alternate Pages and will be used for the public offering by the Registrant. The Resale Prospectus will be substantively identical to the Public Offering Prospectus except for the addition or substitution of the Alternate Pages and will be used for the resale offering by the selling stockholders.

 

 
 

 

The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

 

SUBJECT TO COMPLETION, DATED APRIL 14, 2023

 

PRELIMINARY PROSPECTUS

 

AGAPE ATP CORPORATION

 

 

 

600,000 of Shares of Common Stock

 

 

 

This is a firm commitment initial public offering of 600,000 of our shares of common stock, $0.0001 par value per share. We anticipate that the initial public offering price of our shares will be between US$ 5.50 and US $6.50 per share. The Underwriter is obligated to take and pay for all of the shares if any such shares are taken. We have granted the Underwriter a 15% over-allotment option, exercisable one or more times in whole or in part, to purchase up to 90,000 additional common stock from us at the public offering price, less the underwriting discounts, within 45 days from the date of this prospectus to cover over-allotments, if any. If the Underwriter exercises the option in full, the total underwriting discounts payable will be $358,800, and the total proceeds to us, before expenses, will be $4,126,200.

 

Our common stock currently is quoted on the OTC Markets – Pink Sheets, operated by OTC Markets Group, under the symbol “AATP.” The last reported sale price of our common stock on the OTC Markets – Pink Sheets on August 2, 2022 was $4.01 per share.

 

We have applied to list our common stock on the NASDAQ Capital Market (“NASDAQ”) under the symbol “ATPC”. There can be no assurance that our application will be approved. The closing of this offering is contingent upon the successful listing of our common stock on the Nasdaq Capital Market.

 

Investing in our common stock is highly speculative and involves a significant degree of risk. See “Risk Factors” beginning on page 8 of this prospectus for a discussion of information that should be considered before making a decision to purchase our common stock.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

 

  

Price to

Public

   Underwriting Discount(1)  

Proceeds to us

(before expenses)

 
             
Per Share of Common Stock  $6.50   $0.52   $5.98 
                
Total  $3,900,000   $312,000   $3,588,000 

  

(1) See “Underwriting” for additional disclosure regarding underwriting compensation payable by us.

 

Delivery of the shares of common stock is expected to be made on or about              , 2023.

 

 

 

EF HUTTON
division of Benchmark Investments, LLC

 

The date of this prospectus is              , 2023.

 

 
 

 

TABLE OF CONTENTS

 

  PAGE
PROSPECTUS SUMMARY 3
RISK FACTORS 8
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 21
USE OF PROCEEDS 22
DIVIDEND POLICY 23
CAPITALIZATION 24
DILUTION 25
SELECTED CONSOLIDATED FINANCIAL DATA 26
AGAPE ATP CORPORATION MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 27
BUSINESS 35
REGULATIONS 56
MANAGEMENT 63
EXECUTIVE AND DIRECTOR COMPENSATION 68
CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS 71
PRINCIPAL STOCKHOLDERS 75
DESCRIPTION OF CAPITAL STOCK 76
SHARES ELIGIBLE FOR FUTURE SALE 77
TAXATION 78
UNDERWRITING 83
LEGAL MATTERS 88
EXPERTS 88
WHERE YOU CAN FIND MORE INFORMATION 88
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1

 

 

You should rely only on the information contained in this prospectus or contained in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not, and the Underwriter has not, authorized anyone to provide you with information that is different from that contained in such prospectuses. We are offering to sell shares of our common stock, and seeking offers to buy shares of our common stock, only in jurisdictions where such offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.

 

In this prospectus, we rely on and refer to information and statistics regarding our industry. We obtained this statistical, market and other industry data and forecasts from publicly available information. While we believe that the statistical data, market data and other industry data and forecasts are reliable, we have not independently verified the data.

 

For investors outside of the United States: neither we nor the Underwriter have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.

 

2

 

 

PROSPECTUS SUMMARY

 

This summary highlights information contained elsewhere in this prospectus. Because this is only a summary, it does not contain all of the information that may be important to you. You should read this entire prospectus and should consider, among other things, the matters set forth under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, and our consolidated financial statements and related notes thereto appearing elsewhere in this prospectus before making your investment decision.

 

Overview

 

Agape ATP Corporation provides health solution advisory services to its clients. We primarily focus our efforts on attracting customers in Malaysia. We have an advisory services center called the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and the promotion of health. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled nutritionists and/or dieticians. For the years ended December 31, 2022 and 2021, our revenue was approximately $1.9 million and $1.0 million, respectively, and our gross profit was approximately $1.2 million and $0.7 million, respectively. Our total revenue increased by approximately 82.6% from approximately $1.0 million for the year ended December 31, 2021 to approximately $1.9 million for the year ended December 31,2022. Our gross profit increased by approximately 65.4% from approximately $0.7 million for the year ended December 31, 2021 to approximately $1.2 million for the year ended December 31, 2022.

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company successfully acquired approximately 99.99% of Agape Superior Living Sdn Bhd, a Malaysia company (“ASL”), with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 18 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”). Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with Mr. Steve Yap following which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies. The establishment of DSY Wellness is a further expansion of our business into the health and wellness industry. Mr. Steve Yap readily owns 33 proprietary formulas for treating non-communicable disease which he has agreed to bring into the company for joint commercialization. Mr. Steve Yap also has existing clients receiving traditional complimentary medicine or “TCM” in Indonesia and China.

 

Our Products

 

We offer three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

Our ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

Our ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

Our BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

The newly established subsidiary DSY Wellness is a further expansion of our business into the health and wellness industry and aims to pursue the business of providing traditional and complementary health therapies.

 

Our Strategies

 

We intend to pursue the following strategies in order to further develop and expand our business:

 

  Expand our product range in each of our ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE series;
     
  Further penetrate existing markets;
     
  Deepen our relationship with existing distributors and members;

 

3

 

 

  Further investment into information technology such as the establishment of an e-commerce platform;
     
  Expand into other geographies outside of Malaysia; and
     
 

Pursue growth through acquisitions of other health and wellness service provides.

 

Our Competitive Strengths

 

We believe the following competitive strengths contribute to our success and differentiate us from our competitors:

 

  Well established reputation;
     
  Well-established product portfolio;
     
  Large, highly-motivated distributor base, supported by a successful training methodology;
     
  Scalable business model; and
     
  Founder-led and deeply experienced management team.

 

Our Challenges

 

Our ability to realize our mission and execute our strategies is subject to risks and uncertainties, including those relating to our ability to:

 

  Respond to a highly competitive market;
     
  Respond to concentration risk of heavy reliance on our largest supplier for the supply of products;
     
  Maintain quality product and value;
     
  Create brand influence;
     
  Expand our product offerings; and
     
  Expand our business in Malaysia and globally.

 

Please see “Risk Factors” and other information included in this prospectus for a discussion of these and other risks and uncertainties that we face.

 

Risk Factors

 

An investment in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described in “Risk Factors” beginning on page 8, together with all of the other information contained in this prospectus, including our consolidated financial statements and related notes thereto appearing elsewhere in this prospectus, before investing in our common stock. These risks could materially affect our business, financial condition and results of operations and cause the trading price of our common stock to decline. You could lose part or all of your investment. You should bear in mind, in reviewing this prospectus, that past experience is no indication of future performance. You should read “Special Note Regarding Forward-Looking Statements” for a discussion of what types of statements are forward-looking statements, as well as the significance of such statements in the context of this prospectus.

 

Corporate Information

 

Our principal executive offices are located at 1705 – 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia, Taman Desa, Kuala Lumpur, Malaysia (Post Code: 58100). Our telephone number at this address is +(60) 327325716. Our registered office in Nevada is located at 1645 Village Center Circle, Suite 170, Las Vegas, Nevada, United States, 89134.

 

Our website is http://agapeatpgroup.com/. The information contained on our website or any third-party websites is not a part of this prospectus.

 

4

 

 

Corporate Structure

 

The following diagram illustrates our corporate structure as of the date of this prospectus and upon closing of this offering:

 

 

 

*As of the date of this prospectus.

** Upon closing of this offering and assuming no exercise of the Underwriter’s Warrants and full exercise of the over-allotment option.

 

Note:

 

1.

Represent 19,597,500 shares of common stock held by How Kok Choong as of the date of this prospectus and immediately after this offering, representing 25.99% and 25.43% of the common stock outstanding, respectively.

   
2.

Agape Superior Living Sdn. Bhd. was incorporated in Kuala Lumpur, Malaysia on August 8, 2003. The remaining 0.01% was collectively held by Lim Ah Yew@Lim Soo Yew, Lor Keat Yoon and Teng Woei Wei (wife of How Kok Choong).

   
3.

Agape S.E.A. Sdn. Bhd. was incorporated in Kuala Lumpur, Malaysia on March 4, 2004. 100% of the company’s business is transacted with Agape Superior Living Sdn. Bhd.. The company is considered a VIE of Agape Superior Living Sdn. Bhd. as the latter is the primary beneficiary since it has the following characteristics:

 

  a. The power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and
     
  b. The obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE.

 

However, Agape S.E.A.’s impact to our consolidated financial statements constitutes less than 1% of our total consolidated assets and Agape S.E.A. did not contribute any revenues for us as of December 31, 2020.

 

4. Agape ATP Corporation was incorporated in Labuan, Malaysia on March 6, 2017.
   
5. Agape ATP International Holding Limited was incorporated in Hong Kong on June 1, 2017.
   
6.

Wellness ATP International Holdings Sdn. Bhd. was incorporated in Kuala Lumpur, Malaysia on September 11, 2020.

   
7. DSY Wellness International Sdn. Bhd. was incorporated in Kuala Lumpur, Malaysia on November 11, 2021, as a joint-venture entity between Agape ATP Corporation (Labuan) and Mr. Steve Yap.

 

Conventions That Apply to This Prospectus

 

Unless otherwise indicated or the context otherwise requires, references in this prospectus to:

 

  “dollar,” “USD,” “US$,” or “$” are to U.S. dollars;
     
  “RM” and “Ringgit” are to the legal currency of Malaysia; and
     
  “we,” “us,” “Company,” “Agape”, “Agape ATP” and “our” are to Agape ATP Corporation, the Nevada holding company, and its subsidiaries, and its consolidated affiliated entities.
     
  “ASL” are to Agape Superior Living Sdn Bhd, a Malaysia company and a 99.99% owned subsidiary of Agape ATP;

 

5

 

 

The Offering

 

Offering Price   We currently estimate that the initial public offering price will be between US$ 5.50 and US $6.50 per share
     
Common stock offered by us   600,000 of shares of common stock (or 690,000 shares of common stock if the Underwriter exercises its over-allotment option in full) on a firm commitment basis.
     
Common stock to be outstanding prior to this offering  

75,452,012 shares of common stock.

 

Common stock to be outstanding immediately after this offering  

76,052,012 shares of common stock, assuming the sale of all the shares offered in this prospectus, 76,142,012 shares if the underwriter exercise the over-allotment in full.

 

Gross proceeds to us, net of underwriting discount but before expenses:  

$4,126,200 assuming no exercise of the Underwriter’s Warrants and full exercise of the over-allotment option.

 

Over-allotment option:   We have granted to the Underwriter a 15% over-allotment option, exercisable within 45 days from the closing of this offering, to purchase up to an aggregate of 90,000 additional shares of common stock.
     
Use of proceeds  

We plan to use the net proceeds of this offering primarily for general corporate purposes. For more information on the use of proceeds, see “Use of Proceeds” on page 22.

     
Lock-up   We and each of our stockholders, officers and directors have agreed with the underwriters, subject to certain exceptions, not to sell, transfer or otherwise dispose of any shares of common stock or similar securities for a period of 180 days after the date of this prospectus. See “Shares Eligible for Future Sale” and “Underwriting” for more information.
     
Trading Market  

Our common stock currently is quoted on the OTC Markets – Pink Sheets under the symbol “AATP.” We have applied to list our common stock on the Nasdaq Capital Market under the new symbol “ATPC”. At this time, Nasdaq has not yet approved our application to list our common stock. The closing of this offering is conditioned upon Nasdaq’s final approval of our listing application, and there is no guarantee or assurance that our common stock will be approved for listing on Nasdaq.

 

Concentration of Ownership  

Prior to this offering, our executive officers and directors beneficially own, in the aggregate, approximately 26% of the outstanding shares of our common stock, which will become approximately 25% upon completion of this offering assuming the sale of all the shares offered in this prospectus, no exercise of the Underwriter’s Warrants and full exercise of the over-allotment option.

 

Trading Symbol

 

  “AATP”
Risk factors   You should read the “Risk Factors” section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.

 

6

 

 

Summary Consolidated Financial Data

 

AGAPE ATP CORPORATION

 

The following tables summarize our historical consolidated financial data. We have derived the historical consolidated statements of operations data for the years ended December 31, 2022 and 2021 from our consolidated financial statements included elsewhere in this prospectus. The following summary consolidated financial data should be read in conjunction with the respective section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future, and our results for any interim period are not necessarily indicative of the results to be expected for a full fiscal year.

 

Consolidated Statements of Operations Data for the:

 

   Years Ended December 31, 
   2022   2021 
Revenue  $1,856,564   $1,016,962 
Net loss  $(1,666,079)  $(2,524,680)
Net loss per share – (basic and diluted)  $(0.02)  $(0.01)

 

Consolidated Balance Sheet Data as of:

 

   As of  
   December 31, 2022    December 31, 2021  
             
Total assets  $2,791,749    $ 4,724,535  
Total liabilities  $1,229,295    $ 1,411,899  

 

7

 

 

RISK FACTORS

 

Any investment in our securities involves a high degree of risk. You should carefully consider the risks described below, which we believe represent certain of the material risks to our business, together with the information contained elsewhere in this prospectus, before you make a decision to invest in our shares of common stock. Please note that the risks highlighted here are not the only ones that we may face. For example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair our operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our securities could decline and you could lose all or part of your investment.

 

Risks Related to Our Business and Industry

 

Our business and reputation may be affected by product liability claims, litigation, customer complaints, product tampering, food safety issues, food-borne illnesses, health threats, quality control concerns or adverse publicity relating to our products. Product liability insurance of our supplier may not cover our liability sufficiently or at all.

 

Like other consumer product manufacturers, sale of our products involves an inherent risk of our products being found to be unfit for consumption or cause illness. Products may be rendered unfit for consumption due to raw materials or product contamination or degeneration, presence of microbials, illegal tampering of products by unauthorized third parties or other problems arising during the various stages of the procurement, production, transportation and storage processes. The occurrence of such problems may result in customer complaints, fines, penalties or adverse publicity causing serious damage to our reputation and brand, as well as product liability claims, other legal disputes and loss of revenues. Under certain circumstances, we may be required to recall our products. Even if a situation does not necessitate a product recall, we cannot assure you that product liability claims or other legal disputes will not be asserted against us as a result. Product liability insurance of our supplier may not cover our liability sufficiently or at all and will not cover liability that arises out of our default such as mishandling, poor storage condition and/or contamination of the products by us. As a result, a product liability or other judgment against us, or a product recall, could have a material adverse effect on our business, financial condition or results of operations.

 

Our business is susceptible to food-borne illnesses. We cannot assure you that we are able to effectively prevent all diseases or illnesses caused by our products or contamination of our products. Furthermore, our reliance on third-party product suppliers means that food-borne illness incidents could be caused by our suppliers outside of our control. New illnesses may develop in the future, or diseases with long incubation periods could arise that could give rise to claims or allegations on a retroactive basis. Reports in the media of instances of food-borne illnesses or health threats of our products or any of their major ingredients could adversely and significantly affect our sales, and have significant negative impact on our results of operations. This risk exists even if it were later determined that the illness or health threat in fact was not caused by our products.

 

In addition, adverse publicity about health and safety concerns, whether unfounded or not, may discourage consumers from buying our products. Even if a product liability claim is unsuccessful or is not fully pursued, the negative publicity surrounding any assertion that our products caused personal injury or illness could adversely affect our reputation and our corporate and brand image. If consumers were to lose confidence in our brand and reputation, we could suffer long-term or even permanent declines in our sales and results of operation. The amount of negative news, customers complaints and claims against us may also be very costly and may divert our management’s attention from our business operation.

 

We operate in a highly competitive market. If we do not compete effectively, our prospects, operating results, and financial condition could be materially and adversely affected.

 

The health and wellness market in Malaysia is a mature and a highly competitive market, with companies offering a variety of competitive products and services. We expect competition in our market to intensify in the future as new and existing competitors introduce new or enhanced products and services that are potentially more competitive than our products and services. The health and wellness market has a multitude of participants in the domestic market, including, but not limited, to retail health supplement providers, pharmaceutical companies, and network marketing company which supply health supplement products, such as Elken Group, USANA Group, NHF Group, Young Living, Jeunesse Global Holdings LLC, USA, Shaklee Corporation, VASAYO LLC, Amway Corporation, Sami Direct, Kyäni, Inc., Melaleuca, Inc.

 

We believe many of our competitors and potential competitors may have significant competitive advantages, including but not limited to, longer operating histories, ability to leverage their sales efforts and marketing expenditures across a broader portfolio of products and services, larger and broader customer bases, more established relationships with a larger number of suppliers, greater brand recognition, ability to leverage stores which they may operate, and greater financial, research and development, marketing, distribution, and other capabilities and resources than we do. Our competitors and potential competitors may also be able to develop products and services that are equal or more superior to ours, achieve greater market acceptance of their products and services, and increase sales by utilizing different distribution channels than we do. Some of our competitors may aggressively discount their products in order to gain market share, which could result in pricing pressures, reduced profit margins, lost market share, or a failure to grow market share for us. If we are not able to compete effectively against our current or potential competitors, our prospects, operating results, and financial condition could be materially and adversely affected.

 

We are exposed to concentration risk of heavy reliance on our three largest suppliers for the supply of our products, and any shortage of, or delay in, the supply may significantly impact on our business and results of operation.

 

For the year ended December 31, 2022, we purchased $198,376, $82,434 and $79,365 from three of our major suppliers, one of them being a related party, represented approximately 53.3%, 22.1% and 21.3%, respectively, of our total purchase. For the year ended December 31, 2021, we purchased $28,969 and $27,707 from two of our major suppliers, represented approximately 47.3% and 45.2%, respectively, of our total purchases. Our business, financial condition and operating results depend on the continuous supply of products from our major suppliers and our continuous supplier-customer relationships with them. Our heavy reliance on our major suppliers for the supply of our products will have significant impact on our business and results of operation in the event of any shortage of, or delay in the supply. 

 

We currently do not have long term supply agreements with our three largest suppliers for the year ended December 31, 2022, and we typically make ad hoc purchases through submission of purchase order forms. There is no assurance that our major suppliers will continue to supply their products in the quantities and timeframes required by us to meet the needs of our customers or comply with their supply agreements with us. Our product supply may also be disrupted by potential labor disputes, strike action, natural disasters or other accidents, epidemic and pandemic affecting the supplier. If our major suppliers do not supply products to us in a timely manner or in sufficient quantities, our business, financial condition and operating results may be materially and adversely affected.

 

8

 

 

Furthermore, in the event of any delay in delivery of the products to us, our cash flow or working capital may be materially and adversely affected as a result of the corresponding delay in delivery of our products to our customers, and hence the delay in our receipt of payment from our customers.

 

Our major suppliers may change their existing sales or marketing strategy in respect of the products supplied to us by changing their export strategy, reducing its sales or production volume or changing its selling prices. Consequently, there are no assurances that our major suppliers will not appoint other dealers or distributors which may compete with us in the market where we operate. Furthermore, any significant increase in the selling prices of the products which we source from our suppliers will increase our costs and may adversely affect our profit margin if we are not able to pass the increased costs on to our customers.

 

There are no assurances that there will be no deterioration in our relationships with our major suppliers which could affect our ability to secure sufficient supply of products for our business. In the event that our major suppliers change their sales or marketing strategy or otherwise appoint other dealers or distributors who may compete with us, our business, financial condition and operating results may be materially and adversely affected.

 

We could be adversely affected by a change in consumer preferences, perception and spending habits and failure to develop or enrich our product offering or gain market acceptance of our new products could have a negative effect on our business.

 

The market we operate is subject to changes in consumer preference, perception and spending habits. Our performance depends significantly on factors which may affect the level and pattern of consumer spending in the market we operate. Such factors include consumer preference, consumer confidence, consumer income and consumer perception of the safety and quality of our products. Media coverage regarding the safety or quality of, or diet or health issues relating to, our products or the raw materials, ingredients or processes involved in their manufacturing, may damage consumer confidence in our products. A general decline in the consumption of our products could occur as a result of change in consumer preference, perception and spending habits at any time.

 

Any failure to adapt our product offering to respond to such changes may result in a decrease in our sales if such changes are related to certain of our products. Any changes in consumer preference could result in lower sales of our products, put pressure on pricing or lead to increased levels of selling and promotional expenses. In any event a decrease in customer demand on our products may also result in lower sales and slow down the consumption of our inventory to a low inventory turnover level. Any of these changes could result in a material adverse effect on our business, financial conditions or results of operations.

 

The success of our products depends on a number of factors including our ability to accurately anticipate changes in market demand and consumer preferences, our ability to differentiate the quality of our products from those of our competitors, and the effectiveness of our marketing and advertising campaigns for our products. We may not be successful in identifying trends in consumer preferences and developing products that respond to such trends in a timely manner. We also may not be able to effectively promote our products by our marketing and advertising campaigns and gain market acceptance. If our products fail to gain market acceptance, are restricted by regulatory requirements, or have quality problems, we may not be able to fully recover our costs and expenses incurred in our operation, and our business prospects, financial condition or results of operations may be materially and adversely affected.

 

If we fail to maintain quality products and value, our sales are likely to be negatively affected.

 

Our success depends on the safety and quality of products that we obtain from our suppliers for our customers. Our future customers will identify our brand name with a certain level of quality and value. If we cannot meet this perceived value or level of quality, we may be negatively affected and our operating results may suffer. In addition, any failure on the part of our suppliers to maintain the quality of their products, will in turn substantially harm the results of our business operations, potentially forcing us to identify other suppliers or alter our business strategy significantly.

 

If we are unable to create brand influence, we may not be able to maintain current or attract new users and customers for our products.

 

Our operational and financial performance is highly dependent on the strength of our brand. We believe brand familiarity and preference will continue to have a significant role in winning customers as the decision to buy our products and services. In order to further expand our customer base, we may need to substantially increase our marketing expenditures to enhance brand awareness through various online and offline means. Moreover, negative coverage in the media of our company could threaten the perception of our brand, and we cannot assure you that we will be able to defuse negative press coverage about our company to the satisfaction of our investors, customers and suppliers. If we are unable to defuse negative press coverage about our company, our brand may suffer in the marketplace, our operational and financial performance may be negatively impacted and the price of our shares may decline.

 

Currently, we sell our products, with or without customization, under our brand name “ATP”, to domestic customers in Malaysia and to overseas customers. However, if our competitors initiate a lawsuit against us for infringing their trademark, we may be forced to adopt a new brand name for our products. As a result, we may incur additional marketing cost to raise awareness of such new brand name. We may also be ordered to pay a significant amount of damages, and our business, results of operations and financial condition could be materially and adversely affected.

 

9

 

 

We may be unable to protect our intellectual property rights.

 

We rely on intellectual property laws in Malaysia and other jurisdictions to protect our trademarks. We are the registered owner of two trademarks. We have recently applied to register an additional three trademarks in Malaysia. We cannot assure you that counterfeiting or imitation of our products will not occur in the future or, if it does occur, that we will be able to address the problem in a timely and effective manner. Any occurrence of counterfeiting or imitation of our products or other infringement of our intellectual property rights could negatively affect our brand and our reputation, which in turn adversely affects the results of our operations.

 

Litigation to prosecute infringement of our intellectual property rights could be costly and lengthy and will divert our managerial and financial resources. We will have to bear costs of the intellectual property litigation and may be unable to recover such costs from our opposite parties. Protracted litigation could also result in our customers deferring or limiting their purchase or use of or products until such litigation is resolved. The occurrence of any of the foregoing will have a material adverse effect on our business, financial condition and results of operations.

 

We may incur losses resulting from product liability claims or product recalls or adverse publicity relating to our products.

 

We may incur losses resulting from product liability claims with respect to our products supplied by our supplier. We may face claims or liabilities which may arise if there exist any defects in quality of these products or any of these products are deemed or proven to be unsafe, defective or contaminated. In the event that the use or misuse of any product distributed by us results in personal injury or death, product liability and/or indemnity claims may be brought against us, in addition to our product recalls, and the relevant regulatory authorities in the market we operate may close down some of our related operations and take administrative actions against us. If we experience any business disruption and litigation, we may incur additional costs and have to divert our management’s attention and resources on such matters, which may adversely affect our business, financial condition and results of operations.

 

If we are unable to successfully develop and timely introduce new products or services or enhance existing products or services, our business, financial condition and results of operations may be materially and adversely affected.

 

We must continually source, develop and introduce new products and services as well as improve and enhance our existing products and services to maintain or increase our sales. The success of new or enhanced products or services may depend on a number of factors including, anticipating and effectively addressing user preferences and demand, the success of our sales and marketing efforts, effective forecasting and management of products and services demands, purchase commitments, and the quality of or defects in our products. The risk of not meeting our customers’ preferences and demands through our products and services may result in a shift in market shares, as customers instead choose products and services offered by our competitors. This may result in lower sales revenue, materially and adversely affecting our business, financial condition and results of operations.

 

We may not be able to manage the growth of our business and our expansion plans and operations or implement our business strategies on schedule or within our budget, or at all.

 

We are continually executing a number of growth initiatives, strategies and operating plans designed to enhance our business. In 2022 we plan to increase our revenue stream from health solution advisory services from our “ATP Zeta Health Program”, “ENERGETIQUE” and “BEAUNIQUE” series to align with our growth strategies. Any expansion may increase the complexity of our operations and place a significant strain on our managerial, operational, financial and human resources. Our current and planned personnel, systems, procedures and controls may not be adequate to support our future operations. We cannot assure you that we will be able to effectively manage our growth or to implement all these systems, procedures and control measures successfully. Furthermore, the anticipated benefits from these growth initiatives, strategies and operating plans are based on assumptions that may prove to be inaccurate. Moreover, we may not be able to successfully complete these growth initiatives, strategies and operating plans and realize all of the benefits that we expect to achieve or it may be more costly to do so than we anticipate. If, for any reason, we are not able to manage our growth effectively, the benefits we realize are less than our estimates or the implementation of these growth initiatives, strategies and operating plans adversely affects our operations or costs more or takes longer to effectuate than we expect, and/or if our assumptions prove to be inaccurate, our business and prospects may be materially and adversely affected.

 

In addition, we may seek and pursue opportunities through joint ventures or strategic partnerships for expansion from time to time, and we may face similar risks and uncertainties as listed above. Failure to properly address these risks and uncertainties may materially and adversely affect our ability to carry out acquisitions and other expansion plans, integrate and consolidate newly acquired or newly formed businesses, and realize all or any of the anticipated benefits of such expansion, which may have a material adverse effect on our business, financial condition, results of operations and prospects.

 

We have a limited operating history in the Malaysia health and wellness industry, which makes it difficult to evaluate our future prospects.

 

We launched our ATP Zeta Super Health Program business in June 2016, the same month in which our Company was incorporated, followed by our ENERGETIQUE” and “BEAUNIQUE” series in July 2018 and March 2019, respectively, and thus, we have a limited operating history. We have limited experience in most aspects of our business operation, such as sourcing products for and offering advisory services on all the three programs. As our business develops and as we respond to competition, we may continue to introduce new product and services offerings and make adjustments to our existing product line and services and to our business operation in general. Any significant change to our business model that does not achieve expected results may have a material and adverse impact on our financial condition and results of operations. It is therefore difficult to effectively assess our future prospects.

 

The Malaysia health and wellness industry may not develop as expected. Prospective retail and corporate customers may not be familiar with the development of the market and may have difficulties distinguishing our products from those of our competitors. Convincing prospective customers or distributors of the value of our products or services is important to the success of our business. The risk of failing to convince potential customers or distributors to purchase products or services from us may result in the failure of our business plan. Many customers or distributors may not be interested in purchasing products and services we sell because there is no certainty that our business will succeed.

 

You should consider our business and prospects in light of the risks and challenges we encounter or may encounter given the rapidly evolving market in which we operate and our limited operating history. These risks and challenges include our ability to, among other things:

 

  manage our future growth;
     
  increase the utilization of our products by existing and new customers;
     
  maintain and enhance our relationships with customers and distributors;
     
  improve our operational efficiency;
     
  attract, retain and motivate talented employees;
     
  cope with economic fluctuations;
     
  navigate the evolving regulatory environment; and
     
  defend ourselves against legal and regulatory actions.

 

 

Our historical growth rates may not be indicative of our future growth. If we are unable to manage the growth and increased complexity of our business, fail to control our costs and expenses, or fail to execute our strategies effectively, our business and business prospects may be materially and adversely affected.

 

Our historical growth rates may not be indicative of our future growth, and we may not be able to generate similar growth rates in future periods. Our revenue growth may slow, or our total revenues may decline for a number of possible reasons, including change in consumers’ preferences, changes in regulations and government policies, increasing competition, emergence of alternative business models, and general economic conditions

 

10

 

 

Our total revenues increased by approximately 82.6% from approximately 1.0 million for the year ended December 31, 2021 to approximately 1.9 million for the year ended December 31, 2022. Our gross profits increased by approximately 65.4% from approximately $0.7 million for the year ended December 31, 2021 to approximately $1.2 million for the year ended December 31, 2022.

 

If our growth rate declines, investors’ perceptions of our business and business prospects may be materially and adversely affected and the market price of our shares could decline.

 

Our lack of insurance could expose us to significant costs and business disruption.

 

The health and wellness industry in Malaysia is a mature market. We currently do not have any product liability or disruption insurance to cover our operations in Malaysia or overseas, which, based on public information available to us relating to Malaysia-based health and wellness companies, is consistent with customary industry practice in Malaysia. We have determined that the costs of insuring for these risks and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical for us to have such insurance. If we suffer any losses, damages or liabilities in the course of our business operations, we may not have adequate insurance coverage to provide sufficient funds to cover any such losses, damages or product claim liabilities. Therefore, there may be instances when we will sustain losses, damages and liabilities because of our lack of insurance coverage, which may in turn materially and adversely affect our financial condition and results of operations.

 

A decline in general economic condition could lead to reduced consumer demand and could negatively impact our business operation and financial condition, which in turn could have a material adverse effect on our business, financial condition and results of operations.

 

Our operating and financial performance may be adversely affected by a variety of factors that influence the general economy. Consumer spending habits, including spending for health related products and services we sell, are affected by, among other things, prevailing economic conditions, levels of unemployment, salaries and wage rates, prevailing interest rates, income tax rates and policies, consumer confidence and consumer perception of economic conditions. In addition, consumer purchasing patterns may be influenced by consumers’ disposable income. In the event of an economic slowdown, consumer spending habits could be adversely affected and we could experience lower net sales than expected on a quarterly or annual basis which could have a material adverse effect on our business, financial condition and results of operations.

 

We operate in a heavily regulated industry.

 

Our business is principally regulated by various laws and regulations in the market we operate, such as in Malaysia the Food Act 1983 (ACT 281) and Regulations, Control of Drugs and Cosmetics Regulations 1984 mandate authorization from the Food Safety and Quality Division and National Pharmaceutical Regulatory Agency of the Ministry of Health for our Company’s products to be sold in the country. Various registrations, certificates and/or licenses for the conduct of our business are required under the above laws, which also contain provisions for requirements on the storage, labelling, advertising and importation of some of our products.

 

Based on our experience, some of the laws and regulations of the place where we operate our business are subject to amendments, uncertainty in interpretation and administrative actions from time to time. Therefore, we cannot assure you that, for the implementation of our business plans and the introduction of any new product, we will be able to obtain all the necessary registrations, certificates and/or licenses. Any failure to comply with the above laws and regulations may give rise to fines, administrative penalties and/or prosecution against us, which may adversely affect our reputation, financial condition or results of operation.

 

11

 

 

We may be adversely affected by the performance of third-party contractors.

 

We engaged third-party contractors to carry out logistics services. We endeavor to engage third-party companies with a strong reputation and track record, high performance reliability and adequate financial resources. However, any such third-party contractor may still fail to provide satisfactory logistics services at the level of quality or within the timeframe required by us or our customers. While we generally require our logistics contractors to fully reimburse us for any losses arising from delay in delivery or non-delivery, our results of operation and financial condition may be adversely affected if any of the losses are not borne by them. If the performance of any third-party contractor is not satisfactory, we may need to replace such contractor or take other remedial actions, which could adversely affect the cost structure and delivery schedule of our products and services and thus have a negative impact on our reputation, financial position and business operations. In addition, as we expand our business into overseas markets, there may be a shortage of third-party contractors that meet our quality standards and other selection criteria in such locations and, as a result, we may not be able to engage a sufficient number of high-quality third-party contractors in a timely manner, which may adversely affect our delivery schedules and delivery costs and hence our business, results of operations and financial conditions.

 

We may need additional capital, and financing may not be available on terms acceptable to us, or at all.

 

There is no guarantee that in the future we will generate enough profits to support our business. Although we believe that our anticipated cash flows from operating activities together with cash on hand will be sufficient to meet our anticipated working capital requirements and capital expenditures in the ordinary course of business for the next twelve months, we cannot assure you this will be the case. We may need additional cash resources in the future if we experience changes in business conditions or other developments. We may also need additional cash resources in the future if we find and wish to pursue opportunities for investment, acquisition, capital expenditure or similar actions. If we determine that our cash requirements exceed the amount of cash and cash equivalents we have on hand at the time, we may seek to issue equity or debt securities or obtain credit facilities. The issuance and sale of additional equity would result in further dilution to our stockholders. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations. We cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all.

 

Adverse developments in our existing areas of operation could adversely impact our results of business, results of operations and financial condition.

 

Our operations are focused on utilizing our sales efforts which are principally located in Malaysia. As a result, our results of operations, cash flows and financial condition depend upon the demand for our products in Malaysia. Due to the lack of broad diversification in industry type and geographic location, adverse developments in our current segment of the industry, or our existing areas of operation, could have a significantly greater impact on our business, results of operations and financial condition than if our operations were more diversified.

 

Our internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.

 

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: pertain to the maintenance of records in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

 

12

 

 

In connection with the audit of our consolidated financial statements as of December 31, 2022, we identified three “material weaknesses”, and other control deficiencies including significant deficiencies in our internal control over financial reporting. A “material weakness” is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified related to the Company were: (i) insufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily recording of transactions, address complex U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP; (ii) lack of a functional internal audit department or personnel that monitors the consistencies of the preventive internal control procedures and lack of adequate policies and procedures in internal audit function to ensure that the Company’s policies and procedures have been carried out as planned; (iii) lack of proper IT policies and procedures developed for system change management, user access management, backup management and service organization management.

 

We have taken measures and plan to continue to take measures to remedy these material weaknesses. The measures that we are planning to take include, but not limited to, hiring of suitable IT personnel to develop and implement proper IT policies and procedures for system change management, user access management, backup management and service organization management, form an internal audit function and have plans to hire internal auditors to strengthen our overall governance. All internal auditors will be independent of our operations and will report directly to the audit committee. The implementation of these measures may not fully address the material weaknesses in our internal control over financial reporting, and we cannot conclude that they have been fully remedied. Our failure to correct theses material weaknesses or our failure to discover and address any other material weaknesses could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis.

 

As a public company, we will become subject to the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act, or SOX 404, will require that we include a report from management on the effectiveness of our internal control over financial reporting in our annual report on Form 10-K and in our quarterly report on Form 10-Q if we are qualified as an accelerated filer. Our management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may issue a report that is qualified if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently from us. In addition, after we become a public company, our reporting obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation.

 

During the course of documenting and testing our internal control procedures, in order to satisfy the requirements of SOX 404, we may identify other weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with SOX 404. If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our shares. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial statements from prior periods.

 

13

 

 

Legal disputes or proceedings could expose us to liability, divert our management’s attention and negatively impact our reputation.

 

We may at times be involved in potential legal disputes or proceedings during the ordinary course of business operations relating to product or other types of liability, employees’ claims, labor disputes or contract disputes that could have a material and adverse effect on our reputation, operation and financial condition. If we become involved in material or protracted legal proceedings or other legal disputes in the future, the outcome of such proceedings could be uncertain and could result in settlements or outcomes which materially and adversely affect our financial condition. In addition, any litigation or legal proceedings could incur substantial legal expenses as well as significant time and attention of our management, diverting their attention from our business and operations.

 

Our failure to comply with anti-corruption laws and regulations, or effectively manage our employees, customers and business partners, could severely damage our reputation, and materially and adversely affect our business, financial condition, results of operations and prospects.

 

We are subject to risks in relation to actions taken by us, our employees, third-party customers or third-party suppliers that constitute violations of the anti-corruption laws and regulations. While we adopt strict internal procedures and work closely with relevant government agencies to ensure compliance of our business operations with relevant laws and regulations, our efforts may not be sufficient to ensure that we comply with relevant laws and regulations at all times. If we, our employees, third-party customers or third-party suppliers violate these laws, rules or regulations, we could be subject to fines and/or other penalties. Actions by Malaysia regulatory authorities or the courts to provide an alternative interpretation of the laws and regulations or to adopt additional anti-bribery or anti-corruption related regulations could also require us to make changes to our operations. Our reputation, corporate image, and business operations may be materially and adversely affected if we fail to comply with these measures or become the target of any negative publicity as a result of actions taken by us, our employees, third-party customers or third-party suppliers.

 

An overall decline in the health of the economy and other factors impacting consumer spending, such as natural disasters, outbreak of viruses, illnesses, infectious diseases, contagions and the occurrence of unforeseen epidemics may affect consumer purchases, reduce demand for our products and materially harm our business, results of operations and financial condition.

 

Our business depends on consumer demand for our products and, consequently, is sensitive to a number of factors that influence consumer confidence and spending, including but not limited to, general current and future economic and political conditions, consumer disposable income, recession and fears of recession, unemployment, minimum wages, availability of consumer credit, consumer debt levels, interest rates, tax rates and policies, inflation, war and fears of war, inclement weather, natural disasters, terrorism, active shooter situations, outbreak of viruses, illnesses, infectious diseases, contagions and the occurrence of unforeseen epidemics (including the outbreak of the coronavirus and its potential impact on our financial results) and consumer perceptions of personal well-being and security. For example, in recent years, there have been outbreaks of epidemics in various countries, including Malaysia. Recently, there was an outbreak of a novel strain of coronavirus (COVID-19), which has spread rapidly to many parts of the world, including Malaysia. In March 2020, the World Health Organization declared the COVID-19 a pandemic. The epidemic has resulted in intermittent quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations were adversely affected as a result of the implementation of Movement Control Order (MCO) by the Malaysian government. The impact on the company as a result of the MCO includes:

 

  temporary closure of offices and travel restrictions prevented the company and our distributors from organizing offline events, which in turn stalled our marketing effort;
     
  temporary suspension of product supplies to our distributors and members due supply chain disruption as our suppliers and logistics providers faced disruption and delay in their operation; and

 

14

 

 

  the COVID-19 outbreak has resulted in a decline in overall economic environment, which in turn lower the spending power of the consumer and consequently, the revenue of the company.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the coronavirus cannot be reasonably estimated at this time. There is no guarantee that our total revenues will grow or remain at the similar level year over year in the fiscal year 2023. We may have to record downward adjustments or impairment in the fair value of investments in the fiscal year 2023, if conditions have not been significantly improved and global stock markets have not recovered from recent declines.

 

In general, our business could be adversely affected by the effects of epidemics, pandemic or, including, but not limited to, the COVID-19, avian influenza, severe acute respiratory syndrome (SARS), the influenza A virus, Ebola virus, severe weather conditions such as flood or hazardous air pollution, or other outbreaks. In response to an epidemic, severe weather conditions, or other outbreaks, government and other organizations may adopt regulations and policies that could lead to severe disruption to our daily operations, including temporary closure of our offices and other facilities. These severe conditions may cause us and/or our partners to make internal adjustments, including but not limited to, temporarily closing down business, limiting business hours, and setting restrictions on travel and/or visits with clients and partners for a prolonged period of time. Various impact arising from a severe condition may cause business disruption, resulting in material, adverse impact to our financial condition and results of operations.

 

We face risks related to health epidemics, severe weather conditions and other outbreaks.

 

In recent years, there have been outbreaks of epidemics in various countries, including Malaysia. Recently, there was an outbreak of a novel strain of coronavirus (COVID-19), which has spread rapidly to many parts of the world, including Malaysia. In March 2020, the World Health Organization declared the COVID-19 a pandemic. The epidemic has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia for prolong periods.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, financial impact of our customers or suspension supplies may negatively affect, and could continue to negatively affect, the demand for our products;
     
  our customer may require additional time to pay us or fail to pay us at all, which could significantly increase the amount of accounts receivable and require us to record additional allowances for doubtful accounts. We may have to provide significant sales incentives to our sole customer during the outbreak, which may in turn materially adversely affect our financial condition and operating results;
     
  any disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may also lead to loss of our customers; and
     
  the global stock markets have experienced, and may continue to experience, significant decline from the COVID-19 outbreak and the marketable securities that we have invested in could be materially adversely affected, which may lead to significant impairment in the fair values of our investments and in turn materially adversely affect our financial condition and operating results.

 

Fluctuations in foreign currency exchange rates could have a material adverse effect on our financial results.

 

We earn revenues, pay expenses, own assets and incur liabilities in countries using currencies other than the U.S. dollar, including Australian Dollars, Malaysian Ringgit and Hong Kong Dollars. Since our consolidated financial statements are presented in U.S. dollars, we must translate revenues, income and expenses, as well as assets and liabilities, into U.S. dollars at exchange rates in effect during or at the end of each reporting period. Therefore, increases or decreases in the value of the U.S. dollar against other currencies affect our net operating revenues, operating income and the value of balance sheet items denominated in foreign currencies. We cannot assure you that fluctuations in foreign currency exchange rates, particularly the strengthening or weakening of the U.S. dollar against major currencies would not materially affect our financial results.

 

Our business depends on the continued contributions made by Dr. How Kok Choong, as our founder, chief executive officer, chief operating officer, chairman of the board of Directors, Director and secretary, the loss of who may result in a severe impediment to our business.,

 

Our success is dependent upon the continued contributions made by our CEO and President, Dr. How Kok Choong. We rely on his expertise in business operations when we are developing our business. We have no “Key Man” insurance to cover the resulting losses in the event that any of our officer or directors should die or resign.

If Dr. How Kok Choong cannot serve the Company or is no longer willing to do so, the Company may not be able to find alternatives in a timely manner or at all. This would likely result in a severe damage to our business operations and would have an adverse material impact on our financial position and operating results. To continue as a viable operation, the Company may have to recruit and train replacement personnel at a higher cost. Additionally, if Dr. How Kok Choong joins our competitors or develops similar businesses that are in competition with our Company, our business may also be negatively impacted.

 

Our future success depends on our ability to attract and retain qualified long-term staff to fill management, technology, sales, marketing, and customer services positions. We have a great need for qualified talent, but we may not be successful in attracting, hiring, developing, and retaining the talent required for our success.

 

15

 

 

If we are not able to achieve our overall long-term growth objectives, the value of an investment in our Company could be negatively affected.

 

We have established and publicly announced certain long-term growth objectives. These objectives were based on, among other things, our evaluation of our growth prospects, which are generally driven by the sales potential of many product types, some of which are more profitable than others, and on an assessment of the potential price and product mix. There can be no assurance that we will realize the sales potential and the price and product mix necessary to achieve our long-term growth objectives.

 

We may incur losses resulting from product liability claims or product recalls or adverse publicity relating to our products.

 

We may incur losses resulting from product liability claims with respect to our products supplied by our suppliers. We may face claims or liabilities which may arise if there exist any defects in quality of these products or any of these products are deemed or proven to be unsafe, defective or contaminated. In the event that the use or misuse of any product distributed by us results in personal injury or death, product liability and/or indemnity claims may be brought against us, in addition to our product recalls, and the relevant regulatory authorities in the market we operate may close down some of our related operations and take administrative actions against us. If we experience any business disruption and litigation, we may incur additional costs and have to divert our management’s attention and resources on such matters, which may materially and adversely affect our business, financial condition and results of operations.

 

We had previously relied on the variable interest entity, Agape S.E.A. Sdn Bhd, in Malaysia for our business operations, which may not be as effective in providing operational control or enabling us to derive economic benefits as through ownership of controlling equity interests. While we no longer rely on Agape S.E.A. Sdn Bhd for our operations, we may do so in the future.

 

Agape S.E.A. Sdn Bhd’s equity at risk was insufficient to finance its business activities and it provided all of the Company’s purchases during the fiscal years ended December 31, 2020 and 2019. As a result, it is considered to be a variable interest entity (“VIE”) and the Company is the primary beneficiary since it has both of the following characteristics, (a) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. However, the Company no longer relied on the VIE after the fiscal year ended December 31, 2020. For the years ended December 31, 2022 and 2021, Agape S.E.A. Sdn Bhd did not provide any purchase to the Company. In addition, Agape S.E.A.’s impact to our consolidated financial statements constitutes less than 1% of our total consolidated assets. While the Company have not made any purchases from the VIE for the year ended December 31, 2022, we may expect to continue to rely on ASL’s beneficiary ownership structure with Agape S.E.A. to operate our business. If we fail to continue our beneficiary ownership structure with Agape S.E.A. in the future, it could have a material adverse effect on our financial condition and results of operations.

 

16

 

 

Risks Related to Doing Business in Malaysia

 

Developments in the social, political, regulatory and economic environment in Malaysia may have a material adverse impact on us.

 

Our business, prospects, financial condition and results of operations may be adversely affected by social, political, regulatory and economic developments in Malaysia. Such political and economic uncertainties include, but are not limited to, the risks of war, terrorism, nationalism, nullification of contract, changes in interest rates, imposition of capital controls and methods of taxation.

 

Negative developments in Malaysia’s socio-political environment may adversely affect our business, financial condition, results of operations and prospects. The Malaysian economy registered modest growth of approximately 8.7% and 3.1% in 2022 and 2021 respectively, according to the Department of Statistics Malaysia. Although the overall Malaysian economic environment (in which we predominantly operate) appears to be positive, there can be no assurance that this will continue to prevail in the future. Economic growth is determined by countless factors, and it is extremely difficult to predict with any level of absolute certainty.

 

Furthermore, on March 11, 2020, the World Health Organization or WHO declared the corona virus or COVID-19 a pandemic. To help counter the transmission of COVID-19, from March 18, 2020 to April 26, 2022, the government of Malaysia initiated (i) Movement control orders (“MCO”). The MCO had resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia. (ii) Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia. (iii) Recovery Movement Control Order (“RMCO”). At the height of the pandemic, on January 12, 2021, the Malaysian government even declared a state of emergency nationwide to combat COVID-19. On April 27, 2022, the Malaysian government announced the country had entered into the endemic phase with further easing of restrictions. We are witnessing the adverse impact on the purchasing power of consumers in Malaysia, where our products are mainly sold as a direct result of the prolonged pandemic. As such, the extent to which the coronavirus may continue to adversely impact the Malaysian economy is uncertain. In the event that the Malaysia economy suffers, demand for our products may diminish, which would in turn result in our profitability. This could in turn result in a substantial need for restructuring of our business objectives and could result in a partial or entire loss of an investment in our Company.

 

We are subject to foreign exchange control policies in Malaysia.

 

The ability of our subsidiaries to pay dividends or make other payments to us may be restricted by the foreign exchange control policies in the countries where we operate. For example, there are foreign exchange policies in Malaysia which support the monitoring of capital flows into and out of the country in order to preserve its financial and economic stability. The foreign exchange policies are administered by the Foreign Exchange Administration, an arm of Bank Negara Malaysia (“BNM”), the central bank of Malaysia. The foreign exchange policies monitor and regulate both residents and non-residents. Under the current Foreign Exchange Administration rules issued by BNM, non-residents are free to repatriate any amount of funds from Malaysia in foreign currency other than the currency of Israel at any time (subject to limited exceptions), including capital, divestment proceeds, profits, dividends, rental, fees and interest arising from investment in Malaysia, subject to any withholding tax. In the event BNM or any other country where we operate introduces any restrictions in the future, we may be affected in our ability to repatriate dividends or other payments from our subsidiaries in Malaysia or in such other countries. Since we are a holding company and rely principally on dividends and other payments from our subsidiaries for our cash requirements, any restrictions on such dividends or other payments could materially and adversely affect our liquidity, financial condition and results of operations.

 

Economic, market and political developments in the countries where we operate could have a material and adverse effect on our business.

 

As with all organizations that seek to reduce business risks via geographical expansion, the economic, market and political conditions in other countries, particularly emerging market conditions in Southeast Asia, could have an influence on our business. Any widespread global financial instability or a significant loss of investor confidence in emerging market economies may materially and adversely affect our business, financial condition, results of operations, prospects or reputation.

 

Examples of such external factors or conditions that are outside our control include, but are not limited to the following:

 

  general economic, political and social conditions in Southeast Asian markets;

 

17

 

  

  consumer spending patterns in our key markets;
     
  currency and interest rate fluctuations;
     
  international events and circumstances such as wars, terrorist attacks, natural disasters and political instability; and
     
  changes in legal regimes and governmental regulations, such as licensing and approvals, taxation, duties and tariffs, in key markets and abroad.

 

For example, the global financial markets experienced significant disruptions in 2008 and the United States, Europe and other economies went into recession. The recovery from the lows of 2008 and 2009 was uneven and the global economy has continued to face new challenges. There is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies that have been adopted by the central banks and financial authorities of some of the world’s leading economies, including the United States. For example, in 2013, the Federal Reserve Bank in the United States announced the tapering of its bond-buying program which led to a high degree of volatility in equity markets and substantial devaluations in the currencies of many emerging economies, including markets where we operate. Economic conditions in the countries where we operate might be sensitive to global economic conditions, as well as changes in domestic economic and political policies and the expected or perceived overall economic growth rate in emerging markets. Furthermore, the outbreak of coronavirus disease 2019 was first reported in December 2019 in Wuhan, China. These figures are huge relative to the small size economy of the country. We are witnessing the adverse impact on the purchasing power of consumers in Malaysia, where our products are mainly sold as a direct result of the prolonged pandemic.

 

Management and Governance Risks

 

Risks Related to our Common Stock and this Offering

 

Volatility in our shares price may subject us to securities litigation.

 

The market for our shares may have, when compared to seasoned issuers, significant price volatility and we expect that our share price may continue to be more volatile than that of a seasoned issuer for the indefinite future. In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price of its securities. We may, in the future, be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert management’s attention and resources.

 

We may never be able to pay dividends and are unlikely to do so.

 

To date, we have not paid, nor do we intend to pay in the foreseeable future, dividends on our common stock, even if we become profitable. Earnings, if any, are expected to be used to advance our activities and for working capital and general corporate purposes, rather than to make distributions to stockholders. Since we are not in a financial position to pay dividends on our common stock and future dividends are not presently being contemplated, investors are advised that return on investment in our common stock is restricted to an appreciation in the share price. The potential or likelihood of an increase in share price is uncertain.

 

18

 

 

In addition, under Nevada law, we may only pay dividends subject to our ability to service our debts as they become due and provided that our assets will exceed our liabilities after the dividend. Our ability to pay dividends will therefore depend on our ability to generate sufficient profits. Furthermore, because of the various rules applicable to our operations in Malaysia and the regulations on foreign investments as well as the applicable tax law, we may be subject to further limitations on our ability to declare and pay dividends to our stockholders.

 

Stockholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of securities.

 

Wherever possible, our board of directors will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that the non-cash consideration will consist of shares of our common stock, warrants to purchase shares of our common stock or other securities. In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our stockholders. We are authorized to issue an aggregate of 1,000,000,000 shares of common stock and 200,000,000 shares of preferred stock. We may issue additional shares of common stock or other securities that are convertible into or exercisable for our common stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities for capital raising purposes, or for other business purposes. The future issuance of any such additional shares of our common stock may create downward pressure on the trading price of the common stock. We expect we will need to raise additional capital in the near future to meet our working capital needs, and there can be no assurance that we will not be required to issue additional shares, warrants or other convertible securities in the future in conjunction with these capital raising efforts, including at a price (or exercise prices) below the price you paid for your stock.

 

We are a “smaller reporting company,” and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.

 

We are currently a “smaller reporting company”, meaning that we are not an investment company, an asset- backed issuer, or a majority-owned subsidiary of a parent company that is not a smaller reporting company and annual revenues of less than $50.0 million during the most recently completed fiscal year. In the event that we are still considered a “smaller reporting company,” at such time as we cease being an “emerging growth company,” we will be required to provide additional disclosure in our SEC filings. However, similar to an “emerging growth companies”, “smaller reporting companies” are able to provide simplified executive compensation disclosures in their filings; are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting; and have certain other decreased disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as a “smaller reporting company” may make it harder for investors to analyze our results of operations and financial prospects.

 

19

 

 

The offering price of our shares of common stock offered in the Resale Prospectus Resale is fixed.

 

The selling stockholders of the Resale Prospectus will offer and sell their shares of common stock being offered under the Resale Prospectus at $6.50 per share for the duration of the offering or until the shares are listed on a national securities exchange at which time the shares offered under the Resale Prospectus may be sold at prevailing market prices or privately negotiated prices or in transactions that are not in the public market. We have applied to list our common stock on the NASDAQ Capital Market (“NASDAQ”) under the symbol “ATPC.” No assurance can be given that our application will be approved. The closing of this offering is contingent upon the successful listing of our common stock on the Nasdaq Capital Market.

 

We plan to list our common stock on NASDAQ. We may not be able to maintain our listing on NASDAQ which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.

 

We have applied to list our common stock on the NASDAQ Capital Market (“NASDAQ”) under the symbol “ATPC”. Even if our common stock is approved to be listed on NASDAQ, we cannot assure you that our common stock will continue to be listed on NASDAQ in the future. In order to continue listing our securities on NASDAQ, we must maintain certain financial, distribution and share price levels. Moreover, we must comply with certain listing standards regarding the independence of our board of directors and members of our audit committee. We intend to fully comply with these requirements, but we may not continue to be able to meet these requirements in the future.

 

If NASDAQ delists our securities from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:

 

  a limited availability of market quotations for our securities;
     
  reduced liquidity for our securities;
     
  a determination that our common stock is a “penny stock” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;
     
  a limited amount of news and analyst coverage; and
     
  a decreased ability to issue additional securities or obtain additional financing in the future.

 

The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as “covered securities.” Because we expect that our common stock will be listed on NASDAQ, such securities will be covered securities. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Furthermore, if we were no longer listed on NASDAQ, our securities would not be covered securities and we would be subject to regulations in each state in which we offer our securities.

 

The price of our common stock may rapidly fluctuate or may decline regardless of our operating performance, resulting in substantial losses for investors.

 

The trading price of our common stock following this offering may be subject to instances of extreme stock price run-ups followed by rapid price declines and stock price volatility unrelated to both our actual and expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our stock. Further, the trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume, actual or anticipated fluctuations in our results of operations; the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections; failure of securities analysts to initiate or maintain coverage of our Company, changes in financial estimates or ratings by any securities analysts who follow our Company or our failure to meet these estimates or the expectations of investors; announcements by us or our competitors of significant innovations, acquisitions, strategic partnerships, joint ventures, operating results or capital commitments; changes in operating performance and stock market valuations of other companies in our industry; price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole; changes in our Board or management; sales of large blocks of our ordinary shares, including sales by our executive officers, directors and significant stockholders; lawsuits threatened or filed against us; changes in laws or regulations applicable to our business; the expiration of lock-up agreements; changes in our capital structure, such as future issuances of debt or equity securities; short sales, hedging and other derivative transactions involving our capital stock; general economic and geopolitical conditions, including the current or anticipated impact of military conflict and related sanctions imposed on Russia by the United States and other countries due to Russia’s recent invasion of Ukraine; and the other factors described in this section of the prospectus captioned “Risk Factors.”

 

Certain recent initial public offerings of companies with relatively small public floats have experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company. Our common stock may potentially experience rapid and substantial price volatility, which may make it difficult for prospective investors to assess the value of our common stock.

 

In addition to the risks addressed above under “the price of our common stock may rapidly fluctuate or may decline regardless of our operating performance, resulting in substantial losses for investors,”our common stock may be subject to rapid and substantial price volatility. We may experience extreme stock price volatility unrelated to our actual or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock. Recently, there have been instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with a number of recent initial public offerings, especially among companies with relatively smaller public floats. As a relatively small-capitalization company, we may experience greater stock price volatility, extreme price run-ups, lower trading volume and less liquidity than large-capitalization companies. In particular, our common stock may be subject to rapid and substantial price volatility, low volumes of trades and large spreads in bid and ask prices. Such volatility, including any stock-run up, may be unrelated to our actual or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.

 

In addition, if the trading volumes of our common stock are low, persons buying or selling in relatively small quantities may easily influence prices of our common stock. This low volume of trades could also cause the price of our common stock to fluctuate greatly, with large percentage changes in price occurring in any trading day session. Holders of our common stock may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. Broad market fluctuations and general economic and political conditions may also adversely affect the market price of our common stock. As a result of this volatility, investors may experience losses on their investment in our common stock. A decline in the market price of our common stock also could adversely affect our ability to issue additional common stock or other securities and our ability to obtain additional financing in the future. No assurance can be given that an active market in our common stock will develop or be sustained. If an active market does not develop, holders of our common stock may be unable to readily sell the shares they hold or may not be able to sell their shares at all.

 

20

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains forward-looking statements, including, without limitation, in the sections captioned “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Plan of Operations”, and “Business”. Known and unknown risks, uncertainties and other factors, including those listed under “Risk Factors,” may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.

 

You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to:

 

  Our goals and strategies;
     
  Our future business development, financial conditions and results of operations;
     
  Our expectations regarding demand for and market acceptance of our products and services;
     
  Our ability to attract and retain management;
     
  Our ability to raise capital when needed and on acceptable terms and conditions;
     
  The intensity of competition;
     
  General economic conditions;
     
  Changes in regulations;
     
  Relevant government policies and regulations relating to our industry;
     
  Whether the market for healthcare services continues to grow, and, if it does, the pace at which it may grow;
     
  Our ability to compete against large competitors in a rapidly changing market; and
     
  Our ability to comply with the continued listing standards on the exchange or trading market on which our common stock is listed for trading; and
     
  The impact of COVID-19 on business environment and consumer preference.

 

These forward-looking statements involve various risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Business” and other sections in this prospectus. You should thoroughly read this prospectus and the documents that we refer to with the understanding that our actual future results may be materially different from and worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements.

 

This prospectus contains certain data and information that we obtained from private publications. Statistical data in these publications also include projections based on a number of assumptions. Our industry may not grow at the rate projected by market data, or at all. Failure of this market to grow at the projected rate may have a material and adverse effect on our business and the market price of our common stock. In addition, the rapidly changing nature of the health and wellness industry results in significant uncertainties for any projections or estimates relating to the growth prospects or future condition of our market. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based on these assumptions. You should not place undue reliance on these forward-looking statements.

 

The forward-looking statements made in this prospectus relate only to events or information as of the date on which the statements are made in this prospectus. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this prospectus and the documents that we refer to in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.

 

21

 

 

USE OF PROCEEDS

 

We estimate that we will receive net proceeds from this offering of approximately $3.17 million, or approximately $3.70 million if the Underwriter exercises its over-allotment option in full, after deducting underwriting discounts and the estimated offering expenses payable by us.

 

The primary purposes of this offering are to create a public market of our shares for the benefit of all stockholders, retain talented employees, and obtain additional capital. We plan to use the net proceeds of this offering as follows:

 

  approximately 15% for strengthening sales and marketing of our products, services and branding, including further development and promotion of our e-trading platform;
     
  approximately 40% for research and development (“R&D”) and technological development, including further research on enhancements of components in our current product and service offerings and the construction of a e-trading platform;
     
  approximately 20% for expanding operations into ASEAN and US markets, including expansion of our market share in Indonesia, Singapore and Thailand, collaborations with US companies in terms of product R&D and expansion of e-commerce operations to target US consumers;
     
 

approximately 20% for future vertical and horizontal integrations, including strategic collaborations, mergers & acquisitions of insurance and health care service providers. We will further invest into production resources allowing us to produce our own products, ensuring supply and quality while reducing costs. In relation to the mergers and acquisitions, it will be mainly for our development as a comprehensive wellness ecosystem company. We have identified targets companies matching the following criteria: (i) with profitability and customer base comprising customers from the health care industry; and (ii) with established knowledge base of empirical/holistic skills, knowledge and technologies which are applicable to transform our company into a wellness ecosystem company such as skin care, cosmetic bio lab production, wellness center or complementary medical therapies for chronic health problems, manufacturers of water filtration system, etc.; and

     
  the remainder for working capital and general corporate purposes, including legal, accounting and other professional fees associated with becoming a public company, general and administrative expenses associated with increased operations, and recruitment of talent associated with increase operations.

 

The amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under “Risk Factors.” The foregoing represents our current intentions based upon our present plans and business conditions to use and allocate the net proceeds of this offering. Our management, however, will have significant flexibility and discretion to apply the net proceeds of this offering. If an unforeseen event occurs or business conditions change, we may use the proceeds of this offering differently than as described in this prospectus.

 

22

 

 

DIVIDEND POLICY

 

We have never declared or paid any cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends to holders of our common stock in the foreseeable future.

 

23

 

 

CAPITALIZATION

 

The following table describes our cash and our capitalization as of December 31, 2022:

 

  on an actual basis; and
     
  on an as adjusted basis to reflect our receipt of the net proceeds from this offering after deducting the underwriting discounts, non-accountable expense allowance and estimated offering expenses payable by us.

 

The as adjusted information below is illustrative only and our capitalization following the completion of this offering is subject to adjustment based on the public offering price of our common stock and other terms of this offering determined at pricing. In addition, except for the last column in the first table below, the tables below assume that the Underwriter over-allotment option has not been exercised. You should read this capitalization table together with our consolidated financial statements and the related notes appearing elsewhere in this prospectus and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other financial information included elsewhere in this prospectus.

 

    Actual     Pro Forma Adjusted for IPO(1) (2)     Pro Forma Adjusted for IPO including Over- allotment(3)  
Equity:                        
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding, actual and as adjusted   $ -     $ -     $ -  
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 75,452,012 issued and outstanding, as adjusted     7,545       7,605       7,614  
Additional paid in capital     6,470,716       9,140,822       9,673,163  
Accumulated deficit     (4,945,586 )     (4,945,586 )     (4,945,586 )
Accumulated other comprehensive income     9,266      

9,266

     

9,266

 
Non-controlling interests     20,513     20,513     20,513
Total stockholders’ equity   $ 1,562,454     $ 4,232,620     $ 4,764,970  

 

(1) Gives effect to the sale of common stock at a public offering price of $6.50 per share and to reflect the application of the proceeds after deducting our estimated offering expenses.

 

(2) Pro forma adjusted for IPO additional paid in capital reflects the net proceeds we expect to receive, after deducting the Underwriter discount of 8%, non-accountable expense allowance of 1% and other expenses (all the accountable expenses). We expect to receive net proceeds of $3,169,368 ($3,900,000 offering, less underwriting fee of $312,000 and other offering expenses of $418,632. For an itemization of an estimation of the total offering expenses, see “Item 13. Other Expenses of issuance and Distribution” beginning on page II-1 of this prospectus.

 

(3) Pro forma adjusted for IPO additional paid in capital including the Underwriter’s over-allotment option reflects the net proceeds we expect to receive after the under exercise the over-allotment option in full and after deducting the underwriting discount of 8%, non-accountable expense allowance of 1% and other expenses (all the accountable expenses). We expect to receive net proceeds of $3,701,718 ($4,485,000 offering, less underwriting fee of $358,800 and other offering expenses of $424,482. For an itemization of an estimation of the total offering expenses, see “Item 13. Other Expenses of issuance and Distribution” beginning on page II-1 of this prospectus.

 

24

 

 

DILUTION

 

If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering.

 

Dilution results from the fact that the per share offering price is substantially in excess of the book value per share of common stock attributable to the existing stockholders for our presently outstanding shares of common stock. Net tangible book value per share is determined by dividing our total tangible assets less our total liabilities by the number of shares of our common stock outstanding. Our historical net tangible book value as of December 31, 2022, was $937,562 or $0.01 per share.

 

Our post offering as adjusted net tangible book value, which gives effect to receipt of the net proceeds from the offering and issuance of additional shares in the offering but does not take into consideration any other changes in our net tangible book value after December 31, 2022, will be approximately $4,106,930 or approximately $0.05 per share. This would result in dilution to investors in this offering of approximately $6.45 per share or approximately 99.17% from the assumed offering price of $6.50 per share. Net tangible book value per share would increase to the benefit of present stockholders by $0.04 per share attributable to the purchase of the shares by investors in this offering.

 

The following table sets forth the estimated net tangible book value per share after the offering and the dilution to persons purchasing shares.

 

    Offering(1)     Full Over-
allotment
Post-offering(2)
 
Assumed offering price per common stock   $ 6.50     $ 6.50  
Net tangible book value per common stock as of December 31, 2022   $ 0.01     $ 0.01  
Increase in net tangible book value per share after this offering   $ 0.04     $ 0.05  
Net tangible book value per common stock after the offering   $ 0.05     $ 0.06  
Dilution per common stock to new investors   $ 6.45     $ 6.44  
Dilution per common stock to new investors (%)     99.17 %     99.06 %

 

(1) Assumes gross proceeds from offering of 600,000 shares of common stock.
(2) Assumes gross proceeds from offering of 690,000 shares of common stock, if over-allotment option is exercised in full.

 

The following chart illustrates our pro forma proportionate ownership, upon completion of the offering, by present stockholders and investors in this offering, compared to the relative amounts paid by each. The charts reflect payment by present stockholders as of the date the consideration was received and by investors in this offering at the offering price without deduction of the estimated underwriting discount, non-accountable expense allowance and our estimated offering expenses. The charts further assume no changes in net tangible book value other than those resulting from the offering.

 

    Shares Purchased     Total Consideration    

Average

Price

 
    Number     Percentage     Amount     Percentage     Per Share  
New investors(1)     600,000       0.79 %   $ 3,900,000       37.58 %   $ 6.50  
Existing stockholders     75,452,012       99.21 %   $ 6,478,261       62.42 %   $ 0.09  
Total     76,052,012       100.00 %   $ 10,378,261       100.00 %   $ 0.14  

 

(1) Assuming the offering is fully subscribed.

 

25

 

 

SELECTED CONSOLIDATED FINANCIAL DATA

 

AGAPE ATP CORPORATION

 

The following table presents selected consolidated financial data for the periods and at the dates indicated. The selected consolidated statements of operations data for the years ended December 31, 2022 and 2021, and the selected consolidated balance sheet data as of December 31, 2022 and 2021 have been derived from our consolidated financial statements, included elsewhere in this prospectus. Our historical results for any prior period are not necessarily indicative of results to be expected in any future period, and our results for any interim period are not necessarily indicative of the results expected for a full fiscal year.

 

You should read the following financial information together with the information under “Agape ATP Corporation Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the related notes included elsewhere in this prospectus.

 

Consolidated Statements of Operations Data:

 

   For the
Years Ended December 31,
 
   2022   2021 
Revenue  $1,856,564   $1,016,962 
Cost of revenue   (666,042)   (297,333)
Gross profit   1,190,522    719,629 
Selling, general and administrative expenses   (2,723,788)   (2,578,197)
Loss from operations   (1,533,266)   (1,858,568)
Other expenses, net   (136,868)   (529,045)
Benefit of (Provision) for income taxes   4,055    (137,067)
Net loss   (1,666,079)   (2,524,680)
Net (income) loss attributable to non-controlling interests   (20,820)   436 
Net loss attributable to Agape ATP Corporation  $(1,686,899)  $(2,524,244)
Net loss  $(1,666,079)  $(2,524,680)
Other comprehensive loss   (84,132)   (87,615)
Comprehensive loss  $(1,750,211)  $(2,612,295)
Less: Comprehensive income (loss) attributable to non-controlling interests   20,849    (433)
Comprehensive loss attributable to Agape ATP Corporation  $(1,771,060)  $(2,611,862)
Net loss per share – (basic and diluted)  $(0.02)  $(0.01)
Weighted average number of common shares outstanding (basic and diluted)   87,822,337    376,216,452 

 

Consolidated Balance Sheets Data:

 

   As of  
   December 31,
2022
    December 31,
2021
 
             
Current assets  $2,028,534    $ 3,912,122  
Total assets  $2,791,749    $ 4,724,535  
Current liabilities  $1,229,295    $ 1,312,841  
Total liabilities  $1,229,295    $ 1,411,899  
Total equity  $1,562,454    $ 3,312,636  

 

26

 

 

AGAPE ATP CORPORATION

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND

RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the section headed “Selected Consolidated Financial and Operating Data” and our consolidated financial statements and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” and elsewhere in this prospectus.

 

Company Overview

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation, a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. (“ASL”), a company incorporated in Malaysia.

 

Agape ATP Corporation is an investment holding company that holds 100% of the equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Dr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., an entity incorporated in Malaysia.

 

ASL is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated WATP, a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle. On September 15, 2020, WATP entered into a business collaboration agreement with ASL to carry out certain wellness programs.

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with Mr. Steve Yap which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

The Company and its subsidiaries are principally engaged in the health and wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

27

 

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 18 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

Via ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual. 

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore incorporated WATP in September 2020. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

To further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with Mr. Steve Yap which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

Results of Operation

 

For the years ended December 31, 2022 and 2021

 

Revenue

 

We generated revenue of $1,856,564, which comprised revenue from the Company’s network marketing business of $1,141,307 (approximately 61.5%); and revenue from the Company’s operations in the provision of complementary health therapies of $715,257 (approximately 38.5%) for the year ended December 31, 2022 as compared to $1,016,962, which amount was solely attributable to revenue from the Company’s network marketing business for the year ended December 31, 2021. Revenue from the Company’s network marketing business increased marginally by $124,345 or approximately 12.2%. Total revenue increased by a $839,602 or approximately 82.6%. The increase was predominately due to: (i) the recovery from COVID-19 in Malaysia after April 2022. The Company made progress in revenue generating as Malaysia, where the Company’s operations predominantly reside, has moved to a COVID-19 endemic phase with minimal restrictions on businesses and people movements in the country; and (ii) the Company’s operations in the provision of complementary health therapies since February 2022.

 

Cost of Revenue

 

Cost of revenue for the year ended December 31, 2022 amounted to $666,042 as compared to $297,333 for the year ended December 31, 2021, representing a increase of $368,709 or approximately 124.0%. The increase was in line with the increase in revenue as explained in the above.

 

Cost of revenue typically comprise of freight-in, cost of goods purchased, packing materials and services acquired.

 

28

 

 

Gross Profit

 

Gross profit for the year ended December 31, 2022 amounted to $1,190,522, represented a gross margin of, approximately 64.1%, as compared to $719,629 for the year ended December 31, 2021, which was equivalent to a gross margin of approximately 70.8%. The decrease in gross margin was predominantly due to a lower gross margin associated with the provision of complementary health therapies as compared to the Company’s network marketing business; and promotional activities undertaken by the Company to increase revenue from its network marketing business.

 

Operating Expenses

 

Our operating expenses consist of selling expenses, commission expenses, general and administrative expenses and provision for doubtful accounts.

 

Selling expenses

 

Selling expenses for the year ended December 31, 2022 amounted to $361,414 as compared to $394,682 for the year ended December 31, 2021, a decrease of $33,268 or approximately 8.4%. The Company’s selling expenses typically comprise salaries and benefits expenses, credit card processing fees and promotional expenses. The decrease in selling expenses was predominantly due to decrease in salaries and benefits expenses.

 

Commission expenses

 

Commission expenses were $405,351 and $316,267 for the years ended December 31, 2022 and 2021, respectively, representing an increase of $89,084 or approximately 28.2%. The increase in commission expenses was in line with the increase in revenue.

 

General and administrative expenses (“G&A expenses”)

 

G&A expenses for the year ended December 31, 2022 amounted to $1,957,023, as compared to $1,745,734 for the year ended December 31, 2021, representing an increase of $211,289, or approximately 12.1%. The increase in G&A expenses was mainly due to G&A expenses associated with the provision of complementary health therapies. The Company’s G&A expenses typically comprise of salaries and benefits expenses, rental expenses, professional expenses and depreciation expenses.

 

Provision for doubtful accounts

 

Provision for doubtful accounts were $0 and $121,514 for the years ended December 31, 2022 and 2021 respectively. The provision for doubtful accounts brought forward was in respect of prepayments to a supplier. As the Company’s attempts to recover the prepayments were futile, the entire provision for doubtful accounts of $121,514 was written-off during the year ended December 31, 2022.

 

Other (Expenses) Income

 

For the year ended December 31, 2022, we recorded an amount of $136,868 as other expenses, net as compared to $529,045 other expenses, net for the year ended December 31, 2021, representing a significant decrease of $392,177, or approximately 74.1%, in other expenses, net. The net other expenses of $136,868 incurred during the year ended December 31, 2022 comprised of other expenses of $79,539, interest income of $16,190 and unrealized holding loss on marketable securities of $73,519. The net other expenses of $529,405 incurred during the year ended December 31, 2021 comprised of other expense of $68,323, interest income of $25,570, unrealized holding loss on marketable securities of $505,231 and dividend income from marketable securities of $18,939. The significant decrease of other expenses, net was mainly due to the decrease of unrealized holding loss on marketable securities as a result of market price changes during the year of those investments held by the Company.

 

Benefit of (Provision for) Income Taxes

 

We had benefits of income taxes of $4,055 and provision for income taxes of $137,067 for the years ended December 31, 2022 and 2021, respectively. During the year ended December 31, 2022, our operations in Malaysia recorded benefits of income taxes due to overprovision of taxes in prior years.

 

During the year ended December 31, 2021, we had provision for income taxes of $114,862 due to certain permanent items required for the income taxes provision in Malaysia jurisdiction after our Malaysia local tax audit and had provision for income taxes of $22,205 on U.S. GILTI taxes provision.

 

29

 

 

Net Loss

 

We generated a net loss of $1,666,079 for the year ended December 31, 2022, as compared to $2,524,680 for the year ended December 31, 2021, a decrease of $858,601 or approximately 34.0%, predominately due to reasons as discussed above.

 

Liquidity and Capital Resources

 

Malaysia, where the operations of the Company predominantly reside, officially transitioned to the endemic phase of COVID-19 effective April 1, 2022. Restrictions on businesses and people are minimal.

 

Meanwhile, the government continues to encourage inoculation for those between the ages of 5 to 11 years and its adolescent group which comprised those between the ages 12 and 17. Adults who have been fully vaccinated, i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially resulting in which the demand for our products may be adversely affected ;
  we may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect our financial condition and operating results ; and
  any disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may also lead to loss of our customers.

 

From our experiences operating under the much-restricted COVID-19 environment, we have modified our methods of operations, to build in sufficient buffer in the management of inventories. We may experience slight delay in products delivery lead time but barring unforeseen circumstances, the setback should be temporary.

 

We are currently operating primarily in Malaysia and anticipate expanding into the Asian markets in the future, with a particular focus, at least initially, on expanding into Thailand, Indonesia and Taiwan. We will explore expansion via e-commerce. Now that most nations are living alongside COVID-19, we will re-assess our plans to set up offices in the countries in which we operate to better service our customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that the Company’s total revenues will grow or remain at similar levels year over year in 2023 and beyond.

 

As of December 31, 2022, we had working capital of $799,239 consisting of cash and cash in bank of $523,619 and time deposits of $914,811 as compared to working capital of $2,599,281 consisting of cash and cash in bank of $622,501 and time deposits of $1,975,347 as of December 31, 2021. The Company had a net loss of $1,666,079 for the year ended December 31, 2022 and accumulated deficits of $4,945,586 as of December 31, 2022 as compared to net loss of $2,524,680 for the year ended December 31, 2021 and accumulated deficits of $3,258,687 as of December 31, 2021.

 

In assessing our liquidity and going concern, management is projecting that the company’s revenue will revert to pre-pandemic level, generating sufficient cash therefrom to cover our operating expenses.

 

30

 

 

If our Company is unable to generate sufficient cash flow within the normal operating cycle of a twelve-month period to pay for its future payment obligations, we may have to consider supplementing our available sources of funds through the following sources:

 

  other available sources of financing from Malaysia banks and other financial institutions; and
     
  financial support from our related parties and shareholders.

 

Based on the above initiatives, management is of the opinion that the Company shall have sufficient funds to meet its working capital requirements and debt obligations as they become due in the foreseeable future twelve months from the date of issuance of this Annual Report. However, there is no assurance that management will be successful in its plans.

 

The following summarizes the key components of our cash flows for the years ended December 31, 2022 and 2021:

 

  

For the years ended December 31,

 
   2022   2021 
         
Net cash used in operating activities  $(811,683)  $(845,842)
Net cash used in investing activities   (32,119)   (3,959)
Net cash used in financing activities   (234,466)   (19,061)
Effect of exchange rate on cash and cash equivalents   (81,150)   (50,890)
Net change in cash and cash equivalents  $(1,159,418)  $(919,752)

 

Operating activities

 

Net cash used in operating activities for the year ended December 31, 2022 was $811,683 and were mainly comprised of the net loss of $1,666,079, the non-cash deferred tax benefit of $14,751, the increase in accounts receivables of $2,824, the increase in amount due from related parties of $3,786, the payment of operating lease liabilities of $145,197 and the decrease in other payables (including related parties) and accrued liabilities of $115,085. The net cash used in operating activities was mainly offset by the non-cash depreciation and amortization expense of $73,876, amortization of operating right-of-use assets of $144,064, the unrealized holding loss on marketable securities of $73,519, inventory write-downs of $5,307, the decrease in inventories of $343,483, the refund in prepaid taxes of $263,404, the decrease in prepayments and deposits of $89,113, the increase in accounts payable (including related parties) of $41,422, increase in customer deposits of $94,877 and increase in income tax payables of $6,974.

 

Net cash used in operating activities for the year ended December 31, 2021 was $845,842 and were mainly comprised of the net loss of $2,524,680, dividend income from marketable securities of $18,939, the increase in prepayments and deposits of $128,363, and the payment of operating lease liabilities of $138,143. The net cash used in operating activities was mainly offset by the non-cash depreciation and amortization expense of $77,758, amortization of operating right-of-use assets of $139,451, the unrealized holding loss on marketable securities of $505,231, the non-cash deferred tax expense of $10,127, inventories write-down of $36,241, provision for doubtful accounts of $121,514, the decrease of accounts receivables of $167,566, the decrease in inventories of $192,713, the refund in prepaid taxes of $430,062, the increase in customer deposits of $52,981, the increase in income tax payables of $3,988, and the increase in other payables and accrued liabilities of $226,651.

 

Investing activities

 

Net cash used in investing activities for the year ended December 31, 2022 was $32,119, the amount entirely for the purchase of equipment and intangible assets.

 

Net cash used in investing activities for the year ended December 31, 2021 was $3,959, the amount entirely for the purchase of equipment.

 

Financing activities

 

Net cash used in financing activities for the year ended December 31, 2022 was $234,466, the amount entirely payment of deferred offering cost.

 

31

 

 

Net cash used in financing activities for the year ended December 31, 2021 was $19,061, mainly comprised of payment of deferred offering cost of $15,210 and advances to related parties of $3,851.

 

Credit Facilities

 

We do not have any credit facilities or other access to bank credit.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2022, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

 

Critical Accounting Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for inventories obsolescence, impairment of long-lived assets, allowance for deferred tax assets. Following are the methods and assumptions used in determining our estimates.

 

Estimated allowance for inventories obsolescence

 

Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the years ended December 31, 2022 and 2021, the Company recognize an inventory write-downs of $5,307 and $36,241 respectively.

 

Impairment of long-lived assets

 

Operating right-of-use assets and property, plant and equipment are stated at costs less accumulated depreciation and impairment, if any. In determining whether an asset is impaired, the Company has to exercise judgment and make estimation, particularly in assessing: (1) whether an event has occurred or any indicators that may affect the asset value; (2) whether the carrying value of an asset can be supported by the recoverable amount, in the case of value in use, the present value of future cash flows which are estimating the recoverable amounts including cash flow projections and an appropriate discount rate. Changing the assumptions and estimates, including the discount rates or the growth rate in the cash flow projections, could materially affect the net present value used in the impairment test.

 

As of December 31, 2022 and 2021, the carrying amounts of operating right-of-use assets and property, plant and equipment amounted to $81,133 and $142,149 (December 31, 2021: $237,718 and $215,799), respectively. No impairment losses on operating right-of-use assets and property, plant and equipment were recognized as of December 31, 2022 and 2021.

 

Allowance for deferred tax asset

 

The Company conducts much of its business activities in Malaysia and Hong Kong and is subject to tax in each of these jurisdictions. Significant estimates are required in determining the provision for income taxes. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

 

Deferred tax assets relating to certain temporary differences and tax losses are recognized as management considers it is probable that future taxable profit will be available against which the temporary differences or tax losses can be utilized. Where the expectation is different from the original estimate, such differences will impact the recognition of deferred taxation assets and taxation in the periods in which such estimate is changed.

 

32

 

 

Critical Accounting Policies

 

Revenue recognition

 

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

Under the Company’s network marketing business, the Company issues product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the Company’s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer deposits will be reversed when the coupons are used. The Company’s coupons have a validity period of between six and twelve months. If the Company’s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues.

 

33

 

 

Provision of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person. The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp.

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued.

 

In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASUs 2016-13 and 2019-05 may have on its consolidated financial statements.

 

Except for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.

 

34

 

 

BUSINESS

 

Overview

 

We are a provider of health and wellness products and advisory services in the Malaysian market. We pursue our mission of helping people to create health and wealth by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle. We believe the quality of our products coupled with the effectiveness of our distribution network have been the primary reasons for our success and will allow us to pursue future business expansion. In order to further our supply chain, on May 8, 2020, we acquired 99.99% of Agape Superior Living Sdn Bhd, with the goal of securing an established network marketing sales channel that has been in existence in Malaysia for the past 18 years. On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn. Bhd., a wholly owned subsidiary in Malaysia, with the aim to pursue the business of promoting wellness and wellbeing lifestyle of the community through the provision of services including online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.

 

On September 15, 2020, Wellness ATP International Holdings Sdn. Bhd. entered into a business collaboration agreement with ASL to carry out certain wellness programs.

 

We currently offer three series of products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE. Our ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians. Our ÉNERGÉTIQUE series aims to provide a total dermal solution for healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid and Mousse Facial Cleanser. Our BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions to address genetic variations and deliver a personalized nutrigenomic solution for every individual.

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with Mr. Steve Yap, following which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies. The establishment of DSY Wellness is a further expansion of our business into the health and wellness industry. Mr. Steve Yap readily owns 33 proprietary formulas for treating non-communicable disease which he has agreed to bring into the company for joint commercialization. Mr. Steve Yap also has existing clients receiving traditional complimentary medicine or “TCM” in Indonesia and China.

 

Industry and Market Opportunities 

 

Increasing demand in Dietary Supplement products in The Association of Southeast Asian Nations (“ASEAN”) region.

 

ASEAN markets have continue to see increasing demand in dietary supplement products since 2016 and will continue to do for the foreseeable future. We believe that the ASEAN market for health supplements hold great potential for growth. According to a report published by Zion Market Research entitled “Dietary Supplements Market by Ingredients (Botanicals, Vitamins, Minerals, Amino Acids, Enzymes) for Additional Supplements, Medicinal Supplements, and Sports Nutrition Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028” issued in March 2023, itis estimated that while the global dietary supplements market stood at US$191.1 billion in 2020, it is set to reach US$307.8 billion by 2028, representing a compounded annual growth rate (CAGR) of 5.9% between 2021-2028.

 

 

Source: Zion Market Research

 

According to an article published Janio in December 2019, the nutritional and dietary supplements in the ASEAN region are being prioritized by individuals in order to maintain a balanced diet and lifestyle. Consumers believe that they can make up for certain vitamin deficiencies or dietary deficiencies by consuming nutritional and dietary supplements. Many consumers also use nutritional and dietary supplements for cosmetics purposes, namely, skincare, hair strengthening, and fat burning, particularly in countries such as Malaysia and Vietnam.

 

For example, in Indonesia, the nutritional and dietary supplements market has recorded strong growth due to changes in consumers’ lifestyle habits and increasing awareness of preventive health measures. This is prevalent among the middle-class that has grown from approximately 37.7% of the population in 2003 to approximately 50% the population in 2020. Similarly, prospects for the dietary supplements market in Thailand has been growing since 2015 and is predicted to grow at an average of approximately 7% per year until 2030. In the Philippines, its stable economy has also been contributing to increased financial capability and desire of Filipino consumers to improve both their mental and physical health through supplements. Conversely, Malaysia is ranked as the top country within ASEAN for both obesity and diabetes. Obesity and diabetes have been connected to heart disease and hypertension. As a result, consumers in Malaysia are increasingly aware of such potential health issues associated with eating habits and have become more proactive in searching for consumer health products to prevent such chronic diseases like diabetes and hypertension.

 

35

 

 

Continued Growth in the Skincare products in regions such as Asia-Pacific.

 

We believe that skincare products will remain highly lucrative with further potential for growth. According to Euromonitor, Asia generates approximately 51% of the world’s skin care sales, surpassing Western Europe and North America. Fortune Business Insights puts the Asia-Pacific skincare sector as the largest market in the world, valued at approximately $71.5 billion in 2019 and is expected to reach approximately $95.7 billion by 2024, representing a compound annual growth rate (“CAGR”) of approximately 6%. In terms of volume, the Asia-Pacific region is expected to grow from approximately 8.4 billion units in 2019 to approximately 9.5 billion units in 2024, representing a CAGR of approximately 2.5%.

 

Growth Drivers in the ASEAN Region

 

We believe that the market for the health and wellness industry will continue to see rapid growth, in part due to the rising wealth in the ASEAN region resulting in increased purchase power. According to a publication by the Association of Southeast Asian Nations published in October 2019, it was noted that the ASEAN region ranked as the fourth largest exporting region in the world, with its economic growth continuing to average a rate of 5.4% in the near future. ASEAN countries have established six Free Trade Agreements with seven of the region’s main trading partners – Australia and New Zealand, China, India, South Korea, Japan and Hong Kong. The Comprehensive and Progressive Agreement for Trans-Pacific Partnership is one of the largest Free Trade Agreements in the world and accounts for almost 13.5% of global GDP. The agreement brings together Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam, offering these countries investment access and free trade. It has been estimated, for example, that Vietnam’s GDP could increase by 2% over a decade as a result of new trading opportunities created by the Agreement. Economic wealth has allowed for social development with more than 100 million people estimated to have joined ASEAN’s workforce over the past 20 years and another 59 million people are projected to be added by 2030. We believe a direct advantage of such economic growth is a fast emerging middle class that will be attracted to our company and its products.

 

We believe that generally unhealthy lifestyle in the ASEAN population continues to form a basis for the growth in the health and wellness industry in the region. According to an article published by Market Watch issued in April 2020, it was noted that the ASEAN Dietary Supplement market size is set to reach USD 10.60 billion by 2026, representing a CAGR of 5.60% during the forecast period. Increasing prevalence of lifestyle-induced disorders, or Non-Communicable Diseases (NCDs), such as diabetes and cancer, will be a key factor driving food supplements market growth. Estimates computed by the World Health Organization (WHO) state that close to 8 million people die every year in Southeast Asia due to NCDs, amounting to 55% of the total deaths in the region in a given year. According to the WHO, four risk factors tobacco, alcohol, lack of exercise, and poor diets are primarily responsible for the spread of NCDs in the region. For instance, the WHO found that at least 25% of boys in Malaysia and Thailand are obese and a large number of school children across Southeast Asia are largely physically inactive. Such conditions will contribute to a growth in demand for dietary supplement products, in order to promote a healthier lifestyle.

 

A rapidly aging population in the ASEAN region also promotes the need for preventive measures to mitigate against rising healthcare costs. An International Monetary Fund publication in April 2017 found that in East Asia, the population is projected to be the world’s fastest-aging region with its old-age dependency ratio roughly tripling by current rends by 2050. According to an article by Fortune Business Insights published in April 2020, the aging population in Southeast Asia has led to a significant rise in incidences of lifestyle-related diseases. As a result, healthcare costs will inevitably rise, leading to increased demand in the use of supplements in preventing deteriorative health conditions.

 

36

 

 

Industry Challenges

 

In spite of its high growth, the health and wellness industry also faces certain challenges. We believe the following are some key challenges to the industry:

 

Price sensitivity - health and wellness products such as dietary supplements and skincare products typically have premium prices which may only be affordable to certain segments of the population. Price conscious consumers with low purchasing power may not be able to purchase such products.
   
Consumer awareness – consumer awareness may be low on the benefits of dietary supplements, leading to slower update of products. According to an article published by NuFFood Spectrum Asia in June 2017, it was noted that consumer awareness in the Asia Pacific region is low regarding the benefits of consumption of nutraceutical products.

 

Competitive Landscape

 

The health and wellness industry in ASEAN remains highly competitive and fragmented. Key entry barriers of the industry include the following:

 

Capital requirements – Market participants are required to possess sufficient amount of capital and human resources to sustain their businesses, particularly the product research and development (R&D) process, daily operation costs and maintaining personnel knowledgeable in the products such as dietary consultants.
   
Reputation and relationship with suppliers and customers – In general, current market participants have already established an extensive business network with their upstream product suppliers, as well as established reputable products that attract customers. New market entrants without a prior supply chain and reputable products may find it difficult to build credible relationships with other suppliers or gain the trust of customers.

 

Our Strategies

 

We intend to pursue the following strategies to further develop and expand our business:

 

Expand the product range in each of our ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE series

 

We intend to continue to expand the product range in each of our product lines, namely, ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE series.

 

Further Penetrate Existing Markets.

 

We believe that there are several opportunities to further penetrate our existing markets. For example, besides offering dietary products and services through our ATP Zeta Health Program, we have also expanded our products and services to include beauty and wellness products via the introduction of ÉNERGÉTIQUE and BEAUNIQUE series in July 2018 and March 2019, respectively, with the goal of diversifying our product offerings and catering to broader market demands. Currently we maintain three sales branches in different locations in Malaysia, namely, Kuala Lumpur, Johor Bahru and Ipoh, and appointed three stockists, to whom the Company can assign its products, at two other locations in Malaysia to further cater to our distributors, members and customers.

 

Currently, the Company’s distributors and members mainly consists of the Malaysian Chinese community. Due to the fact that Bumiputra, consisting of Malays and other indigenous peoples, comprises 62% of the Malaysian population estimated at approximately 32.6 million (as compared to the Chinese community which comprises less than 21%), we believe there is opportunity for further penetration of our products into the existing Malaysian market.  

 

As we further grow our business we may further expand our local sales centers to additional locations with the aim to further distribute our products and appeal to local demands.

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness with Mr. Steve Yap following which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies. The establishment of DSY Wellness is a further expansion of our business into the health and wellness industry, with target customers including patients with chronic health disorder, chronic health issues and non-communicable diseases. We will also promote the prevention of chronic health disorder through lifestyle and nutrition programs supported by the health therapies of DSY Wellness.

 

37

 

 

Deepening our Relationships with Existing Members.

 

We offer membership and distributor discounts on all our product offerings. Customers are able to become lifetime members by paying a one-time membership fee with the purchase of specific products. Members who reach a predetermined amount of purchases per year are automatically promoted to become a distributor who also enjoys bonuses for products that they sell to other customers, as well as bonuses from the collective performance of their network group. As our members and distributors recognize the value of our platform and the quality of our products, they typically purchase additional products utilizing their membership and discount entitlements. Our sales strategy is focused on expanding our revenue per member. We believe there is significant opportunity for existing members to become distributers, as well as for distributors to further recruit new distributors under their network.

 

Further Investment into Information Technology such the Establishment of an E-Commerce platform.

 

In 2019, we embarked upon a strategic initiative to establish e-commerce through the setup of e-trading of our products on an existing Malaysian e-trading platform to increase the efficiency of our supply chain, to better support and service our distributors and members, and to establish a global reach. Our e-trading initiative will be actively promoted for online recruitment of new members by existing distributors, as well as to provide direct sales to customers. Once the E-trading platform has provided tangible results in the Malaysia market, we intend to expand the platform to other geographic markets in order to duplicate its success.

 

In line with the current popularity of using social influencers to boost product demand, the Company is also exploring the appointment of key social influencers with significant number of followers as ambassadors for the Company’s products.

 

Geographic Expansion.

 

A key component of our strategy is to enter into and expand into new markets with similar cultures and a high demand for health and nutrition products. For example, the majority of our product information sessions and training seminars for distributors are currently conducted in Mandarin, which is the common language spoken amongst the majority of our distributors. We intend to invest into other Asian markets such as Taiwan, where Mandarin is also widely used and understood, allowing for the seamless transition in distributor training and membership recruitment.

 

With a view to facilitate geographical expansion, our future e-trading platform will also increases efficiency of our supply chain to better support and service our distributors and members as well as to provide online recruitment of new members by existing distributors and to provide direct sales to customers. Once the E-trading platform has provided tangible results in the Malaysia market, we intend to expand the platform to other geographic markets in order to duplicate its success.

 

Pursue Growth Through the Acquisition of Other Health and Wellness Services Providers

 

The health and wellness industry is highly fragmented, and we intends to pursue growth through the acquisitions of services providers in the ASEAN with a strong brand presence in their area of operations. In reviewing potential targets, we identified target companies matching the following criterial (i) with profitability and customer base comprising customers from health care industry; and (ii) with established knowledge base of empirical/holistic skills, knowledge and technologies which are applicable to transform our company into a wellness ecosystem company such as skin care, cosmetic biological lab production, wellness center or complementary medicine therapies for chronic health problems, manufacturers of water filtration system, etc.

 

Our Competitive Strengths

 

We believe the following competitive strengths contribute to our success and differentiate us from our competitors:

 

Well Established Reputation.

 

We have a well-established reputation in the Malaysia market, where our newly acquired subsidiary, Agape Superior Living Sdn Bhd has been operating as a reputable provider of our ATP Zeta Health Program for over 18 years.

 

Well-Established Product Portfolio.

 

We are committed to building our brand, and distributor and customer loyalty by providing quality health-oriented and wellness products. We have no expenditures or expenses relating to research and development of our products. We leverage our team of in-house nutritional consultants with rich experience gained in the area of nutritionist work, in collaborating with our customers and clients to understand the health and wellness market via a process of consultative review. We then communicate our findings and proposals to third-party suppliers to improve formulations, and to bring about new products for distributors and members who are ready to market to end-users.

 

38

 

 

Large, Highly-Motivated Distributor Base, Supported By Successful Training Methodology.

 

We had over 128,619 members, including 56,459 distributors, as of December 31, 2022. Because we believe the direct sales model is the most effective way to sell our products, we devote significant resources and management attention to assist our distributers in recruiting and retaining our members. We provide our distributors with successful training methodology, which includes meetings, workshops and activities to create social connections among distributors to develop proficiency of knowledge, confidence and skills to build recruitment strength. We structured our compensation system to encourage distributors to remain active in the business and to build a distributor network of their own, which can serve to increase their income and to increase our product sales. In order to encourage entrepreneurship within our distributors, we also maintain  six service centers, including three operated by our stockists, to better service our distributors and members.

 

Scalable Business Model.

 

Our business model enables us to grow our business with minimal investment in our infrastructure and other fixed costs. We do not require a company-employed sales force to market and sell our products. As a result, we do not incur direct incremental cost to add a new distributor. Our distributor compensation varies directly with sales. In addition, our distributors bear the majority of our consumer marketing expenses. Furthermore, we can readily increase inventory and distribution of our products as a result of our partnerships with our third-party suppliers.

 

Deeply Experienced Founder-led Management Team.

 

Our founder, Dr. How Kok Choong, has led our company through its steady growth for over 18 years. In Malaysia, Dr. How Kok Choong was recognized by the Junior Chamber Malaysia (JCM) as an Outstanding Young Malaysian 2003, and was awarded the title of Justice of Peace of Malaysia since 2005. Dr. How received the Outstanding Asian Community Contribution Award in 2011, Malaysia Top Team 50 Enterprise Award in 2011 and 2016, The Contributor Award (Medical and Health Research) in 2012, “Man of The Year” in Worldwide Excellence Award in 2015, “Man of The Year” in McMillan Global Award in 2016, The Distinguished Asia Pacific Outstanding Entrepreneur Lifetime Achievement Award in 2019, World Outstanding Chinese Entrepreneur Lifetime Award in 2019 and Certified Professional Trainer of The International Professional Managers Association in 2019.

 

Mr. Lee Kam Fan, Andrew serves as our chief financial officer since January 2021. Prior to joining the Company in January 2021, Mr. Lee has approximately 38 years of accounting and finance related experience. Since July 2014, Mr. Lee has been the proprietor of Andrew Lee & Company. Mr. Lee is an associate member of the Institute of Chartered Accountants in England and Wales since April 2019, a certified public accountant (practicing) of the Hong Kong Institute of Certified Public Accountants since May 2010, a fellow member of the Association of International Accountants since December 2006, and an associate member and certified tax advisor of the Tax Institute of Hong Kong since July 2010. Mr. Lee received his bachelor’s degree in business administration at the Open University of Hong Kong in June 2004 and his master’s degree in professional accounting from the Hong Kong Polytechnic University in November 2010.

 

Mr. Tjong Budisantoso, PhD was appointed as an executive director on April 3, 2023. Prior to joining the Company, Mr. Budisantoso, PhD had over 10 years of marketing and education related experience. Since June 2020, Mr. Budisantoso, PhD, has been a Dean of School of Business, Indonesia International Institute for Life Sciences, and since March 1, 2020 Mr. Budisantoso, PhD, has been a Director of Recruitment, Marketing & Institutional Development of Kalbis Institute. Since April 2017 Mr. Budisantoso, PhD, has been a Vice Rector in charge of Admission & Recruitment, Marketing, and Institutional Development, of Indonesia International Institute for life Sciences. From October 2011 to May 2016, Mr. Budisantoso, PhD was a lecturer at James Cook University Singapore Campus. From June 2010 to May 2016, Mr. Budisantoso, PhD was a Course Leader at the Center of Commerce and Management, Royal Melbourne Institute of Technology (RMIT), where he coordinated course for Market Research, Buyer Behavior and Marketing Management (Executive-MBA) courses. From February 2010 to May 2016, Mr. Budisantoso, PhD was a lecturer at Center of Commerce and Management, Royal Melbourne Institute of Technology, where he was teaching Marketing Principles, Market Research and Marketing Management. From 1998 to January 2010, Mr. Budisantoso, PhD was a lecturer at Faculty of Economics, Widya Mandala Catholic University Surabaya, where he was teaching Marketing Principles, Global Marketing, E-Marketing and Current Issues in Marketing. From 2008 to 2009, Mr. Budisantoso, PhD was a Director at the Indonesian Center for Retailing Surabaya. Mr. Budisantoso, Phd graduated with a bachelor of Business Administration from the Atma Jaya University, Indonesia in 1994, and graduated with a master of business administration from the Monash University, Australia, and Magister Manajemen, Institut Pengembangan Manajemen Indonesia (IPMI), Indonesia in 2001. Mr. Budisantoso, PhD obtained a doctorate of Marketing from the University of Notre Dame Australia in 2006. Mr. Budisantoso, PhD obtained a Graduate Certificate in Teaching & Learning from Royal Melbourne Institute of Technology in 2011.

 

Mr. Steve Yap serves as the director and is responsible for the operation of DSY Wellness International Sdn Bhd. Mr. Steve Yap is a well-respected figure in the field of nutritional, metabolic and anti-ageing medicine in Malaysia, and is a certified nutritional practitioner. Mr. Steve Yap is committed to developing and promoting self-empowering health preventive programs for the public to cope with chronic health disorders. Over the years, Mr. Steve Yap has served in various technical committees within the Ministry of Health Malaysia. Currently, he is a member of the traditional & complementary medicine council , which involved in the drafting of the Traditional and Complementary Medicine (T&CM) Act 2016 in Malaysia. Mr. Steve Yap is also president for the Association of Nutritional Medicine Practitioners . With Mr. Steve Yap’s involvement, we believe he will significantly enhance the technical capability of the company and accelerates the development of the group in the field of wellness.

 

Collectively, our senior leadership team has extensive management skills, accounting, financial and nutritional knowledge and expertise.

 

Product Overview

 

We offer three series of products: (i) ATP Zeta Health Program, (ii) ÉNERGÉTIQUE and (iii) BEAUNIQUE.

 

Our ATP Zeta Health Program is a health program designed to promote health and general wellbeing, as well as to prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. At its core, the ATP Zeta Super Health Program is focused upon biological energy, Adenosine Triphosphate (ATP), at the cellular level. The stimulation of ATP production at the cellular level can increase an individual’s metabolic rate in order to promote and maintain normal and healthy functioning of the body’s systems. Our program emphasizes nutrient absorption through the membrane ion channel in order to provide complete and balanced nutrients to improve cellular health. Thus, ATP Zeta Super Health Program provides ionized and high zeta potential (high bioavailability) nutrients to enhance the absorption at the cellular level.

 

Our ÉNERGÉTIQUE product series is comprised of ÉNERGÉTIQUE Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The ÉNERGÉTIQUE Mask series is formulated with triple action natural ingredients and advanced technology. The innovative combination of award-winning patented liposome encapsulating the customized fast acting patented essence, produces micro-particle liposome which, when combined with collagen peptide Tencel film, creates an effective formulation that benefits the skin at the cellular level. The ÉNERGÉTIQUE series aims to provide a total dermal solution for healthy skin beginning at the cellular level. There are three types of face masks in the ÉNERGÉTIQUE Mask Series, each addressing a specific skin condition. They are: N°1 Med-Hydration, N°2 Med-Whitening and N°3 Med-Firming. Advanced genetic analysis and clinical trials conducted revealed the benefits and efficacy of the patented functional essence. The ÉNERGÉTIQUE Mask Series has clinically shown deep penetration of liposomal essence into deep skin layers within 5 minutes application, in order to deliver immediate, deep-reaching and long-lasting benefits of skin hydration, whitening, and firming.

 

39

 

 

The ÉNERGÉTIQUE Hyaluronic Acid Serum is formulated with four functional hyaluronic acid and a unique peptide. It is a scientifically advanced and intensive quintuple action serum designed to promote skin hydration, reparation and regeneration to enhance skin viscoelasticity for improved skin firmness.

 

The ÉNERGÉTIQUE Mousse Facial Cleanser is formulated with the mildest surface-active agents available on the market. It takes the form of a unique mousse like-foam that delivers a comfortable and soft feeling to the skin during and after use without compromising the moisturizing level and viscoelastic properties of the skin. Its PH-balanced formula is suitable for all skin types for an effortless cleansing routine.

 

Our BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a personalized nutrigenomic solution for every individual.

 

ATP Zeta Health Program

 

The following is a list of our ATP Zeta Health Program products:

 

ATP1s Survivor Select

 

ATP1s Survivor Select contains various essential nutrients required by the human body to maintain normal metabolism, which includes productions of biological energy (ATP). Effective production of ATP enhances both physical, as well as mental health, and helps the body build resistance to diseases.

 

 

Benefits:

 

  Stimulates instant bio-energy production at the cellular level to ensure sufficient supply of bio energy for body cells.
  Promotes better metabolism at the cellular level.
  Promotes healthy and optimal growth of bones, teeth and muscle tissue of children.
  Improves the digestion and nutrient absorption powers of our bodies cells.
  Promotes cell detoxification and repair capabilities in order to enhance cell self-healing ability.

 

ATP2 Energized Mineral Concentrate

 

ATP2 is a nutritional supplement made from the finest plant substances and also is a proprietary formulation of a super-energized colloidal concentrate developed from a dibase solution. Its formula supports and enhances nutritional biochemical activities.

 

40

 

 

 

Benefits:

 

  Supports and enhances nutritional biochemical activities (nutrient absorption and waste metabolism).
  Breaks down or oxidises toxins and waste material to promote cellular detoxification and improve blood circulation.
  Increases cellular respiration and energy production to reduce fatigue and maintain energy levels.
  Increases oxygen levels in body cells to create a higher oxygen environment in the body, which helps to prevent the growth of harmful pathogens that contribute to diseases.
  Provides sufficient antioxidants that act as a superior scavenger of free radicals, in order to strengthen the body cells resistance against oxidative damages.

 

ATP3 Ionized Cal-Mag 

 

ATP3 Ionized Cal-Mag is a specialized calcium and magnesium minerals supplement that is designed to transform into an ionic form completely before entering the body. This is compatible to the cellular ion channel theory, that all cellular metabolisms are dependent on ionic transmission, in order to achieve the highest absorption rate. This product was tested for its nanoparticle by the National Measurement Institute of Australian Government, with proven content of nanosized calcium and magnesium that has better absorption and bio-availability.

 

 

Benefits:

 

  Strengthens our bone systems and promotes better bone development.
  Strengthens the teeth structure and prevents teeth damages.
  Provides abundant ionic calcium and magnesium, in order to prevent chronic diseases through better blood circulation and acid-base regulation.
  Promotes better relaxation of the nervous system and regulations of neurotransmitters, which helps to enhance sleep quality.
  Promotes better relaxation of muscles to prevent muscle soreness and cramps.

 

41

 

 

ATP4 Omega Blend

 

ATP4 Omega Blend is a proprietary oil blend that is rich in undamaged polyunsaturated essential fatty acid, which is fully extracted from plant-based ingredients. It provides a bio-effective balance of both essential fatty acids, Omega 3 and Omega 6 which are the important structural components of cell membranes that cannot be synthesized by humans.

 

 

Benefits:

 

  Regulates cholesterol and triglycerides in order levels to promote better blood circulation.
  Regulates inflammation, the unifying component of many diseases, and enhances cell repairing activities.
  Regulates hormones production and functions in the body through the supply of the balanced ratio of Omega 3 and Omega 6.
  Promotes healthy functioning of the brain through the maintenance of healthy impulse transmission in brain cells that is crucial for memory and learning ability.

 

ATP5 BetaMaxx

 

ATP5 BetaMaxx is derived from the cell wall of premium food-grade baker’s yeast and is a medical breakthrough result of more than 50 years of intensive research and studies by scientists and physicians. This product combines the immunostimulatory properties of molecularly structured beta 1-3, 1-6-D-glucan with other immunomodulating compounds that work to make ATP5 a unique and effective natural product.

 

 

42

 

 

Benefits:

 

  Strengthens the function of immune cells in order to build up a better immune response of body for external and internal protection.
  Promotes better cell repairing and regulates inflammatory responses in wound healing.
  Enhances the function of immune cells against damages caused by radiation.
  Helps to normalize blood sugar levels.

 

AGN-Vege Fruit Fiber

 

AGN-Vege Fruit Fiber is a special nutrition-based formula for intestines and the stomach. It consists of four essential components for gastrointestinal health effects - fiber, probiotic the “friendly bacteria,”, prebiotic fructooligosaccharides (FOS) and digestive enzymes.

 

 

Benefits:

 

  Promotes better bowel movement and prevents low-fiber diet-induced constipation.
  Maintains bowel health. FOS helps increase intestinal bifidobacteria and helps maintain a good intestinal environment.
  Slows the absorption of sugar and lipid into the bloodstream which helps improve blood sugar and cholesterol levels.
  Induces better satiety, which results in reduced total food intake and helps in achieving an ideal weight management.

 

AGP1-Iron

 

AGP1-Iron is the purest and most advanced Colloidal Iron that is sourced from the remains of an ancient rainforest which contains the most active plant-based element from nature. The colloidal nanosized iron provides high zeta potential that promotes better absorption and cellular iron uptake through the ion channel.

 

43

 

 

Benefits:

 

  Promotes better hemoglobin production to improve iron deficiency anemia.
  Iron is a component of hemoglobin in red blood cell which carries oxygen to all part of the body. As a result, it helps to improve blood circulation and prevent some oxygen deficiency symptoms through enhancement of oxygen delivery and nutrient circulation as well as toxins excretion.
  Iron is a factor in red blood cell formation. It promotes hemoglobin production hence is suitable especially for women and individual who suffered accidental bleedings.

 

YFA-Young Formula

 

YFA-Young Formula is a 100% natural unique formula, a combination of amino acid, vitamins, and minerals. It is an anti-aging and youthful maintenance supplement. It stimulates the pituitary gland to release endocrine hormones such as human growth hormone (HGH) to stimulate synergies, thus achieving the efficacy of anti-ageing through the promotion of cells vitality and strengthening of organ functionality.

 

 

44

 

 

Benefits:

 

  Enhances the production of bio-energy ATP and metabolism, which aids in reducing body fat accumulation and promote strong muscle building.
  Stimulates the production of collagen to restore skin elasticity and reduce wrinkles.
  Reduces pigmentation and dark spots on the face caused by hormonal imbalances.
  HGH builds and repairs tissues, and thus, has an effect on hair cells at the hair root to promote healthy hair growth.
  Enhances memory and cardiovascular function and prevents various chronic diseases due to HGH deficiency.

 

 

BEAUNIQUE Mito+ and Mitogize

 

We discontinued ATP Regal Mitogize on October 1, 2019. In its stead, an enhanced formula, the BEAUNIQUE Mito+ was introduced in November 2019. As a strong antioxidant drink with great flavor and taste, the preeminence of BEAUNIQUE Mito+ is its ability to further protect and stimulate mitochondria (the membrane-bound organelles which produces energy for cells) in cellular energy (ATP) production with the added advantage of fewer total sugars and calories. The new formula is comprised of 11 food groups, including potent mangosteen skin extract. Backed by advanced scientific research and tested on 88 nutrigenomic profiles, the new formulation revealed enhanced antioxidant properties. 96.34% DPPH Radical Scavenging activity, an approximate 22% increase compared to Mitogize.

 

Benefits:

 

Cellular health
 
Effective antioxidants to protect against cellular oxidative damages.
   
Immune health
 
Enhanced adaptive immune response.
Provides anti-inflammatory functionality.
Strengthens immunity against bacteria and viruses.
   
Metabolic health
 
Reduces the risk of obesity.
Reduces the risk of vascular diseases.
Reduces the risk of a Type II Diabetic.
   
Brain health
 
Reduces the risk of neurodegenerative diseases.
   
Skin health
 
Systemic photoprotection.
Reduces dark spot formation.
Alleviates skin wrinkles and inflammation induced by UV-B irradiation.

 

DSY Wellness

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness with Mr. Steve Yap following which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies. The establishment of DSY Wellness is a further expansion of our business into the health and wellness industry. DSY Wellness offers health consultancy and advice, as well as nutritional supplements at medical dosages, as prescribed by in-house nutritional practitioners.

 

45

 

 

ORYC-Organic Youth Care Cleansing Bar

 

ORYC-Organic Youth Care Cleansing Bar is a natural, organic cleansing soap for skin. It contains pure Australian-accredited natural and organic plant oils acting as a high quality and natural skin lubricant. It maintains the softness of the skin while promoting skin beauty and radiance.

 

 

Benefits:

 

  With its biodynamic avocado oil and vanilla extract, it removes impurities, leaving skin clear, fresh and clean.
  With its biodynamic, coconut, almond and olive oil, it moisturizes and texturizes the skin in order to prevent skin drying.
  In acting as natural anti-bacterial and anti-inflammatory agents, it reduces the risks of skin infections and allergies.

 

*References alluding to the efficacy and effects of our products are based on client testimonials.

 

ÉNERGÉTIQUE

 

The following is a list of our ÉNERGÉTIQUE products:

 

N°1 Med-Hydration

 

Formulated with a patented Sea Grape (Caulerpa lentillifera) extract, the N°1 Med-Hydration enhances skin moisture and luminosity. This treatment effectively improves the moisture content of the inner skin layer and rejuvenate the skin barrier function in order to avoid moisture loss.

 

 

46

 

 

Benefits:

 

  Locking the skin moisture and nutrients, strengthening the skin barrier function and boosting the skin’s moisture level.
  Increases the skin’s natural moisturizing factor (PCA) and skin layer glycoprotein connectivity to maintain the skin’s moisture.
  Effectively retains water, provides moisturization, restores skin elasticity, and promotes the growth of fibroblasts for moisturization, removes dryness, regains skin’s elasticity and smoothness.
  Delivers an instant boost of skin moisture content up to 45.7% in just 5 minutes of application and synergistically ensuring a profound and long-lasting skin moisturization and hydration.

 

N°2 Med-Whitening

 

Formulated with patented Peach Blossom Stem Cell Extract, N°2 Med-Whitening has clinically shown its efficacy in inhibiting the melanin synthesis, down-regulating the melanin synthesis gene, boosting skin moisture level and protecting skin against UV radiation.

 

 

Benefits:

 

  Suppresses melanin production and fights against UV radiation in order to protect skin cells and result in whitening effect.
  Stimulates interstitial hyperplasia cell and helps in increasing the moisturizing ceramide by 7.4 times in order to remove skin roughness and smoothing skin.
  Enhances the skin brightness up to 6.3% in just 5 minutes of application and synergistically rejuvenate a profound and long-lasting skin.

 

N°3 Med-Firming

 

Formulated with the patented Djulis (Chenopodium formosanum Koidz) Seed Extract, the native cereal plant in Taiwan is traditionally called “ruby of cereals.” The formulation is clinically proven to be effective in stimulation of collagen secretion and anti-advances glycation end-products (AGEs) reducing the glycation of skin collagen, providing protection and maintenance of the basal skin collagen production.

 

47

 

 

 

Benefits:

 

  Suppresses the skin collagen glycation process, reduces collagen loss, and enhances collagen secretion.
  Repairs dead skin tissue, smooths wrinkles to restore the smoothness and health of the skin.
  Prevents wrinkles formation and provides the essential skin moisture content.
  Boosts skin elasticity by up to 14.4%. and improves sagging skin by 135 in just 5 minutes of application.

 

BEAUNIQUE

 

The Company’s BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver personalized nutrigenomic solutions for every individual.

 

Trim+

 

Trim+ is the first product launched under this series, which utilizes advanced technology to extract patented active ingredients in foods. Trim+ has been scientifically proven to be effective in inhibiting the activities of carbohydrates digestive enzymes, which results in a reduction of the breakdown and absorption of sugars.

 

 

48

 

 

Benefits:

 

  Reduces total carbohydrates calories intake with scientifically proven effect on weight management.
  Regulates blood sugar levels with scientifically proven efficacy.
  Improves cellular uptake of sugars for bioenergy ATP production.
  Maintains insulin hormone balance and helps prevent diabetes.
  Improves blood lipids compositions and helps prevent cardiovascular disease.

 

ÉNERGÉTIQUE

 

On November 3, 2019, the Company expanded its beauty products under the ÉNERGÉTIQUE series, to include beauty essentials of the skincare routine, i.e. the ÉNERGÉTIQUE Hyaluronic Acid Serum and ÉNERGÉTIQUE Mousse Facial Cleanser. These products have extended the ÉNERGÉTIQUE brand vision in offering a total dermal solution for a healthy skin beginning from the cellular level.

 

ÉNERGÉTIQUE Hyaluronic Acid (HA) Serum

 

Formulated with four functional hyaluronic acids and a unique peptide, this scientifically advanced and intensive quintuple action serum has been proven to deliver 5Rs dermal benefits. Filled in an innovative yet convenient and hygienics syringe packaging, this HA serum also ensures consumer benefits for every skin type.

 

 

Benefits:

 

  REBALANCE - Hydrates the skin surface by forming a protection layer and keeps the skin moisturized even after cleansing.
  RECOVER – Repairs the out-balanced lamellar layer to act as a barrier to prevent skin moisture from evaporation.
  REGENERATE - Promotes the production of Type I pro-collagen and boost the skin’s own production of Hyaluronic Acid up to 3 times.
  REHYDRATE - Nano-sized particles with high capacity of water-holding allows deep penetration and bestows moisture from inside the skin. Long-lasting moisture retention up to 72 hours.
  REMODELLING - Proven to increase skin firmness +200% (cheek, under-eye and neck). Enhance skin viscoelasticity to improves skin roughness.

 

49

 

 

ÉNERGÉTIQUE Mousse Facial Cleanser

 

Formulated with mild surface-active agents available on the market, this facial cleanser is designed to deliver a distinct cleansing benefits to consumers. The unique mousse like-foam delivers a comfortable and soft feeling of the skin during and after use without compromising the moisturizing level and viscoelastic properties of the skin.

 

 

Benefits:

 

  1. ALL SKIN TYPE

 

  Hypoallergenic
  Non-comedogenic

 

  2. BALANCE

 

  pH-balanced formula with buffer capacity at pH 5.5 of the skin.

 

  3. COMFORTABLE

 

  Mild to the skin and the eyes without irritating or drying your skin.
  Comfortable and soft feeling prolonged comfortability to your skin before and after use.

 

  4. DENSE

 

  Mousse-like foam very fine porous foam and smooth skin-feel during use.

 

  5. EFFORTLESSLY

 

  Easily remove light makeup, dirt and impurities.
  Easy to rinse with no residual.

 

Our Business Model

 

We believe that the direct-selling channel is ideally suited to marketing our products, because sales of health solution and personal care products are strengthened by ongoing personal contact between retail consumers and distributors. This personal contact may enhance consumers’ nutritional and health education and motivate consumers to begin and maintain wellness and weight management programs. In addition, by using our products themselves, distributors can provide first-hand testimonials of product effectiveness, which can serve as a powerful sales tool.

 

50

 

 

We are focused on building and maintaining our distributor network by offering financially rewarding and flexible career opportunities through the sale of quality, innovative products to health conscious consumers. We believe the income opportunity provided by our bonus program appeals to a broad cross-section of our members, particularly those seeking to supplement family income, start a home business or pursue entrepreneurial, full and part-time, employment opportunities. Our distributors, who are all independent third parties, profit from selling our products and also earning bonuses through performance of their network group, the establishment of their own network group and the performance of distributors recruited under their own network group. Top performing distributors with their own physical stores may also become stockists of the company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory in their store premises, with the requirement that all product sales are monitored through our centralized stock tracking system and accounted back to us. The stockists have the option of returning or exchanging any unsold inventory consigned to them.

 

We enable distributors to maximize their potential by providing a broad array of motivational, educational and support services. We motivate our distributors through our performance-based compensation plan, product-training seminars, workshops and participation in routine promotional activities.

 

We are committed to providing professionally designed educational training materials that our distributors can use to enhance recruitment and to maximize their sales. We conduct several training sessions per year to motivate our distributors. These training events teach our distributors not only how to develop invaluable business-building and leadership skills, but also how to differentiate our products with their consumers, including information sessions presented by in-house nutritional consultants.

 

Our corporate-sponsored training events provide a forum for distributors, who otherwise operate independently, to share ideas with us and each other. In addition we are also developing an e-marketing and e-trading platform allowing for marketing and trading of products to members, as well as online recruitment of new members and to provide direct sales to customers.

 

We are committed to providing our distributors with quality products to help them increase sales and recruit additional distributors. We leverage our team of in-house nutritional consultants with rich experience gained in the area of nutrition, in collaborating with our customers and clients to understand the health and wellness market via a process of consultative review. This review team is headed by the Head of Product Development. We then communicate our findings and proposals to third-party suppliers to improve formulations, to bring about new products for distributors and members who are ready to market to end-users.

 

We place a strong emphasis on the science of nutrition. We have obtained the appropriate authorizations from the Food Safety and Quality Division, and the National Pharmaceutical Regulatory Agency of the Ministry of Health, Malaysia for all our products. Whenever products are purchased for inventory replenishment, samples are randomly selected from every batch for testing at laboratories registered with the Ministry of Health Malaysia.

 

Our Customers

 

General

 

We provide health and wellness products and advisory services to health-conscious customers in the Malaysian market. Such customers are able to enjoy membership discounts across all our products by becoming a member.

 

Our distributors enjoy further discounts on all of our products. Besides our three sales branches located in Kuala Lumpur, Johor Bahru and Ipoh, our products are all distributed to customers and members by our distributor’s networks, which are comprised of three stockists who are also independent distributors, whose store premises are located in two other locations in Malaysia.

 

We believe that our products are particularly well-suited for direct distribution because the sale of health and nutrition products are strengthened by ongoing personal contact between retail customers and distributors. We believe our continued commitment to source quality science-based products will enhance our ability to attract new customer, as well as increase the productivity and retention of our distributors.

 

51

 

 

Structure of the membership program

 

Our customers are able to become lifetime members by paying a one-time membership fee with the purchase of specific products. Doing so allows the customer to enjoy membership discounts on all our products.

 

Members who accumulate a predetermined number of purchases are automatically promoted to become a distributor of the Company. Other than helping distributors achieve physical health and wellness through the use of our products, we offer our distributors, who are independent third parties, bonuses based on various performance factors. Distributors are required to maintain a predetermined number of purchases per year in order to maintain their distributor status.

 

Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory in their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The stockists shall have the option to either return or exchange the Company’s inventory consigned to them that are unsold.

 

The following table sets forth the number of members and distributors at the dates indicated:

 

   Number of Distributors   Number of Members   Total Number of Distributors and Members 
As at December 31, 2022   

56,459

    

72,160

    128,619 

 

Distributors’ and members’ earnings

 

Distributors and members earn profits from the sales of our products to customers. Distributors enjoy additional discounts compared to members, allowing them to earn higher direct profits through the differences in pricing when selling products they bought at distributors’ prices which are more favorable than member’s prices to customers.

 

Members are encouraged to build their respective network group. Members are promoted to distributors if they manage to recruit the requisite number of members; and the network group is able to achieve set sales targets. Other than preferential distributor pricing for the purchase of the Company’s products, distributors enjoy bonuses from the collective performance of their network group. There are several levels of distributors depending on the size and the collective sales performance of their respective network group. Each level affords bonus benefits in a different form in ascending order. A higher-level distributor will be compensated with higher returns in the form of bonus entitlements.

 

Distributors and members motivation and training

 

We believe that motivation, inspiration and training are key elements in the success of sales via network group marketing. Together with our distributors and members, we have established a consistent schedule of gatherings to support those needs. We conduct several training sessions per year to educate and motivate our distributors and members. The training sessions are typically presented by in-house staff with suitable background in nutrition, in order to provide key nutrition information about our products, as well as providing workshops to promote presentation skills to attending participants.

 

Our Suppliers

 

Currently, all of our products are acquired from unrelated third parties located in Australia, the United States, Germany and Malaysia, and rebranded by us. Due to the high costs associated with research and development of nutrition and health products, we do not maintain any facilities to produce our products. We have no expenditures or expenses relating to research and development of our product. We leverage our team of in-house nutritional consultants with rich experience gained in the area of nutritionist work, in collaborating with our customers and clients to understand the health and wellness market via a process of consultative review. We then communicate our findings and proposals to third-party suppliers to improve formulations and to bring about new products for distributors and members who are ready to market to end-users.

 

Up to the year ended December 31, 2020, we purchased from Agape S.E.A. Sdn Bhd, one of our largest suppliers, through the SEA Supply Agreement. For more information, please see “The SEA Supply Agreement” below. For the year ended December 31, 2021, we purchased from our two largest suppliers through purchase order forms which included customary terms including unit price, quantity, total price of the orders, and order lead times. We did not enter into any long term supply agreements with our major suppliers for the year ended December 31, 2022.

 

52

 

 

The SEA Supply Agreement

 

Agape S.E.A Sdn Bhd is a dietary supplement company founded in Malaysia. We originally entered into the SEA Supply Agreement with Agape S.E.A. Sdn Bhd, in May 2018, which was one of our largest suppliers at the time. Under the SEA Supply Agreement we purchased dietary supplement products and skincare products from Agape S.E.A.

 

The following summarizes the major terms of the SEA Supply Agreement:

 

Sales of Goods:   The agreement stipulates the type of goods sold, transported and delivered, with a minimum quantity per order between 5,000 to 10,000 units per order.
     
Purchase price:   The agreement stipulates that the Company shall place order for goods using a purchase order. The purchase prices under the SEA Supply Agreement are based on and in accordance with each purchase order. Agape S.E.A shall be responsible for all taxes in connection with the purchase of goods under the SEA Supply Agreement.
     
Payment:   Payment for goods is due within seven days of the date of the Agape S.E.A’s invoice, which date will not be before the date of delivery of goods.
     
Delivery:   The delivery date and delivery destination of each purchase shall be determined by both parties in a purchase order. Agape S.E.A. shall deliver the goods in accordance with the terms and conditions specified separately in each purchase order, including without limitation the quantity and delivery date. The Company is responsible for freight insurance arising from shipment to a single delivery destination. For destinations outside of Malaysia, the Company is also responsible for freight, freight insurance, tariffs and custom clearance fees.
     
Risk of Loss:   Title to and risk of loss of the goods shall pass to the Company upon shipment of the goods.
     
Right of Inspection   The Company shall be allowed to examine the goods once received and shall do so within fourteen days after the receipt of the goods. In the event the Company discovers any damages, shortages or other nonconformance of the goods, the Company shall notify Agape S.E.A within fourteen days specifying the basis of the claim. In the event of nonconformance, the Company has the following options:
     
    -retuning the goods for a replacement at Agape S.E.A’s expense;-returning the goods at Agape S.E.A’s expense for a credit of the full purchase price on future transactions; or-returning the goods at Agape S.E.A’s expense for a full refund of the purchase price.
     
Warranties:   The buyer acknowledges that it has not relied on, and that Agape S.E.A has not made any representations or warranties with respect to the quality or condition of the goods, and is purchasing the goods on an “as is” basis.
     
Security Interest:   The Company grants Agape S.E.A a security interest in the goods, until the Company has paid the seller in full for the goods.

 

53

 

 

Seller Representations and Warranties:   Agape S.E.A warrants that the goods are free, and at the time of delivery will be free, from any security interest or other liens or encumbrances, and there are no outstanding titles or claims of title hostile to the rights of Agape S.E.A in the goods.
     
Limitation of Liability:   Agape S.E.A will not be liable for any indirect, special, consequential or punitive damages (including lost profits) arising out of or relating to this agreement or the transactions contemplated by it contemplates.
     
Assignment:   Neither party may not assign any of its rights or delegate any performance under the agreement, except with prior consent from the other party
     
Governing Law:   The terms of the agreement shall be governed by and construed in accordance with the laws of the State of England.
     
Breach/ Termination:   Each party has an obligation to notify the other party of any breach, and where the breach is rectifiable, the breaching party has 21 days from the date of notification of its breach to rectify.

 

Quality Control

 

At present, our products are predominately sold in Malaysia. As the contents and combination of the main ingredients in our ATP Zeta Health Program and BEAUNIQUE series are categorized as health food rather than medicines or drugs, all of our products require authorization from the Food Safety and Quality Division of the Ministry of Health, Malaysia according to the Food Act 1983 (ACT 281) & Regulations in order to be sold in the country. Accordingly, we have obtained the appropriate authorizations from the Food Safety and Quality Division of the Ministry of Health, Malaysia for all products in our ATP Zeta Health Program and BEAUNIQUE series.

 

Our ÉNERGÉTIQUE series is regulated under the Control of Drugs and Cosmetics Regulations 1984, the Ministry of Health, Malaysia. We have also obtained the appropriate authorizations for distribution and sale of the products.

 

Inventory

 

The Company operates a central warehouse at its head office in Kuala Lumpur, Malaysia, which typically maintains an inventory reserve of up to 6 months per product. Inventory is transferred to the Company’s sales branches via ordering through the Company’s centralized stock tracking system. Stockists of the Company are required to have physical stores, and enjoys the benefit of being able to store certain amount of inventory in their stores for convenience. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The stockists shall have the option to either return or exchange the Company’s inventory consigned to them that are unsold.

 

Seasonality

 

The Company’s business is generally not subject to any seasonality factors.

 

Warranty

 

Our products include a customer satisfaction guarantee. Under this guarantee, within 90 days of purchase, any customer who is not satisfied with our product for any reason may return it or any unused portion of it to the distributor from whom it was purchased for a full refund from the Company or credit toward the purchase of another product.

 

Historically, product returns have not been significant.

 

54

 

 

E-commerce system

 

In order to facilitate our continued growth and to support distributor activities, we continually invest and upgrade our platforms. In 2019, we invested in an initiative to establish e-commerce through the setup of e-trading of our products on an existing Malaysian e-commerce trading platform. Our e-trading initiative will be actively promoted for online recruitment of new members by existing distributors and to provide direct sales to customers. Once the E-trading platform has provided tangible results in the Malaysia market, we intend to expand the platform to other geographic markets in order to duplicate its success. We also intend to approach online social influencers as part of our marketing strategy to promote our products and our e-commerce platform.

 

Intellectual Property

 

We consider trademarks, patents and copyrights to protect our intellectual property rights critical to our success. We are the registered owner of five registered trademarks and with 1 trademark pending registration in Malaysia. We have one applied to register an additional one trademarks in Malaysia. We are also the registered owner of five domain names, namely “agapeatpgroup.com”, “agapeatpcorporation.com”, “atpsummit.com”, “agapeatpgroup.my” and “agapeatpgroup.com.my.”

 

Category   Registration Number   Trade Marks Logo   Ownership   Country   Effective Date and Duration
Trademark   06010456  

 

 

[Class 30]

  Agape Superior Living Sdn. Bhd.   Malaysia  

May 20, 2016

For 10 Years

                     
Trademark   2017005364       Agape ATP Corporation   Malaysia   May 05, 2017
For 10 Years
                     
        [Class 35]            
                     
Trademark   2019023588  

 

[Class 3]

  Agape ATP Corporation   Malaysia  

July 03, 2019

For 10 Years

                     
Trademark   2019023590     Agape ATP Corporation   Malaysia  

July 03, 2019

For 10 Years

                     
        [Class 5]            
                     
Trademark   2019023589     Agape ATP Corporation   Malaysia   July 03, 2019
For 10 Years
                     
        [Class 16]            
                     
Trademark   2019036886     Agape Superior Living Sdn. Bhd.   Malaysia   June 03, 2019
For 10 Years
                     
        [Class 5]            

 

Employees

 

As at December 31, 2022 we had 30 employees (excluding our Directors). The following table sets forth the number of employees by function:

 

Function 

Number of

employees

 
     
Senior Management   

1

 
Business Development Department   2 
Finance Department   5 
Human Resources Department   5 
Operations Department   8 
Product Development Department   3 
Marketing Department   3 
Corporate Affairs Department   3 
Total   30 

 

Properties

 

We currently lease 6 properties ranging from approximately 2,500 to 11,900 square feet in Kuala Lumpur, Johor Bahru and Ipoh which primarily carry out the functions of a staff accommodation, warehouse, office, service centers and sales branches in different regions of Malaysia.

 

Insurance

 

The Employees’ Social Security Act, 1969, Malaysia mandates employers and employees to make a monthly contribution to the Social Security Organisation, Malaysia, (“SOCSO”) for any employee who is employed for wages paid under a contract of service or apprenticeship with an employer for the purpose of providing social security protection to employees and their dependents against occupational injuries, including industrial accident, accident during emergency at the employers’ premises, occupational diseases and commuting accidents. Depending on the monthly wages earned by the employee, employers shall cause to be deducted from the respective employee’s wages, amounts that ranges between RM0.10 to RM19.75 for monthly wages between RM30 to RM4,000. The employers’ contribution correspond to the said rates are between RM0.4 to RM69.05. Rates applicable to both the employee and employer are fixed at the maximum rate of RM19.75 and RM69.05 respectively. Employees who have attained 60 years of age are not required to contribute to the scheme. The employer’s responsibility towards this group shall be at a reduced rate which ranges between MYR0.30 to RM49.40 for the said wage band.

 

Other than SOCSO, effective January 1, 2018, employees and employers in the private sector are mandated to contribute to an employment insurance system, (“EIS”) under the Employment Insurance System Act, 2017. Both the employee and employer shall contribute at an equal rate at 0.2% of the employee’s wages under the scheme, subject to a maximum monthly wage rate of RM4,000. No further contribution to the scheme is required from the employee or the employer for employees who have attained 60 years of age; and employees aged 57 and above who have no prior contributions are exempted.

 

We do not have any third-party liability insurance to cover claims in respect of personal injury or property or environmental damage arising from accidents on our property or relating to our operations. Such insurance is not mandatory according to the laws and regulations of Malaysia. We typically do not require our distributors to purchase insurance regarding their operations. We believe this practice is consistent with customary industry standards.

 

Legal Proceeding

 

We are not subjected to nor engaged in any litigation, arbitration or claim of material importance, and no litigation, arbitration or claim of material importance is known to us to be pending or threatened by or against our Company that would have a material adverse effect on our Company’s results of operations or financial condition.

 

55

 

 

REGULATIONS

 

This section sets forth a summary of the most significant rules and regulations that affect our business activities in Malaysia or the rights of our stockholders to receive dividends and other distributions from us.

 

Regulations Related to Health and Wellness

 

The Food Act 1983 (Act 281) and the Food Regulations 1985

 

The primary legislations governing the various aspects of food safety and quality control in Malaysia are (i) the Food Act 1983 (Act 281) (“the 1983 Act”); and (ii) the Food Regulations 1985 (“the 1985 Regulations”), both under the purview of the Food Safety and Quality Division (FSQD) of the Ministry of Health, Malaysia. The ministry also oversees the implementation and enforcement of the legislations. The objective of the 1983 Act is to ensure that the public is protected from health hazards and fraud in the preparation, sale and use of foods and for matters incidental thereto or connected therewith.

 

The 1983 Act and the 1985 Regulations are applicable to all foods sold in the country either locally produced or imported, covers a broad spectrum from compositional standards to food additives, nutrient supplements, contaminants, packages and containers, food labelling, procedure for taking samples, food irradiation, and penalty.

 

The 1983 Act strictly prohibits food adulteration, food containing substances injurious to health and food unfit for human consumption. The legislation also ensures that consumer gets the right information from product labels; and that claims on food labels are legitimate.

 

Food as defined under the 1983 Act, includes every article manufactured, sold or represented for use as food or drink for human consumption or which enters into or is used in the composition, preparation, preservation, of any food or drink and includes confectionery, chewing substances and any ingredient of such food, drink, confectionery or chewing substances. This includes food for special dietary use for persons with specific diseases, disorders or medical conditions, and food which contain quantities of added nutrients allowable under the 1983 Act and the 1985 Regulations.

 

The general requirements on product labelling for food on sale provided under the 1985 Regulations are as follows:

 

(i) All labels shall be durably marked on the material of the package or on material firmly attached to the package.
   
(ii) All text should be in Bahasa Malaysia, i.e. the official language of Malaysia, if the food is produced, prepared or packaged in Malaysia. If the food is imported, all text should be in Bahasa Malaysia or English. In either case, translation into other languages may be included.
   
(iii) Important particulars required on product labels are:

 

  A description of the food containing the common name of its principal ingredients. In the case of mixed and blended food, the appropriate description that the contents are mixed or blended. Where the food contains beef or pork, or its derivatives, or lard, a statement to that effect. Alcohol where presence in the food should be clearly marked in capital bold-faced lettering of a non-serif character not smaller than 6 point, in the form, “CONTAINS ALCOHOL”. Where the food consists of two or more ingredients, other than water, food additives and added nutrient, the appropriate designation of each of those ingredients in descending order of proportion by weight, and wherever required by the 198s Regulations, a declaration of the proportion of such ingredient. Any ingredients known to cause hypersensitivity shall be declared on the label.
     
  Quantity of the food package.

 

56

 

 

  The name and address of the manufacturer and packer, or the owner of the rights of manufacture or packing or the agent of any of them, for food manufactured or packed in Malaysia; and the additional information of the name and address of the importer in Malaysia and country of origin for imported food.
     
  Depending on its composition, words such as “genetically modified (name of ingredient)”, “produced from genetically modified (name of ingredient)”, or “gene derived from (common name of such animal”) shall appear on the label.
     
  Marked with the expiry date or the date of minimum durability of that food.
     
  If the validity of date marking of food is dependent on its storage, then the storage direction of that food shall also be required on its label.

 

Further, based on the Guide to Nutrition Labelling and Claims, the nutritional information that must be declared on a product label are energy, protein, carbohydrate and fat. In addition, total sugars must also be declared for ready-to-drink beverages. Information on energy value is to be expressed as kcal (kilocalories) per 100 g or per 100 ml of the food or per package if the package contains only a single portion. In addition, the energy value should also be given for each serving of the food as quantified on the label. Besides kcal, energy value may also be expressed as kilojoule (kJ). The amount of protein, carbohydrate and fat should be expressed as g per 100 g or per 100 ml of the food or per package if the package contains only a single portion. In addition, the amount of these nutrients in the food should also be given for each serving of the food as quantified on the label.

 

Other than the mandatory nutrients, other nutrients may also be displayed on the nutrition label. These include vitamins and minerals, dietary fibre, sodium, cholesterol, fatty acids, amino acid, nucleotide and other food components.

 

Both ATP Zeta Health Program and BEAUNIQUE product series are regulated under the 1983 Act and the 1985 Regulation. ASL, the product owner of these product series are subject to 1983 Act and the 1985 Regulation.

 

Traditional and Complementary Medicine (T&CM) Act 2016 [Act 775]

 

The Traditional and Complementary Medicine (T&CM) Act 2016 [Act 775] (the “TCM Act”) is an act to provide for the establishment of the T&CM Council to regulate the T&CM services in Malaysia and to provide for matters connected therewith. The TCM Act received Royal Assent on 2 March 2016 and was published in the Federal Government Gazette on 10 March 2016.

 

The enforcement of the TCM Act is implemented in phases. Phase 1 begun operation on August 1, 2016 with the establishment of the T&CM Council, identification of recognized practice areas, setting up the registration criteria for recognized practice areas, designation of practitioner body under section 42 of the TCM Act and enforcement of the various sections under Phase 1 in the TCM Act.

 

Phase 2 of the TCM Act begun operation on March 1, 2021 and include the registration of T&CM practitioners in recognized practice areas with the T&CM Council, the enforcement of various sections under the TCM Act and the operation of T&CM Regulations 2021. The transitional period of Phase 2 of the TCM Act began on March 1, 2021 and will last until February 29, 2024.

 

The business activities of DSY Wellness International Sdn Bhd, our complementary health therapies are regulated under TCM Act. DSY Wellness International Sdn Bhd complementary health therapies are subject to TCM Act.

 

Control of Drugs and Cosmetics Regulations 1984

 

The Malaysian government enacted the Control of Drugs and Cosmetics Regulations 1984 (“the 1984 Regulations”) to regulate the manufacture, sell, supply, import, possess or administer of cosmetics. The authority that oversee the 1984 Regulations is the National Pharmaceutical Regulatory Agency (“NPRA”) under the Ministry of Health, Malaysia. All cosmetics industry players who intend to manufacture or import any cosmetic, must apply the notification of cosmetics (“NOC”) through NPRA.

 

Pursuant to Regulation 18A of the 1984 Regulations, cosmetics cannot be manufactured or sold if:

 

(i) The cosmetic has not been notified with the NPRA;
   
(ii) The person is a not person who has been designated to place the notified cosmetics in the market;
   
(iii) The cosmetic is a notified cosmetic but it has been mixed with poison (as defined by the Poisons Act 1952);
   
(iv) The notified cosmetic has been mixed with a registered product;
   
(v) The cosmetic is labelled with another name other than the name notified by the Director of Pharmaceutical Services;
   
(vi) The cosmetic has been labelled in a way that does not comply with any directives/guidelines issued by the Director of Pharmaceutical Services;
   
(vii) The cosmetic’s notification has been cancelled by the Director of Pharmaceutical Services; or
   
(viii) The cosmetic is labelled with words, symbols or safety features that claim to be true but is otherwise.

 

ÉNERGÉTIQUE product series are regulated under the 1984 regulation. ASL, the product owner of these product series is subject to the 1984 Regulations and relevant regulation.

 

57

 

 

Regulations Related to Consumer Protection

 

Consumer Protection Act 1999 (Act 599)

 

The principal law for consumer protection in Malaysia is the Consumer Protection Act 1999 (Act 599) (“the 1999 Act”). The 1999 Act establishes various consumer protection mechanisms in Malaysia, and bridge gaps that may occur in other major laws, which may be inadequate in protecting consumers. The government agency which is primarily responsible for policy-making and law enforcement on consumer protection in Malaysia is the Ministry of Domestic Trade and Consumer Affairs (MDTCA). The MDTCA is also responsible for receiving consumer complaints and acts as a secretariat to the National Consumer Advisory Council (NCAC) – an institution established by the Minister of Domestic Trade and Consumer Affairs to advise him on any relevant consumer issues and the implementation of the 1999 Act.

 

The 1999 Act has undergone several amendments since its enactment to cover various emerging issues relating to consumers, including the inclusion unfair contract terms, inclusion of credit sale agreements of goods and the most recent amendment on July 23, 2019 related to Tribunal for Consumer Claims Malaysia. Amendments to this Act are to increase the jurisdiction limit of claim hearing from RM25,000.00 to RM50,000.00 and the increase of maximum penalty for non-compliance with the Tribunal’s award.

 

The 1999 Act covers almost every aspects of consumer protection; ranging from misleading and deceptive conducts, false representation and unfair practices; safety of goods and services; unfair contract terms; guarantees in respect of the supply of goods and services; and product liability; to the establishment, structure and functions of the National Consumer Advisory Council; the Committee on Advertisement; the Tribunals for Consumer Claims; and other matters related to enforcement, offences, remedies, and compensation.

 

All series products produced by us in Malaysia are subject to Consumer Protection Act 1999 (Act 599).

 

Direct Sales and Anti-Pyramid Scheme Act 1993 (Act 500) and Regulations.

 

In Malaysia, network marketing is regulated by the Direct Sales and Anti-Pyramid Scheme Act 1993 (Act 500) (“the 1993 Act) and Regulations. The 1993 Act provides for the licensing of persons carrying on direct sales business, for the regulation of direct selling, for prohibiting pyramid scheme or arrangement, chain distribution scheme or arrangement, or any similar scheme or arrangement, and for other matters connected therewith. The implementation and enforcement of the 1993 Act is governed by the Ministry of Domestic Trade and Consumer Affairs.

 

Under the 1993 Act, subject to section 14 and 42 no person shall carry on any direct sales business unless it is a company incorporated under the Companies Act 1965 and holds a valid licence granted under Section 6. The Controller may grant licence under Section 6 of the 1993 Act with conditions and licensee shall comply with the any conditions of the licence imposed by the Controller. By virtue of Section 8 of the 1983 Act, the Controller has the power to revoke a licence granted if he is satisfied that there are grounds on which his power to revoke a licence is exercisable under subsection 8(1). In lieu of revocation of licence, the Controller may restrict the licence by:

 

(a) Imposing limits on the duration of the licence;
   
(b) Imposing conditions as he thinks desirable or expedient for the protection of the purchasers; or
   
(c) Imposing both limits and conditions on the licence.

 

58

 

 

We have the responsibility to ensure that our marketing plan is in compliance with the Direct Sales (Scheme and Conduct) Regulations 2001, not promoting pyramid scheme and have the following characteristics:

 

(a) In the presentation of the direct sales scheme, a person who carries on any direct sales business shall not mislead participants by overemphasizing on disproportionately high bonus or bonus payout. Each participant shall be provided with sales kit that includes the marketing plan and code of conduct of the company.
   
(b) Any person who carries on a direct sales business shall provide an incentive based on the volume or quantity of goods or services sold or distributed by each participant and not based on recruitment of persons into the scheme.
   
(c) Participants not to purchase goods or services in an unreasonable amount. Each participant is required to purchase goods or service in an amount that can be expected to be resold or consumed within a reasonable period of time.

 

Regulations Related to Intellectual Property Rights

 

Intellectual property system in Malaysia is administered by the Intellectual Property Corporation of Malaysia (MyIPO), an agency under the Ministry of Domestic Trade and Consumer Affairs.

 

Trademarks Act 2019 (Act 815)

 

The Trademarks Act 2019 (Act 815) (“the 2019 Act”) officially came into force in Malaysia on 27 December 2019. The Act repealed the Trade Marks Act 1976 and is seen as opportune in enabling Malaysia to adhere not only to commercial demands and sophistication of the current era, but also to international standards and procedures. The Trademarks Regulations 2019 is also now in force having been gazetted in the Government Gazette on 27 December 2019.

 

Malaysia is also a member of various trademark-related treating, including:

 

(i) Protocol relating to the Madrid Agreement concerning the International Registration of Marks since 27 December 2019;
   
(ii) Nice Agreement concerning the International Classification of Goods and Services since 28 September 2007;
   
(iii) Paris Convention for the Protection of Industrial Property since 1 January 1989; and
   
(iv) Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) since 1 January 1995.

 

The 2019 Act provides that any person who claims to be the bona fide proprietor of a trademark may apply for the registration of the trademark if:

 

(i) the person is using or intends to use the trademark in the course of trade; or
   
(ii) the person has authorised or intends to authorise another person to use the trademark in the course of trade.

 

The 2019 Act has also expanded the types of trademark recognized for registration to be more than just word, logo, numbers, name. signature, letter and to include shape of goods or their packaging, colour, sound, scent, hologram, positioning marks and sequence of motion of any combination thereof; provided that they must be signs capable of being represented graphically. ​

 

In general, Malaysia provides for protection for both registered and unregistered trademarks. Unregistered trademarks are protected under common law rights, particularly in the tort of passing off. In fact even during the examination of trademark, the Registrar shall refuse, under relative grounds of Section 24(4) of the 2019 Act, to register it if the mark’s use in Malaysia is prevented by virtue of any rule of law protecting an unregistered trademark or other sign used in the course of trade including the law of passing of.

 

The scope of trademark infringement and its exemptions has been substantially expanded by the 2019 Act. There could now be infringement even in the use of a similar mark on similar goods or services (as opposed to being identical). Liability will stick to secondary users who know or have reasons to believe that such use is without authorization of the trademark proprietor.

 

The 2019 Act and relevant regulation are applicable own our brand, word, logo, numbers, name. signature, letter and to include shape of goods or their packaging, color, sound, scent, hologram, positioning marks and/or sequence of motion of any combination.

 

Copyright Act 1987 (Act 332)

 

Copyright protection in Malaysia is governed by the Copyright Act 1987 (Act 332) (“the 1987 Act) which provides comprehensive protection for copyrightable works. The 1987 Act outlines the nature of works eligible for copyright (which includes computer software), the scope of protection, and the manner in which the protection is accorded. A unique feature of the 1987 Act is the inclusion of provisions for enforcing the Act, which include such powers to enter premises suspected of having infringing copies and to search and seize infringing copies and contrivances. Malaysia is a signatory of the Berne Convention. Foreign works of non-Berne member countries are also protected if they are made in Malaysia and are published in Malaysia within thirty days of their first publication in the country of origin.

 

59

 

 

Unlike trademarks, designs and patents (other intellectual property rights), there is no specific system of registration for copyright in Malaysia. Although copyright is a non-registrable right in Malaysia and enjoys automatic protection, ownership of copyright is difficult to establish. As such, proper documentation can be prepared to prove ownership. Copyright owners can claim ownership by way of a Statutory Declaration or by filing a Voluntary Notification at the MyIPO.

 

The definition of a literary work now includes table or compilations “whether or not expressed in words, figures or symbols and whether or not in a visible form”. The owner of copyright in a work including a derivative work, will have the exclusive right to control “the transmission of a work through wire or wireless means to the public, including the making available of a work to the public in such a way that members of the public may access the work from a place and at a time individually chosen by them”.

 

It is also an infringement of copyright to circumvent any effective technological measures aimed at restricting access to works, removal or alteration of any electronic rights management information without authority, or distribution, importation for distribution or communication to the public, without authority, works or copies of works in respect of which electronic rights management information has been removed or altered without authority.

 

The 1987 Act and the relevant regulations are benefited us which we are eligible to claim ownership by compiling proper documentation to prove ownership via a Statutory Declaration or by filing a Voluntary Notification at the MyIPO.

 

Regulations Related to Employment and Social Security

 

Employment Act 1955 (Act 265)

 

The Employment Act 1955 (Act 265) (“the 1955 Act) is the primary legislation on labour matters in Malaysia. The 1955 Act provides for minimum work requirements and benefits of employment, such as maximum working hours, overtime entitlement, leave entitlement, maternity protection and termination benefits. The 1955 Act applies only to employees earning a monthly wages of not more than RM2,000.00 or to employees, irrespective of their monthly wages, who are engaged in manual labour, including artisan or apprentice, or who are engaged in the operation of maintenance of mechanically propelled vehicles operated for the transport of passengers or goods or for commercial purposes, or who supervise or oversee other employees engaged in manual labour or who are engaged in any capacity in any vessel registered in Malaysia or who are engaged as domestic servant.

 

Children and Young Persons (Employment) Act 1966 (Act 350)

 

Children and Young Person (Employment) Act 1996 (Act 350) (“the 1996 Act”) prohibits children from working near hazardous and poisonous material. The 1996 Act defines a “child” is a person who is under the age of fifteen years and a “young person” is a person who is fifteen or older, but below the age of eighteen years. The 1996 Act goes on to provide the minimum working hours for a child and young person. Further, under 1996 Act no child or young person shall be, or be required or permitted to be, engaged in any employment contrary to the provisions of the Factories and Machinery Act 1967 (Act 139), the Occupational Safety and Health Act 1994 (Act 514) or the Electricity Supply Act 1990 (Act 447) or in any employment requiring him to work underground. Any person contravening the provisions under the 1996 Act shall be guilty of an offense and shall be liable on conviction to imprisonment of not exceeding 2 years or to fine not exceeding RM50,000 or to both; and for repeat offenders, shall be liable on conviction to imprisonment of not exceeding 5 years or to fine not exceeding RM100,000 or to both.

 

Employees’ Provident Fund Act 1991 (Act 452)

 

The Employees’ Provident Fund Act 1991 (Act 452) (“the 1991 Act”) imposes the statutory obligations on employers and employees to make contribution towards the Employees Provident Fund, which is essentially a fund established as a scheme of savings for employees’ retirement and the management of savings for the retirement purposes. Under the 1991 Act, any employer who fails to pay the necessary contributions shall be liable to imprisonment for a term not exceeding three years or to a fine not exceeding ten thousand ringgit or to both.

 

60

 

 

Employee’ Social Security Act 1969 (Act 4)

 

The Employee’s Social Security Act 1969 (Act 4) (“the 1969 Act’) was implemented to provide protection for employees and their families against economic and social distress in situations where the employees sustain injury or death. The schemes of social security under the 1969 Act are administered by Social Security Organization (“SOCSO”) and are financed by compulsory contributions made by the employers and the employees. Under the 1969 Act, any person who fails to make contribution shall be all be punishable with imprisonment for a term which may extend to two years, or with fine not exceeding ten thousand ringgit, or with both.

 

Employment Insurance System Act 2017 (Act 800)

 

SOCSO reached a milestone when the Employment Insurance System Act 2017 (Act 800) was introduced and enforced from 28 December 2017 with the aim to provide protection and assist workers who have lost employment through two (2) main components namely, the Employment Insurance and Active Labour Market Policies. The Employment Insurance System (EIS) provides protection to workers who have lost their employment through income replacement, reskilling and upskilling training to enhance their employability as well as employment services so that they can secure other suitable jobs fast.

 

Our all employees which under definition of the Employment Act 1955 (Act 265) (“the 1955 Act) are subject to the provision of Employees’ Provident Fund Act 1991 (Act 452), Employee’ Social Security Act 1969 (Act 4), and Employment Insurance System Act 2017 (Act 800).

 

Regulation Related to Taxation

 

Income Tax Act 1967 (Act 53)

 

The Income Tax Act 1967 (Act 53) (“the 1967 Act”) imposes a tax, known as income tax, for each year of assessment upon the income accruing in or derived from Malaysia, or received in Malaysia from other countries. A company is a tax resident in Malaysia if its management or control is exercised in Malaysia and generally, the place where directors’ meetings are held concerning management and control of the company are considered in determining where the management and control of the company is exercised.

 

Under the 1967 Act, any person who makes an incorrect tax return by omitting or understating income or gives incorrect information affecting chargeability to tax otherwise than in good faith shall be guilty of an offence and shall upon conviction be liable to a fine not less than RM1,000.00 and not more than RM10,000.00 and shall pay a special penalty of double the amount of tax which had been undercharged.

 

The Company which is incorporated under Companies Act 2016 (Act 777) is subject to Income Tax Act The Company which is incorporated under Companies Act 2016 (Act 777) is subject to Income Tax Act.

 

Regulation Related to Foreign Exchange Control

 

Financial Services Act 2013 (Act 758)

 

The Financial Services Act 2013 (Act 758) provides regulation and supervision of financial institutions, payment systems and other relevant entities and the oversight of the money market and foreign exchange market to promote financial stability and for related, consequential or incidental matters.

 

Pursuant to the Foreign Exchange Administration Rules, a resident entity with domestic ringgit is only allowed to invest abroad up to RM50 million per calendar year (“the Maximum Foreign Investment”). For the avoidance of doubt, the limit of such Maximum Foreign Investment applies to the resident entities within the group of companies.

 

Notwithstanding the above, the Foreign Exchange Administration Rules allows non-residents to remit out divestment proceeds, profits, dividends or any income arising from investments in Malaysia. Repatriation, however, must be made in foreign currency.

 

As such, if our operating subsidiaries intend to invest exceeding the Maximum Foreign Investment, we are required to seek approval from the controller of Foreign Exchange, Central Bank of Malaysia

 

Regulation Related to Competition Law

 

Competition Act 2010 (Act 712)

 

In Malaysia, under the Competition Act 2010 (Act 712) (“the 2010 Act), such provisions may be considered to be anti-competitive if they are found to significantly prevent, restrict or distort competition in any market for goods or services. The 2010 Act is regulated by the Malaysia Competition Commission (“MyCC”), an independent body established under the Competition Commission Act 2010 (Act 713) to enforce the 2010 Act. The Competition Commission Act 2010 empowers MyCC to carry out functions such as implement and enforce the provisions of the 2010 Act, issue guidelines in relation to the implementation and enforcement of the competition laws, act as advocate for competition matters; carry out general studies in relation to issues connected with competition in the Malaysian economy or particular sectors of the Malaysian economy; inform and educate the public regarding the ways in which competition may benefit consumers in and the economy of Malaysia.

 

61

 

 

The 2010 Act prohibits horizontal or vertical agreements between enterprises that either the object or effect of significantly preventing, restricting or distorting competition in Malaysia. This is referred to as “Chapter One Prohibition”. MyCC has indicated in its “Guidelines on Chapter 1 Prohibition” that in general, anti-competitive agreements will not be considered “significant” if:

 

(i) the parties to the agreement are competitors who are in the same market and their combined market share of the relevant market does not exceed 20%’ or
(ii) the parties to the agreement are not competitors and their individual market share in relevant market is not more than 25%.

 

Further, the 2010 Act also prohibits enterprises from abusing their “dominant position” in a market. This is referred to as the “Chapter Two Prohibition”. The term “dominant position “refers to one or more enterprises possessing such significant power in a market that they are able to adjust prices, outputs, or trading terms without effective constraint from competitors or potential competitors. There are no specific thresholds for abuse of a dominant position However, the following are the types of abuses prohibited under the 2010 Act; (i) predatory behaviour (for example, margin squeeze, and predatory pricing); (ii) refusal to supply; (iii) buying up scarce supply; and (iv) limiting output.

 

Pursuant to MyCC “Guidelines on Chapter 2 Prohibition”, market share above 60% would be indicative that an enterprise is dominant. Nevertheless, market share shall not by itself be regarded as conclusive of dominance and other factors will be taken into account is assessing whether an enterprise is dominant.

 

In there is any infringement with the 2010 Act, MyCC may (i) require that the infringement be ceased immediately; (ii) specify steps which are required to be taken by the infringing enterprise(s) to bring the infringement to an end; (iii) impose financial penalties which could, for example, be 10% of the worldwide turnover of the relevant enterprise over the period during which an infringement occurred; or (iv) take any number of other actions, including imposing sanctions and penalties, as they deem appropriate.

 

We shall ensure there is any infringement with the 2010 Act, which we shall not:

 

(a) Be the parties to the agreement are competitors who are in the same market and their combined market share of the relevant market exceed 20%; or

 

(b) Be the parties to the agreement are not competitors and their individual market share in relevant market is more than 25%.

 

Regulation Related to Establishment, Operation and Management of Malaysia Subsidiaries

 

Companies Act 2016 (Act 777)

 

The Companies Act 2016 (Act 777) (“the 2016 Act”) stipulates that a company must be registered with the Companies Commission Malaysia in order to engage in any business activity. Under the 2016 Act, a company shall have - (a) a name; (b) one or more members, having limited or unlimited liability for the obligations of the company; (c) in the case of a company limited by shares, one or more shares; and (d) one or more directors. With the liberalization in Malaysia equity policy, foreign companies/investors generally could hold 100% equity in majority industries except for strategic sectors of national interest such as water, telecommunications, ports, and energy. For every industry, there are specific sector regulations issued by the relevant governmental departments. These include regulations that could impose restrictions on the foreign ownership of equity of a company, require higher paid up capital requirements and also prior regulatory approval before the commencement of business operations. However, limits on foreign ownership do remain in place across many sectors such as telecommunications, oil & gas, tourism, wholesale and retail distributive trade, and financial services. A corporation is a “wholly-owned subsidiary” of another corporation if it has no members except— (a) that other corporation or its nominee; or (b) a wholly-owned subsidiary of that other corporation or its nominee. Private companies require a minimum of one director. A director shall ordinarily reside in Malaysia by having a principal place of residence in Malaysia.

 

Pursuant to the 2016 Act, appointment of an auditor is mandatory. However, the Registrar may exempt private companies from appointing an auditor where the Company is dormant, a zero-revenue company or a threshold-qualified company. Companies that elect to be exempted from audit must still lodge unaudited financial statements and the required statutory certificates with the Registrar of Companies. Since the coming into effect of the 2016 Act, private companies are no longer obligated to convene annual general meetings. However, stockholders have the right to request for the directors of the company to convene a general meeting. This right is however subject to the requirements in Section 311 of the 2016 Act.

 

For all companies incorporated in Malaysia (except in Labuan, Malaysia) are subject to the Companies Act 2016 (Act 777).

 

62

 

 

MANAGEMENT

 

Directors and Executive Officers

 

The following table sets forth information regarding our executive officers and directors as of the date of this prospectus:

 

Directors and Executive Officers (Last Name, First Name)   Age   Position/ Title
How Kok Choong   59   Chief Executive Officer, President, Director, Chief Operating Officer, Chairman of the board of Directors and Secretary

Tjong Budisantoso

  50   Director

Lee Kam Fan Andrew

  61   Chief Financial Officer

Ramesh Ruben Louis

  45   Independent Director Nominee

Vong John Hing

  69   Independent Director Nominee
Chee Chin Aik   43   Independent Director Nominee

 

* Each of Mr. Ramesh Ruben Louis, Dr. John Hing Vong and Mr. Chee Chin Aik has accepted our appointment to be our independent director, effective upon the SEC’s declaration of effectiveness of our registration statement on Form S-1, of which this prospectus is a part.

 

Dr. How Kok Choong is our founder and serves as our Chief Executive Officer, President, Director Chief Operating Officer, Chairman of the Board of Directors and Secretary since 2016. Dr. How is primarily responsible for overall development and business strategies, financial, administrative and human resources affairs of the Company. Dr. How has more than 20 years of experience in the senior management roles in the health and wellness industry. From 1987 to 2016, Dr. How was with the San Hin Group of Companies and his last position held was the group chief executive officer for the group. Since August 2003, Dr. How began to work for AGAPE Superior Living International Group as the global president and continues to hold this position. Further, since September 2009, Dr. How has worked for TH3 Holdings Sdn Bhd as president. Dr. How obtained a master’s degree and a doctorate degree in Business Administrative from Newport University, USA in December 1997 and December 2000, respectively. In Malaysia, Dr. How Kok Choong was recognized by the Junior Chamber Malaysia (JCM) as an Outstanding Young Malaysian 2003, and was awarded the title of Justice of Peace of Malaysia since 2005. Dr. How Kok Choong received the Outstanding Asian Community Contribution Award in 2011, Malaysia Top Team 50 Enterprise Award in 2011 and 2016, The Contributor Award (Medical and Health Research) in 2012, “Man of The Year” in Worldwide Excellence Award in 2015, “Man of The Year” in McMillan Global Award in 2016, The Distinguished Asia Pacific Outstanding Entrepreneur Lifetime Achievement Award in 2019, World Outstanding Chinese Entrepreneur Lifetime Award in 2019 and Certified Professional Trainer of The International Professional Managers Association in 2019.

 

Mr. Tjong Budisantoso, PhD was appointed as an executive director on April 3, 2023. Prior to joining the Company, Mr. Budisantoso, PhD had over 10 years of marketing and education related experience. Since June 2020, Mr. Budisantoso, PhD, has been a Dean of School of Business, Indonesia International Institute for Life Sciences, and since March 1, 2020 Mr. Budisantoso, PhD, has been a Director of Recruitment, Marketing & Institutional Development of Kalbis Institute. Since April 2017 Mr. Budisantoso, PhD, has been a Vice Rector in charge of Admission & Recruitment, Marketing, and Institutional Development, of Indonesia International Institute for life Sciences. From October 2011 to May 2016, Mr. Budisantoso, PhD was a lecturer at James Cook University Singapore Campus. From June 2010 to May 2016, Mr. Budisantoso, PhD was a Course Leader at the Center of Commerce and Management, Royal Melbourne Institute of Technology (RMIT), where he coordinated course for Market Research, Buyer Behavior and Marketing Management (Executive-MBA) courses. From February 2010 to May 2016, Mr. Budisantoso, PhD was a lecturer at Center of Commerce and Management, Royal Melbourne Institute of Technology, where he was teaching Marketing Principles, Market Research and Marketing Management. From 1998 to January 2010, Mr. Budisantoso, PhD was a lecturer at Faculty of Economics, Widya Mandala Catholic University Surabaya, where he was teaching Marketing Principles, Global Marketing, E-Marketing and Current Issues in Marketing. From 2008 to 2009, Mr. Budisantoso, PhD was a Director at the Indonesian Center for Retailing Surabaya. Mr. Budisantoso, PhD graduated with a bachelor of Business Administration from the Atma Jaya University, Indonesia in 1994, and graduated with a master of business administration from the Monash University, Australia, and Magister Manajemen, Institut Pengembangan Manajemen Indonesia (IPMI), Indonesia in 2001. Mr. Budisantoso, PhD obtained a doctorate of Marketing from the University of Notre Dame Australia in 2006. Mr. Budisantoso, PhD obtained a Graduate Certificate in Teaching & Learning from Royal Melbourne Institute of Technology in 2011.

 

Mr. Lee Kam Fan, Andrew serves as our chief financial officer of the Company. Prior to joining the Company in January 2021, Mr. Lee has approximately 38 years of accounting and finance related experience. Since July 2014, Mr. Lee has been the proprietor of Andrew Lee & Company. Since June 2010, Mr. Lee served as an adjunct lecturer of the HKICPA Processional Examinations Preparatory Programme at HKU Space. From January 2011 to October 2015, Mr. Lee served as the managing director at ANSA CPA Limited. From September 2010 to October 2012, Mr. Lee served as an independent non-executive director at Sunrise (China) Technology Group Limited (currently referred to as KOALA Financial Group Limited (Hong Kong stock code: 08226)). From March 2006 to April 2017, Mr. Lee was in cooperation with Friedman LLP to oversee financial statements are prepared in accordance with U.S. GAAP. From October 2000 to December 2010, Mr. Lee served as an audit manager and subsequently a partner at Clodick & Company. From April 1998 to September 2000, Mr. Lee served as a director at Nitwell Business Services Limited. From August 1994 to April 1998, Mr. Lee was an assistant audit manager at Cheng, Kwok & Chang. From July 1990 to July 1994, Mr. Lee served as an accountant at K.C. Manufacturing Company. From April 1989 to July 1990, Mr. Lee served as an accountant at Haldane, Midgley & Booth. From January 1987 to April 1989, Mr. Lee served as an audit senior at RSM Nelson Wheeler. From October 1985 to December 1986, Mr. Lee served as an audit assistant at Andrew Ma & Company. From April 1983 to September 1985, Mr. Lee served as an audit Clerk at Anthony Y.T. Tse & Company. Mr. Lee is an associate member of the Institute of Chartered Accountants in England and Wales since April 2019, a certified public accountant (practicing) of the Hong Kong Institute of Certified Public Accountants since May 2010, a fellow member of the Association of International Accountants since December 2006, and an associate member and certified tax advisor of the Tax Institute of Hong Kong since July 2010. Mr. Lee received his bachelor’s degree in business administration at the Open University of Hong Kong (currently referred to as Hong Kong Metropolitan University) in June 2004 and his master’s degree in professional accounting from the Hong Kong Polytechnic University in November 2010.

 

Mr. Ramesh Ruben Louis, PhD will serve as our independent director upon effectiveness of the registration statement of which this prospectus forms a part. Prior to joining the Company, Mr. Louis, PhD has approximately 25 years of accounting and finance related experience. Since January 2011, Mr. Louis, PhD has been an executive director and principal consultant of Assurance Threesixty Consulting. Since November 2009, Mr. Louis, PhD has been a professional freelance trainer and consultant at My Learning Training Resources, where he conducted various training courses including training for MIA, ACCA, CPA Australia ISCA Singapore. From May 2006 to October 2009, Mr. Louis, PhD was an executive director at Anuarul Azizan Chew Group, where he was involved in internal audit, risk management and review/assessment of internal controls assignments of various organisations including public listed companies in Malaysia. From 2000 to 2006, Mr. Louis, PhD worked in BDO Binder, where he worked in areas including corporate finance and assurance advisory, his last role being assistant audit manager. From 1997 to 1998, Mr. Louis, PhD was an audit assistant at Arthur Andersen & Co. Mr. Louis, PhD graduated with a bachelor of accounting from the National University of Malaysia in 2000, and graduated with a master of business administration from the University of Strathclyde, United Kingdom in 2012. Mr. Louis, PhD obtained a doctorate of philosophy from the University of Malaya in September, 2021. Mr. Louis, PhD became a member of CPA Malaysia in 2005, a member of the Institute of Internal Auditors Malaysia in 2010 and a member of the Association of Chartered Certified Accountants in 2011. Mr. Louis, PhD is also a director of Greenpro Capital Corp., Seatech Ventures Corp. and Fortune Valley Treasures, Inc.

 

Dr. Vong John Hing, PhD will serve as our independent director upon effectiveness of the registration statement of which this prospectus forms a part. Prior to joining the Company, Dr. Vong, PhD has over 44 years of fintech and education experience. Dr. Vong, Phd is currently the lead of sustainable finance at ClimateWorks Australia since September 2021, a non-executive independent council member of Regional Bank since June 2013, and a senior technical specialist of the United Nations since May 2003. Dr. Vong, PhD has been a senior technical specialist at Asian Development Bank from January 2019 to February 2022, and a senior technical consultant at World Bank Group from September 2006 to June 2021. Dr. Vong, PhD has been a professor at the National University of Singapore from May 2015 to April 2017, foundation director of the Fintech Academy at the Singapore Management University from June 2013 to December 2014 and associate professor at James Cook University Singapore from February 2012 to June 2013. From October 2008 to October 2011, Dr. Vong, PhD was a deputy chief executive officer at Sacombank in Vietnam. In 2002 Dr. Vong, PhD was a senior consultant at PAGF- DFAT  Australia in the Philippines. From February 1999 to February 2001, Dr. Vong, PhD was a team leader at Deloitte Australia. From 1994 to 1998 Dr. Vong, PhD was a regional director- lecturer of the Massachusetts Institute Technology and Nanyang Fellows Program at Nanyang Technological University. From May 1978 to August 1993, Dr. Vong, PhD was a senior executive at HSBC Holdings plc in various offices in Australia and Asia. Dr. Vong, PhD completed the public disputes program in advanced negotiation at MIT-Harvard University Consensus Building Institute in 2006. Dr. Vong, PhD graduated with a BA in economics at Birmingham City University, and a MBA in economics strategy and finance at University of Bradford. He received his PhD from the University of Bradford in MIS business intelligence. Dr. Vong, PhD is currently a member of CPA Australia.  

 

Mr. Chee Chin Aik will serve as our independent director upon effectiveness of the registration statement of which this prospectus forms a part. Prior to joining the Company, Mr. Chee has approximately 20 years of finance related experience. Mr. Chee is currently the head of South East Asia, cash and non-cash equity sales, global markets at HSBC Singapore. From October 2020 to May 2022, Mr. Chee was an executive director, head of Malaysia equity distribution and board member of JPMorgan Chase & Co. Mr. Chee has also worked at Credit Suisse for various periods, as director in institutional equity sales for Malaysia and Singapore from January 2019 to September 2020, as vice president in institutional equity sales in Singapore from January 2015 to December 2018, and associate in institutional equity sales in Singapore from April 2013 to December 2014. From January 2009 to August 2011, Mr. Chee worked as analyst and trader in equity derivatives and proprietary trading at Aminvestment Bank Berhad in Malaysia. From October 2007 to September 2008, Mr. Chee worked as equity research analyst at Credit Lyonnais Securities Asia Pacific Markets in Malaysia. From October 2006 to July 2007, Mr. Chee worked as associate in fixed income currencies and commodities at Goldman Sachs in USA. From July 2004 to October 2006, Mr. Chee worked as analyst for fixed income, corporate advisory division at Lehman Brothers Holdings Inc in USA. From Jun 2002 to July 2004, Mr. Chee worked as associate in financial regulatory and cycle examination group at National Association of Securities Dealers (FINRA) in USA. Mr. Chee graduated with a bachelor of arts from Franklin & Marshall College and MBA in finance from the University of Chicago Booth School of Business.

 

63

 

 

Employment Agreements

 

We have entered into employment agreements with all of our executive officers. Under these agreements, each of our executive officers is employed for a specified time period. We may terminate employment for cause, at any time, without advance notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or any crime involving moral turpitude, negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. We may also terminate an executive officer’s employment without cause upon advance written notice or payment in-lieu of notice. In such case of termination by us, we will provide severance payments to the executive officer as expressly required by applicable law of the jurisdiction where the executive officer is based. The executive officer may resign at any time upon advance written notice.

 

Each executive officer has agreed to hold, both during and after the termination or expiry of his or her employment agreement, in strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets of our clients or prospective clients, or the confidential or proprietary information of any third party received by us and for which we have confidential obligations.

 

Terms of Directors and Officers

 

Our officers are elected by and serve at the discretion of the board of directors and the stockholders voting by ordinary resolution.

 

Compensation of Directors and Executive Officers

 

For the years ended December 31, 2022 and 2021, we paid an aggregate of approximately $289,957 and $275,210, respectively, in cash and benefits to our executive officers. We do not have a share incentive program to provide for grants of awards to our directors and executive officers. We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and directors. We have no service contracts with any of our directors providing for benefits upon termination of employment.

 

Board of Directors and Committees

 

Our board of directors will consist of five directors, including three independent directors. We will establish three committees under the board of directors immediately upon the effectiveness of our registration statement on Form S-1, of which this prospectus is a part: an audit committee, a compensation committee and a nominating and corporate governance committee. We intend to adopt and approve a charter for each of the three committees prior to consummation of this offering. Each of the committees of the board of directors shall have the composition and responsibilities described below.

 

Audit Committee

 

Mr. Louis, PhD, Dr. Vong, PhD, and Mr. Chee will be the members of our Audit Committee where Mr. Louis, PhD shall serve as the chairman. All proposed members of our Audit Committee will satisfy the independence standards promulgated by the SEC and by NASDAQ as such standards apply specifically to members of audit committees.

 

64

 

 

We intend to adopt and approve a charter for the Audit Committee prior to consummation of this offering. In accordance with our Audit Committee’s Charter, our Audit Committee shall perform several functions, including:

 

  evaluate the independence and performance of, and assess the qualifications of, our independent auditor, and engage such independent auditor;
     
  approve the plan and fees for the annual audit, quarterly reviews, tax and other audit-related services, and approve in advance any non-audit service to be provided by the independent auditor;
     
  monitor the independence of the independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;
     
  reviewing our financial statements and our management’s discussion and analysis of financial condition and results of operations to be included in our annual and quarterly reports to be filed with the SEC;
     
  oversee all aspects our systems of internal accounting control and corporate governance functions on behalf of the board;
     
  review and approve in advance any proposed related-party transactions and report to the full board of directors on any approved transactions; and
     
  provide oversight assistance in connection with legal, ethical and risk management compliance programs established by management and the board of directors, including Sarbanes-Oxley Act implementation, and make recommendations to the board of directors regarding corporate governance issues and policy decisions.

 

It is determined that Mr. Louis, PhD possesses accounting or related financial management experience that qualifies him as an “audit committee financial expert” as defined by the rules and regulations of the SEC.

 

Compensation Committee

 

Mr. Louis, PhD, Dr. Vong, PhD and Mr. Chee will be the members of our Compensation Committee where Dr. Vong, PhD shall be the chairman. All proposed members of our Compensation Committee will be qualified as independent under the current definition promulgated by NASDAQ. We intend to adopt and approve a charter for the Compensation Committee prior to consummation of this offering. In accordance with the Compensation Committee’s Charter, the Compensation Committee shall be responsible for overseeing and making recommendations to the board of directors regarding the salaries and other compensation of our executive officers and general employees and providing assistance and recommendations with respect to our compensation policies and practices.

 

Nominating and Governance Committee

 

Mr. Louis, PhD, Dr. Vong, PhD, and Mr. Chee will be the members of our Nominating and Governance Committee where Mr. Chee shall serve as the chairman. All proposed members of our Nominating and Governance Committee will be qualified as independent under the current definition promulgated by NASDAQ. The board of directors intends to adopt and approve a charter for the Nominating and Governance Committee prior to consummation of this offering. In accordance with the Nominating and Governance Committee’s Charter, the Nominating and Corporate Governance Committee shall be responsible for identifying and proposing new potential director nominees to the board of directors for consideration and reviewing our corporate governance policies.

 

Director Independence

 

Our board of directors reviewed the materiality of any relationship that each of our proposed directors has with us, either directly or indirectly. Based on this review, it is determined that Mr. Louis, PhD, Dr. Vong, PhD and Mr. Chee will be “independent directors” as defined by NASDAQ. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management.

 

65

 

 

Family Relationships

 

There is no family relationship among any of our directors or executive officers.

 

Board Leadership Structure and Role in Risk Oversight

 

Our Board of Directors, or the Board, is primarily responsible for overseeing our risk management processes on behalf of our company. The Board receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding our company’s assessment of risks. In addition, the Board focuses on the most significant risks facing our company and our company’s general risk management strategy, and also ensures that risks undertaken by our company are consistent with the board’s appetite for risk. While the Board oversees our company’s risk management, management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our board leadership structure supports this approach.

 

Compensation Committee Interlocks and Insider Participation

 

None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers on our board of directors or compensation committee.

 

Code of Ethics

 

We have a code of ethics that applies to all of our employees, including our principal executive officer, principal financial officer and principal accounting officer, and the Board. A copy of this code is available in our employee handbook and under the “About Us – Code of Conduct” section of our website at www.agapeatpgroup.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of our applicable trading market concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus.

 

Involvement in Certain Legal Proceedings

 

To our knowledge, our directors and executive officers have not been involved in any of the following events during the past ten years:

 

  any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
     
  any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
     
  being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;
     
  being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

 

66

 

 

  being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
     
  being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

Involvement in Certain Legal Proceedings

 

To our knowledge, our directors and executive officers have not been involved in any of the following events during the past ten years:

 

  any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
     
  any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
     
  being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;
     
  being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
     
  being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
     
  being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

67

 

 

EXECUTIVE AND DIRECTOR COMPENSATION

 

Executive Officers’ Compensation

 

The following table sets forth information concerning the annual and long-term compensation earned by or paid to our Chief Executive Officer and to other persons who served as executive officers as at fiscal years ended December 31, 2022 and 2021, or the named executive officers, for services as executive officers for the said fiscal year.

 

Summary Compensation Table

 

Name and
Principal
Position
  Fiscal
Year
  Salary   Stock
Award
  Option
Awards
  Non-Equity
Incentive Plan
Compensation
  Change in
Pension Value
and Non-
Qualified
Deferred
Compensation
Earnings
  All Other
Compensation
  Total  
          ($)   ($)   ($)   ($)   ($)   ($)   ($)  
How Kok Choong     2022    

289,957

                   

   

289,957

 

Chief Executive Officer, President, Director, Chief Operating Officer, Chairman of the board of Directors and Secretary

    2021    

275,210

                   

   

275,210

 
                                                   

Lee Kam Fan Andrew

    2022     46,440                         46,440  
Chief Financial Officer     2021     46,988                         46,988  

 

68

 

 

Employment Agreements

 

How Kok Choong

 

Dr. How currently devotes approximately 90% per week of his time to manage the affairs of the Company. He has agreed to work with no remuneration nor drawn any (i) bonus; (ii) stock compensation; (iii) option awards; (iv) non-equity incentive plan compensation; (v) non-qualified deferred compensation earnings; and (vi) any other compensations until such time as the Company receives significant revenues necessary to provide management salaries. At this time, we cannot accurately estimate when significant revenues will occur to implement this compensation, or what the amount of the compensation will be.

 

Lee Kam Fan Andrew

 

On January 12, 2021, we entered into an Executive Employment Agreement with Mr. Lee Kan Fan Andrew, our Chief Financial Officer. Pursuant to the agreement, Mr. Lee is employed as our Chief Financial Officer. During the term of his employment, Mr. Lee will be entitled to a base salary at the annualized rate of $3,870. Pursuant to the agreement, Mr. Lee may be terminated for “cause” as defined in the agreement and Mr. Lee may resign upon the provision of a prior notice in writing not less than one (1) months to the Company or payment in lieu of notice at any time. In the event Mr. Lee is terminated without cause, we will be required to pay Mr. Lee all accrued salary, reimbursement for all business expenses. In the event Mr. Lee is terminated with cause, dies or is disabled, we will be required to pay Mr. Lee all accrued salary. Under the agreement Mr. Lee is subject to confidentiality restrictions.

 

Incentive Bonus

 

The Board may grant incentive bonuses to our executive officer and/or future executive officers in its sole discretion, if the Board of Directors believes such bonuses are in the Company’s best interest, after analyzing our current business objectives and growth, if any, and the amount of revenue we are able to generate each month, which revenue is a direct result of the actions and ability of such executives.

 

Option Exercises and Stock Vested

 

We have not granted any stock options to our executive officers since our incorporation.

 

Long-term, Stock Based Compensation

 

In order to attract, retain and motivate executive talent necessary to support the Company’s long-term business strategy we may award our executive and any future executives with long-term, stock-based compensation in the future, at the sole discretion of our Board of Directors, which we do not currently have any immediate plans to award. We have not granted any stock options to our executive officers since our incorporation.

 

No Pension Benefits

 

We do not maintain any plan that provide for payments or other benefits to our executive officers at, following or in connection with retirement and including, without limitation, any tax-qualified defined benefit plans or supplemental executive retirement plans.

 

69

 

 

No Nonqualified Deferred Compensation

 

We do not maintain any defined contribution or other plan that provides for the deferral of compensation on a basis that is not tax-qualified.

 

Director Compensation

 

Name
(Last name, First name)
   Fees Earned or Paid in Cash $     Stock Awards $     Option Awards $     Non-equity Incentive Plan Compensation $     Change in Pension Value and Non-Qualified Deferred Compensation Earnings     All Other Compensation $     

Total

$*

 
How Kok Choong   

289,957

                        289,957 

Tjong Budisantoso

                            

Ramesh Ruben Louis

           

                 
John Hing Vong                            
Chee Chin Aik                            

 

March 2023, Mr. Shaharuddin resigned from the board of directors, effective immediately, due to his demise.

 

Mr. Ramesh Ruben Louis was appointed to the Board of Directors of our company to serve as independent director. On March 30, 2022, Mr. Louis, PhD entered into an agreement pursuant to which he will serve as an independent director of the Company upon SEC’s declaration of effectiveness of our registration statement on Form S-1. During the term of the agreement, Mr. Louis will be entitled to director fees of US$21,600 per annum. Pursuant to the agreement, Mr. Louis may be terminated for “cause” as defined in the agreement and Mr. Louis may resign upon the provision of a prior notice in writing not less than 14 days to the Company.

 

Professor Dr. John Hing Vong was appointed to the Board of Directors of our company to serve as independent director. On September 12, 2022, Dr. Vong, PhD entered into an agreement pursuant to which he will serve as an independent director of the Company upon SEC’s declaration of effectiveness of our registration statement on Form S-1. During the term of the agreement, Dr. Vong, PhD will be entitled to director fees of US$21,600 per annum. Pursuant to the agreement, Dr. Vong, PhD may be terminated for “cause” as defined in the agreement and Dr. Vong, PhD may resign upon the provision of a prior notice in writing not less than 14 days to the Company.

 

Chee Chin Aik was appointed to the Board of Directors of our company to serve as independent director. On November 30, 2022, Mr. Chee entered into an agreement pursuant to which he will serve as an independent director of the Company upon SEC’s declaration of effectiveness of our registration statement on Form S-1. During the term of the agreement, Mr. Chee will be entitled to director fees of US$21,600 per annum. Pursuant to the agreement, Mr. Chee may be terminated for “cause” as defined in the agreement and Mr. Chee may resign upon the provision of a prior notice in writing not less than 14 days to the Company.

 

On April 3, 2023, Mr. Tjong Budisantoso, PhD was appointed to the Board of Directors of our company to serve as director. Mr. Budisantoso, PhD entered into an agreement pursuant to which he will serve as a director. Upon SEC’s declaration of effectiveness of our registration statement on Form S-1 Mr. Shaharuddin will be entitled to a base salary at the monthly remuneration of $3,000 and also a stock-based compensation of $60,000 worth of common stock per annum. Pursuant to the agreement, Mr. Shaharuddin may be terminated for “cause” as defined in the agreement and Mr. Shaharuddin may resign upon the provision of a prior notice in writing not less than three (3) months to the Company or payment in lieu of notice at any time. 

 

70

 

 

CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS

 

SEC rules require us to disclose any transaction since the beginning of our last fiscal year or any currently proposed transaction in which we are a participant in which the amount involved exceeded or will exceed $120,000 and in which any related person has or will have a direct or indirect material interest. A related person is any executive officer, director, nominee for director, or holder of 5% or more of our common stock, or an immediate family member of any of those persons.

 

On May 8, 2020, the Company acquired approximately 99.99% of the issued share capital of Agape Superior Living Sdn Bhd from Dr. How Kok Choong. Dr. How received an aggregate consideration of $1,714,003, which was determined based on the net asset carrying value of ASL as at March 31, 2020. The aggregate consideration was satisfied by (i) the offset of the consideration whereby the Company has a loan receivable of $656,495 as of March 31, 2020 due from Dr. How; and (ii) the allotment and issue of the common stock of the Company. The Company allotted and issued 162,694 shares of the Company’s common stock, each with a par value $0.0001, representing approximately 0.0432% of the total issued and outstanding shares in the Company after the issuance of the shares, which was valued at $1,057,508 based on the closing price of $6.50 of the Company as quoted on the OTC Market on March 31, 2020.

 

On July 1, 2020, the Company and Dr. How Kok Choong agreed to amend the Share Exchange agreement and enter into a supplemental agreement share exchange agreement (the “Supplemental Share Exchange Agreement”). In accordance with Supplemental Share Exchange Agreement, Dr. How received an aggregate consideration of $1,804,046, which was determined based on the net asset carrying value of ASL as at March 31, 2020. The aggregate consideration shall be satisfied by (i) the offset of the consideration whereby the Company has a loan receivable of $656,495 as of March 31, 2020 due from Dr. How; and (ii) the allotment and issuance of common stock of the Company. The Company allotted and issued 176,547 shares of the Company’s common stock, par value $0.0001 (the “Shares”), representing approximately 0.0469% of the total issued and outstanding shares in the Company after the issuance of the Shares, which is valued at $1,147,551 based on the closing price of $6.50 of the Company as quoted on the OTC Market on March 31, 2020.

 

On February 1, 2021, Dr. How Kok Choong, our CEO and director, was appointed as the non-executive Chairman of Vettons. Vettons Sdn Bhd (“Vettons”) is an e-commerce company through which ASL conducts some of its distribution activities to its members. As of December 31, 2020, the Company has accounts receivable of $172,757 from Vettons, representing 100% of our accounts receivable.

 

In December 2021, there were share forfeiture agreements (the “Share Forfeiture Agreements”) between the Company and (i) HKC Talent Limited; (ii) various stockholders of the Company (the “Forfeiting Stockholders”), pursuant to which:

 

(i) HKC Talent Limited had agreed to forfeiture of 41,750,000 shares of common stock of the Company, and

 

(ii) the Forfeiting Stockholders had agreed to forfeiture, in aggregate, 44,242,000 shares of common stock of the Company. Included in (ii) is 11,242,000 shares forfeited from HKC Holdings Sdn. Bhd, a company in which Dr. How Kok Choong, is a stockholder. As a result, the outstanding shares was reduced by 85,992,000 shares of common stock.

 

On January 20, 2022, a share forfeiture agreement (the “Share Forfeiture Agreement”) was entered between the Company and Dr. How Kok Choong, pursuant to which Dr. How agreed to forfeit 215,008,035 shares of common stock of the Company.

 

*HKC Holdings Sdn Bhd is owned and controlled by How Kok Choong who is our executive officer and director. As such, HKC Holdings Sdn Bhd. is regarded a related party.

 

With regards to all of the above transactions we claim an exemption from registration afforded by Section 4a(2) and/or Regulation S of the Securities Act of 1933, as amended (“Regulation S”) due to the fact that the issuance of stock was made to non-U.S. persons (as defined under Rule 902 section (k)(2)(i) of Regulation S), pursuant an offshore transactions, and no directed selling efforts were made in the United States by the issuer, a distributor, any of their respective affiliates, or any person acting on behalf of any of the foregoing.

 

71

 

 

The Company’s related party list and relationship are as follows:

 

Related parties   Relationships
     
Agape ATP (Asia) Limited   Dr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited.
     
DSY Wellness & Longevity Center Sdn Bhd   Mr. Steve Yap, a director of DSY Wellness International Sdn Bhd, is also a director of DSY Wellness & Longevity Center Sdn Bhd.
     
CTA Nutriceuticals (Asia) Sdn Bhd   The directors and shareholders of CTA are related parties to Mr. Steve Yap, a director of DSY International Wellness Sdn Bhd
     
DSY Beauty Sdn Bhd   The directors and shareholders of DSY Beauty are related parties to Mr. Steve Yap, a director of DSY Wellness International Sdn Bhd
     
TH3 Technology Sdn Bhd   Dr. How Kok Choong, the CEO and director of the Company is also a director of TH3 Technology Sdn Bhd.
     
Redboy Picture Sdn Bhd   Dr. How Kok Choong, the CEO and director of the Company is also a director of Redboy Picture Sdn Bhd.

 

Related party balances as of December 31, 2022 and 2021 are as per table below:

 

Amount due from related parties

 

          As of December 31,  
Name of Related Party   Relationship   Nature   2022     2021  
                     
TH3 Technology Sdn Bhd (“TH3”)   Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3   Prepayment of IT expenses   $ 1,273     $ -  
DSY Beauty Sdn Bhd (“DSY Beauty”)   The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd   Deposits for products purchases     9,261       -  
Agape ATP (Asia) Limited (“AATP Asia”)   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia   Expenses paid for AATP Asia     -       2,214  
Hostastay Sdn. Bhd. “Hostastay”   Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021   Sublease rent due from Hostastay     -       4,790  
Total           $ 10,534     $ 7,004  

 

Accounts payable – related parties

 

          As of December 31,  
Name of Related Party   Relationship   Nature   2022     2021  
                     
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)   The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd   Purchases of products for the provision of complementary health therapies   $ 25,387     $      -  
DSY Beauty Sdn Bhd (“DSY Beauty”)   The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd   Purchases of beauty products     224       -  
Total           $ 25,611     $ -  

 

72

 

 

Other payable – related parties

 

            As of December 31,  
Name of Related Party   Relationship   Nature   2022     2021  
                     
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)   The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd   Purchase of products for general use   $ 2,149     $ -  
DSY Beauty Sdn Bhd (“DSY Beauty”)   The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd   Purchase of products for general use     2,147       -  
Mr. How Kok Choong   Mr. How Kok Choong, the CEO and director of the Company   Commission expense     584       -  
Total           $ 4,880     $ -  

 

Related party transactions for years ended December 31, 2022 and 2021, are as per table below:

 

Purchases

 

         

For the years ended

December 31,

 
Name of Related Party   Relationship   Nature   2022     2021  
                     
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)   The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd   Purchases of products for the provision of complementary health therapies   $ 198,376     $ -  
DSY Beauty Sdn Bhd (“DSY Beauty”)   The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd   Purchases of beauty products     3,975       718  
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)   Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.   Purchases of products for the provision of complementary health therapies     124       -  
Total           $ 202,475     $ 718  

 

Other income

 

       

For the years ended

December 31,

 
Name of Related Party  Relationship  Nature  2022   2021 
               
Hostastay Sdn. Bhd.  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rental income due from Hostastay  $-   $4,345 
Total       $-   $4,345 

 

73

 

 

Other purchases

 

         

For the years ended

December 31,

 
Name of Related Party   Relationship   Nature   2022     2021  
                     
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)   The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd   Purchases of products for the provision of complementary health therapies   $ 5,431     $ -  
DSY Beauty Sdn Bhd (“DSY Beauty”)   The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd   Purchases of beauty products     6,888       -  
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)   Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.   Purchases of products for the provision of complementary health therapies     4       -  
Total           $ 12,323     $ -  

 

Commission expense

 

          For the years ended December 31,  
Name of Related Party   Relationship   Nature   2022     2021  
                     
Mr. How Kok Choong   Mr. How Kok Choong, the CEO and director of the Company   Commission expense   $ 16,590     $ 12,758  
Total           $ 16,590     $ 12,758  

 

Other expenses

 

        For the years ended
December 31,
 
Name of Related Party  Relationship  Nature  2022   2021 
               
TH3 Technology Sdn Bhd (“TH3”)  Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3  IT support services fee  $56,450   $- 
Redboy Picture Sdn Bhd (“Redboy”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy  Sponsorship fee   22,686    718 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Office rental expenses   21,779    - 
Total        $100,915   $718 

 

74

 

 

PRINCIPAL STOCKHOLDERS

 

Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of our common stock which may be acquired upon exercise of stock options or warrants which are currently exercisable or which become exercisable within 60 days of the date of the applicable table below are deemed beneficially owned by the holders of such options and warrants and are deemed outstanding for the purpose of computing the percentage of ownership of such person, but are not treated as outstanding for the purpose of computing the percentage of ownership of any other person. Subject to community property laws, where applicable, the persons or entities named in the tables below have sole voting and investment power with respect to all shares of our common stock indicated as beneficially owned by them.

 

The following table sets forth certain information, as of the date of this prospectus, with respect to the beneficial ownership of the outstanding common stock by (i) any holder of more than five (5%) percent; (ii) each of our executive officers and directors; and (iii) our directors and executive officers as a group. Except as otherwise indicated, each of the stockholders listed below has sole voting and investment power over the shares beneficially owned.

 

Name of Beneficial Owner (1)   Common Stock Beneficially Owned     Percentage of Common Stock (1)     Voting Shares of Preferred Stock     Preferred Stock Voting Percentage Beneficially Owned     Total Voting Percentage Beneficially Owned  
How Kok Choong, Chief Executive Officer, Chief Operating Officer, Chairman of the board of Directors, Secretary, and Director; collectively this includes HKC Holdings Sdn Bhd (2) (3)*     19,608,998       25.99 %            -                 -       25.99 %
Mohd Shaharuddin Bin Abdullah     -       -       -       -       -  
Tjong Budisantoso     -       -       -       -       -  
Lee Kam Fan Andrew     -       -       -       -       -  
All officers and directors as a group     19,608,998       25.99 %     -       -       25.99 %

 

 

    * Officer and/or director of the company.

 

(1) Applicable percentage ownership is based on 75,452,012 shares of common stock issued and outstanding and 200,000,000 preferred shares authorized but none were issued and outstanding as of the date of this prospectus. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities.
   
(2) The address of How Kok Choong is c/o Agape ATP Corporation, 1705 – 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia, Taman Desa, 58100 Kuala Lumpur, Malaysia.
   
(3) HKC Holdings Sdn Bhd is owned and controlled by How Kok Choong who is our chief executive officer, chief operating officer, chairman of the board of Directors, Director and secretary.

 

75

 

 

DESCRIPTION OF CAPITAL STOCK

 

We have authorized capital stock consisting of 1,000,000,000 shares of common stock, par value $0.0001 per share, and 200,000,000 shares of preferred stock, par value $0.0001 per share. As of December 31, 2022, we had 75,452,012 shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.

 

Common Stock

 

All outstanding shares of common stock are of the same class and have equal rights and attributes. The holders of common stock are entitled to one vote per share on all matters submitted to a vote of stockholders of the company. All stockholders are entitled to share equally in dividends, if any, as may be declared from time to time by the Board of Directors out of funds legally available. In the event of liquidation, the holders of common stock are entitled to share ratably in all assets remaining after payment of all liabilities. The stockholders do not have cumulative or pre-emptive rights.

 

Preferred Stock

 

Our Certificate of Incorporation authorizes the issuance of up to 200,000,000 shares of preferred stock with designations, rights and preferences determined from time to time by our Board of Directors. Accordingly, our Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting, or other rights which could adversely affect the voting power or other rights of the holders of the common stock. In the event of issuance, the preferred stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of our company, which is sometimes referred to in corporate parlance as a “poison pill”.

 

Options and Restricted Stock

 

As of December 31, 2022, other than the securities described above, we do not have any outstanding options or restricted stock.

 

Other Convertible Securities

 

As of December 31, 2022, other than the securities described above, we do not have any outstanding convertible securities.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

We have not adopted any compensatory or benefit plans for future issuances of our securities.

 

Market for Common Equity and Related Stockholder Matters

 

Our common stock is presently quoted on the OTC Markets – Pink Sheets under the symbol “AATP”. Although there is currently a bid and offer quotation for the common stock, such bid and offer are for limited and insignificant number of shares. The last sale price recorded was $4.01 per share on August 2, 2022. Because trading has been sporadic and irregular, there is no established public trading market for our common stock.

 

We plan to apply to list our common stock on the NASDAQ as soon as practical. No assurance can be given that our application will be approved by the NASDAQ. If our Common Stock is listed on the NASDAQ, we will be subject to continued listing requirements and corporate governance standards of NASDAQ. We expect the compliance with these new rules and regulations to significantly increase our legal, accounting and financial compliance costs.

 

As of the date of this prospectus, there are approximately 1,323 holders of record of our common stock.

 

Transfer Agent

 

The stock transfer agent for our securities is Vstock Transfer, LLC, 18 Lafayette Place, Woodmere, New York 11598 and telephone number is +1 (212) 828-8436.

 

76

 

 

SHARES ELIGIBLE FOR FUTURE SALE

 

Immediately prior to this offering, there was little to no trading activity in our common stock. Future sales of substantial amounts of common stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock.

 

All shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our “affiliates,” as that term is defined in Rule 144 under the Securities Act, whose sales would be subject to the Rule 144 resale restrictions described below, other than the holding period requirement.

 

Restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, described below. Restricted securities may also be sold outside of the United States to non-U.S. persons in accordance with Rule 904 of Regulation S.

 

Lock-Up

 

For further details on the lock-up agreements, see the section entitled “Underwriting – Lock-Up Agreements.”

 

Rule 144

 

Some of our stockholders will be forced to hold their shares of our common stock for at least a six-month period before they are eligible to sell those shares, and even after that six-month period, sales may not be made under Rule 144 promulgated under the Securities Act unless we and such stockholders are in compliance with other requirements of Rule 144.

 

In general, Rule 144 provides that (i) any of our non-affiliates that has held restricted common stock for at least six months is thereafter entitled to sell its restricted stock freely and without restriction, provided that we remain compliant and current with our SEC reporting obligations, and (ii) any of our affiliates, which includes our directors, executive officers and other person in control of us, that has held restricted common stock for at least six months is thereafter entitled to sell its restricted stock subject to the following restrictions: (a) we are compliant and current with our SEC reporting obligations, (b) certain manner of sale provisions are satisfied, (c) a Form 144 is filed with the SEC, and (d) certain volume limitations are satisfied, which limit the sale of shares within any three-month period to a number of shares that does not exceed the greater of 1% of the total number of outstanding shares. A person who has ceased to be an affiliate at least three months immediately preceding the sale and who has owned such shares of common stock for at least one year is entitled to sell the shares under Rule 144 without regard to any of the limitations described above.

 

Rule 701

 

In general, Securities Act Rule 701 allows a stockholder who purchased shares of capital stock pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of ours during the immediately preceding 90 days to sell those shares in reliance upon Securities Act Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. All holders of Rule 701 shares, however, are required to wait until ninety (90) days after the date of this prospectus before selling shares pursuant to Rule 701.

 

Regulation S

 

Regulation S provides generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act.

 

77

 

 

TAXATION

 

Malaysia Taxation

 

The following discussion is a summary of the more relevant taxes that are applicable to our Malaysian subsidiaries with regards to transactions that they may enter into with a foreign holding company, i.e. AATP. It excludes specifically all Malaysian taxes that our Malaysian subsidiaries are subject to arising from their respective business activities in Malaysia such as income tax, various types of taxes imposable on transactions entered into in the course of conducting their business activities and taxes on capital gains. Generally, there is no taxes on capital gains in Malaysia except for real property gains tax (“RPGT”) which is a tax on gains arising from the disposal of real property or shares in real property companies (“RPC”). Neither subject affects our Malaysian subsidiaries as none of them were engaged in activities in the said areas.

 

The type of transactions that Malaysian subsidiaries typically enter into with their foreign holding company (that is not attributable to a business carried on in Malaysia by the foreign holding company) are royalties, interest or service fees. With respect to such income, the tax liability of the foreign holding company, it being a non-resident will be settled by way of withholding tax (“WHT”) deducted by the paying entity, i.e. the Malaysian subsidiary. The following are WHT rates that apply as per the double taxation agreement (“DTA”) th exists between the United States of America and Malaysia: (Royalty: 10%, Interest: 15%, Dividends: 0%, Income other than royalty and interest: 10%)

 

Payments of the above types of income to non-residents (except for dividends) are subject to WHT which is due and payable to the Inland Revenue Board (IRB) within one month after paying or crediting such payments. There is no WHT on dividends paid by Malaysian companies.

 

Tax administration

 

Transfer pricing

 

Transfer pricing (TP) legislation

 

The basis for determining proper compensation is, almost universally, the arm’s length principle which has also been accepted by the Inland Revenue Board (“IRB”).

 

The arm’s length principle was incorporated into Section 140A of the Malaysian Income Tax Act 1967. It allows the Director General Inland Revenue (“DGIR”) to adjust any transfer prices between related parties in Malaysia which, in the view of the DGIR, do not meet the arm’s length standard.

 

What constitutes “arm’s length” is not defined in the Income Tax Act 1967. Consequently, the IRB has issued the TP Rules 2012 and the revised TP Guidelines 2012 to give guidance on the arm’s length standard that is acceptable to the IRB. The TP Rules and Guidelines seek to provide guidance on the application of the law on controlled transactions, the acceptable methodologies as provided in the rules and administrative requirements including the types of records and documentation expected from taxpayers involved in TP arrangements.

 

Advance pricing arrangements (APA)

Companies are allowed to apply for APAS from the DGIR. The objective of establishing APAS is to provide an avenue for taxpayers to obtain certainty upfront that their related party transactions meet the arm’s length standard. The IRB has issued the APA Rules 2012 and APA Guidelines 2012 to give guidance on the matter.

 

Statute of limitation for TP adjustments

The statute of limitation is seven (7) years from the expiration of an assessment year (“YA”) for raising an assessment or additional assessment for that YA in respect of TP adjustments for a transaction entered into between associated persons not at arm’s length.

 

78

 

 

Country-by-Country Reporting

 

The Malaysian Country-by-Country Rules require a Malaysian multinational corporation (“MNC”) group with total consolidated group revenue of RM3 billion and above in the financial year (“FY”) preceding the reporting FY (i.e. FY commencing on or after 1 January 2017) to prepare and submit the Country-by-Country Report to the IRB no later than 12 months after the close of each FY.

 

Malaysian entities of foreign MNC groups will generally not be required to prepare and file Country-by-Country Reports as the obligation to file will be with the ultimate holding company in the jurisdiction it is tax resident in, However, a notification to the IRB may be required.

 

United States Federal Income Taxation

 

The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this prospectus, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the “Code”), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the “IRS”), in each case in effect as of the date of this prospectus. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Non-U.S. Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock.

 

This discussion is limited to Non-U.S. Holders that hold our common stock as a “capital asset” within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder’s particular circumstances, including the impact of the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation:

 

  U.S. expatriates and former citizens or long-term residents of the United States;
  persons subject to the alternative minimum tax;
  persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment;
  banks, insurance companies, and other financial institutions;
  brokers, dealers or traders in securities;
  “controlled foreign corporations,” “passive foreign investment companies,” and corporations that accumulate earnings to avoid U.S. federal income tax;
  partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
  tax-exempt organizations or governmental organizations;
  persons deemed to sell our common stock under the constructive sale provisions of the Code;
  persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and
  tax-qualified retirement plans.

 

If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.

 

79

 

 

INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.

 

Definition of a Non-U.S. Holder

 

For purposes of this discussion, a “Non-U.S. Holder” is any beneficial owner of our common stock that is neither a “U.S. person” nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following:

 

  an individual who is a citizen or resident of the United States;
  a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;
  an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
  a trust that (1) is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more “United States persons” (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.

 

Distributions

 

As described in the section entitled “Dividend Policy,” we do not anticipate paying any cash dividends on our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S. Holder’s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under “—Sale or Other Taxable Disposition.”

 

Subject to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the lower treaty rate). A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.

 

If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States.

 

Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules.

 

80

 

 

Sale or Other Taxable Disposition

 

A Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless:

 

  the gain is effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable);
  the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or
  our common stock constitutes a U.S. real property interest (“USRPI”) by reason of our status as a U.S. real property holding corporation (“USRPHC”) for U.S. federal income tax purposes.

 

Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items.

 

Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by certain U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses.

 

With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a Non-U.S. Holder of our common stock will not be subject to U.S. federal income tax if our common stock is “regularly traded,” as defined by applicable Treasury Regulations, on an established securities market, and such Non-U.S. Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder’s holding period.

 

Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules.

 

Information Reporting and Backup Withholding

 

Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the Non-U.S. Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office of a non-U.S. broker that does not have certain enumerated relationships with the United States generally will not be subject to backup withholding or information reporting.

 

81

 

 

Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established.

 

Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder’s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.

 

Additional Withholding Tax on Payments Made to Foreign Accounts

 

Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or “FATCA”) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a “foreign financial institution” or a “non-financial foreign entity” (each as defined in the Code), unless (1) the foreign financial institution undertakes certain diligence and reporting obligations, (2) the non-financial foreign entity either certifies it does not have any “substantial United States owners” (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1) above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain “specified United States persons” or “United States-owned foreign entities” (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.

 

Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our common stock, and will apply to payments of gross proceeds from the sale or other disposition of such stock on or after January 1, 2019.

 

Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock.

 

82

 

 

UNDERWRITING

 

Under the terms and subject to the conditions of an underwriting agreement dated the date of this prospectus, the Underwriter named below, for whom EF Hutton, division of Benchmark Investments, LLC is acting as the underwriter, have severally agreed to purchase, and we have agreed to sell to them, the number of shares of common stock at the initial public offering price, less the underwriting discount, as set forth on the cover page of this prospectus and as indicated below:

 

Underwriter  Number
of
Shares
 

EF Hutton, division of Benchmark Investments, LLC

   

600,000

 
          
Total   

600,000

 

  

The Underwriter is offering the shares subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the Underwriter to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by its counsel and to other conditions. The Underwriter is obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the Underwriter is not required to take or pay for the shares covered by the Underwriter’s option to purchase additional shares described below.

 

We have granted to the Underwriter an option, exercisable for forty-five (45) days from the closing of this offering, to purchase up to 90,000 additional shares of common stock at the initial public offering price listed on the cover page of this prospectus, less underwriting discount. The Underwriter may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with this offering. To the extent the option is exercised, the Underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares as the number listed next to the underwriter’s name in the preceding table bears to the total number of shares listed next to the names of the Underwriter in the preceding table.

 

The Underwriter will offer the shares to the public at the initial public offering price set forth on the cover of this prospectus and to selected dealers at the initial public offering price less a selling concession not in excess of $       per share. After this offering, the initial public offering price, concession and reallowance to dealers may be reduced by the Underwriter. No change in those terms will change the amount of proceeds to be received by us as set forth on the cover of this prospectus. The securities are offered by the Underwriter as stated herein, subject to receipt and acceptance by them and subject to their right to reject any order in whole or in part.

 

Discount and Expenses

 

If we complete this offering, then on the closing date, we will pay the Underwriter a discount of 8% of the value of the shares of common stock sold in this offering for the investors introduced by the Underwriter, and 6% of the aggregate gross proceeds of this offering of the common stock for the investors introduced by the Company. We have also agreed to pay the Underwriter an additional non-accountable expense allowance, equal to one percent (1%) of the gross proceed received by us from the sale of our shares of common stock.

 

The following table summarizes the compensation and estimated expenses we will pay in the offering. Such amounts are shown assuming both no exercise and full exercise of the Underwriter’s over-allotment option.

 

   No Exercise of Over-allotment Option  

Exercise of Over-allotment Option

 
   Per Share   Total   Per Share   Total 
Maximum public offering price  $6.50   $3,900,000   $6.50   $4,485,000 
Underwriting discount (8%)  $0.52   $312,000   $0.52   $358,800 
Proceeds, before expenses, to us  $5.98   $3,588,000   $5.98   $4,126,200 

 

We have also agreed to reimburse the Underwriter for all of its reasonable out-of-pocket expenses, including reasonable fees and expenses of its legal counsel, roadshow expenses, offering materials, cost associated with closing volumes and commemorative mementos, and book building software in an aggregate amount not to exceed $204,500 in connection with the offering.

 

We have paid a non-accountable non-refundable advance of $50,000 to the Underwriter.

 

We expect our total expenses for this offering to be approximately $878,834, exclusive of the above discount. If we complete this offering, then on the closing date, we will issue shares to investors.

 

We have agreed to indemnify the Underwriter against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the Underwriter may be required to make in respect of those liabilities.

 

In connection with this offering, the Underwriter or certain of the securities dealers may distribute prospectuses electronically. No forms of prospectus other than printed prospectuses and electronically distributed prospectuses that are printable in Adobe PDF format will be used in connection with this offering.

 

83

 

 

Underwriter Warrant

 

We have also agreed to grant to the Underwriter a warrant covering a number shares of common stock equal to 7% of the common stock sold by the Underwriter in this public offering (the “Underwriter Warrant”). The Underwriter Warrant will be exercisable, commencing six (6) months from the effective date of offering and will expire on fifth year anniversary of the date of the commencement of sales in this offering. The Underwriter Warrant will be exercisable at a price equal to 110% of the initial public offering price. The Underwriter Warrant shall not be redeemable or cancellable. We will register the shares underlying the Underwriter Warrant and file all necessary undertakings in connection therewith. The Underwriter Warrant may not be exercised, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days beginning on the date of commencement of sales of this offering (in accordance with FINRA Rule 5110), except that they may be assigned, in whole or in part, to any officer or partner of the Underwriter, and to members of the syndicate or selling group and their respective officers or partners. The Underwriter Warrants may be exercised as to all or a lesser number of shares, will provide for cashless exercise and will contain provisions for one demand registration and unlimited “piggyback” registration rights at our expense with a duration of more than five years and seven years, respectively, from the commencement of sales of the offering. We have registered the Underwriter Warrant and the shares underlying the Underwriter Warrant in this offering.

 

Right of First Refusal

 

Following the closing of this offering, the Underwriter shall have an irrevocable right of first refusal (the “Right of First Refusal”), for a period of twelve (12) months after the closing of the offering (the “RoFR Period”), to act as sole investment banker, sole book-runner, and/or sole placement agent, at the Underwriter’s sole discretion, for each and every future public and private equity and debt offering, including all equity linked financings (each, a “Subject Transaction”), during such twelve (12) month period, of the Company, or any successor to or any current or future subsidiary of the Company, on terms and conditions customary to the Underwriter for such Subject Transactions. The Underwriter shall have the sole right to determine whether or not any other broker dealer shall have the right to participate in a Subject Transaction and the economic terms of such participation. For the avoidance of any doubt, the Company shall not retain, engage or solicit any additional investment banker, book-runner, financial advisor, underwriter and/or placement agent in a Subject Transaction without the express written consent of the Underwriter.

 

Lock-Up Agreements

 

All of our stockholders, executive officers and directors have agreed not to register, offer, sell, contract to sell or grant (except for private transfers and in such case only with the express requirement that such shares continue to be subject to the same lock-up) any of our shares of common stock or any securities convertible into or exercisable or exchangeable for our shares of common stock or any warrants to purchase our shares of common stock (including, without limitation, securities of our company which may be deemed to be beneficially owned by such individuals in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon the exercise of a stock option or warrant) for a period of 180 days after the closing date of this offering. Upon the expiration of these lock-up agreements, additional shares of common stock will be available for sale in the public market.

 

Market and Pricing Considerations

 

Prior to this offering, our common stock was quoted on the OTC Markets – Pink Sheets, and there was a limited public market for our common stock. The public offering price was determined based upon the price at which our common stock was quoted on the OTC Markets – Pink Sheets, as well as by negotiations between us and the Underwriter. Among the factors considered in determining the initial public offering price are the future prospects of our company and our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, market prices of securities and certain financial and operating information of companies engaged in activities similar to those of our company.

 

An active trading market for our common stock may not develop. It is possible that after this offering the shares of common stock will not trade in the public market at or above the initial offering price.

 

84

 

 

Discretionary Shares

 

The Underwriter will not sell any shares in this offering to accounts over which it exercises discretionary authority, without first receiving written consent from those accounts.

 

Application for Listing on the NASDAQ Capital Market

 

We have applied to list our common stock on the Nasdaq Capital Market.

 

Price Stabilization, Short Positions and Penalty Bids

 

In order to facilitate the offering of our common stock, the Underwriter may engage in transactions that stabilize, maintain or otherwise affect the price of our common stock. These activities may raise or maintain the market price of our common stock above independent market levels or prevent or retard a decline in the market price of our common stock. The Underwriter is not required to engage in these activities, and may end any of these activities at any time. We and the Underwriter have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act.

 

Foreign Regulatory Restrictions on Purchase of our Shares

 

We have not taken any action to permit a public offering of our shares outside the United States or to permit the possession or distribution of this prospectus outside the United States. People outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to this offering of our shares and the distribution of this prospectus outside the United States.

 

Notice to Prospective Investors in the European Economic Area

 

In relation to each member state of the European Economic Area, no offer of shares which are the subject of the offering has been, or will be made to the public in that Member State, other than under the following exemptions under the Prospectus Directive:

 

  (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive;
     
  (b)

to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the Underwriter for any such offer; or

     
  (c) in any other circumstances falling within Article 3(2) of the Prospectus Directive,

 

provided that no such offer of shares referred to in (a) to (c) above shall result in a requirement for the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.

 

Each person located in a Member State to whom any offer of shares is made or who receives any communication in respect of an offer of shares, or who initially acquires any shares will be deemed to have represented, warranted, acknowledged and agreed to and with the Underwriter and the Company that (1) it is a “qualified investor” within the meaning of the law in that Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2) in the case of any shares acquired by it as a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, the shares acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified investors, as that term is defined in the Prospectus Directive, or in circumstances in which the prior consent of the Underwriter has been given to the offer or resale; or where shares have been acquired by it on behalf of persons in any Member State other than qualified investors, the offer of those shares to it is not treated under the Prospectus Directive as having been made to such persons.

 

85

 

 

The Company, the Underwriter and their respective affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgments and agreements.

 

This prospectus has been prepared on the basis that any offer of shares in any Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Member State of shares which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or the Underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the Company nor the Underwriter have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the Company or the Underwriter to publish a prospectus for such offer.

 

For the purposes of this provision, the expression an “offer of shares to the public” in relation to any common stock in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the common stock to be offered so as to enable an investor to decide to purchase or subscribe the common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression “Prospectus Directive” means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each Member State.

 

The above selling restriction is in addition to any other selling restrictions set out below.

 

Notice to Prospective Investors in Hong Kong

 

The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b) in other circumstances which do not result in the document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the securities has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the Securities and Futures Ordinance and any rules made under that Ordinance.

 

Notice to Prospective Investors in Singapore

 

This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of Non-CIS Securities may not be circulated or distributed, nor may the Non-CIS Securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

 

86

 

 

Where the Non-CIS Securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

 

  (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
     
  (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,

 

securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the Non-CIS Securities pursuant to an offer made under Section 275 of the SFA except:

 

  (a) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;
     
  (b) where no consideration is or will be given for the transfer;
     
  (c) where the transfer is by operation of law;
     
  (d) as specified in Section 276(7) of the SFA; or
     
  (e) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

 

87

 

 

LEGAL MATTERS

 

Certain legal matters with respect to the validity of the shares of common stock offered hereby and U.S. federal securities law will be passed upon for us by Loeb & Loeb LLP, New York, New York. Legal matters as to Malaysia law will be passed upon for us by Lee & Poh Partnership. Loeb & Loeb, LLP may rely upon Lee & Poh Partnership. with respect to matters governed by Malaysian law. Hunter Taubman Fischer & Li LLC is acting as U.S. securities counsel for the Underwriter. Lee & Poh Partnership is acting as Malaysia counsel for the Underwriter.

 

EXPERTS

 

The consolidated financial statements for the years ended December 31, 2022 and 2021, included in this Registration Statement have been so included in reliance on the report of Marcum Asia CPAs LLP and Friedman LLP, independent registered public accounting firms, given on the authority of said firm in auditing and accounting. The office of Marcum Asia CPAs LLP is located at 7 Pennsylvania Plaza Suite 830, New York, NY 10001. The office of Friedman LLP is located at One Liberty Plaza, 165 Broadway 21st Floor, New York, NY 10006.

  

WHERE YOU CAN FIND MORE INFORMATION

 

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the common stock offered by this prospectus. This prospectus, which is part of the registration statement, omits certain information, exhibits, schedules and undertakings set forth in the registration statement. For further information pertaining to us and our common stock, reference is made to the registration statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents or provisions of any documents referred to in this prospectus are not necessarily complete, and in each instance where a copy of the document has been filed as an exhibit to the registration statement, reference is made to the exhibit for a more complete description of the matters involved.

 

Registration statements and certain other filings made with the SEC electronically are publicly available through the SEC’s web site at http://www.sec.gov. The registration statement, including all exhibits and amendments thereto, has been filed electronically with the SEC.

 

We are subject to the information and periodic reporting requirements of the Exchange Act and, accordingly, we file annual reports containing financial statements audited by an independent registered public accounting firm, quarterly reports containing unaudited financial data, current reports and other reports and information with the SEC. You may inspect and copy each of our periodic reports, proxy statements and other information at the SEC’s public reference room, and at the web site of the SEC referred to above.

 

88

 

 

AGAPE ATP CORPORATION

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

  Page
Consolidated Financial Statements  
   
Report of Independent Registered Public Accounting Firm (PCAOB ID: 5395) F-2
Report of Independent Registered Public Accounting Firm (PCAOB ID: 711) F-3
Consolidated Balance Sheets F-4
Consolidated Statements of Operations and Comprehensive Loss F-5
Consolidated Statements of Changes in Stockholders’ Equity F-6
Consolidated Statements of Cash Flows F-7
Notes to Consolidated Financial Statements F-8

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

To the Board of Directors and

Stockholders of Agape ATP Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of Agape ATP Corporation (the “Company”) as of December 31, 2022, the related consolidated statement of operation, comprehensive loss, stockholders’ equity and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

/s/ Marcum Asia CPAs LLP

 

Marcum Asia CPAs LLP

 

We have served as the Company’s auditor since 2019 (such date takes into account the acquisition of certain assets of Friedman LLP by Marcum Asia CPAs LLP effective September 1, 2022)

 

New York, New York
March 31, 2023

 

F-2

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and

Stockholders of Agape ATP Corporation

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheet of Agape ATP Corporation (the “Company”) as of December 31, 2021, and the related consolidated statement of operations and comprehensive loss, changes in stockholders’ equity and cash flow for the year ended December 31, 2021, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the result of its operations and its cash flow for the year ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provide a reasonable basis for our opinion.

 

/s/ Friedman LLP

 

We have served as the Company’s auditor since 2019 through 2022

 

New York, New York

March 28, 2022

 

 

F-3

 

 

AGAPE ATP CORPORATION

CONSOLIDATED BALANCE SHEETS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   2022   2021 
   As of December 31, 
   2022   2021 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents (Included $1,609 and $17,493 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)  $1,438,430   $2,597,848 
Accounts receivable   2,826    - 
Amount due from related parties   10,534    7,004 
Inventories   46,277    375,535 
Prepaid taxes (Included $1,741 and $1,357 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)   339,367    636,218 
Prepayments and deposits   191,100    295,517 
Total Current Assets   2,028,534    3,912,122 
           
OTHER ASSETS          
Property and equipment, net   142,149    215,799 
Intangible assets, net   24,044    3,660 
Operating right-of-use assets   81,133    237,718 
Investment in marketable securities   16,687    89,001 
Investment in non-marketable securities   -    1,500 
Deferred offering costs   499,202    264,735 
Total other assets   763,215    812,413 
           
TOTAL ASSETS  $2,791,749   $4,724,535 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable  $28,833   $13,715 
Accounts payable – related parties   25,611    - 
Customer deposits   363,018    279,689 
Operating lease liabilities   82,708    157,094 
Other payables and accrued liabilities ($1,090 and $1,548 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of December 31, 2022 and 2021, respectively.)   713,277    858,355 
Other payable – related parties   4,880    - 
Income tax payable   10,968    3,988 
Total Current Liabilities   1,229,295    1,312,841 
           
NON-CURRENT LIABILITIES          
Operating lease liabilities  $-   $83,484 
Deferred tax liabilities   -    15,574 
Total Non-current Liabilities   -    99,058 
           
TOTAL LIABILITIES  $1,229,295   $1,411,899 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding   -    - 
Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 75,452,012 and 290,460,047 shares issued and outstanding as of December 31, 2022 and 2021, respectively.   7,545    29,046 
Additional paid in capital   6,470,716    6,449,215 
Accumulated deficit   (4,945,586)   (3,258,687)
Accumulated other comprehensive income   9,266    93,398 
TOTAL AGAPE CORPORATION STOCKHOLDERS’ EQUITY   1,541,941    3,312,972 
           
NON-CONTROLLING INTERESTS   20,513    (336)
           
TOTAL EQUITY   1,562,454    3,312,636 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $2,791,749   $4,724,535 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

 

AGAPE ATP CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   2022   2021 
   For the years ended December 31, 
   2022   2021 
         
REVENUE  $1,856,564   $1,016,962 
           
COST OF REVENUE   (666,042)   (297,333)
           
GROSS PROFIT   1,190,522    719,629 
           
SELLING   (361,414)   (394,682)
COMMISSION   (405,351)   (316,267)
GENERAL AND ADMINISTRATIVE   (1,957,023)   (1,745,734)
PROVISION FOR DOUBTFUL ACCOUNTS   -    (121,514)
TOTAL OPERATING EXPENSES   (2,723,788)   (2,578,197)
           
LOSS FROM OPERATIONS   (1,533,266)   (1,858,568)
           
OTHER INCOME (EXPENSES)          
Other expenses, net   (79,539)   (68,323)
Interest income   16,190    25,570 
Unrealized holding loss on marketable securities   (73,519)   (505,231)
Dividend income from marketable securities   -    18,939 
TOTAL OTHER EXPENSES, NET   (136,868)   (529,045)
           
LOSS BEFORE INCOME TAXES   (1,670,134)   (2,387,613)
           
BENEFIT OF (PROVISION FOR) INCOME TAXES   4,055    (137,067)
           
NET LOSS   (1,666,079)   (2,524,680)
           
NET (INCOME) LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS   (20,820)   436 
           
NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION  $(1,686,899)  $(2,524,244)
           
NET LOSS  $(1,666,079)  $(2,524,680)
           
OTHER COMPREHENSIVE LOSS          
Foreign currency translation adjustment   (84,132)   (87,615)
           
TOTAL COMPREHENSIVE LOSS   (1,750,211)   (2,612,295)
           
Less: Comprehensive income (loss) attributable to non-controlling interests   20,849    (433)
           
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION  $(1,771,060)  $(2,611,862)
           
LOSS PER SHARE          
Basic and diluted  $(0.02)  $(0.01)
           
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING          
Basic and diluted   87,822,337    376,216,452 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

 

AGAPE ATP CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

                                    
    COMMON STOCK    ADDITIONAL         ACCUMULATED OTHER    NON-    TOTAL 
    Number of shares    Par value    PAID IN CAPITAL    ACCUMULATED
DEFICIT
    COMPREHENSIVE INCOME    CONTROLLING INTERESTS    STOCKHOLDERS’
EQUITY
 
Balance as of December 31, 2020   376,452,047   $37,645   $6,440,616   $(734,443)  $181,016   $-   $5,924,834 
Forfeiture of common stock   (85,992,000)   (8,599)   8,599    -    -    -    - 
Contributions from non-controlling interest shareholders   -    -    -    -    -    97    97 
Net loss   -    -    -    (2,524,244)   -    (436)   (2,524,680)
Foreign currency translation adjustment   -    -    -    -    (87,618)   3    (87,615)
Balance as of December 31, 2021   290,460,047    29,046    6,449,215    (3,258,687)   93,398    (336)   3,312,636 
Forfeiture of common stock   (218,008,035)   (21,501)   21,501    -    -    -    - 
Net loss   -    -    -    (1,686,899)   -    20,820    (1,666,079)
                                    
Foreign currency translation adjustment   -    -    -    -    (84,132)   29    (84,103)
Balance as of December 31, 2022   72,452,012   $7,545   $6,470,716   $(4,945,586)  $9,266   $20,513   $1,562,454 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6

 

 

AGAPE ATP CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Currency expressed in United States Dollars (“US$”)

 

   2022   2021 
   For the years ended December 31, 
   2022   2021 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(1,666,079)  $(2,524,680)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   71,754    75,797 
Amortization   2,122    1,961 
Amortization of operating right-of-use assets   144,064    139,451 
Unrealized holding loss on marketable securities   73,519    505,231 
Dividend income from marketable securities   -    (18,939)
Deferred tax (benefit) expense   (14,751)   10,127 
Inventory write-down   5,307    36,241 
Provision for doubtful accounts   -    121,514 
Changes in operating assets and liabilities:          
Accounts receivables   (2,824)   167,566 
Amount due from related parties   (3,786)   - 
Inventories   343,483    192,713 
Prepaid taxes   263,404    430,062 
Prepayments and deposits   89,113    (128,363)
Accounts payable   15,825    - 
Accounts payable – related parties   25,597    - 
Customer deposits   94,877    52,981 
Operating lease liabilities   (145,197)   (138,143)
Other payables and accrued liabilities   (119,963)   226,651 
Other payables – related parties   4,878    - 
Income tax payables   6,974    3,988 
Net cash used in operating activities   (811,683)   (845,842)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of equipment   (9,433)   (3,959)
Purchase of intangible assets   (22,686)   - 
Net cash used in investing activities   (32,119)   (3,959)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Deferred offering costs   (234,466)   (15,210)
Advances to related parties   -    (3,851)
Net cash used in financing activities   (234,466)   (19,061)
           
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS   (81,150)   (50,890)
           
DECREASE IN CASH AND CASH EQUIVALENTS   (1,159,418)   (919,752)
           
CASH AND CASH EQUIVALENTS, beginning of year   2,597,848    3,517,600 
           
CASH AND CASH EQUIVALENTS, end of year  $1,438,430   $2,597,848 
           
SUPPLEMENTAL CASH FLOWS INFORMATION          
Income taxes paid  $78,511   $326,838 
           
SUPPLEMENTAL NON-CASH FLOWS INFORMATION          
Changes in right-of-use assets and lease liabilities due to lease modifications  $-   $3,250 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-7

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation (“AATP LB”), a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. (“ASL”), a company incorporated in Malaysia.

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited (“AATP HK”), a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., a network marketing entity incorporated in Malaysia.

 

Agape Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

The accompanying consolidated financial statements reflect the activities of the Company, AATP LB, AATP HK, WATP, ASL and its variable interest entity (“VIE”), Agape S.E.A. Sdn. Bhd. (“SEA”) (See Note 3), and DSY Wellness.

 

Details of the Company’s subsidiaries:

 

  Subsidiary company name  Place and date of incorporation  Particulars of issued capital  Principal activities  Proportional of ownership interest and voting power held 
                
1. Agape ATP Corporation  Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each  Investment holding   100%
                 
2. Agape ATP International Holding Limited  Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each  Wholesaling of health and wellness products; and health solution advisory services   100%
                 
3. Agape Superior Living Sdn. Bhd.  Malaysia,
August 8, 2003
  9,590,598 shares of ordinary share of RM1 each  Health and wellness products and health solution advisory services via network marketing   99.99%
                 
4. Agape S.E.A. Sdn. Bhd.  Malaysia,
March 4, 2004
  2 shares of ordinary share of RM1 each  VIE of Agape Superior Living Sdn. Bhd.   VIE 
                 
5. Wellness ATP International Holdings Sdn, Bhd  Malaysia,
September 11, 2020
  100 shares of ordinary share of RM1 each  The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns   100%
                 
6. DSY Wellness International Sdn Bhd.  Malaysia,
November 11, 2021
  1,000 shares of ordinary share of RM1 each  Provision of complementary health therapies   60%

 

F-8

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND (CONT’D)

 

Business Overview

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

Via ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

To further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (“DSY Wellness”) with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”).

 

The consolidated financial statements include the financial statements of the Company, its subsidiaries and its VIE over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.

 

F-9

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Principles of consolidation

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. As of and for the year ended December 31, 2022, SEA, the only VIE of the Company has no significant operations.

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for inventories obsolescence, impairment of long-lived assets, allowance for deferred tax assets. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

Cash and cash equivalents represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

 

Accounts receivable

 

Accounts receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of December 31, 2022 and 2021, no allowance of doubtful accounts was recorded.

 

F-10

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Inventories

 

Inventories consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value.

 

For the years ended December 31, 2022 and 2021, the Company recognized $5,307 and $36,241 inventory write-down; and $142,466 and $0 inventory write-off, respectively.

 

Prepaid taxes

 

Prepaid taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax.

 

Prepayments and deposits

 

Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the allowance policy and update it if necessary. For the years ended December 31, 2022 and 2021, the Company wrote-off allowance for doubtful accounts of $120,372 and $0, respectively. As of December 31, 2022 and 2021, there was $0 and $121,514 allowance for the doubtful accounts recorded.

 

Property and equipment, net

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:

 

    Useful Life
     
Computer and office equipment   5-7 years
Furniture & fixtures   6-7 years
Leasehold improvements   Lease Term
Vehicle   5 years

 

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.

 

F-11

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Intangible assets, net

 

Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:

 

Classification   Useful Life
     
Computer software   5 years

 

Impairment for long-lived assets

 

Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and 2021, no impairment of long-lived assets was recognized.

 

Deferred offering costs

 

Deferred offering costs represents costs associated with the Company’s current offering which will be netted against the proceeds from the Company’s current offering.

 

Investment in marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s consolidated statements of operations and comprehensive income (loss) in the caption of “unrealized holding gain loss on marketable securities” in each reporting period.

 

Investment in non-marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

 

F-12

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Customer deposits

 

Customer deposits represent amounts advanced by customers on product orders and unapplied unexpired coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.

 

Revenue recognition

 

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

Under the Company’s network marketing business, the Company issues product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the Company’s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer deposits will be reversed when the coupons are used. The Company’s coupons have a validity period of between six and twelve months. If the Company’s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues. For the years ended December 31, 2022 and 2021, the Company recognized $7,543 and $15,209 as forfeited coupon income, respectively.

 

As of December 31, 2022, the Company had contracts for the sales of health and wellness products amounting to $17,912 which it is expected to fulfill within 12 months from December 31, 2022.

 

Sales of products for the provision of complementary health therapies

 

Products for the provision of complementary health therapies are predominantly Chinese herbs in different forms, processed or otherwise, for prescriptions for treating non-communicable diseases.

 

F-13

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Provision of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person.

 

The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program is completed in the final day of the health camp. For the years ended December 31, 2022 and 2021, revenues from providing health and wellness services are $145,510 and $7,543, respectively.

 

Disaggregated information of revenues by products and services are as follows:

 

   2022   2021 
   For the years ended December 31, 
   2022   2021 
         
Survivor Select  $122,470   $83,904 
Energized Mineral Concentrate   -    52,047 
Ionized Cal-Mag   148,219    39,527 
Omega Blend   272,332    222,718 
BetaMaxx   137,447    208,043 
Vege Fruit Fiber   -    65,757 
Iron   16,697    28,114 
Young Formula   31,403    52,425 
Organic Youth Care Cleansing Bar   -    5,137 
ATPR Mito+   271,493    183,800 
Lipomask   -    15,331 
Energetique   49,089    25,574 
Trim+   88,613    27,042 
Others – Products for the provision of complementary health therapies   569,823    - 
Others   3,468    - 
Total revenues – products   1,711,054    1,009,419 
Health and Wellness services   145,510    7,543 
Total revenues – products and services  $1,856,564   $1,016,962 

 

F-14

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Cost of revenue

 

Cost of revenue comprised freight-in, the purchase cost of manufactured goods for sale to customers and products for the provision of complementary health therapies. Cost of revenue amounted to $666,042 (including inventory write-downs of $5,307 and inventory written-off of $142,466) and $297,333 (including inventory write-downs of $36,241) for the years ended December 31, 2022 and 2021, respectively.

 

Shipping and handling

 

Shipping and handling charges amounted to $16,585 and $11,054 for the years ended December 31, 2022 and 2021, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.

 

Advertising costs

 

Advertising costs amounted to $4,688 and $20,218 for the years ended December 31, 2022 and 2021, respectively. Advertising costs are expensed as incurred and included in selling expenses.

 

Commission expenses

 

Commission expenses are the Company’s most significant expenses. As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $405,351 and $316,267 for the years ended December 31, 2022 and 2021, respectively.

 

Defined contribution plan

 

The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $133,489 and $99,488 for the years ended December 31, 2022 and 2021, respectively.

 

The related contribution plans include:

 

  - Social Security Organization (“SOSCO”) – 1.75% based on employee’s monthly salary capped of RM 5,000;
  - Employees Provident Fund (“EPF”) –based on employee’s monthly salary, 13% for employee earning RM5,000 and below; and 12% for employee earning RM5,001 and above.
  - Employment Insurance System (“EIS”) – 0.2% based on employee’s monthly salary capped of RM 5,000;
  - Human Resource Development Fund (“HRDF”) – 1% based on employee’s monthly salary

 

F-15

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. $0 and $395 penalties and interest incurred related to underpayment of income tax for the years ended December 31, 2022 and 2021, respectively.

 

The Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of their jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Net income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

 

Non-controlling interest

 

Non-controlling interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals. The non-controlling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company.

 

F-16

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended December 31, 2022 and 2021, there were no dilutive shares.

 

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive income (loss).

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

   2022   2021 
   As of December 31, 
   2022   2021 
         
Period-end MYR : US$1 exchange rate   4.41    4.18 
Period-end HKD : US$1 exchange rate   7.80    7.80 

 

   2022   2021 
   For the years ended December 31, 
   2022   2021 
         
Period-average MYR : US$1 exchange rate   4.41    4.14 
Period-average HKD : US$1 exchange rate   7.83    7.77 

 

F-17

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Leases

 

The Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that does not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company’s leases include one or more options to renew, which is typically at the Company’s sole discretion. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications result in re-measurement of the right of use (“ROU”) assets and lease liabilities. Operating ROU assets and lease liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.

 

F-18

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT’D)

 

Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.

 

The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued.

 

In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASUs 2016-13 and 2019-05 may have on its consolidated financial statements.

 

Except for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements of operations and cash flows.

 

3. VARIABLE INTEREST ENTITY (“VIE”)

 

SEA is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL’s purchases. Its equity at risk was insufficient to finance its activities and 100% of its business is transacted with ASL. Therefore, it was considered to be a VIE and ASL is the primary beneficiary since it has both of the following characteristics:

 

  a. The power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and
  b. The obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE.

 

Accordingly, the accounts of SEA is consolidated in the accompanying financial statements.

 

F-19

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

3. VARIABLE INTEREST ENTITY (“VIE”) (CONT’D)

 

The carrying amount of the VIE’s assets and liabilities were as follows:

 

           
   As of December 31, 
   2022   2021 
         
Current assets  $3,350   $18,850 
Current liabilities   (43,512)   (51,272)
Net deficit  $(40,162)  $(32,422)

 

           
   As of December 31, 
   2022   2021 
         
Current assets:          
Cash  $1,609   $17,493 
Prepaid taxes   1,741    1,357 
Total current assets  $3,350   $18,850 
           
Current liabilities:          
Accounts payable – intercompany  $42,422   $49,724 
Other payables and accrued liabilities   1,090    1,548 
Total current liabilities  $43,512   $51,272 
           
Net deficit  $(40,162)  $(32,422)

 

The summarized operating results of the VIE’s are as follows:

 

           
   For the years ended December 31, 
   2022   2021 
         
Operating revenues  $-   $- 
Gross profit  $-   $- 
Loss from operations  $(9,432)  $(21,966)
Net loss  $(9,432)  $(27,966)

 

4. CASH AND CASH EQUIVALENTS

 

As of December 31, 2022 and 2021 the Company had $1,438,430 and $2,597,848, respectively, of cash and cash equivalents, which consisted of $513,152 and $554,864, respectively, of cash in banks and $914,811 and $1,975,347, respectively, of time deposits placed with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranges between 1.10% to 1.88% per annum. As of December 31, 2022 and 2021, $231,187 and $295,761 of these balances are not covered by deposit insurance, respectively.

 

F-20

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

5. ACCOUNTS RECEIVABLE

 

           
   As of December 31, 
   2022   2021 
Accounts receivable  $2,826   $- 
Allowance for doubtful accounts   -    - 
Total  $2,826   $- 

 

6. INVENTORIES

 

Inventories consist of the following:

 

    2022    2021 
   As of December 31, 
    2022    2021 
Finished goods  $46,277   $375,535 

 

For the years ended December 31, 2022 and 2021, the Company recognized $5,307 and $36,241 inventory write-down; and $142,466 and $0 inventory write-off, respectively.

 

7. PREPAYMENTS AND DEPOSITS

 

           
   As of December 31, 
   2022   2021 
Receivables from sales distributors  $43,596   $115,379 
Deposits to suppliers   147,504    301,233 
Subtotal   191,100    416,612 
Less: Provision for doubtful accounts   -    (121,095)
Total  $191,100   $295,517 

 

Movements of allowance for doubtful accounts are as follows:

 

           
   For the years ended December 31, 
   2022   2021 
Beginning balance  $121,095   $- 
Addition   -    121,514 
Write off   (120,372)   - 
Exchange rate effect   (723)   (419)
Ending balance  $-   $121,095 

 

F-21

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

8. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consist of the following:

 

           
   As of December 31, 
   2022   2021 
Computer and office equipment  $87,428   $82,298 
Furniture & fixtures   115,789    122,185 
Leasehold improvements   191,965    202,570 
Vehicle   93,535    98,702 
Subtotal   488,717    505,755 
Less: accumulated depreciation   (346,568)   (289,956)
Total  $142,149   $215,799 

 

Depreciation expense for the years ended December 31, 2022 and 2021 amounted to $71,754 and $75,797, respectively.

 

9. INTANGIBLE ASSETS, NET

 

Intangible assets, net, consist of the following:

 

           
   As of December 31, 
   2022   2021 
Computer software  $55,348   $34,453 
Less: accumulated amortization   (31,304)   (30,793)
Total  $24,044   $3,660 

 

Amortization expense for the years ended December 31, 2022 and 2021 amounted to $2,122 and $1,961, respectively.

 

10. INVESTMENT IN MARKETABLE SECURITIES

 

  (i) On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.
     
  (ii) On July 30, 2018, the Company disposed 20 shares of common stock in Greenpro Capital Corp. for $125 at a purchase price of $6.2613 per share.
     
  (iii) On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.
     
  (iv) On July 19, 2022, Greenpro Capital Corp. filed a certificate of change with the Secretary of State of Nevada to effect a reverse split of the company’s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at July 28, 2022, the Company has an investment of 116,646 common stock of Greenpro Capital Corp. The Company’s investment of 116,646 common stock of Greenpro Capital Corp. was reduced to 11,665 subsequent to the reverse stock split.
     
  (v) On November 3, 2020, the Company received dividend of 6,667 shares of common stock in DSwiss, Inc. for $76,671 at fair value of $11.50 per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares
     
  (vi) On December 9, 2020, the Company received dividend of 16,663 shares of common stock in DSwiss, Inc. for $83,315 at fair value of $5 per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.’s shares.
     
  (vii) On September 27, 2021, the Company received dividend of 11,665 shares of common stock in SEATech Ventures Corp. for $18,874 at fair value of $1.62 per share from Greenpro Capital Corp as a dividend income since Greenpro Capital Corp previously owned these shares.
     
  (viii) On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. (a non-marketable security) for $1,500 at purchase price of $0.0001 per share. Phoenix Plus Corp. obtained approval for Depository Trust Company eligibility on April 26, 2022. Since the commencement of trading of common stock of Phoenix Plus Corp. on May 18, 2022, to March 9, 2023, there were only 200 shares of common stock of the company traded. The Company deems there is an absence of a readily determinable fair value of the common stock of Phoenix Plus Corp. and has continued to value its investment in the company Phoenix Plus Corp. at cost.

 

F-22

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

10. INVESTMENT IN MARKETABLE SECURITIES (CONT’D)

 

           
   As of December 31, 
   2022   2021 
Cost of investment  $89,001   $577,035 
Transfer from non-marketable security   1,500    - 
Dividend income from Greenpro Capital Corp.   -    18,939 
Unrealized holding loss   (73,519)   (505,231)
Exchange rate effect   (295)   (1,742)
Investment in marketable securities  $16,687   $89,001 

 

11. INVESTMENT IN NON-MARKETABLE SECURITIES

 

On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. for $1,500 at purchase price of $0.0001 per share. Phoenix Plus Corp. attained its effective date with the Securities Exchange Commission for listing on OTC (Pink Sheet), U.S. on March 12, 2021, and obtained approval for Depository trust Company (“DTC”) eligibility on April 26, 2022. Accordingly, stocks of Phoenix Plus Corp. can be traded on OTC. As such the investment in Phoenix Plus Corp. was transferred to marketable securities.

 

Phoenix Plus Corporation  2022   2021 
   As of December 31, 
Phoenix Plus Corporation  2022   2021 
Cost of investment  $1,500   $1,500 
Less: Transfer to investment in marketable securities   (1,500)   - 
Investment in non-marketable securities   -    1,500 

 

12. CUSTOMER DEPOSITS

 SCHEDULE OF CUSTOMER DEPOSITS

   2022   2021 
   As of December 31, 
   2022   2021 
Customer deposits  $289,487   $273,581 
Unexpired product coupons   73,531    6,108 
Total  $363,018   $279,689 

 

Customer deposits represent amounts advanced by customers on product orders and unexpired product coupons issued to the Company’s members and distributors of its network marketing business.

 

13. OTHER PAYABLES AND ACCRUED LIABILITIES

 

           
   As of December 31, 
   2022   2021 
Professional fees  $324,629   $436,541 
Promotion expenses   38,583    36,024 
Payroll   21,164    22,669 
Amounts held in eWallets   216,049    223,781 
Tax penalty   75,000    75,000 
Others   37,852    64,340 
           
Total  $713,277   $858,355 

 

The Company requires all members and distributors of its network marketing business to maintain an electronic wallet (eWallet) account with the Company. The eWallet is primarily for the crediting of any commission payment that falls below RM100 (or $22.70). Commission payment exceeding the RM100 threshold shall only be credited into the member’s or distributor’s eWallet upon request. The eWallet functionality allows the members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods provided that each of the withdrawal amount exceeds RM100. Amounts held in eWallets are reflected on the balance sheet as a current liability.

 

F-23

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. RELATED PARTY BALANCES AND TRANSACTIONS

 

Related party balances

 

Amount due from related parties

 

Name of Related        As of December 31, 
Party  Relationship  Nature  2022   2021 
               
TH3 Technology Sdn Bhd (“TH3”)  Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3  Prepayment of IT expenses  $1,273   $- 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd 

Deposits for products

purchases

   9,261    - 
Agape ATP (Asia) Limited (“AATP Asia”)  Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia  Expenses paid for AATP Asia   -    2,214 
Hostastay Sdn. Bhd.
“Hostastay”
  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rent due from Hostastay   -    4,790 
Total        $10,534   $7,004 

 

Accounts payable – related parties

 

Name of Related        As of December 31, 
Party  Relationship  Nature  2022   2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $25,387   $- 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   224    - 
Total        $25,611   $- 

 

F-24

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. RELATED PARTY BALANCES AND TRANSACTIONS (CONT’D)

 

Related party balances

 

Other payable - related parties

 

Name of Related        As of December 31, 
Party  Relationship  Nature  2022   2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchase of products for general use  $2,149   $- 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchase of products for general use   2,147    - 
Mr. How Kok Choong  Mr. How Kok Choong, the CEO and director of the Company  Commission expense   584    - 
Total        $4,880   $- 

 

Related party transactions

 

Purchases

 

Name of Related        For the years ended December 31, 
Party  Relationship  Nature  2022   2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $198,376   $- 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   3,975    718 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Purchases of products for the provision of complementary health therapies   124    - 
Total        $202,475   $718 

 

F-25

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. RELATED PARTY BALANCES AND TRANSACTIONS (CONT’D)

 

Related party transactions

 

Other income

 

Name of Related        For the years ended December 31,  
Party  Relationship  Nature  2022   2021  
                
Hostastay Sdn. Bhd.  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021  Sublease rental income due from Hostastay  $-   $4,345  
Total        $-   $4,345  

 

Other purchases

 

Name of Related        For the years ended December 31, 
Party  Relationship  Nature  2022   2021 
               
CTA Nutriceuticals (Asia) Sdn Bhd (“CTA”)  The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd  Purchases of products for the provision of complementary health therapies  $5,431   $- 
DSY Beauty Sdn Bhd (“DSY Beauty”)  The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd  Purchases of beauty products   6,888    - 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Purchases of products for the provision of complementary health therapies   4    - 
Total        $12,323   $- 

 

F-26

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. RELATED PARTY BALANCES AND TRANSACTIONS (CONT’D)

 

Related party transactions

 

Commission expense

 

Name of Related        For the years ended December 31, 
Party  Relationship  Nature  2022   2021 
               
Mr. How Kok Choong  Mr. How Kok Choong, the CEO and director of the Company  Commission expense  $16,590   $12,758 
Total        $16,590   $12,758 

 

Other expenses

 

Name of Related        For the years ended December 31, 
Party  Relationship  Nature  2022   2021 
               
TH3 Technology Sdn Bhd (“TH3”)  Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3  IT support services fee  $56,450   $- 
Redboy Picture Sdn Bhd (“Redboy”)  Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy  Sponsorship fee   22,686    718 
DSY Wellness & Longevity Center Sdn Bhd (“DSYWLC”)  Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.  Office rental expenses   21,779    - 
Total        $100,915   $718 

 

F-27

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

15. STOCKHOLDERS’ EQUITY

 

Preferred stock

 

As of December 31, 2022 and 2021, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.

 

Common stock

 

As of December 31, 2022 and 2021, there were 1,000,000,000 common stocks authorized, 75,452,012 and 290,460,047 shares issued and outstanding, respectively.

 

In December 2021, there were share forfeiture agreements (the “Share Forfeiture Agreements”) between the Company and (i) HKC Talent Limited; (ii) various shareholders of the Company (the “Forfeiting Shareholders”), pursuant to which: (i) HKC Talent Limited had agreed to forfeiture of 41,750,000 shares of common stock of the Company, and (ii) the Forfeiting Shareholders had agreed to forfeiture, in aggregate, 44,242,000 shares of common stock of the Company. Included in (ii) is 11,242,000 shares forfeited from HKC Holdings Sdn. Bhd, a company in which Mr. How Kok Choong, the CEO and director of the Company, is a shareholder. As a result, the outstanding shares was reduced by 85,992,000 shares of common stock.

 

A share forfeiture agreement (the “Share Forfeiture Agreement”) dated January 20, 2022, between the Company and Mr. How Kok Choong, the CEO and director of the Company, pursuant to which Mr. How Kok Choong agreed to forfeit 215,008,035 shares of common stock of the Company. As a result, the outstanding shares was reduced by 215,008,035 shares of common stock.

 

There were no stock options, warrants or other potentially dilutive securities outstanding as of December 31, 2022 and 2021.

 

16. NON-CONTROLLING INTEREST

 

The Company’s non-controlling interest consists of the following:

 

           
   As of December 31, 
   2022   2021 
DSY Wellness:          
Paid-in capital  $97   $97 
Accumulated surplus (deficit)   20,384    (436)
Accumulated other comprehensive income   32    3 
Non Controlling interest Gross   20,513    (336)
ASL   -    - 
Total  $20,513   $(336)

 

F-28

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

17. INCOME TAXES

 

The United States and foreign components of loss before income taxes were comprised of the following:

 

           
   For the years ended December 31, 
   2022   2021 
Tax jurisdictions from:          
Local – United States  $(736,946)  $(706,659)
Foreign – Malaysia   (864,794)   (1,064,314)
Foreign – Hong Kong   (68,394)   (616,640)
           
Loss before income tax  $(1,670,134)  $(2,387,613)

 

The benefit of (provision for) income taxes consisted of the following:

 

           
   For the years ended December 31, 
   2022   2021 
Current:          
- Local  $-   $(22,205)
- Foreign   (10,962)   (104,735)
           
Deferred:          
- Local   -    - 
- Foreign   

15,017

    (10,127)
           
Benefit of (Provision for) income taxes  $4,055   $(137,067)

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan) and Hong Kong that are subject to taxes in the jurisdictions in which they operate, are as follows:

 

United States of America

 

Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate tax rate of 21% on its taxable income. Agape ATP Corporation also subject to controlled foreign corporations Subpart F income (“Subpart F”) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of 35%. In addition, the Tax Cuts and Jobs Act imposed a global intangible low-taxed income (“GILTI”) tax, which is a tax on certain off-shore earnings at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are applied.

 

For the year ended December 31, 2022 and 2021, the Company’s foreign subsidiaries did not generate any income that were subject to Subpart F tax and GILTI tax.

 

F-29

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

17. INCOME TAXES (CONT’D)

 

As of December 31, 2022 and 2021, the operations in the United States of America incurred approximately $1,357,000 and $620,000, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income or Subpart F and GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of December 31, 2022 and 2021 were approximately $285,000 and $130,000, respectively.

 

For the year ended December 31, 2021, the Company re-visited its fiscal 2020 U.S. income taxes and determined its stock dividend from Greenpro Capital Corp as a result of its Spin-off of DSwiss Inc.’s shares in 2020 were subject to Subpart F and GILTI taxes. As a result, the Company incurred additional income taxes expenses of $22,205, including interest and penalty of $395, for the year ended December 31, 2021, after utilizing its estimated cumulative net operating losses (“NOL”) of $312,608 as of December 31, 2020. As a result, the Company’s deferred tax assets of estimated NOL of $65,648 were fully utilized and reduced to $0.

 

Malaysia

 

Changes to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandate companies incorporated in Labuan to satisfy the “substantial activity requirements” to qualify for the preferential tax rate of 3% on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the “substantial activity requirements” was issued. As Agape ATP Corporation did not maintain a permanent establishment in Labuan, and therefore did not satisfy the said requirements, the company was subjected to tax at 24% on its net audited profit. On June 11, 2021, Agape ATP Corporation made an irrevocable election to be taxed under the Malaysian Income Tax Act 1967 as the elected tax regime is more tax efficient to the entity compare to LBATA.

 

Agape Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd and Wellness ATP International Holdings Sdn Bhd. are governed by the income taxes laws of Malaysia and the income taxes provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income taxes rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000) for the year ended December 31, 2022 and 2021, with the remaining balance being taxed at the 24% rate.

 

As of December 31, 2022 and 2021, the operations in the Malaysia incurred approximately $1,723,000 and $946,000, respectively, of cumulative net operating losses (“NOL”) which can be carried forward to offset future taxable income. Approximately $790,000, $897,000 and $36,000 of the net operating loss carry forwards will expire in 2028, 2029 and 2030, respectively, if unutilized. The deferred tax valuation allowance as of December 31, 2022 and 2021 were approximately $408,000 and $217,000, respectively.

 

Hong Kong

 

Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction.

 

F-30

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

17. INCOME TAXES (CONT’D)

 

The following table reconciles the local (United States) statutory rates to the Company’s effective tax rate for the periods indicated below:

 

           
   For the years ended December 31, 
   2022   2021 
U.S. statutory rate   21.0%   21.0%
Valuation allowance   (22.9)%   (17.0)%
Differential tax rate in Malaysia   1.0%   3.0%
Permanent difference   

1.2

%(1)   (12.7)%(2)
Effective tax rate   0.3%           (5.7)%      

 

  (1) The amount comprised:
 
    - 1.2% being expenses incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.
     
  (2) The amount comprised:
 
    - 6.2% being income derived in AATP HK that were not taxable in the Malaysia tax returns; and
    - 6.5% being expenses incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.

 

The following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:

 

           
   As of December 31, 
   2022   2021 
Deferred tax assets:          
Net operating loss carry forwards in U.S.  $284,959   $153,061 
Net operating loss carry forwards in Malaysia   408,226    227,106 
Less: valuation allowance   (693,185)   (380,167)
Deferred tax liabilities:          
Depreciation   -    (15,574)
Deferred tax liabilities, net  $-   $(15,574)

 

Uncertain tax positions

 

The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December 31, 2022 and 2021, the Company did not have any significant unrecognized uncertain tax positions. The Company did not incur interest and penalties tax for the years ended December 31, 2022 and 2021.

 

F-31

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. CONCENTRATIONS OF RISKS

 

(a) Major customers

 

For the years ended December 31, 2022 and 2021, no customer accounted for 10.0% or more of the Company’s total revenues.

 

As of December 31, 2022, five individual customers accounted for approximately 72.0% of the Company’s balance of accounts receivable. There was no accounts receivable balance as of December 31, 2021.

 

(b) Major vendors

 

For the year ended December 31, 2022, three vendors accounted for approximately 53.3%, 22.1% and 21.3% of the Company’s total purchases. For the year ended December 31, 2021, two vendors accounted for approximately 47.3% and 45.2% of the Company’s total purchases.

 

Via a dividend distribution, the Company acquired 23,330 shares of common stock of DSwiss, Inc., represents approximately 0.01% ownership, that the Company accounted for as investment in marketable securities (See Note 11). DSwiss, Inc.’s wholly owned subsidiary is the vendor that accounted for the Company’s total purchases of approximately 22.1% and 47.3% for the years ended December 31, 2022 and 2021, respectively.

 

As of December 31, 2022, three vendors accounted for approximately 46.6%, 25.8% and 23.9% of the Company’s total balance of accounts payable, respectively. CTA Nutriceuticals (Asia) Sdn Bhd, a related company, accounted for approximately 47% of the Company’s total balance of accounts payable. As of December 31, 2021, one vendor accounted for 100% of the total balance of accounts payable.

 

(c) Commission Expenses to Sales Distributors and Stockists

 

For the year ended December 31, 2022, one sales distributor accounted for approximately 10.3% of the Company’s total commission expense. For the year ended December 2021, one sales distributor accounted for approximately 17.9% of the Company’s total commission expense.

 

(d) Credit risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of December 31, 2022 and 2021, $513,152 and $554,864 were deposited with financial institutions, respectively, $231,187 and $295,761 of these balances are not covered by deposit insurance. While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.

 

(e) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

F-32

 

 

AGAPE ATP CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

19. COMMITMENTS AND CONTINGENCIES

 

Lease commitments

 

On April 1, 2020, the Company adopted ASC 842 for ASL’s office space lease and sales and training center as the lease commencement date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $490,000, with a corresponding right-of-use (“ROU”) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

On May 31, 2021, the Company entered into two separate two-year leases extension with the modified lease expiring May 31, 2023 for its office space and expiring August 31, 2023 for its training center. The lease modification required the Company to re-measure the ROU assets and lease liabilities based on the modified leases. The Company recognized a reduction of $3,250 in ROU assets and lease liabilities upon lease modifications based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

On October 1, 2021, the Company entered into a two-years lease for an apartment to serve as staff accommodation. The Company recognized lease liabilities of approximately $9,777, with a corresponding right-of-use (“ROU”) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

On November 1, 2021, the Company entered into a two-years lease for a branch office and operating centre. The Company recognized lease liabilities of approximately $10,864, with a corresponding right-of-use (“ROU”) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

As of December 31, 2022, the weighted remaining term of the lease is approximately 0.54 years.

 

The five-year maturity of the Company’s operating lease liabilities is as follow:

 

      
Twelve Months Ending December 31,  Operating lease liabilities 
     
2023  $84,146 
Thereafter   - 
Total lease payments   84,146 
Less: interest   (1,439)
Present value of lease liabilities  $82,707 

 

The Company also leased one office and operation center, and one shophouse with an expiring term of twelve months or less, which were classified as operation leases. Since the lease terms for these leases were twelve months or less, a lessee is permitted to elect not to recognize lease assets and liabilities. The Company has elected not to recognize lease assets and liabilities on these leases. As of December 31, 2022, the Company’s commitment for minimum lease payment under these operating leases within the next twelve months were $567.

 

Rent expense for the years ended December 31, 2022 and 2021 was $190,547 and $179,562, respectively.

 

Contingencies

 

Legal

 

From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.

 

COVID-19

 

Malaysia, where the operations of the Company predominantly reside, officially transitioned to the endemic phase of COVID-19 effective April 1, 2022. Restrictions on businesses and people are minimal. Meanwhile, the government continues to encourage inoculation for those between the ages of 5 and 11 years and its adolescent group which comprised those between the ages 12 and 17. Adults who have been fully vaccinated, i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially resulting in which the demand for our products may be adversely affected;
  we may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect our financial condition and operating results; and
  any disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may also lead to loss of our customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that the Company’s total revenues will grow or remain at similar levels year over year in 2023 and beyond.

 

20. SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date of issuance of this consolidated financial statements, and does not identify any events with material financial impact on the Company’s consolidated financial statements.

 

F-33

 

 

AGAPE ATP CORPORATION

 

 

600,000 Shares of Common Stock

 

 

 

PROSPECTUS

 

 

 

 

EF HUTTON

Division of Benchmark Investments, LLC

 

 

You should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the date of this prospectus, regardless of the time of the delivery of this prospectus or the sale of these securities.

 

Until            , 2022, all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriter with respect to their unsold subscriptions.

 

The date of this prospectus is              , 2023

 

   

 

 

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

 

SUBJECT TO COMPLETION, DATED ________, 2023

 

PRELIMINARY PROSPECTUS

  

Agape ATP Corporation

 

 

30,269,516 Shares of Common Stock

 

This prospectus relates to the resale of 30,269,516 shares of our common stock by the selling stockholders named in this prospectus. The selling stockholders will offer and sell their shares of common stock being offered under this prospectus at $6.50 per share on the OTC Markets – Pink Sheets under the symbol “AATP” or in private transactions for the duration of this offering or until the shares are listed on a national securities exchange at which time the shares may be sold at prevailing market prices or privately negotiated prices or in transactions that are not in the public market. We have applied to list our common stock on the NASDAQ Capital Market (“NASDAQ”) under the symbol “ATPC”. No assurance can be given that our application will be approved. The closing of this offering is contingent upon the successful listing of our common stock on the Nasdaq Capital Market.

 

We are a reporting company under Section 15(d) of the Securities Exchange Act of 1934, as amended. Our common stock is currently quoted on the OTC Markets – Pink Sheets, operated by OTC Markets Group, under the symbol “AATP.” The last reported sale price of our common stock on the OTC Markets – Pink Sheets on August 2, 2022 was $4.01 per share. We urge prospective purchasers of our Common Stock to obtain current information about the market prices of our Common Stock. There is a limited public trading market for our common stock.

 

Investing in our securities involves risks. You should carefully consider the risk factors beginning on page 8 of this prospectus and set forth in the documents incorporated by reference herein before making any decision to invest in our securities.

 

Neither the U.S. Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this registration statement. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is       , 2023

 

SS-1

 

 

THE OFFERING

 

  Common stock offered by us:   0 shares
       
  Common Stock offered by the selling stockholders   30,269,516 shares
       
  Common stock to be outstanding prior to this offering:   75,452,012 shares of common stock
       
  Common stock to be outstanding after the offering:   76,052,012 shares (1)
       
  Use of proceeds:   We will not receive any of the proceeds from the sale of the common stock by the selling stockholders named in this prospectus.

 

(1) Assumes the issuance by us of our common stock pursuant to the public offering prospectus filed contemporaneously herewith, no exercise of the underwriters’ over-allotment option and all of our common stock to be sold by the selling stockholders pursuant to the Resale Prospectus filed contemporaneously herewith are sold.

 

SS-2

 

 

USE OF PROCEEDS

 

We will not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders.

 

SS-3

 

 

SELLING STOCKHOLDERS

 

The following table sets forth the names of the selling stockholders, the number of shares of common stock owned by each selling stockholder immediately prior to the date of this prospectus and the number of shares to be offered by the selling stockholder pursuant to this prospectus. The table also provides information regarding the beneficial ownership of our common stock by the Selling Stockholder as adjusted to reflect the assumed sale of all of the shares offered under this prospectus.

 

Percentage of beneficial ownership before this offering is based on 75,452,012 shares of our common stock outstanding as December 31, 2022. Beneficial ownership is based on information furnished by the selling stockholders. Unless otherwise indicated and subject to community property laws where applicable, the selling stockholder named in the following table has, to our knowledge, sole voting and investment power with respect to the shares beneficially owned by him.

 

None of the selling stockholders has had any position, office or other material relationship within past three years with the Company. None of the selling stockholders is a broker dealer or an affiliate of a broker dealer. None of the selling stockholders has an agreement or understanding to distribute any of the shares being registered. Each selling stockholder may offer for sale from time to time any or all of the shares, subject to the lock up agreements described in the “Selling Stockholder Plan of Distribution.” The table below assumes that the selling stockholders will sell all of the shares offered for sale hereby. A selling stockholder is under no obligation to sell any shares pursuant to this prospectus.

 

Name of Selling
Stockholder
  Share
Beneficially
Owned Prior
to Offering
    Maximum
Number of
Shares to be
Sold
    Number of
Shares
Owned
after Offering
    Percentage
Ownership
After Offering (%)
 
HKC TALENT LIMITED     8,245,000       3,300,000       4,945,000       6.42  
SHIUH CHOENG OOI     490,000       490,000       -       0.00  
KWAI FAH MOOK     451,000       451,000       -       0.00  
LEE MEE TAN     441,000       441,000       -       0.00  
YEE YEN CHAI     400,000       400,000       -       0.00  
SHEUE YUEN BEH     375,000       375,000       -       0.00  
BEE KIM SER     350,000       350,000       -       0.00  
FOOK SENG YONG     350,000       350,500       -       0.00  
LAY YEN KENG     342,500       342,500       -       0.00  
WENG ONN CHOO     330,000       330,000       -       0.00  
SIAW WEI TEH     317,500       317,500       -       0.00  
KOCK LEONG SIOW     317,000       317,000       -       0.00  
LAI KHUANG TANG     311,000       311,000       -       0.00  
SIEW GIM LAW     310,000       310,000       -       0.00  
POI CHIN WONG     310,000       310,000       -       0.00  
YIT KEONG CHIN     310,000       310,000       -       0.00  
YEW SENG TAN     300,000       300,000       -       0.00  
YONG LEONG KENG     285,000       285,000       -       0.00  
MEI MEI KOR     280,000       280,000       -       0.00  
WAI PENG SEW     265,000       265,000       -       0.00  
MUN FONG CHEAH     250,000       250,000       -       0.00  
WEI TONG CHEE     250,000       250,000       -       0.00  
PEK FEN LEONG     245,000       245,000       -       0.00  
TZY THENG OOI     245,000       245,000       -       0.00  
LI CHENG SOOI     243,000       243,000       -       0.00  
SOON PENG LEONG     240,000       240,000       -       0.00  
KIM YOON YONG     235,000       235,000       -       0.00  
LEE ENG TAN     235,000       235,000       -       0.00  
KING HONG KEE     230,000       230,000       -       0.00  
BEE KIM LAU     230,000       230,000       -       0.00  
EWE BOEY TEH     222,500       222,500       -       0.00  
SOONG FEI YONG     216,000       216,000       -       0.00  
LAY HIONG CHAN     215,000       215,000       -       0.00  
WAI HOONG LAM     215,000       215,000       -       0.00  
HENG HONG GAN     210,000       210,000       -       0.00  
LAY SAM LEE     207,000       207,000       -       0.00  
MEE CHON CHAI     205,000       205,000       -       0.00  
CHIUN YIN LAI     204,000       204,000       -       0.00  
BRANDON KHAI LI YEO     203,154       203,154       -       0.00  
JIN YOONG LIONG     200,000       200,000       -       0.00  
YAW CHONG LAW     200,000       200,000       -       0.00  
YAW HONG LAW     200,000       200,000       -       0.00  
YE BEI SIM     200,000       200,000       -       0.00  
CHUN FAI YAT     200,000       200,000       -       0.00  
SIAW BOON TEH     200,000       200,000                  

 

SS-4

 

 

HOONG LING CHING     200,000       200,000       -       0.00  
JESSICA CHIA WEN SIM     200,000       200,000       -       0.00  
CHOY KIEN ONG     197,000       197,000       -       0.00  
SHI CHENG CHIN     156,000       156,000       -       0.00  
SIEW KIM TEOH     150,000       150,000       -       0.00  
DAMON TESTAVERDE     150,000       150,000       -       0.00  
SAU KHUAN CHOY     135,000       135,000       -       0.00  
LEE LI PING     131,913       131,913       -       0.00  
LAY CHING TAN     130,000       130,000       -       0.00  
BAK HAA HOW     130,000       130,000       -       0.00  
YOKE WAH LEONG     115,000       115,000       -       0.00  
SING HOE KOR     110,000       110,000       -       0.00  
SUI YEE TEE     107,000       107,000       -       0.00  
YOKE MOOI YONG     106,000       106,000       -       0.00  
YAT LONG LEE     106,000       106,000       -       0.00  
PAY FAH LYE     105,000       105,000       -       0.00  
KAH HOU LUM     105,000       105,000       -       0.00  
CHOY LING WONG     105,000       105,000       -       0.00  
KAH MEI WONG     102,000       100,200       -       0.00  
PHOENIX 16 SDN BHD     100,200       100,000       -       0.00  
JIAN CHENG LOO     100,000       100,000       -       0.00  
SWEE PEI NGU     100,000       100,000       -       0.00  
JUN HENG CHEN     100,000       100,000       -       0.00  
POH ONN ONG     100,000       100,000       -       0.00  
WOOI THONG OOI     100,000       100,000       -       0.00  
JIN FOONG LIM     100,000       100,000       -       0.00  
LEAN HOOI LEE     100,000       100,000       -       0.00  
WOON CHEN HO     100,000       100,000       -       0.00  
YAT HENG CHAN     100,000       100,000       -       0.00  
YUEN LOY CHONG     100,000       100,000       -       0.00  
YONG ZHEN NING SHERMAN     100,000       100,000       -       0.00  
TONG KIM LOOI     100,000       100,000       -       0.00  
YOKE LIM TANG     97,000       97,000       -       0.00  
FOO CHOO AU     95,000       95,000       -       0.00  
CHEE KEONG SOO     88,000       88,000       -       0.00  
JIN XUAN HOLDINGS SDN BHD     87,500       87,500       -       0.00  
EE CHIET YAP     85,000       85,000       -       0.00  
KWONG SENG CHAN     82,000       82,000       -       0.00  
SWEE TIAN GOH     80,000       80,000       -       0.00  
SIOK MING LAM     80,000       80,000       -       0.00  
POH YIN SEK     80,000       80,000       -       0.00  
SAN SANG MENG     76,000       76,000       -       0.00  
SIEW MOI HOO     75,000       75,000       -       0.00  
TENG WOEI SHY     75,000       75,000       -       0.00  
CHUN KEAT QUAH     71,000       71,000       -       0.00  
MAN MAN WONG     70,000       70,000       -       0.00  
SIEW WAH TAN     70,000       70,000       -       0.00  
KIAH LING TAN     70,000       70,000       -       0.00  
LEONG CHOY LOH     70,000       70,000       -       0.00  
JOOI PENG ENG     65,000       65,000       -       0.00  
SAU KUAN YEE     61,000       61,000       -       0.00  
YUEN PENG CHAN     60,000       60,000       -       0.00  
YUIN MIN LAI     60,000       60,000       -       0.00  

 

SS-5

 

 

JENNY PON     60,000       60,000       -       0.00  
LEE ZI HAN     60,000       60,000       -       0.00  
TAK PEER EU     60,000       60,000       -       0.00  
KWOK HUNG TSE     59,000       59,000       -       0.00  
PUA SUAT CHOO     57,000       57,000       -       0.00  
LOON HUA PHANG @ DAVID PHANG     55,000       55,000       -       0.00  
HUEY WEN LIM     52,000       52,000       -       0.00  
TENG PIN KHOO     52,000       52,000       -       0.00  
LOU FOOK TAK     52,000       52,000       -       0.00  
CEDE & CO     50,000       50,000       -       0.00  
YET LIEN LIM     50,000       50,000       -       0.00  
SHENG CHEE LIM     50,000       50,000       -       0.00  
TET EAN HEW     50,000       50,000       -       0.00  
THIAN CHAI KHOO     50,000       50,000       -       0.00  
CHUAN SANG CHAI     50,000       50,000       -       0.00  
CHONG KEAT ONG     50,000       50,000       -       0.00  
LAWRENCE CHOON YIAP LAY     50,000       50,000       -       0.00  
WAI LING SEW     50,000       50,000       -       0.00  
TEH LEE SUAN     50,000       50,000       -       0.00  
SHI, KUI     50,000       50,000       -       0.00  
SITTI ZAINAB BT TARUNA     50,000       50,000       -       0.00  
HEW LI YOONG     50,000       50,000       -       0.00  
TAN SWEE LI     50,000       50,000       -       0.00  
HEW TET MIN     50,000       50,000       -       0.00  
MEI YIN LEONG     45,000       45,000       -       0.00  
ANG ONG     45,000       45,000       -       0.00  
SAU KAY YEE     45,000       45,000       -       0.00  
HONG WENG LUM     45,000       45,000       -       0.00  
ONG CHOO KEAT     44,000       44,000       -       0.00  
HUECK CAPITAL SDN BHD     43,718       43,718       -       0.00  
HEW YUEN HOAY     43,000       43,000       -       0.00  
WEI CHOONG CHONG     42,500       42,500       -       0.00  
WENG CHOON FAN     42,000       42,000       -       0.00  
SOON LEE     41,000       41,000       -       0.00  
KUM LOON WONG     40,000       40,000       -       0.00  
YAP HOONG YANG     40,000       40,000       -       0.00  
LEONG SAN FATT     40,000       40,000       -       0.00  
PUI YEE LEE     40,000       40,000       -       0.00  
LOW LEE SUN     40,000       40,000       -       0.00  
WANG CHONG     39,000       39,000       -       0.00  
WEI LEONG CHONG     37,500       37,500       -       0.00  
SOO TENG TAN     37,000       37,000       -       0.00  
SAW BEE YAN     37,000       37,000       -       0.00  
FONG YOKE KAM     36,000       36,000       -       0.00  
GUAN SENG TAN     35,000       35,000       -       0.00  
CHOON YEAN OOI     35,000       35,000       -       0.00  
HUI SHUANG KHOO     35,000       35,000       -       0.00  
KUM LIN LAI     35,000       35,000       -       0.00  
SHIN SHIAW KOR     35,000       35,000       -       0.00  
CHOON KEAT LEE     35,000       35,000       -       0.00  
KHAY PENG KHOO     35,000       35,000       -       0.00  
LUM KAH KEONG     35,000       35,000       -       0.00  
GOH KUEN HOONG     34,000       34,000       -       0.00  

 

SS-6

 

 

LAI YEE YING     32,210       32,210       -       0.00  
VERN LIM GOH     30,500       30,500       -       0.00  
GAN PUI KUAN     30,023       30,023       -       0.00  
KAM LEONG KONG     30,000       30,000       -       0.00  
YIK LOONG ONG     30,000       30,000       -       0.00  
SEE SENG LEE     30,000       30,000       -       0.00  
JING LIU     30,000       30,000       -       0.00  
BEE CHEW TOH     30,000       30,000       -       0.00  
YEOW CHOONG WONG     30,000       30,000       -       0.00  
AH HONG QUAH     30,000       30,000       -       0.00  
SER BEE HWEE     30,000       30,000       -       0.00  
SWE LAN MOK     30,000       30,000       -       0.00  
LOH AH KEEN     30,000       30,000       -       0.00  
BOH CHIN YIN     30,000       30,000       -       0.00  
CHAN MENG CHERK     30,000       30,000       -       0.00  
CHAN WAI CHON     30,000       30,000       -       0.00  
CHAN YOKE YENG     30,000       30,000       -       0.00  
DANG PEK SOON     30,000       30,000       -       0.00  
KHOO CHI TUAN     30,000       30,000       -       0.00  
KHOR CHIN LING     30,000       30,000       -       0.00  
LAM JEN THOU     30,000       30,000       -       0.00  
LAU HUI YAN     30,000       30,000       -       0.00  
LAW TIEN SUNG     30,000       30,000       -       0.00  
THYE ZEN SAN     30,000       30,000       -       0.00  
LEE SEE FUI     30,000       30,000       -       0.00  
LEE YEN FEI     30,000       30,000       -       0.00  
LIEW SOOK MEI     30,000       30,000       -       0.00  
LIM CHIN KHENG     30,000       30,000       -       0.00  
LOO WEN YI     30,000       30,000       -       0.00  
NG SWEE PENG     30,000       30,000       -       0.00  
NGO CHANG LAI     30,000       30,000       -       0.00  
OH SIEW YIEN     30,000       30,000       -       0.00  
WONG MUN LENG     30,000       30,000       -       0.00  
YONG KHONG WEE     30,000       30,000       -       0.00  
WANG HUN     30,000       30,000       -       0.00  
CHIN WEI LIM     30,000       30,000       -       0.00  
MING YEAN LEE     29,500       29,500       -       0.00  
LUM PUI LENG     29,000       29,000       -       0.00  
LIT CHEAN KHOO     28,000       28,000       -       0.00  
AIRLIFT EXPRESS SDN BHD     27,910       27,910       -       0.00  
KHOR CHOON WEI     27,846       27,846       -       0.00  
LAM SEX TIAN     27,417       27,417       -       0.00  
SEE WAN TANG     26,000       26,000       -       0.00  
LAW YEN SHI     25,700       25,700       -       0.00  
SHOO TAI HEA     25,000       25,000       -       0.00  
TAN HOCK ENG     25,000       25,000       -       0.00  
WON SIN THEN     25,000       25,000       -       0.00  
SU ING LEE     25,000       25,000       -       0.00  
KAM FOONG LEONG     25,000       25,000       -       0.00  
CHIN CHYANG CHUA     25,000       25,000       -       0.00  
MUN HENG CHEN     25,000       25,000       -       0.00  
LENG LAI LEE     25,000       25,000       -       0.00  
CHIANG WEI PING     25,000       25,000       -       0.00  
YUAN YU YA     24,500       24,500       -       0.00  
JUN XIANG KHOO     24,000       24,000       -       0.00  

 

SS-7

 

 

YU HSIN NI     23,200       23,200       -       0.00  
BOY MING CHONG @ SWEE FONG CHONG     23,000       23,000       -       0.00  
CHEW LIM LAY BENG     22544       22544       -       0.00  
PHAIK NGOH CHUAH     22,000       22,000       -       0.00  
KONG KENG YIT     22,000       22,000       -       0.00  
TEH LEE LEEN     22,000       22,000       -       0.00  
YEE ZHENG YIP     21,740       21,740       -       0.00  
BENG SHEAN ONG     21,000       21,000       -       0.00  
LIM KIM SWEE     21,000       21,000       -       0.00  
KONG NYOONG LEE     21,000       21,000       -       0.00  
YU WEI VEN     20,414       20,414       -       0.00  
GEE KHENG TEOH     20,000       20,000       -       0.00  
FUNG CHING CHIN     20,000       20,000       -       0.00  
MIN FUN LEE     20,000       20,000       -       0.00  
POOI FOON TAN     20,000       20,000       -       0.00  
SIN WEI GAN     20,000       20,000       -       0.00  
POW LEONG YONG     20,000       20,000       -       0.00  
HA NGOW ONG     20,000       20,000       -       0.00  
LAI HAR KOW     20,000       20,000       -       0.00  
THAIM MENG KHOO     20,000       20,000       -       0.00  
AH MOOI HU     20,000       20,000       -       0.00  
CHUN HAO QUAH     20,000       20,000       -       0.00  
PIK HOON HO     20,000       20,000       -       0.00  
POH KUEN SEK     20,000       20,000       -       0.00  
POH MEI SEK     20,000       20,000       -       0.00  
AMAR FAROUQ BIN KAMARUDDIN     20,000       20,000       -       0.00  
LEE JIANN YAG     20,000       20,000       -       0.00  
TAN BOO PAR     20,000       20,000       -       0.00  
LIM SIEW LEAN     19,021       19,021       -       0.00  
YAP LING HUI     19,000       19,000       -       0.00  
QUEK MEE SIM     19,000       19,000       -       0.00  
LEE CHONG CHOW     19,000       19,000       -       0.00  
KAU YAN TUCK     18,105       18,105       -       0.00  
KHOO TANG ENG     18,000       18,000       -       0.00  
MEI NGOR BEH     17,000       17,000       -       0.00  
CHEONG CHUI LENG     17,000       17,000       -       0.00  
CHOW CHIN FONG     16,576       16,576       -       0.00  
TENG HOOI GOH     16,000       16,000       -       0.00  
AH NIN HU     16,000       16,000       -       0.00  
YIT MING LEE     16,000       16,000       -       0.00  
CHEW WEN FRY     16,000       16,000       -       0.00  
LEE CHEN WEI     16,000       16,000       -       0.00  
TAI CHING LOON     15,979       15,979       -       0.00  
YU WEI JOO     15,586       15,586       -       0.00  
YEOH LAY TENG     15,152       15,152       -       0.00  
FOOK KIT THAM     15,000       15,000       -       0.00  
SIEW MEI MOO     15,000       15,000       -       0.00  
TEOW THEAM ANG     15,000       15,000       -       0.00  
YET SEE THOO     15,000       15,000       -       0.00  
TIONG CHING TEE     15,000       15,000       -       0.00  
KOK WENG YEE     15,000       15,000       -       0.00  
LOO MI TANG     15,000       15,000       -       0.00  
SOW CHOY YEE     15,000       15,000       -       0.00  

 

SS-8

 

 

YING CHEANG LAI     15,000       15,000       -       0.00  
MOOI LIM     15,000       15,000       -       0.00  
PING WAI LAM     15,000       15,000       -       0.00  
GOOI AN TAN     15,000       15,000       -       0.00  
KAM YAU LEONG     15,000       15,000       -       0.00  
CHAU JINN YEE     15,000       15,000       -       0.00  
FE LIX LIM     15,000       15,000       -       0.00  
KAR MUN LIM     15,000       15,000       -       0.00  
LAY PIN LEE     15,000       15,000       -       0.00  
HSIEH HSIU-CHU     15,000       15,000       -       0.00  
SIEW HEOH LIM     15,000       15,000       -       0.00  
GAN SHAW SIANG     15000       15,000       -       0.00  
CHEN TEAK HUAT     14,707       15,000       -       0.00  
AI LING PANG     14,000       15,000       -       0.00  
ONG SOH CHING     14,000       15,000       -       0.00  
BEH YEN THING     14,000       15,000       -       0.00  
CHAN KOK HONG     14,000       15,000       -       0.00  
TAN PEE LEE     14,000       15,000       -       0.00  
CHEN MEE CHING     13,891       15,000       -       0.00  
BEE CHENG LAW     13,000       15,000       -       0.00  
AH MAY LAU     13,000       15000       -       0.00  
BENG HEOK TAN     12,500       14,707       -       0.00  
BERNARD TATT LENG LEE     12,500       14,000       -       0.00  
CHEW NGEE@CHOW YEE     12,000       14,000       -       0.00  
LEE LING TING     12,000       14,000       -       0.00  
PUEA FANG ENG     12,000       14,000       -       0.00  
HUI XIAN HENG     12,000       14,000       -       0.00  
TEK CHIN HEW     12,000       13,891       -       0.00  
CHAI VOON FEI     12,000       13,000       -       0.00  
GOH JIA YING     12,000       13,000       -       0.00  
HENG SENG CHONG     12,000       12,500       -       0.00  
WONG HANG CHEI     12,000       12,500       -       0.00  
TEE KIM HUAT     12,000       12,000       -       0.00  
LEE SONG YEOW     12,000       12,000       -       0.00  
NG KWAN-U     11,305       12,000       -       0.00  
LEE SIEW TSUNG     11,000       12,000       -       0.00  
CHIOH SEOK KIM     11,000       12,000       -       0.00  
GOH AIK CHUAN     11,000       12,000       -       0.00  
YIP SWEE LIAN     11,000       12,000       -       0.00  
WAN SOOK MEE     11,000       12,000       -       0.00  
HONG MUI YONG     10,500       12,000       -       0.00  
CHEN TEIK FOOI     10,001       12,000       -       0.00  
LIM AH BOEY     10,000       12,000       -       0.00  
HENG CHOY LAI     10,000       11,305       -       0.00  
IVY GAIK HWA LIM     10,000       11,000       -       0.00  
WEI LIN MOO     10,000       11,000       -       0.00  
YEE FIEH CHIN     10,000       11,000       -       0.00  
AI NING TING     10,000       11,000       -       0.00  
WEI HWA LIM     10,000       11,000       -       0.00  
SEE WERN GOH     10,000       10,500       -       0.00  
SZE YEE CHUAR     10,000       10,000       -       0.00  
TUAN NEO SEET @ SIEW KWAN TAY     10,000       10,000       -       0.00  
VOON SEONG FOO     10,000       10,000       -       0.00  
WAH CHYE LIM     10,000       10,000       -       0.00  
FOOK EE CHAN     10,000       10,000       -       0.00  
GAIK FOON LAU     10,000       10,000       -       0.00  
GUN HENG CHAN     10,000       10,000       -       0.00  

 

SS-9

 

 

KIAN LEONG WONG     10,000       10,000       -       0.00  
XIN YI KHOO     10,000       10,000       -       0.00  
YEAP TUAN ONG     10,000       10,000       -       0.00  
YEN CHIN OOI     10,000       10,000       -       0.00  
YONG HUI LAW     10,000       10,000       -       0.00  
TEK KHION HEW     10,000       10,000       -       0.00  
KAM MOI MONG     10,000       10,000       -       0.00  
SIEW CHOO TIONG     10,000       10,000       -       0.00  
FUI LIN CHONG     10,000       10,000       -       0.00  
CHANG YUNG HOO     10,000       10,000       -       0.00  
CHEE KONG SOO     10,000       10,000       -       0.00  
CHEE LOI CHENG     10,000       10,000       -       0.00  
YUN CHYN HO     10,000       10,000       -       0.00  
AH CHONG LOH     10,000       10,000       -       0.00  
SUJANI GUNTORO     10,000       10,000       -       0.00  
WAI WAH LEE     10,000       10,000       -       0.00  
CHUN SHU OOI     10,000       10,000       -       0.00  
KAH YI MOO     10,000       10,000       -       0.00  
KIAH LOON TAN     10,000       10,000       -       0.00  
KIM HUAT LEE     10,000       10,000       -       0.00  
LEE LEE TAN     10,000       10,000       -       0.00  
LEE YONG DEANG     10,000       10,000       -       0.00  
MUN YEE CHIN     10,000       10,000       -       0.00  
SIENG ONG YAP     10,000       10,000       -       0.00  
SOH JIA MUN     10,000       10,000       -       0.00  
SIEW FOONG SUM     10,000       10,000       -       0.00  
TIO HOCK LAI     10,000       10,000       -       0.00  
CHEW LAY BEE     10,000       10,000       -       0.00  
KENG YONG SENG     10,000       10,000       -       0.00  
LEE LE TAN     10,000       10,000       -       0.00  
NAI CHOON SIANG     10,000       10,000       -       0.00  
NG HOY BAN     10,000       10,000       -       0.00  
ONG EWE HIN     10,000       10,000       -       0.00  
YEE SAU CHOY     10,000       10,000       -       0.00  
TANG LAI KHUANG     10,000       10,000       -       0.00  
LAM CHIAN KOK     10,000       10,000       -       0.00  
CHUNG TU KENG     10,000       10,000       -       0.00  
CHUNG WOOI HEN     10,000       10,000       -       0.00  
KUAN YING WONG     9,500       9,500       -       0.00  
TANG PEI SAN     9,250       9,250       -       0.00  
CHRISTINA LIN LEAN TAN     9,000       9,000       -       0.00  
MEI YIN LEE     9,000       9,000       -       0.00  
HUAN HING CHAN     9,000       9,000       -       0.00  
KEE SIONG CHIN     9,000       9,000       -       0.00  
SEE HUI KHOR     9,000       9,000       -       0.00  
WONG TAI     9,000       9,000       -       0.00  
LAI YUIN PIN     9,000       9,000       -       0.00  
NGOI KAM HEONG     9,000       9,000       -       0.00  
ONG SEOK GNOH     9,000       9,000       -       0.00  
RUONAN KOH     9,000       9,000       -       0.00  
LEE CHEE HOOI     9,000       9,000       -       0.00  
LIM CHEE WAH     9,000       9,000       -       0.00  
ONG SIEW CHONG @     9,000       9,000       -       0.00  
ENG KHENG LAU     8,500       8,500       -       0.00  
CHEN HOOY LEE     8,320       8,320       -       0.00  

 

SS-10

 

 

TAN MING FU     8,000       8,000       -       0.00  
LIEW KENG TECK     8,000       8,000       -       0.00  
ONG ENG YEW     8,000       8,000       -       0.00  
MAH POOI YAN     8,000       8,000       -       0.00  
TEH MEI KUIN     8,000       8,000       -       0.00  
ONG BENG SHEAN     8,000       8,000       -       0.00  
TERRENCE TAN HUAT HIN     8,000       8,000       -       0.00  
TAN KIM LYE     8,000       8,000       -       0.00  
HAU WAN HOCK     8,000       8,000       -       0.00  
SHI YNG LOH     7,500       7,500       -       0.00  
KENG SUAN BEH     7,500       7,500       -       0.00  
SHED HEONG LOW     7,500       7,500       -       0.00  
KIM YONG KHOO     7,500       7,500       -       0.00  
AIK HONG HO     7,500       7,500       -       0.00  
KIM SENG WONG     7,500       7,500       -       0.00  
SIEW HING NG     7,500       7,500       -       0.00  
PANG ENG MAY     7,273       7,273       -       0.00  
HONG SENG LIM     7,000       7,000       -       0.00  
WAI YEE LEE     7,000       7,000       -       0.00  
CHOI SIM TEOH     7,000       7,000       -       0.00  
YOKE MUN SEK     7,000       7,000       -       0.00  
YIT FONG CHAN     7,000       7,000       -       0.00  
YE CHENG CHIN     7,000       7,000       -       0.00  
SENG CHONG NG     7,000       7,000       -       0.00  
PUA PUA ENG     7,000       7,000       -       0.00  
POH MEE HOR     7,000       7,000       -       0.00  
YOONG YEW PHANG     7,000       7,000       -       0.00  
BEH KEAN THYE     7,000       7,000       -       0.00  
BEH YEN SUN     7,000       7,000       -       0.00  
CHIAM AH SIEW     7,000       7,000       -       0.00  
CHONG YEONG KON     7,000       7,000       -       0.00  
CHOW CHIA SIN     7,000       7,000       -       0.00  
CHU SHIH KAN     7,000       7,000       -       0.00  
CHUA YAH LI     7,000       7,000       -       0.00  
HENG YIANG CHURN     7,000       7,000       -       0.00  
KENG SHI YUN     7,000       7,000       -       0.00  
KHOR CHEE GUAN     7,000       7,000       -       0.00  
KHOR YING YING     7,000       7,000       -       0.00  
LAM KIM SING     7,000       7,000       -       0.00  
LAU HIN REEI     7,000       7,000       -       0.00  
LEE SEU WEE     7,000       7,000       -       0.00  
LIM HOCK KENG     7,000       7,000       -       0.00  
NG SIEW BOON     7,000       7,000       -       0.00  
NGAN SIEW BUN     7,000       7,000       -       0.00  
ONG SWEE SUNG     7,000       7,000       -       0.00  
SHIEW BEH BEE     7,000       7,000       -       0.00  
SIM POH SUAN     7,000       7,000       -       0.00  
SOON HEOH KEE     7,000       7,000       -       0.00  
TAN SOH YEOK     7,000       7,000       -       0.00  
YEE CHOW HOI     7,000       7,000       -       0.00  
LEE CHEE HOONG     7,000       7,000       -       0.00  
TSANG TUNG     7,000       7,000       -       0.00  
HUANG XIUYING     7,000       7,000       -       0.00  
TING-YEN KUO     7,000       7,000       -       0.00  
WONG KAM WENG     7,000       7,000       -       0.00  

 

SS-11

 

 

CHRISTOPHER JOHN BAPTIST     6,060       6060       -       0.00  
CHAN BOON LIANG     6,000       6,000       -       0.00  
YOON SUN HOO     6,000       6,000       -       0.00  
YEE WON CHIN     6,000       6,000       -       0.00  
MOOI SEE KHOR     6,000       6,000       -       0.00  
LIM CHIEW WEI     6,000       6,000       -       0.00  
CHEONG CHEE SENG     6,000       6,000       -       0.00  
HIEW OI CHOO     6,000       6,000       -       0.00  
KUAY SEIONG LEE     6,000       6,000       -       0.00  
LAM CHEE MIN     6,000       6,000       -       0.00  
LEE TIAN CHIAT     6,000       6,000       -       0.00  
NG PAN LIAN     6,000       6,000       -       0.00  
ONG XIN MIN     6,000       6,000       -       0.00  
PHUAH CHIN CHYE     6,000       6,000       -       0.00  
GOH LYE CHOO     6,000       6,000       -       0.00  
SIVA SHANMUGAM A/L DHANAPALU     6,000       6,000       -       0.00  
CHU MIN-CHANG     6,000       6,000       -       0.00  
EU TAK PEER     6,000       6,000       -       0.00  
SHIM PHUI SAN     6,000       6,000       -       0.00  
NG HOOI HAR     5,636       5,636       -       0.00  
MICHAEL ALEXON TAY KAI FOONG     5,520       5,520       -       0.00  
THUM XUE SHENG     5,500       5,500       -       0.00  
CHIA CHOON MIN     5,500       5,500       -       0.00  
CHIN WEI LIM     5,000       5,000       -       0.00  
LEE YING HO     5,000       5,000       -       0.00  
PEI NGIN NG     5,000       5,000       -       0.00  
REN LI CHAI     5,000       5,000       -       0.00  
CHUN YEEN OOI     5,000       5,000       -       0.00  
FOONG YEE LAW     5,000       5,000       -       0.00  
CZEE TING LEE     5,000       5,000       -       0.00  
SHAN SHAN LING     5,000       5,000       -       0.00  
SIEW WAN TANG     5,000       5,000       -       0.00  
WOOI LIANG LEE     5,000       5,000       -       0.00  
AH HONG TAN     5,000       5,000       -       0.00  
AH PENG YEE     5,000       5,000       -       0.00  
AH SUAN HUNG     5,000       5,000       -       0.00  
ALAN YAP @ LEE CHERN YAP     5,000       5,000       -       0.00  
BEE KIAN WONG     5,000       5,000       -       0.00  
SIEW LING LEW     5,000       5,000       -       0.00  
SIEW MOI KOK     5,000       5,000       -       0.00  
SIEW PENG TANG     5,000       5,000       -       0.00  
SIEW YEN TAN     5,000       5,000       -       0.00  
SIN LAI CHANG     5,000       5,000       -       0.00  
SIN YAU CHEAH     5,000       5,000       -       0.00  
SING KIAT KOR     5,000       5,000       -       0.00  
SIOK CHIN YEE     5,000       5,000       -       0.00  
SIT MOOI LEONG     5,000       5,000       -       0.00  
SIWE LEY LIAU     5,000       5,000       -       0.00  
SOON LING CHENG     5,000       5,000       -       0.00  
STEPHEN KOK HIN LEONG     5,000       5,000       -       0.00  
SU LING TAN     5,000       5,000       -       0.00  
SIEW KUAN CHEN     5,000       5,000       -       0.00  
SIEW LAY LAW     5,000       5,000       -       0.00  
SUI CHENG CHAN     5,000       5,000       -       0.00  
YUN HIN LOH     5,000       5,000       -       0.00  

 

SS-12

 

 

ABDUL MU’IZZ BIN ABD KAHAR     5,000       5,000       -       0.00  
CHEONG KEE TAN     5,000       5,000       -       0.00  
HAN KHUAN HONG     5,000       5,000       -       0.00  
JUN GIAP LAU     5,000       5,000       -       0.00  
KIM SOON LIM     5,000       5,000       -       0.00  
MEI FAH YAP     5,000       5,000       -       0.00  
PENG LEE     5,000       5,000       -       0.00  
PUI YAN GAN     5,000       5,000       -       0.00  
SIEW MEI YEOH     5,000       5,000       -       0.00  
YEN PIN BEH     5,000       5,000       -       0.00  
ZHI WEI TAN     5,000       5,000       -       0.00  
CHANG BOON BEH     5,000       5,000       -       0.00  
BOON AI HENG @ BOON AI ONG     5,000       5,000       -       0.00  
BOON HONG ANG     5,000       5,000       -       0.00  
CHUO JVIN TEE     5,000       5,000       -       0.00  
DARREN KHAI XU YEO     5,000       5,000       -       0.00  
LI LEAN LIM     5,000       5,000       -       0.00  
SENG CHAI ONG     5,000       5,000       -       0.00  
SOO LENG NG     5,000       5,000       -       0.00  
TAN CHAN     5,000       5,000       -       0.00  
TECK WEE TAN     5,000       5,000       -       0.00  
YEE CHIN WONG     5,000       5,000       -       0.00  
SWEE CHIN LIM     5,000       5,000       -       0.00  
SWEE WAN LAM     5,000       5,000       -       0.00  
TAI CHU LEE     5,000       5,000       -       0.00  
TECK ONN LEONG     5,000       5,000       -       0.00  
TECK SEONG WONG     5,000       5,000       -       0.00  
TECK VOON WONG     5,000       5,000       -       0.00  
TENG CHEN MOO     5,000       5,000       -       0.00  
TENG PONG MOO     5,000       5,000       -       0.00  
TIONG WAN TEY     5,000       5,000       -       0.00  
WAI LIENG NG     5,000       5,000       -       0.00  
WEI KIAT TAN     5,000       5,000       -       0.00  
WEI LING NG     5,000       5,000       -       0.00  
ZHI WEN LOW     5,000       5,000       -       0.00  
AH MENG TAN     5,000       5,000       -       0.00  
AIK KUAN CHEAH     5,000       5,000       -       0.00  
ANNE GAIK LIN LIM     5,000       5,000       -       0.00  
ASIA AN KHONG     5,000       5,000       -       0.00  
BENG TECK HEE     5,000       5,000       -       0.00  
CHAU SOON TIONG     5,000       5,000       -       0.00  
CHEE NENG YONG     5,000       5,000       -       0.00  
CHIN WOO KHOR     5,000       5,000       -       0.00  
CHING MEI WAI     5,000       5,000       -       0.00  
CHOON HEE HAR     5,000       5,000       -       0.00  
CHUI CHIN LOH     5,000       5,000       -       0.00  
CHUI NGO KEONG     5,000       5,000       -       0.00  
DORIS HONG GEK TAN     5,000       5,000       -       0.00  
ENG CHAI LIM     5,000       5,000       -       0.00  
ENG ENG TAN     5,000       5,000       -       0.00  
ENG HOO CHOO     5,000       5,000       -       0.00  
FAN HON CHONG     5,000       5,000       -       0.00  
HENG TING CHI     5,000       5,000       -       0.00  
HEOK KENG ENG     5,000       5,000       -       0.00  
HOAY NEE KHOO     5,000       5,000       -       0.00  
HONG CHU CHIA     5,000       5,000       -       0.00  

 

SS-13

 

 

HOOI JING TAN   5,000    5,000    -    0.00 
HUEY PING TAN   5,000    5,000    -    0.00 
KAM LAI WONG   5,000    5,000    -    0.00 
KENG HUA HOO   5,000    5,000    -    0.00 
KENG WOH LEONG   5,000    5,000    -    0.00 
KHENG SIANG LIM   5,000    5,000    -    0.00 
KHOW CHING CHEN   5,000    5,000    -    0.00 
KOOI HIANG OOI   5,000    5,000    -    0.00 
LEE LEE NG   5,000    5,000    -    0.00 
LEE SIANG LIM   5,000    5,000    -    0.00 
MEI FONG LEE   5,000    5,000    -    0.00 
MENG YEP CHAN   5,000    5,000    -    0.00 
MOI HWA LIM   5,000    5,000    -    0.00 
XIN HUI KHOO   5,000    5,000    -    0.00 
YAH LING TAN   5,000    5,000    -    0.00 
YAU KWANG CH’NG   5,000    5,000    -    0.00 
YEE CHEN OH   5,000    5,000    -    0.00 
YEE SIANG ONG   5,000    5,000    -    0.00 
WEI YEE SOO   5,000    5,000    -    0.00 
YEOK HONG LIM   5,000    5,000    -    0.00 
WENG KONG CHOH   5,000    5,000    -    0.00 
YEOK KIM KONG   5,000    5,000    -    0.00 
YEW CHUNG LAU   5,000    5,000    -    0.00 
YIK SING ONG   5,000    5,000    -    0.00 
YIN FHAN CHOY   5,000    5,000    -    0.00 
YIN PENG SIN   5,000    5,000    -    0.00 
YOKE FAR WONG   5,000    5,000    -    0.00 
NGIT KUAI CHEONG   5,000    5,000    -    0.00 
PEI HEE TEH   5,000    5,000    -    0.00 
PENG LEONG TAN   5,000    5,000    -    0.00 
PUI YEE YAP   5,000    5,000    -    0.00 
RHUN YAN LEE   5,000    5,000    -    0.00 
SAW LING QUAH   5,000    5,000    -    0.00 
SEE YONG LOW   5,000    5,000    -    0.00 
SEET LEE YONG   5,000    5,000    -    0.00 
SEWU WAH TEOH   5,000    5,000    -    0.00 
SIEW ENG KWAH   5,000    5,000    -    0.00 
SIEW FONG LOW   5,000    5,000    -    0.00 
SIEW KEEN CHOK   5,000    5,000    -    0.00 
SIEW LING TAN   5,000    5,000    -    0.00 
SOCK KIEW LING   5,000    5,000    -    0.00 
SOK KEAN TIAH   5,000    5,000    -    0.00 
SOO KHENG TEOH   5,000    5,000    -    0.00 
SOOI SEAN LEE   5,000    5,000    -    0.00 
SWEE YIN CHONG   5,000    5,000    -    0.00 
WAI SEE NG   5,000    5,000    -    0.00 
WEI KEAT KOH   5,000    5,000    -    0.00 
WEI LIH CHONG   5,000    5,000    -    0.00 
WENG FUI CHAN   5,000    5,000    -    0.00 
WENG HOE LAU   5,000    5,000    -    0.00 
YEE TENG LOW   5,000    5,000    -    0.00 
YEW HENG KOEY   5,000    5,000    -    0.00 
YIIK YEK WONG   5,000    5,000    -    0.00 

 

SS-14

 

 

YIP HING WONG   5,000    5,000    -    0.00 
YOKE LAN CHOW   5,000    5,000    -    0.00 
YU LEAN LIM   5,000    5,000    -    0.00 
YONG MENG TEO   5,000    5,000    -    0.00 
YONG QUAN LAW   5,000    5,000    -    0.00 
YUEN LIAN CHEN   5,000    5,000    -    0.00 
YUEN WAH CHONG   5,000    5,000    -    0.00 
AH WAH TING   5,000    5,000    -    0.00 
CHAN THONG LOW   5,000    5,000    -    0.00 
CHONG KEOW CHAN   5,000    5,000    -    0.00 
HONG YEAN LUM   5,000    5,000    -    0.00 
KOK TONG MOK   5,000    5,000    -    0.00 
LAI NGO EU   5,000    5,000    -    0.00 
LAY PENG KUOK   5,000    5,000    -    0.00 
LI WEI LEE   5,000    5,000    -    0.00 
LI YEE LEE   5,000    5,000    -    0.00 
MOOI MOOI HEE   5,000    5,000    -    0.00 
PUI FONG CHONG   5,000    5,000    -    0.00 
BING BOON CHONG   5,000    5,000    -    0.00 
BOON KWAN YEAP   5,000    5,000    -    0.00 
BOON SIN QUAH   5,000    5,000    -    0.00 
CHAI YIN SIOW   5,000    5,000    -    0.00 
CHAO WEY QUAH   5,000    5,000    -    0.00 
CHEE HONG ANG   5,000    5,000    -    0.00 
CHEE RAI LIM   5,000    5,000    -    0.00 
CHIA YEE TAN   5,000    5,000    -    0.00 
CHIN CHEW SO   5,000    5,000    -    0.00 
CHIN SENG TEOH   5,000    5,000    -    0.00 
CHING HWA WOO   5,000    5,000    -    0.00 
CHING WEI TAN   5,000    5,000    -    0.00 
SENG LOY CHEE   5,000    5,000    -    0.00 
SIEW SENG LOH   5,000    5,000    -    0.00 
YAN YAT HAH   5,000    5,000    -    0.00 
CHOOI NAI NG   5,000    5,000    -    0.00 
CHOW HELEN   5,000    5,000    -    0.00 
CHU LENG CHAN   5,000    5,000    -    0.00 
CHUEN YUONG CHEW   5,000    5,000    -    0.00 
CHUN KIT SOO   5,000    5,000    -    0.00 
CHUN YEW YEE   5,000    5,000    -    0.00 
ERIC SZE HERN CHEN   5,000    5,000    -    0.00 
FOON YIN CHOONG   5,000    5,000    -    0.00 
GUAT LEE TAN   5,000    5,000    -    0.00 
HAM FAH CHIN   5,000    5,000    -    0.00 
HAW LEONG LING   5,000    5,000    -    0.00 
HAW SYUAN CHAN   5,000    5,000    -    0.00 
HIONG LANG LING   5,000    5,000    -    0.00 
HO CHENG CHAN   5,000    5,000    -    0.00 
HOCK CHOON LING   5,000    5,000    -    0.00 
HOCK GUAN YEOH   5,000    5,000    -    0.00 
HOCK MING TAN   5,000    5,000    -    0.00 
HOU TING CHONG   5,000    5,000    -    0.00 
HUI FANG TAN   5,000    5,000    -    0.00 
HUI LING ONG   5,000    5,000    -    0.00 
JACKIE CHOOI LIN LING   5,000    5,000    -    0.00 
JIANG WEN NG   5,000    5,000    -    0.00 

 

SS-15

 

 

JOO LIANG YEK   5,000    5,000    -    0.00 
CHOI CHOI WONG   5,000    5,000    -    0.00 
SIOK YING HEN   5,000    5,000    -    0.00 
THAI LIM NGAI   5,000    5,000    -    0.00 
AH THYE SUM   5,000    5,000    -    0.00 
KAM HONG YONG   5,000    5,000    -    0.00 
SAN WAH LING @ SIN WAH LIN   5,000    5,000    -    0.00 
YIN MAI WONG   5,000    5,000    -    0.00 
CYNTHIA SHING YEH CHE   5,000    5,000    -    0.00 
FRANCIS @ PERNG LI YONG   5,000    5,000    -    0.00 
KEE BING WONG   5,000    5,000    -    0.00 
KEE HIAN WONG   5,000    5,000    -    0.00 
LEE HUANG NG   5,000    5,000    -    0.00 
OOI LING ONG   5,000    5,000    -    0.00 
ROYCE KAO TZIAT YEOH   5,000    5,000    -    0.00 
TIAM LAI TAN@ YOKE FOONG CHAN   5,000    5,000    -    0.00 
CHUN YING WU   5,000    5,000    -    0.00 
NAN ANN LOW   5,000    5,000    -    0.00 
SENG DIONG TIANG   5,000    5,000    -    0.00 
DENNIS SOON CHIN LIM   5,000    5,000    -    0.00 
PEAK CHOO LOW   5,000    5,000    -    0.00 
JOSEPH KAI WEI KOR   5,000    5,000    -    0.00 
KAI CHEONG LOKE   5,000    5,000    -    0.00 
KAR MIN SOO   5,000    5,000    -    0.00 
KAR YAN KONG   5,000    5,000    -    0.00 
KAR YEE KONG   5,000    5,000    -    0.00 
KEA CHAI LING   5,000    5,000    -    0.00 
KEAN HOONG WONG   5,000    5,000    -    0.00 
KEAN MING WONG   5,000    5,000    -    0.00 
KEAT KOK YEOH   5,000    5,000    -    0.00 
KENG LENG CHAN   5,000    5,000    -    0.00 
KHAI WAI LOW   5,000    5,000    -    0.00 
KIN PAO KONG   5,000    5,000    -    0.00 
KING YONG KEE   5,000    5,000    -    0.00 
KOK KEONG PEE   5,000    5,000    -    0.00 
KOK SHOONG NG   5,000    5,000    -    0.00 
KOOI LEAN OOI   5,000    5,000    -    0.00 
KOOI SIM TAN   5,000    5,000    -    0.00 
KUN SENG CHEW   5,000    5,000    -    0.00 
KYE SWEN KHOR   5,000    5,000    -    0.00 
LAY KIM KUOK   5,000    5,000    -    0.00 
LEAN KEONG TAN   5,000    5,000    -    0.00 
LEE CHEN DEO   5,000    5,000    -    0.00 
LEE HOW CHIN   5,000    5,000    -    0.00 
LEE WEN WOO   5,000    5,000    -    0.00 
LEE YEE CHEONG   5,000    5,000    -    0.00 
LENG LENG GOH   5,000    5,000    -    0.00 
LEONG SENG WONG   5,000    5,000    -    0.00 
LIAN HUI TAN   5,000    5,000    -    0.00 
MEE GOKE TANG   5,000    5,000    -    0.00 
CHIEW TEE WONG   5,000    5,000    -    0.00 
SHIN JOWL TAN   5,000    5,000    -    0.00 
LIM HONG CHAN   5,000    5,000    -    0.00 
LIP TATT YAP   5,000    5,000    -    0.00 
LIZA CHIEW WEI WONG   5,000    5,000    -    0.00 

 

SS-16

 

 

LUIS R DUTAN   5,000    5,000    -    0.00 
MEE CHAN WONG   5,000    5,000    -    0.00 
MEE CHOO BEH   5,000    5,000    -    0.00 
MEI HAR TEE   5,000    5,000    -    0.00 
MEI LING TEN   5,000    5,000    -    0.00 
MENG KWAN LIM   5,000    5,000    -    0.00 
MEOW NING ANG   5,000    5,000    -    0.00 
MICHELLE KUAN WEI SHIA   5,000    5,000    -    0.00 
MING YONG LEE   5,000    5,000    -    0.00 
MOOI SUAN BEH   5,000    5,000    -    0.00 
PAK LING LEE   5,000    5,000    -    0.00 
PEI XIAN CHAN   5,000    5,000    -    0.00 
PEIK HOON TAN   5,000    5,000    -    0.00 
POH TEE KHOO   5,000    5,000    -    0.00 
POH YEE ONG   5,000    5,000    -    0.00 
POOI LING PANG   5,000    5,000    -    0.00 
PRASERT SAE LOI @ BOON KEAN LOI   5,000    5,000    -    0.00 
PU YUN LEE   5,000    5,000    -    0.00 
REN HAO PANG   5,000    5,000    -    0.00 
SAW PHAIK CHEAH   5,000    5,000    -    0.00 
SEE FONG YAP   5,000    5,000    -    0.00 
SEEN HENG LEE   5,000    5,000    -    0.00 
SEK FOO LEE   5,000    5,000    -    0.00 
SENG YI NG   5,000    5,000    -    0.00 
SHEUE NIE TAN   5,000    5,000    -    0.00 
SIEN CHUEN TEE   5,000    5,000    -    0.00 
SIEW HONG TEO   5,000    5,000    -    0.00 
JOO HENG LEE   5,000    5,000    -    0.00 
YEE JING WONG   5,000    5,000    -    0.00 
BENJAMIN ENG KEEN ONG   5,000    5,000    -    0.00 
NAI FOO YEAP   5,000    5,000    -    0.00 
MEI LING TEE   5,000    5,000    -    0.00 
SIEW YOKE TAN   5,000    5,000    -    0.00 
SAU PING PAT LAI   5,000    5,000    -    0.00 
CHUN LOONG TEOH   5,000    5,000    -    0.00 
RENE CAMPOS   5,000    5,000    -    0.00 
LIP CHIN HO   5,000    5,000    -    0.00 
BEE HONG ANG   5,000    5,000    -    0.00 
FU KANG CHOR   5,000    5,000    -    0.00 
LIN LIN LIM   5,000    5,000    -    0.00 
SENG SEONG U   5,000    5,000    -    0.00 
BENG SENG SOOI   5,000    5,000    -    0.00 
SING KIONG TING   5,000    5,000    -    0.00 
AH CHU TING @ KOK CHENG TING   5,000    5,000    -    0.00 
JOGINDER KAUR A/P GIAN SINGH @ KINA S   5,000    5,000    -    0.00 
KIM FOONG LEE   5,000    5,000    -    0.00 
CHANG CHIANG JU   5,000    5,000    -    0.00 
CHEW SOON HOCK   5,000    5,000    -    0.00 
HOOI HAR NG   5,000    5,000    -    0.00 
HOOI HOE NG   5,000    5,000    -    0.00 
CHANG CHONG CHIEK   5,000    5,000    -    0.00 
CHEAH LAY JAN   5,000    5,000    -    0.00 
CHIA NOI KEE   5,000    5,000    -    0.00 
CHONG BENG GEOK   5,000    5,000    -    0.00 
FOO AIK SEN   5,000    5,000    -    0.00 
GOH LI LING   5,000    5,000    -    0.00 
KHOR KENG BENG   5,000    5,000    -    0.00 
LEE LI SEE   5,000    5,000    -    0.00 
LIONG KHIM YUN   5,000    5,000    -    0.00 

 

SS-17

 

 

NG KONG SOON     5,000       5,000       -       0.00  
NGAN SIEW CHIN     5,000       5,000       -       0.00  
TAN KAR YIAN     5,000       5,000       -       0.00  
PANG AH SENG     5,000       5,000       -       0.00  
TANG LOO SEE     5,000       5,000       -       0.00  
TOH LAN KIM     5,000       5,000       -       0.00  
YAN LAI KUAN     5,000       5,000       -       0.00  
CHIN HEONG CHIA     5,000       5,000       -       0.00  
JEFFREY ANAK LUKE JELY     5,000       5,000       -       0.00  
CHONG SWEE YIN     5,000       5,000       -       0.00  
YA YOKE CHUAN     5,000       5,000       -       0.00  
CHIA GET KIANG     5,000       5,000       -       0.00  
CHOY SAU KHUAN     5,000       5,000       -       0.00  
YAW LEE ENG     5,000       5,000       -       0.00  
LEE YING HO     5,000       5,000       -       0.00  
CHONG YOKE CHOO     5,000       5,000       -       0.00  
YONG POW LEONG     5,000       5,000       -       0.00  
NGU GOH HUI     4,500       4,500       -       0.00  
TAN BOON YEE     4,500       4,500       -       0.00  
HOW KHOON MENG     4,500       4,500       -       0.00  
HSU YUAN, HSIAN-WAN     4,300       4,300       -       0.00  
KUO TING-YEN     4,300       4,300       -       0.00  
LIN SIEW MEI     4,187       4,187       -       0.00  
MEI CHING JOO     4,000       4,000       -       0.00  
LUM LEE CHIN     4,000       4,000       -       0.00  
YAP SENG FUNG     4,000       4,000       -       0.00  
GOH YIN SOON     4,000       4,000       -       0.00  
CHIN FA HOY     4,000       4,000       -       0.00  
CHIA SIN HOCK     4,000       4,000       -       0.00  
ANG CHYE HOON     4,000       4,000       -       0.00  
CHAI KAR YAN     4,000       4,000       -       0.00  
CHEONG LING     4,000       4,000       -       0.00  
CHEW LIM LAY BENG     4,000       4,000       -       0.00  
CHIEW POH IM     4,000       4,000       -       0.00  
CHIN KAM SOON     4,000       4,000       -       0.00  
CHIN KIM MEEI     4,000       4,000       -       0.00  
CHIN SIEW CHING     4,000       4,000       -       0.00  
CHIN SIN MOOI     4,000       4,000       -       0.00  
CHOO CHIEH TA     4,000       4,000       -       0.00  
CHOONG MOOI MOOI     4,000       4,000       -       0.00  
CHUAH SIONG TENG     4,000       4,000       -       0.00  
CYNTHIA LOH MEI OON     4,000       4,000       -       0.00  
GAN AH TOOH     4,000       4,000       -       0.00  
GOH SIEW BIN     4,000       4,000       -       0.00  
HIEW HUEI PANG     4,000       4,000       -       0.00  
HOO MEI SING     4,000       4,000       -       0.00  
IVY LOW CHIEW NI     4,000       4,000       -       0.00  
KHOR KOON HOE     4,000       4,000       -       0.00  
KOH CHEE YONG     4,000       4,000       -       0.00  
KOR KOK KEONG     4,000       4,000       -       0.00  
LAM AH CHONG     4,000       4,000       -       0.00  
LEE CHOON JUAN     4,000       4,000       -       0.00  
LEE SIEW YING     4,000       4,000       -       0.00  
LEE WAI SENG     4,000       4,000       -       0.00  
LIEW KIAM KHEN     4,000       4,000       -       0.00  
LIEW KIM NYEAN     4,000       4,000       -       0.00  

 

SS-18

 

 

LIM BING LING     4,000       4,000       -       0.00  
LIM HONG CHOONG     4,000       4,000       -       0.00  
LIM OON SIN     4,000       4,000       -       0.00  
LIM SOK PENG     4,000       4,000       -       0.00  
LING YOON CHANG     4,000       4,000       -       0.00  
LOH CHUI CHUI     4,000       4,000       -       0.00  
LOK YUH TENG     4,000       4,000       -       0.00  
LOW WEY LIANG     4,000       4,000       -       0.00  
NG BOON GHEE     4,000       4,000       -       0.00  
NG KIEW HEONG     4,000       4,000       -       0.00  
NG SENG FANG     4,000       4,000       -       0.00  
OH KAH LEE     4,000       4,000       -       0.00  
OH SANG SIK     4,000       4,000       -       0.00  
ONG SHUE LING     4,000       4,000       -       0.00  
OOI KEAN HONG     4,000       4,000       -       0.00  
PAN KOK KEE     4,000       4,000       -       0.00  
PHANG PEI LIN     4,000       4,000       -       0.00  
PUTT YOKE POI     4,000       4,000       -       0.00  
QUAH LAY HOOI     4,000       4,000       -       0.00  
SUM LYE YENG     4,000       4,000       -       0.00  
TAI CHOO YOKE     4,000       4,000       -       0.00  
TAN CHIN KHEONG     4,000       4,000       -       0.00  
TAN CHOON CHUI     4,000       4,000       -       0.00  
TAN LIAN WEI     4,000       4,000       -       0.00  
TAN LIE HAU     4,000       4,000       -       0.00  
TANG SIANK CHIN     4,000       4,000       -       0.00  
TEOH MENG PIN     4,000       4,000       -       0.00  
TUNG MAY YOKE     4,000       4,000       -       0.00  
WONG MEE KAM     4,000       4,000       -       0.00  
WONG MEI NGOH     4,000       4,000       -       0.00  
YEM HUI KIM     4,000       4,000       -       0.00  
CHANG MEI HUI     4,000       4,000       -       0.00  
TEO KUET TZE     4,000       4,000       -       0.00  
TAN KIM AN     4,000       4,000       -       0.00  
KONG MEI KENG     4,000       4,000       -       0.00  
CHAN POH YIN     4,000       4,000       -       0.00  
HING PUI LEE     4,000       4,000       -       0.00  
LEE CHOW YOONG     4,000       4,000       -       0.00  
LIM SEOW FON     4,000       4,000       -       0.00  
LIM YEOK LEAN     4,000       4,000       -       0.00  
CHIN KEE SIONG     4,000       4,000       -       0.00  
CHEAH SIN CHYE     4,000       4,000       -       0.00  
LEE WAI CHENG     4,000       4,000       -       0.00  
LIM SEN HUAI     3,985       3,985       -       0.00  
PHOENIX PLUS HOLDING SDN BHD     3,500       3,500       -       0.00  
TAN PEI LENG     3,500       3,500       -       0.00  
CHU SOO LING     3,500       3,500       -       0.00  
HO YEEK MING     3,500       3,500       -       0.00  
NG HAEN JIAN     3,500       3,500       -       0.00  
THUM KUM WYE     3,500       3,500       -       0.00  
TING SING CHUNG     3,500       3,500       -       0.00  
ONG YEE LYN     3,080       3,080       -       0.00  
THIAN KAH TUCK     3,000       3,000       -       0.00  
YAP GEOK HWA     3,000       3,000       -       0.00  
SUET MOOI TAN     3,000       3,000       -       0.00  
TAN KIM FEN     3,000       3,000       -       0.00  

 

SS-19

 

 

LEE KIM SIONG     3,000       3,000       -       0.00  
SIEW SEAN KOR     3,000       3,000       -       0.00  
LIEW TONG HON     3,000       3,000       -       0.00  
CHIA MING MING     3,000       3,000       -       0.00  
KONG GAIK CHENG     3,000       3,000       -       0.00  
LOONG YAN SANG     3,000       3,000       -       0.00  
TAY JUN JIE     3,000       3,000       -       0.00  
FRANCIS PERNG LI YONG     3,000       3,000       -       0.00  
LAI MEI FANG     3,000       3,000       -       0.00  
SIEW SIN TAN     2,500       2,500       -       0.00  
CHOON HAN LEE     2,500       2,500       -       0.00  
SOCK HWA LIM     2,500       2,500       -       0.00  
THIAM CHAI LEE     2,500       2,500       -       0.00  
TZE SHIAN OOI     2,500       2,500       -       0.00  
KOW FOONG LEE     2,500       2,500       -       0.00  
WOAN SHIN TOH     2,500       2,500       -       0.00  
YI SHENG YONG     2,500       2,500       -       0.00  
MOOI CHOO LEE     2,500       2,500       -       0.00  
CHAN FATT WONG     2,500       2,500       -       0.00  
CHOI HAR CHAN     2,500       2,500       -       0.00  
KAM TAI YANG     2,500       2,500       -       0.00  
KOON SIM NG     2,500       2,500       -       0.00  
CHEE FUN TENG     2,500       2,500       -       0.00  
CHEE WAI JAN     2,500       2,500       -       0.00  
CHEE YUEN SIAW     2,500       2,500       -       0.00  
CHIN YEE OON     2,500       2,500       -       0.00  
JOO WEI TAN     2,500       2,500       -       0.00  
KAR LING MOY     2,500       2,500       -       0.00  
LIH LING SOOI     2,500       2,500       -       0.00  
LIH WEN SOOI     2,500       2,500       -       0.00  
LING YEOK TAN     2,500       2,500       -       0.00  
MOO TAN TEH     2,500       2,500       -       0.00  
CHEN JUNG KET     2,500       2,500       -       0.00  
BAK CHOO TAN     2,500       2,500       -       0.00  
LIM CHAI LENG     2,500       2,500       -       0.00  
TAY YEK CHIEW     2,500       2,500       -       0.00  
NG LEAN HUAT     2,200       2,200       -       0.00  
LEE AI PIN     2,200       2,200       -       0.00  
TENG AH CHOY     2,200       2,200       -       0.00  
MARGARET LIM     2,200       2,200       -       0.00  
LEE HOAY SAN     2,020       2,020       -       0.00  
WONG KOK CHUEN     2,000       2,000       -       0.00  
YEW YEE CIN     2,000       2,000       -       0.00  
NG KOK LEONG     2,000       2,000       -       0.00  
LOH SOON YONG     2,000       2,000       -       0.00  
TAN TEIK MENG     2,000       2,000       -       0.00  
AZAM MUDZAFFAR BIN OTHMAN     2,000       2,000       -       0.00  
CHAI LEE WAN     2,000       2,000       -       0.00  
KUAN YOKE FONG     2,000       2,000       -       0.00  
KONG MUN KIT     2,000       2,000       -       0.00  
ANG HOCK SIANG     2,000       2,000       -       0.00  
NIUN LILY     2,000       2,000       -       0.00  
BEH LAY POH     2,000       2,000       -       0.00  
LIW PIK CHIN     2,000       2,000       -       0.00  
YEE THIAM KHENG     2,000       2,000       -       0.00  
SIN LEK PHENG     2,000       2,000       -       0.00  

 

SS-20

 

 

CHONG NYOK MOY     2,000       2,000       -       0.00  
TAN BENG LOOI     2,000       2,000       -       0.00  
YANG CHEE HOAY     2,000       2,000       -       0.00  
TEH SIEW BEE     2,000       2,000       -       0.00  
SIM WEI BEE     2,000       2,000       -       0.00  
CHEY YEN SIEW     2,000       2,000       -       0.00  
HENG KUNG SIAH     2,000       2,000       -       0.00  
LIEW MIN LONG     2,000       2,000       -       0.00  
YEE TUCK KEIN     2,000       2,000       -       0.00  
YONG WEI SING     2,000       2,000       -       0.00  
MOO SWEE LIN     2,000       2,000       -       0.00  
HO SOOK KEAM     2,000       2,000       -       0.00  
NURUL SAFA LIM BINTI ABDULLAH     2,000       2,000       -       0.00  
PHUAH KEE HUAH     2,000       2,000       -       0.00  
YEE LEE CHIA     2,000       2,000       -       0.00  
ONG KAH KI     2,000       2,000       -       0.00  
WOO CHI KIN     2,000       2,000       -       0.00  
CHAN FOOK SENG     2,000       2,000       -       0.00  
LEE ZHAO ING     2,000       2,000       -       0.00  
YONG SIANG CHIN     2,000       2,000       -       0.00  
WONG LAN CHING     2,000       2,000       -       0.00  
CHONG EE THIAN     2,000       2,000       -       0.00  
NG HOCK LOO     2,000       2,000       -       0.00  
LEE SEE WAI     2,000       2,000       -       0.00  
CHONG YOKE MUI     2,000       2,000       -       0.00  
TIMOTHY JIM ENG     2,000       2,000       -       0.00  
OH ANG SANG & OH ENG SANG     2,000       2,000       -       0.00  
CHO YANG YANG BILLY     2,000       2,000       -       0.00  
EWE BOON KOOI     2,000       2,000       -       0.00  
KUMUTHAM A/P RAJOO     2,000       2,000       -       0.00  
YUEN QING NIAN     2,000       2,000       -       0.00  
HENG SWEE LEE     2,000       2,000       -       0.00  
HUANG XU XIANG     2,000       2,000       -       0.00  
LOH YUEN WAH     2,000       2,000       -       0.00  
GOH CHIEW SIA     2,000       2,000       -       0.00  
POH SAIK PIN     2,000       2,000       -       0.00  
ANG BEE HWA     2,000       2,000       -       0.00  
ANG SOON HENG     2,000       2,000       -       0.00  
ANG SUE KHOON     2,000       2,000       -       0.00  
AW MOI     2,000       2,000       -       0.00  
BAH CHANG XUN     2,000       2,000       -       0.00  
CARMEN YONG     2,000       2,000       -       0.00  
CHAI FATT ANN     2,000       2,000       -       0.00  
CHAN LAI FONG     2,000       2,000       -       0.00  
CHAN POH SIM     2,000       2,000       -       0.00  
CHAN SI YUAN     2,000       2,000       -       0.00  
CHAN WAH SENG     2,000       2,000       -       0.00  
CHAN WENG KWONG     2,000       2,000       -       0.00  
CHAN YEN FATT     2,000       2,000       -       0.00  
CHANG CHEW KIT     2,000       2,000       -       0.00  
CHANG HUI YEE     2,000       2,000       -       0.00  
CHARLES CHEE VUI KHONG     2,000       2,000       -       0.00  
CHEAH MEAR KAI     2,000       2,000       -       0.00  
CHEONG KAH LIN     2,000       2,000       -       0.00  
CHEONG KIN FONG     2,000       2,000       -       0.00  
CHEW LI QIN     2,000       2,000       -       0.00  

 

SS-21

 

 

CHIA CHIN BONG     2,000       2,000       -       0.00  
CHIA LI HUEY     2,000       2,000       -       0.00  
CHIN CHEE KHUEN     2,000       2,000       -       0.00  
CHIN FOO YOONG     2,000       2,000       -       0.00  
CHIN KAR LING     2,000       2,000       -       0.00  
CHIN KIEW KWONG     2,000       2,000       -       0.00  
CHOK YUN TAI     2,000       2,000       -       0.00  
CHONG MEI HONG     2,000       2,000       -       0.00  
CHONG MOK CHAN     2,000       2,000       -       0.00  
CHONG SIEW HEONG     2,000       2,000       -       0.00  
CHONG SOON PENG     2,000       2,000       -       0.00  
CHONG WEN YANN     2,000       2,000       -       0.00  
CHOR KIM HOONG     2,000       2,000       -       0.00  
CHOY KOK CHOONG     2,000       2,000       -       0.00  
CHUA SEE HOCK     2,000       2,000       -       0.00  
CHUA TING TING     2,000       2,000       -       0.00  
CHUAH SEAK HWA     2,000       2,000       -       0.00  
CHUAH YONG XUANG     2,000       2,000       -       0.00  
CHUN LEAN SAN     2,000       2,000       -       0.00  
DAVID NG PEI SHENG     2,000       2,000       -       0.00  
DWEE WAI HA     2,000       2,000       -       0.00  
EDDIE NORMAN VAZ     2,000       2,000       -       0.00  
ENG BEE YONG     2,000       2,000       -       0.00  
ENG CHUONG SHYUAN     2,000       2,000       -       0.00  
ERIN PUNG XIU YI     2,000       2,000       -       0.00  
FIONA TAN EI HWA     2,000       2,000       -       0.00  
FONG TING HOOI     2,000       2,000       -       0.00  
FOO NYEN FOH     2,000       2,000       -       0.00  
FOO TUCK HENG     2,000       2,000       -       0.00  
FOONG YOKE CHENG     2,000       2,000       -       0.00  
FREDDIE NG CHUN KIT     2,000       2,000       -       0.00  
GAN KAI LING     2,000       2,000       -       0.00  
GAN WEI JIEH     2,000       2,000       -       0.00  
GOH POH TIANG     2,000       2,000       -       0.00  
HAH CHEE KEONG     2,000       2,000       -       0.00  
HAH KIN KEONG     2,000       2,000       -       0.00  
HAH LING HUI     2,000       2,000       -       0.00  
HAH SHIAU HUI     2,000       2,000       -       0.00  
HAW KAH HEE     2,000       2,000       -       0.00  
HELEN SHIM     2,000       2,000       -       0.00  
HIEW TEIK VOOI     2,000       2,000       -       0.00  
HO HWEE GEOK     2,000       2,000       -       0.00  
HO LAI KHUAN     2,000       2,000       -       0.00  
HOE HOCK KEAT     2,000       2,000       -       0.00  
HOO CHING CHING     2,000       2,000       -       0.00  
JOANNE CH’NG SUE IMM     2,000       2,000       -       0.00  
KALIMUTHU A/L GOVINDASAMY     2,000       2,000       -       0.00  
KENG SING HUAT     2,000       2,000       -       0.00  
KENNETH NEO TERK CHERN     2,000       2,000       -       0.00  
KHOO JIN CHAO     2,000       2,000       -       0.00  
KHOO KENG GIN     2,000       2,000       -       0.00  
KHOO LAY CHENG     2,000       2,000       -       0.00  
KHOO TENG CHEONG     2,000       2,000       -       0.00  
KHOO WEI HAU     2,000       2,000       -       0.00  
KHOO YUIH CHYUN     2,000       2,000       -       0.00  
KHOR CHEE BOAY     2,000       2,000       -       0.00  

 

SS-22

 

 

KOH SIEW PING     2,000       2,000       -       0.00  
KOK KWAI SUN     2,000       2,000       -       0.00  
KOK WAI HIEN     2,000       2,000       -       0.00  
KONG CHUN HERNG     2,000       2,000       -       0.00  
KONG DING WEI     2,000       2,000       -       0.00  
KU YING CHYE     2,000       2,000       -       0.00  
LAI WENG KIN     2,000       2,000       -       0.00  
LAM MEI KUEN     2,000       2,000       -       0.00  
LAM WAN JOE     2,000       2,000       -       0.00  
LAU KOK CHOY     2,000       2,000       -       0.00  
LAW PENG MOOI     2,000       2,000       -       0.00  
LAWRENCE TANG ZHI QIAN     2,000       2,000       -       0.00  
LEAN SZE LU     2,000       2,000       -       0.00  
LEE BEE PHENG     2,000       2,000       -       0.00  
LEE BOON LONG     2,000       2,000       -       0.00  
LEE CHAI THUAN     2,000       2,000       -       0.00  
LEE CHEE HIAN     2,000       2,000       -       0.00  
LEE CHIN KHOON     2,000       2,000       -       0.00  
LEE CHOW LIN     2,000       2,000       -       0.00  
LEE FOO YEE     2,000       2,000       -       0.00  
LEE KIM GUAN     2,000       2,000       -       0.00  
LEE SOOK CHENG     2,000       2,000       -       0.00  
LEE WAI LING     2,000       2,000       -       0.00  
LEE YAP HUNG     2,000       2,000       -       0.00  
LEE YEAP KEONG     2,000       2,000       -       0.00  
LEE YEOW THAI     2,000       2,000       -       0.00  
LEONG MEI YING     2,000       2,000       -       0.00  
LEONG PUI KEONG     2,000       2,000       -       0.00  
LEONG YAO CHUAN     2,000       2,000       -       0.00  
LEOW XUE YING     2,000       2,000       -       0.00  
LIEW CHEE HOWE     2,000       2,000       -       0.00  
LIEW CHING MOAY     2,000       2,000       -       0.00  
LIEW KEE BOON     2,000       2,000       -       0.00  
LIEW KEN KIEW     2,000       2,000       -       0.00  
LIEW KHIN SIANG     2,000       2,000       -       0.00  
LIEW YEAN KIM     2,000       2,000       -       0.00  
LIM CHENG KOOK     2,000       2,000       -       0.00  
LIM GUAN JIE     2,000       2,000       -       0.00  
LIM KAR PIN     2,000       2,000       -       0.00  
LIM KOK SWEE     2,000       2,000       -       0.00  
LIM MEA CHIAN     2,000       2,000       -       0.00  
LIM MUI GEIK     2,000       2,000       -       0.00  
LIM SIEW MOOI     2,000       2,000       -       0.00  
LIM SWEE MIN     2,000       2,000       -       0.00  
LIM TENG TENG     2,000       2,000       -       0.00  
LIM YOKE KHUAN     2,000       2,000       -       0.00  
LIONG LENG TAI     2,000       2,000       -       0.00  
LO TING KUAN     2,000       2,000       -       0.00  
LOH NAN CHOON     2,000       2,000       -       0.00  
LOH SIEW LING     2,000       2,000       -       0.00  
LOH YE WAH     2,000       2,000       -       0.00  
LOO MEI YONG     2,000       2,000       -       0.00  
LOO YOOK PIN     2,000       2,000       -       0.00  
LOOI SUET HUI     2,000       2,000       -       0.00  
LOUIE XIN RU KIM     2,000       2,000       -       0.00  

 

SS-23

 

 

LOW CHIN KEE     2,000       2,000       -       0.00  
MAK WAI YEN     2,000       2,000       -       0.00  
MOO AI NAH     2,000       2,000       -       0.00  
NG CHOR KUAN     2,000       2,000       -       0.00  
NG KENG LEE     2,000       2,000       -       0.00  
NG LEE MENG     2,000       2,000       -       0.00  
NG LING LONG     2,000       2,000       -       0.00  
NG MUN AIK     2,000       2,000       -       0.00  
NG MUN SAN     2,000       2,000       -       0.00  
NG WAI KEANG     2,000       2,000       -       0.00  
NG WUAN SEAN     2,000       2,000       -       0.00  
NGAN SIEOW HUI     2,000       2,000       -       0.00  
NGAN WAN CHIN     2,000       2,000       -       0.00  
NYEU HOOI PING     2,000       2,000       -       0.00  
OH KENG YEANG     2,000       2,000       -       0.00  
ONG BENG CHOO     2,000       2,000       -       0.00  
ONG BOON PEI     2,000       2,000       -       0.00  
ONG CHING CHUAN     2,000       2,000       -       0.00  
ONG SAW CHOO     2,000       2,000       -       0.00  
ONG YUN PING     2,000       2,000       -       0.00  
OO AI MEE     2,000       2,000       -       0.00  
OOI BOON SEONG     2,000       2,000       -       0.00  
OOI BOON SHIEH     2,000       2,000       -       0.00  
OOI CHARD SENG     2,000       2,000       -       0.00  
OOI CHEONG HEAN     2,000       2,000       -       0.00  
OOI GUAT HUA     2,000       2,000       -       0.00  
HO LEE LEE     2,000       2,000       -       0.00  
OOI HEOI SAN     2,000       2,000       -       0.00  
OOI LEAN CHOO     2,000       2,000       -       0.00  
OOI PEIK HOON     2,000       2,000       -       0.00  
PARVEEN KAUR A/P AWTAR SINGH     2,000       2,000       -       0.00  
PHUN CHOONG PHOOI     2,000       2,000       -       0.00  
PIONG KOK CHONG     2,000       2,000       -       0.00  
PONG POT NYONG     2,000       2,000       -       0.00  
PUA CHEE KUAN     2,000       2,000       -       0.00  
SAY HUEY SHIN     2,000       2,000       -       0.00  
SEAK LAI GOON     2,000       2,000       -       0.00  
SHU MEI CHIN     2,000       2,000       -       0.00  
SOI MOI     2,000       2,000       -       0.00  
SUBAGARAN A/L LETCHUMANAN     2,000       2,000       -       0.00  
SUBRAMANIAM A/L A MUTHUKARAPAN     2,000       2,000       -       0.00  
TAI CHOON YIN     2,000       2,000       -       0.00  
TAM ING HAUR     2,000       2,000       -       0.00  
TAN AEE @ TAN BOON SOON     2,000       2,000       -       0.00  
TAN CHUN YONG     2,000       2,000       -       0.00  
TAN HIANG BOON     2,000       2,000       -       0.00  
TAN HUI SIEW     2,000       2,000       -       0.00  
TAN LEONG SENG     2,000       2,000       -       0.00  
TAN PEE YING     2,000       2,000       -       0.00  
TAN PEK YANG     2,000       2,000       -       0.00  
TAN PENG TENG     2,000       2,000       -       0.00  
TAN SIO FUI     2,000       2,000       -       0.00  
TAN SOO NGOH     2,000       2,000       -       0.00  
TAN SZE MIN     2,000       2,000       -       0.00  
TAN TECK SENG     2,000       2,000       -       0.00  
TANG KING HEOK     2,000       2,000       -       0.00  

 

SS-24

 

 

TANG YONG SENG     2,000       2,000       -       0.00  
TEH SOON LAI     2,000       2,000       -       0.00  
TENG SZE CHEW     2,000       2,000       -       0.00  
TEOH SOAY ANG     2,000       2,000       -       0.00  
TEONG AH MAI     2,000       2,000       -       0.00  
TEY EE LAI     2,000       2,000       -       0.00  
THEN FOO SING     2,000       2,000       -       0.00  
THONG MEE MIN     2,000       2,000       -       0.00  
TING AAI HONG     2,000       2,000       -       0.00  
TIONG SIEW MING     2,000       2,000       -       0.00  
TNEH HUN NGEE     2,000       2,000       -       0.00  
TOH MUN YEW     2,000       2,000       -       0.00  
WEE CHOY TENG     2,000       2,000       -       0.00  
WEE HON CHUNG     2,000       2,000       -       0.00  
WEE TEO WEI     2,000       2,000       -       0.00  
WONG BOON TONG     2,000       2,000       -       0.00  
WONG CHOY THAI     2,000       2,000       -       0.00  
WONG HUN CHIAT     2,000       2,000       -       0.00  
WONG LAI HWA     2,000       2,000       -       0.00  
WONG MUN FONG     2,000       2,000       -       0.00  
WONG SEET WAN     2,000       2,000       -       0.00  
WONG SIEW MOH     2,000       2,000       -       0.00  
WONG SWEE YEN     2,000       2,000       -       0.00  
WONG YEE YING     2,000       2,000       -       0.00  
WONG YOON MOOI     2,000       2,000       -       0.00  
WONG YOON YIN     2,000       2,000       -       0.00  
YAN LAI FONG     2,000       2,000       -       0.00  
YANG HUI SHEE     2,000       2,000       -       0.00  
YAP CHIN LEONG     2,000       2,000       -       0.00  
YAP ENG KEONG     2,000       2,000       -       0.00  
YAP ZHEN YU     2,000       2,000       -       0.00  
YAU CHEW HUN     2,000       2,000       -       0.00  
YEAP HOCK HIN     2,000       2,000       -       0.00  
YEONG YIP HING     2,000       2,000       -       0.00  
YONG MEI CHI     2,000       2,000       -       0.00  
YONG WENG CHAN     2,000       2,000       -       0.00  
YONG WENG KAM     2,000       2,000       -       0.00  
LEE CHONG SENG     2,000       2,000       -       0.00  
HO YOKE FOON     2,000       2,000       -       0.00  
TING YEE PING     2,000       2,000       -       0.00  
MOHAMAD ANUAR BIN SAIDIN     2,000       2,000       -       0.00  
YIP YUEN TAT     2,000       2,000       -       0.00  
NG CHAU JEUN     2,000       2,000       -       0.00  
NG AI REEN     2,000       2,000       -       0.00  
THAM WEI PING     2,000       2,000       -       0.00  
LEOW YIT WOON     2,000       2,000       -       0.00  
LEE WAI YEE     2,000       2,000       -       0.00  
BOON KIM SWEE     2,000       2,000       -       0.00  
SOO PHAIK CHEOK     2,000       2,000       -       0.00  
TAN CHIN POH     2,000       2,000       -       0.00  
TOH WEI LUR     2,000       2,000       -       0.00  
WONG NG CHOON     2,000       2,000       -       0.00  
LEONG KAH MUN     2,000       2,000       -       0.00  
JOANNE CHEAH YEE SWAN     2,000       2,,000       -       0.00  
PHANG KHAR WEI     1,983       1,983       -       0.00  
CLARE W TULUS     1,900       1,900       -       0.00  
TAN YIH MEAN     1,820       1,820       -       0.00  
KOH HEE LIAN     1,500       1,500       -       0.00  
LIEW YONG HUAT     1,500       1,500       -       0.00  
KOR HUR CHEN     1,500       1,500       -       0.00  
TAN KEAN WIN     1,500       1,500       -       0.00  
LIM KOK SEONG     1,500       1,500       -       0.00  
KAM YUEN YEE     1,320       1,320       -       0.00  
YONG SIT FONG     1,100       1,100       -       0.00  
TRICIA KONG YUN FUN     1,100       1,100       -       0.00  
CHIN SU SIM     1,000       1,000       -       0.00  
HOONG LI KUO     1,000       1,000       -       0.00  
LEE BEE CHENG     1,000       1,000       -       0.00  
CHUA BOON BOON     1,000       1,000       -       0.00  
LEE CHONG SOON     1,000       1,000       -       0.00  
NGAN BEE KIAW     1,000       1,000       -       0.00  
KHO KHENG SIONG     1,000       1,000       -       0.00  
THEN SHWU WON     1,000       1,000       -       0.00  
JEN HUI TEO     1,000       1,000       -       0.00  
KOK HOONG CHEU     1,000       1,000       -       0.00  
SHERN KWOK LIM     1,000       1,000       -       0.00  
CHAI HWEE HU     1,000       1,000       -       0.00  
LIM POH CHOON     1,000       1,000       -       0.00  
FONG SIEW MOI     1,000       1,000       -       0.00  
LEE CHUN WEI     1,000       1,000       -       0.00  
YEE TUCK YEIN     1,000       1,000       -       0.00  
TEH ENG LOON     1,000       1,000       -       0.00  
HENG LEE KUAN     1,000       1,000       -       0.00  
NG HUE BOON     1,000       1,000       -       0.00  
CHIN WHY LEONG     1,000       1,000       -       0.00  
CHEOK SOOK PENG     1,000       1,000       -       0.00  
TEOH AI MUI     1,000       1,000       -       0.00  
NG LAI CHOON     1,000       1,000       -       0.00  
CHANG HUI CHIN     1,000       1,000       -       0.00  
NG LEE LEE     1,000       1,000       -       0.00  
KHAW HWEE YONG     1,000       1,000       -       0.00  
LEE BEE HONG     1,000       1,000       -       0.00  
WAN CHEN CHOK     1,000       1,000       -       0.00  
CHAN KAH JUNE     1,000       1,000       -       0.00  
CHEW SIEW ENG     1,000       1,000       -       0.00  
SU WEI SIONG     1,000       1,000       -       0.00  
TAN POH ENG     1,000       1,000       -       0.00  
LAI YEW HONG     1,000       1,000       -       0.00  
YEE TUCK LOONG     1,000       1,000       -       0.00  
LEONG KANG WEI     1,000       1,000       -       0.00  
ANG CHAN OOI     1,000       1,000       -       0.00  
CHIA YIT MEI     1,000       1,000       -       0.00  
KHAW GUAT HOON     1,000       1,000       -       0.00  
LAI YEIN HONG     1,000       1,000       -       0.00  
LOW YEONG KEONG     1,000       1,000       -       0.00  
NG KHENG HANG     1,000       1,000       -       0.00  
NGU CHANG YUAN     1,000       1,000       -       0.00  
TAM WEI YEE     1,000       1,000       -       0.00  
TAN YONG CHEN     1,000       1,000       -       0.00  
NG GUAN HWA     1,000       1,000       -       0.00  
YEOH CHE CHIAN     1,000       1,000       -       0.00  
PEONG SIOW FONG     1,000       1,000       -       0.00  
TAN CHEE WEI     1,000       1,000       -       0.00  
KOAY SEE BENG     1,000       1,000       -       0.00  
LOO AH MOY     1,000       1,000       -       0.00  
LAU LAY PING     1,000       1,000       -       0.00  
HO AIK HONG     800       800       -       0.00  
GOOI MING SHENG     700       700       -       0.00  
KOH KIM SAI     700       700       -       0.00  
WON NGAR TENG     500       500       -       0.00  
CHONG ZHI YING     350       350       -       0.00  
LING CHEK PING     350       350       -       0.00  
SEAH AH HENG     350       350       -       0.00  
Total     35,214,516       30,269,516       4,945,000       6.50  

 

(1) Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, securities that are currently convertible or exercisable into shares of our common stock, or convertible or exercisable into shares of our common stock within 60 days of the date hereof are deemed outstanding. Such shares, however, are not deemed outstanding for the purposes of computing the percentage ownership of any other person. Except as indicated in the footnotes to the following table, each stockholder named in the table has sole voting and investment power with respect to the shares set forth opposite such stockholder’s name.

 

SS-25

 

 

SELLING STOCKHOLDERS PLAN OF DISTRIBUTION

 

Our common stock is presently quoted on the OTC Markets – Pink Sheets under the symbol “AATP”. Although there is currently a bid and offer quotation for the common stock, such bid and offer are for limited and insignificant number of shares. The last sale price recorded was $4.01 per share on August 2, 2022. Because trading has been sporadic and irregular, there is no established public trading market for our common stock.

 

The selling stockholders will offer and sell their shares of common stock being offered under this prospectus at $6.50 per share on the OTC Markets – Pink Sheets under the symbol “AATP” or in private transactions for the duration of this offering or until the shares are listed on a national securities exchange at which time the selling stockholders and any of their pledgees, donees, assignees and successors-in-interest may, from time to time, sell any or all of their shares of common stock being offered under this prospectus on any stock exchange, market or trading facility on which shares of our common stock are traded or in private transactions. We have applied to list our common stock on the NASDAQ Capital Market (“NASDAQ”) under the symbol “ATPC”. No assurance can be given that our application will be approved.

 

The selling stockholders may use any one or more of the following methods when disposing of shares:

 

  ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
  block trades in which the broker-dealer will attempt to sell the shares as agent but may position; and resell a portion of the block as principal to facilitate the transaction;
  purchases by a broker-dealer as principal and resales by the broker-dealer for its account;
  an exchange distribution in accordance with the rules of the applicable exchange;
  privately negotiated transactions;
  to cover short sales made after the date that the registration statement of which this prospectus is a part is declared effective by the SEC;
  broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
  a combination of any of these methods of sale; and
  any other method permitted pursuant to applicable law.

 

The shares may also be sold under Rule 144 under the Securities Act of 1933, as amended, if available for a selling stockholder, rather than under this prospectus. The selling stockholders have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if they deem the purchase price to be unsatisfactory at any particular time.

 

The selling stockholders may pledge their shares to their brokers under the margin provisions of customer agreements. If a selling stockholder defaults on a margin loan, the broker may, from time to time, offer and sell the pledged shares.

 

Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated, which commissions as to a particular broker or dealer may be in excess of customary commissions to the extent permitted by applicable law.

 

If sales of shares offered under this prospectus are made to broker-dealers as principals, we would be required to file a post-effective amendment to the registration statement of which this prospectus is a part. In the post-effective amendment, we would be required to disclose the names of any participating broker-dealers and the compensation arrangements relating to such sales.

 

The selling stockholders and any broker-dealers or agents that are involved in selling the shares offered under this prospectus may be deemed to be “underwriters” within the meaning of the Securities Act in connection with these sales. Commissions received by these broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting discount under the Securities Act. Any broker-dealers or agents that are deemed to be underwriters may not sell shares offered under this prospectus unless and until we set forth the names of the underwriters and the material details of their underwriting arrangements in a supplement to this prospectus or, if required, in a replacement prospectus included in a post-effective amendment to the registration statement of which this prospectus is a part.

 

The selling stockholders and any other persons participating in the sale or distribution of the shares offered under this prospectus will be subject to applicable provisions of the Exchange Act, and the rules and regulations under that act, including Regulation M. These provisions may restrict activities of, and limit the timing of purchases and sales of any of the shares by, the selling stockholders or any other person. Furthermore, under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously engaging in market making and other activities with respect to those securities for a specified period of time prior to the commencement of such distributions, subject to specified exceptions or exemptions. All of these limitations may affect the marketability of the shares. 

 

SS-26

 

 

Rule 2710 requires members firms to satisfy the filing requirements of Rule 2710 in connection with the resale, on behalf of selling stockholders, of the securities on a principal or agency basis. NASD Notice to Members 88-101 states that in the event a Selling Stockholder intends to sell any of the shares registered for resale in this prospectus through a member of FINRA participating in a distribution of our securities, such member is responsible for insuring that a timely filing, if required, is first made with the Corporate Finance Department of FINRA and disclosing to FINRA the following:

 

  it intends to take possession of the registered securities or to facilitate the transfer of such certificates;
  the complete details of how the selling stockholders’ shares are and will be held, including location of the particular accounts;
  whether the member firm or any direct or indirect affiliates thereof have entered into, will facilitate or otherwise participate in any type of payment transaction with the selling stockholders, including details regarding any such transactions; and
  in the event any of the securities offered by the selling stockholders are sold, transferred, assigned or hypothecated by any Selling Stockholder in a transaction that directly or indirectly involves a member firm of FINRA or any affiliates thereof, that prior to or at the time of said transaction the member firm will timely file all relevant documents with respect to such transaction(s) with the Corporate Finance Department of FINRA for review.

 

No FINRA member firm may receive compensation in excess of that allowable under FINRA rules, including Rule 2710, in connection with the resale of the securities by the selling stockholders, which total compensation may not exceed 8%.

 

If any of the shares of common stock offered for sale pursuant to this prospectus are transferred other than pursuant to a sale under this prospectus, then subsequent holders could not use this prospectus until a post-effective amendment or prospectus supplement is filed, naming such holders. We offer no assurance as to whether any of the selling stockholders will sell all or any portion of the shares offered under this prospectus.

 

We have agreed to pay all fees and expenses we incur incident to the registration of the shares being offered under this prospectus. However, each selling stockholder and purchaser is responsible for paying any discount, and similar selling expenses they incur.

 

We and the selling stockholders have agreed to indemnify one another against certain losses, damages and liabilities arising in connection with this prospectus, including liabilities under the Securities Act.

 

SS-27

 

 

LEGAL MATTERS

 

Certain legal matters with respect to the validity of the shares of common stock offered hereby and U.S. federal securities law will be passed upon for us by Loeb & Loeb LLP, New York, New York. Legal matters as to Malaysia law will be passed upon for us by Lee & Poh Partnership. Loeb & Loeb, LLP may rely upon Lee & Poh Partnership. with respect to matters governed by Malaysian law. Hunter Taubman Fischer & Li LLC is acting as U.S. securities counsel for the Underwriter. Lee & Poh Partnership is acting as Malaysia counsel for the Underwriter.

 

SS-28

 

 

AGAPE ATP CORPORATION

 

30,269,516 Shares of Common Stock

 

PROSPECTUS

 

You should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the date of this prospectus, regardless of the time of the delivery of this prospectus or the sale of these securities.

 

Until       , 2023, all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriter with respect to their unsold subscriptions.

 

The date of this prospectus is        , 2023

 

SS-29

 

 

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

 

ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

 

Set forth below is an estimate (except for SEC registration and FINRA filing fees, which are actual) of the approximate amount of the types of fees and expenses listed below that were paid or are payable by us in connection with the issuance and distribution of the shares of common stock to be registered by this registration statement.

 

Item  Amount to
be paid
 
SEC registration fee  $

31,747

FINRA filing fee   

63,300

Nasdaq listing fee   

75,000

 
Legal fees and expenses   

275,000

Accounting fees and expenses   

85,000

U.S. GAAP Consulting   

79,288

 
Transfer agent fees and expenses   

5,000

 
Underwriter expense reimbursement   

254,500

 
Printing and engraving expenses   

7,500

 
Miscellaneous expenses   

2,500

 
Total  $

878,834

 

 

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

The Company’s directors and executive officers are indemnified as provided by the Nevada Revised Statutes and its Bylaws. These provisions state that the Company’s directors may cause the Company to indemnify a director or former director against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, actually and reasonably incurred by him as a result of him acting as a director. The indemnification of costs can include an amount paid to settle an action or satisfy a judgment. Such indemnification is at the discretion of the Company’s board of directors and is subject to the Securities and Exchange Commission’s policy regarding indemnification.

 

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, or otherwise, The Company has been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.

 

ITEM 15. RECENT SALE OF UNREGISTERED SECURITIES

 

No underwriter were involved in the issuance of the securities noted below. All of the securities issued below were deemed to be exempt from registration under the Securities Act in reliance upon Regulation S for offerings made outside of the United States.

 

  On April 5, 2017, the Company acquired Agape ATP Corporation, a company incorporated in Labuan, Malaysia.
     
  On April 10, 2017, the Company issued 245,000,000 and 70,000,000 shares of common stock to Dr. How Kok Choong and HKC Holdings Sdn Bhd respectively, each with a par value of $0.0001 per share, for total additional working capital of $31,500. HKC Holdings Sdn Bhd is owned and controlled by Dr. How Kok Choong who is our chief executive officer, chief operating officer, chairman of the board of Directors, Director and secretary.
     
  On May 8, 2020, the Company acquired approximately 99.99% of the issued share capital of Agape Superior Living Sdn Bhd, a company incorporated in Malaysia from Dr. How Kok Choong.

 

II-1
 

 

ITEM 16. EXHIBITS AND FINANCIAL STATEMENTS

 

Exhibits

 

See the Exhibit Index attached to this registration statement, which is incorporated by reference herein.

 

ITEM 17. UNDERTAKINGS

 

The undersigned registrant hereby undertakes to:

 

(1) File, during any period in which offers or sells are being made, a post-effective amendment to this registration statement:

 

(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

 

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

 

(iii) To include material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 and Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

 

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

II-2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in Kuala Lumpur, Malaysia, on April 14, 2023.

 

  AGAPE ATP CORPORATION
     
  By: /s/ How Kok Choong
  Name: How Kok Choong
  Title:

Director, Chairman of the Board of Directors, Chief Executive Officer, Chief Operating Officer and Secretary

(Principal Executive Officer)

 

POWER OF ATTORNEY

 

Each person whose signature appears below constitutes and appoints each of How Kok Choong and Lee Kam Fan Andrew as attorneys-in-fact with full power of substitution for him or her in any and all capacities to do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933, as amended (the “Securities Act”), and any rules, regulations and requirements of the Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act of shares of common stock of the registrant (the “Shares”), including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to the Registration Statement on Form S-1 (the “Registration Statement”) to be filed with the Securities and Exchange Commission with respect to such Shares, to any and all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such Registration Statement; and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ How Kok Choong   Chief Executive Officer, Chief Operating Officer, Director, Chairman of the Board of Directors and Secretary   April 14, 2023
How Kok Choong   (Principal Executive Officer)    
         
/s/ Lee Kam Fan Andrew   Chief Financial Officer   April 14, 2023

Lee Kam Fan Andrew

  (Principal Financial and Accounting Officer)    
         

/s/ Tjong Budisantoso

  Director  

April 14, 2023

Tjong Budisantoso

       

 

II-3
 

 

EXHIBIT INDEX

 

Exhibit
Number
  Description
1.1   Form of Underwriting Agreement
     
3.1**   Articles of Incorporation of the Registrant, as currently in effect
     
3.2**   Bylaws of the Registrant, as currently in effect
     
3.3*   Amended and Restated Articles of Incorporation of the Registrant (effective upon closing of the offering)
     
3.4*   Amended and Restated Bylaws of the Registrant (effective upon closing of the offering)
     
4.1*   Registrant’s Specimen Certificate for Common Stock
     
4.2*   Form of Underwriter’s Warrant
     
5.1*   Opinion of Loeb & Loeb LLP as to the legality of the securities being registered
     
10.1**   Direct Sales Licence of Agape Superior Living Sdn. Bhd. issued by Ministry of Domestic Trade, dated April 20, 2018
     
10.2**   Tenancy Agreement by and between Canggih Pesaka Sdn Bhd and Agape Superior Living Sdn. Bhd., dated April 20, 2018
     
10.3   Warehousing and Distribution Agreement between Agape Superior Living Sdn Bhd and City-Link Express (M) Sdn Bhd dated January 12, 2021
     
10.4   Renewal of Warehousing and Distribution Agreement between Agape Superior Living Sdn Bhd and City-Link Express (M) Sdn Bhd dated January 10, 2023
     
10.5   Tenancy Agreement between Guan Kee Machinery & Equipment (M) Sdn Bhd and Agape Superior Living Sdn Bhd dated July 30, 2022.
     
10.6#   Tenancy Agreement between Banjaran Purnama Sdn Bhd and Agape Superior Living Sdn Bhd dated November 19, 2021
     
10.7#   Tenancy Agreement between Canggih Pesaka Sdn Bhd and Agape Superior Living Sdn Bhd dated August 25, 2021 for Lot 1705-1708, 17th Floor, Tower 2, Fable Towers
     
10.8#   Tenancy Agreement between Canggih Pesaka Sdn Bhd and Agape Superior Living Sdn Bhd dated August 25, 2021 for Lot 1605-1606, 16th Floor, Tower 2, Fable Towers
     
10.9#   Tenancy Agreement between See Li Chiann and Agape Superior Living Sdn. Bhd. and Terence W Tulus dated October 1, 2021
     
10.10*   Executive Director Agreement with Dr. How Kok Choong
     
10.11#   Executive Director Agreement with Mr. Tjong Budisantoso, PhD
     
10.12**  

Executive Employment Agreement with Mr. Lee Kam Fan

     
10.13**  

Independent Director Agreement with Mr. Ramesh Ruben Louis

     
10.14  

Form of Independent Director Agreement with Professor Dr. John Hing Vong 

     
10.15   Form of Independent Director Agreement with Mr. Chee Chin Aik
     
21.1**   List of Subsidiaries of the Registrant
     
23.1   Consent of Marcum Asia CPAs LLP, an independent public accounting registered firm
     
23.2   Consent of Friedman, LLP, an independent registered public accounting firm
     
23.3*   Consent of Loeb & Loeb LLP (included in Exhibit 5.1)
     
23.4*   Consent of Lee & Poh Partnership.
     
24.1   Power of Attorney (included on signature page)
     
107   Filing Fee Table

 

 

* To be filed by amendment.
** Previously filled
#

Certain identified information redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

 

II-4

 

Exhibit 1.1

 

AGAPE ATP CORPORATION

 

UNDERWRITING AGREEMENT

 

[●], 2023

 

EF Hutton,

division of Benchmark Investments, LLC

590 Madison Avenue, 39th Floor

New York, NY 10022

 

Ladies and Gentlemen:

 

The undersigned, AGAPE ATP CORPORATION, a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with several underwriters (such underwriters, including the Representative (as defined below and if there are no underwriters other than the Representative, references to multiple underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as underwriter), the “Underwriters” and each an “Underwriter”) named in Schedule A hereto for which EF Hutton, division of Benchmark Investments, LLC is acting as the representative to the several Underwriters (in such capacity, the “Representative”) to issue and sell an aggregate of [●] shares of common stock of the Company (“Firm Shares”), par value $0.0001 per share (“Common Stock”). The Company has also granted to the Representative an option to purchase up to [●] additional shares of Common Stock, on the terms and for the purposes set forth in Section 2(c) hereof (the “Additional Shares”). The Firm Shares and any Additional Shares purchased pursuant to this Agreement are herein collectively referred to as the “Offered Securities.” The offering and sale of the Offered Securities contemplated by this Agreement is referred to herein as the “Offering.”

 

The Company confirms its agreement with the Underwriters as follows:

 

SECTION 1. Representations and Warranties of the Company.

 

The Company represents and warrants to the Underwriters as follows with the understanding that the same may be relied upon by the Underwriters in this Offering, as of the date hereof and as of the Closing Date (as defined below) and each Option Closing Date (as defined below), if any:

 

(a) Filing of the Registration Statement. The Company has prepared and filed with the U.S. Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1 (File No. 333-239951), which contains a form of prospectus to be used in connection with the Offering. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto contained in the registration statement at the time such registration statement became effective, in the form in which it was declared effective by the Commission under the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations promulgated thereunder (the “Securities Act Regulations”), and including any required information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A under the Securities Act, or pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules and regulations promulgated thereunder (the “Exchange Act Regulations”), is called the “Registration Statement.” Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act is called the “Rule 462(b) Registration Statement,” and from and after the date and time of filing of the Rule 462(b) Registration Statement, the term “Registration Statement” shall include the Rule 462(b) Registration Statement. Such prospectus, in the form first filed pursuant to Rule 424(b) under the Securities Act after the date and time that this Agreement is executed and delivered by the parties hereto, or, if no filing pursuant to Rule 424(b) under the Securities Act is required, the form of final prospectus relating to the Offering included in the Registration Statement at the effective date of the Registration Statement, is called the “Prospectus.” All references in this Agreement to the Registration Statement, the preliminary prospectus included in the Registration Statement (each, a “preliminary prospectus”), the Prospectus, or any amendments or supplements to any of the foregoing, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”). The preliminary prospectus that was included in the Registration Statement immediately prior to the Applicable Time (as defined below) is hereinafter called the “Pricing Prospectus.” Any reference to the “most recent preliminary prospectus” shall be deemed to refer to the latest preliminary prospectus included in the registration statement. Any reference herein to any preliminary prospectus or the Prospectus or any supplement or amendment to either thereof shall be deemed to refer to and include any documents incorporated by reference therein as of the date of such reference.

 

1

 

 

(b) “Applicable Time” means 5:00 pm, Eastern Time, on the date of this Agreement.

 

(c) Compliance with Registration Requirements. The Registration Statement has been declared effective by the Commission under the Securities Act and the Securities Act Regulations on [●]. The Company has complied, to the Commission’s satisfaction, with all requests of the Commission for additional or supplemental information. No stop order preventing or suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission.

 

Each preliminary prospectus and the Prospectus when filed complied or will comply in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR (except as may be permitted by Regulation S-T under the Securities Act), was identical in content to the copy thereof delivered to the Underwriters for use in connection with the Offering, other than with respect to any artwork and graphics that were not filed. The Registration Statement and any post-effective amendment to the Registration Statement , at the time it became effective and at all subsequent times until the expiration of the prospectus delivery period required under Section 4(3) of the Securities Act, complied and will comply in all material respects with the Securities Act and the Securities Act Regulations and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus, as amended or supplemented, as of its date and at all subsequent times until the Underwriters have completed the Offering, did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, or any post-effective amendment to the Registration Statement, or in the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, made in reliance upon and in conformity with information relating to the Underwriters furnished to the Company in writing expressly for use therein, it being understood and agreed that the only such information furnished on behalf of the Underwriters consists of (i) the name of the Underwriters contained on the cover page of the Registration Statement, Pricing Prospectus and Prospectus, (ii) the table listing the names of the Underwriters and the allocation of shares between the Underwriters in the “Underwriting” section in the Prospectus, and (ii) the sub-sections titled “Price Stabilization, Short Positions and Penalty Bids,” “Market and Pricing Considerations,” and “Foreign Regulatory Restrictions on Purchase of our Shares” in each case under the caption “Underwriting” in the Prospectus (the “Underwriters Information”). There are no contracts or other documents required to be described in the Pricing Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that have not been fairly and accurately described in all material respects or filed as required.

 

(d) Disclosure Package. The term “Disclosure Package” shall mean (i) the Pricing Prospectus, as amended or supplemented, (ii) each issuer free writing prospectus, as defined in Rule 433 under the Securities Act (each, an “Issuer Free Writing Prospectus”), if any, identified in Schedule B hereto, (iii) the pricing terms set forth in Schedule C to this Agreement, and (iv) any other free writing prospectus that the parties hereto shall hereafter expressly agree in writing to treat as part of the Disclosure Package. As of the Applicable Time, the Disclosure Package did not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements in or omissions from the Disclosure Package based upon and in conformity with the Underwriters Information.

 

2

 

 

(e) Company Not Ineligible Issuer. (i) At the time of filing the Registration Statement and (ii) as of the date of the execution and delivery of this Agreement, the Company was not and is not an Ineligible Issuer (as defined in Rule 405 under the Securities Act), without taking account of any determination by the Commission pursuant to Rule 405 under the Securities Act that it is not necessary that the Company be considered an Ineligible Issuer.

 

(f) Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus includes any information that conflicts with the information contained in the Registration Statement, including any document incorporated by reference therein that has not been superseded or modified. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with the Underwriters Information.

 

(g) Offering Materials Furnished to the Underwriters. The Company has delivered to the Underwriters copies of the Registration Statement and of each consent and certificate of experts filed as a part thereof, and each preliminary prospectus and the Prospectus, as amended or supplemented, in such quantities and at such places as the Underwriters have reasonably requested in writing.

 

(h) Distribution of Offering Material by the Company. The Company has not distributed and will not distribute, prior to the completion of the Underwriters’ purchase of the Offered Securities, any offering material in connection with the Offering other than a preliminary prospectus, the Pricing Prospectus, the Prospectus, any Issuer Free Writing Prospectus reviewed and consented to by the Underwriters, and the Registration Statement.

 

(i) The Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.

 

(j) Authorization of the Offered Securities. The Offered Securities to be sold by the Company through the Underwriters have been duly and validly authorized by all required corporate action and have been reserved for issuance and sale pursuant to this Agreement and, when so issued and delivered by the Company, will be validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company. The Company has sufficient shares of Common Stock for the issuance of the Offered Securities issuable pursuant to the Offering as described in the Prospectus.

 

(k) No Applicable Registration or Other Similar Rights. Except as otherwise disclosed in the Registration Statement, there are no persons with registration or other similar rights to have any securities of the Company registered for sale under the Registration Statement.

 

(l) No Material Adverse Change. Except as otherwise disclosed in the Disclosure Package, subsequent to the respective dates as of which information is given in the Disclosure Package: (i) there has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, prospects or operations, whether or not arising from transactions in the ordinary course of business, of the Company (any such change, a “Material Adverse Change”); (ii) the Company has not incurred any material liability or obligation, indirect, direct or contingent, not in the ordinary course of business nor entered into any material transaction or agreement not in the ordinary course of business; and (iii) there has been no dividend or distribution of any kind declared, paid or made by the Company in respect of its capital stock.

 

(m) Independent Accountants. Marcum Asia CPAs LLP and Friedman LLP (the “Accountants”), which have expressed their opinions with respect to the audited financial statements (which term as used in this Agreement includes the related notes thereto) of the Company filed with the Commission as a part of the Registration Statement and included in the Disclosure Package and the Prospectus, are each an independent registered public accounting firm as required by the Securities Act and the Exchange Act.

 

3

 

 

(n) Preparation of the Financial Statements. Each of the historical financial statements of the Company, respectively, filed with the Commission as a part of the Registration Statement and included in the Disclosure Package and the Prospectus, presents fairly the information provided as of and at the dates and for the periods indicated (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by U.S. generally accepted accounting principles (“U.S. GAAP”). Such financial statements comply as to form with the applicable accounting requirements of the Securities Act and the Securities Act Regulations and have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. No other financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement. Each item of historical financial data relating to the operations, assets or liabilities of the Company set forth in summary form in each of the preliminary prospectuses and the Prospectus fairly presents such information on a basis consistent with that of the complete financial statements contained therein.

 

(o) Incorporation and Good Standing. The Company has been duly formed and is validly existing and in good standing as a company limited by shares under the laws of the jurisdiction of its formation and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement. As of the Closing Date, the Company does not own or control, directly or indirectly, any corporation, association or other entity that is not otherwise disclosed in the Disclosure Package or the Prospectus.

 

(p) Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as set forth in each of the Disclosure Package and the Prospectus (other than for subsequent issuances, if any, pursuant to employee benefit plans described in each of the Disclosure Package and the Prospectus or upon exercise of outstanding options or warrants described in the Disclosure Package and Prospectus, as the case may be). The Common Stock conforms, and, when issued and delivered as provided in this Agreement, the Offered Securities will conform, in all material respects to the description thereof contained in each of the Disclosure Package and Prospectus. All of the issued and outstanding shares of Common Stock, par value $0.0001 per share, have been duly authorized and validly issued, are fully paid and non-assessable and have been issued in compliance with applicable laws. None of the outstanding shares of Common Stock were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company other than those described in the Disclosure Package and the Prospectus. The description of the Company’s stock option and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Disclosure Package and the Prospectus accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options and rights. No further approval or authorization of any shareholder, the Board of Directors or others is required for the issuance and sale of the Offered Securities. Except as set forth in the Disclosure Package and the Prospectus, there are no shareholders agreements, voting agreements or other similar agreements with respect to the Company’s shares of Common Stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s shareholders.

 

4

 

 

(q) Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. The Company is not in violation of its articles of incorporation, as amended and/or restated, or in default (or, with the giving of notice or lapse of time, would be in default) (“Default”) under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease or other instrument to which it is a party or by which it may be bound (including, without limitation, any agreement or contract filed as an exhibit to the Registration Statement or to which any of the property or assets of the Company are subject (each, an “Existing Instrument”)), except for such Defaults as would not, individually or in the aggregate, result in a Material Adverse Change. The Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Disclosure Package and the Prospectus (i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the articles of incorporation, as amended and/or restated, of the Company, (ii) will not conflict with or constitute a breach of, or Default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to, or require the consent of any other party to, any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company, except in the case of each of clauses (ii) and (iii), to the extent such conflict, breach Default or violation could not reasonably be expected to result in a Material Adverse Effect. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Disclosure Package and the Prospectus, except the registration or qualification of the Offered Securities under the Securities Act and applicable state securities or blue sky laws and from the Financial Industry Regulatory Authority (“FINRA”).

 

(r) Subsidiaries and Consolidated Affiliated Entity. Each of the Company’s direct and indirect subsidiaries (each a “Subsidiary” and collectively, the “Subsidiaries”) and each of the entities which the Company indirectly controls through contractual arrangements (each a “Consolidated Affiliated Entity” and collectively the “Consolidated Affiliated Entities”) has been identified on Schedule E hereto. Each of the Subsidiaries and the Consolidated Affiliated Entities has been duly formed, is validly existing under the laws of the United States, Hong Kong or Malaysia, as the case may be, and in good standing under the laws of the jurisdiction of its incorporation, has full power and authority (corporate or otherwise) to own its property and to conduct its business as described in the Prospectus, and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change on the Company, its Subsidiaries and the Consolidated Affiliated Entities, taken as a whole. Except as otherwise disclosed in the Disclosure Package and the Prospectus, all of the equity interests of each Subsidiary have been duly and validly authorized and issued, are owned directly or indirectly by the Company, are either paid in accordance with its articles of association or not paid but still within the payment schedule of its articles of association and non-assessable and are free and clear of all liens, encumbrances, equities or claims (“Liens”); all of the equity or sponsorship interests in the Consolidated Affiliated Entities have been duly and validly authorized and issued, are either paid in accordance with its articles of association or not paid but still within the payment schedule of its articles of association and non-assessable and are owned as described in the Prospectus, and, except as described in the Prospectus, free and clear of all Liens. None of the outstanding share capital or equity interest in any Subsidiary or the Consolidated Affiliated Entity was issued in violation of preemptive or similar rights of any security holder of such Subsidiary or the Consolidated Affiliated Entity. All of the constitutive or organizational documents of each Subsidiary and the Consolidated Affiliated Entity comply with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect. Apart from the Subsidiaries, the Company has no direct or indirect subsidiaries or any other company over which it has direct or indirect effective control. Other than the Subsidiaries and the Consolidated Affiliated Entities, the Company does not directly or indirectly control any entity through contractual arrangements or otherwise such that the entity would be deemed a consolidated affiliated entity whose financial results would be consolidated under U.S. GAAP with the financial results of the Company on the consolidated financial statements of the Company, regardless of whether the Company directly or indirectly owns less than a majority of the equity interests of such person.

 

5

 

 

(s) No Material Actions or Proceedings. Except as otherwise disclosed in the Registration Statement, Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (collectively, “Actions”) pending or, to the Company’s knowledge, threatened (i) against the Company, any Subsidiary or Consolidated Affiliated Entity, (ii) which have as the subject thereof any officer or director (in such capacities) of, or property owned or leased by, the Company, where in any such case (A) there is a reasonable possibility that such Action might be determined adversely to the Company, any Subsidiary or Consolidated Affiliated Entity, and (B) any such Action, if so determined adversely, would reasonably be expected to result in a Material Adverse Change or adversely affect the consummation of the transactions contemplated by this Agreement. Except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, no material labor dispute with the employees of the Company, any Subsidiary or Consolidated Affiliated Entity exists or, to the Company’s knowledge, is threatened or imminent. None of the Company’s, its Subsidiaries’ or the Consolidated Affiliated Entities’ employees is a member of a union that relates to such employee’s relationship with the Company, such Subsidiary or Consolidated Affiliated Entity, and neither the Company nor any of its Subsidiaries nor the Consolidated Affiliated Entities is a party to a collective bargaining agreement, and the Company, its Subsidiaries and Consolidated Affiliated Entities believe that their relationships with their employees are good. No executive officer of the Company, to the knowledge of the Company, is in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company, any of its Subsidiaries or Consolidated Affiliated Entities to any liability with respect to any of the foregoing matters. Except as otherwise disclosed in the Registration Statement, any preliminary prospectus, the Disclosure Package and the Prospectus, the Company, its Subsidiaries and Consolidated Affiliated Entities are in compliance with all applicable laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. Except as otherwise disclosed in the Registration Statement, any preliminary prospectus, the Disclosure Package and the Prospectus, neither the Company or any Subsidiary or Consolidated Affiliated Entity, nor to the knowledge of the Company, any director or officer of the Company, is or has within the last 10 years been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. Except as otherwise disclosed in the Disclosure Package and the Prospectus, there has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company.

 

(t) Intellectual Property Rights. Each of the Company, its Subsidiaries and the Consolidated Affiliated Entities owns, possesses or licenses, and otherwise has legally enforceable rights to use all patents, patent applications, trademarks, trade names, copyrights, domain names, licenses, approvals and trade secrets (collectively, “Intellectual Property Rights”) reasonably necessary to conduct its business as now conducted or, otherwise, as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, except to the extent such failure to own, possess or have other rights to use such Intellectual Property would not be expected to result in a Material Adverse Change. Except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus: (i) neither the Company nor any Subsidiary or Consolidated Affiliated Entity has received any written notice of infringement or conflict with asserted Intellectual Property Rights of others; (ii) the Company, its Subsidiaries and the Consolidated Affiliated Entities are not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement, Disclosure Package and the Prospectus and are not described in all material respects; (iii) none of the technology employed by the Company, its Subsidiaries or the Consolidated Affiliated Entities has been obtained or is being used by the Company, its Subsidiaries or the Consolidated Affiliated Entities in violation of any contractual obligation binding on the Company, the Subsidiaries or the Consolidated Affiliated Entities or, to the Company’s knowledge, in violation of the rights of any persons; and (iv) neither the Company, nor any Subsidiary or Consolidated Affiliated Entity is subject to any judgment, order, writ, injunction or decree of any court or any governmental department, commission, board, bureau, agency or instrumentality, or any arbitrator, nor has it entered into nor is it a party to any agreement made in settlement of any pending or threatened litigation, which materially restricts or impairs its use of any Intellectual Property Rights.

 

(u) All Necessary Permits, etc. Except as otherwise disclosed in the Disclosure Package and the Prospectus, the Company, its Subsidiaries and the Consolidated Affiliated Entities possess such valid and current certificates, authorizations or permits issued by the applicable regulatory agencies or bodies necessary to conduct their respective business, and neither the Company nor its Subsidiaries and the Consolidated Affiliated Entities have received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit.

 

6

 

 

(v) Title to Properties. Except as otherwise disclosed in the Disclosure Package and the Prospectus, the Company, its Subsidiaries and the Consolidated Affiliated Entities have good and marketable title to all the properties and assets reflected as owned by it in the financial statements referred to in Section 1(n) above (or elsewhere in the Disclosure Package and the Prospectus), in each case free and clear of any security interest, mortgage, lien, encumbrance, equity, adverse claim or other defect, except such as do not materially and adversely affect the value of such property and do not materially interfere with the use made or proposed to be made of such property by the Company. The real property, improvements, equipment and personal property held under lease by the Company, its Subsidiaries and the Consolidated Affiliated Entities are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company, its Subsidiaries and the Consolidated Affiliated Entities.

 

(w) Tax Law Compliance. Except as otherwise disclosed in the Registration Statement, any preliminary prospectus, the Disclosure Package and the Prospectus, the Company, its Subsidiaries and the Consolidated Affiliated Entities have each filed necessary income tax returns or has timely and properly filed requested extensions thereof and has paid taxes required to be paid by them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them in all material respects. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section 1(n) above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company has not been finally determined.

 

(x) Company Not an “Investment Company.” The Company is not, and after giving effect to payment for the Offered Securities and the application of the proceeds as contemplated under the caption “Use of Proceeds” in each of the Disclosure Package and the Prospectus will not be, required to register as an “investment company” within the meaning of the Investment Company Act of 1940, as amended (the “Investment Company Act”).

 

(y) Insurance. Each of the Company, the Subsidiaries and the Consolidated Affiliated Entities is insured against such losses and risks and in such amounts as the Company believes are prudent and customary in the businesses in which they are engaged as the Company reasonably believes are adequate and customary for companies engaged in similar businesses. The Company has no reason to believe that it will not be able (i) to renew its or their existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its or their business as now conducted at a cost that would not have a Material Adverse Effect, except in each case as described in each of the Registration Statement, the Disclosure Package and the Prospectus.

 

(z) No Price Stabilization or Manipulation. The Company has not taken and will not take, directly or indirectly, any action designed to, or that might be reasonably expected to cause or result in, stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale of the Offered Securities.

 

(aa) Related Party Transactions. There are no business relationships or related-party transactions involving the Company or any other person required to be described or filed in the Registration Statement, or described in the Disclosure Package or the Prospectus, that have not been as set forth in the Registration Statement, the Prospectus and the Pricing Prospectus.

 

(bb) Disclosure Controls and Procedures. To the extent required, the Company has established and maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) of the Exchange Act Regulations) designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company is not aware of (a) any significant deficiency in the design or operation of internal controls which could adversely affect the Company’s ability to record, process, summarize and report financial data or any material weaknesses in internal controls or (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls.

 

7

 

 

 

(cc) Company’s Accounting System. The Company maintains a system of accounting controls designed to provide reasonable assurances that (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

(dd) Money Laundering Law Compliance. The operations of the Company are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any competent governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

(ee) OFAC. (i) Neither the Company, its Subsidiaries and the Consolidated Affiliated Entities nor, to the knowledge of the Company, any director, officer, or employee of the Company, its Subsidiaries and the Consolidated Affiliated Entities, or any other person authorized to act on behalf of the Company, its Subsidiaries and the Consolidated Affiliated Entities, is an individual or entity (“Person”) that is, or is owned or controlled by a Person that is:

 

A. the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council (“UNSC”), the European Union (“EU”), His Majesty’s Treasury (“HMT”), or other relevant sanctions authority (collectively, “Sanctions”), nor

 

B. located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran, Libya, North Korea, Sudan and Syria).

 

(ii) The Company will not, directly or indirectly, use the proceeds of the Offering, or lend, contribute or otherwise make available such proceeds to any Subsidiary or Consolidated Affiliated Entity, joint venture partner or other Person:

 

A. to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or

 

B. in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the Offering, whether as underwriter, advisor, investor or otherwise).

 

(ff) Foreign Corrupt Practices Act. Neither the Company, its Subsidiaries and the Consolidated Affiliated Entities, nor, to the knowledge of the Company, any director, officer, or employee of the Company, its Subsidiaries and the Consolidated Affiliated Entities or any other person authorized to act on behalf of the Company has, directly or indirectly, knowingly given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder or otherwise subject the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding.

 

8

 

 

(gg) Compliance with Sarbanes-Oxley Act of 2002. The Company has taken all necessary actions to ensure that, upon the effectiveness of the Registration Statement, it will be in compliance with any provision applicable to it of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and the rules and regulations promulgated in connection therewith, including, without limitation, Section 402 related to loans and Sections 302 and 906 related to certifications of the Sarbanes-Oxley Act.

 

(hh) Exchange Act Filing. A registration statement in respect of the shares of Common Stock has been filed on Form 8-A pursuant to Section 12(b) of the Exchange Act, which registration statement complies in all material respects with the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the shares of Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.

 

(ii) Earning Statements. The Company will make generally available (which includes filings pursuant to the Exchange Act made publicly through the EDGAR system) to its security holders as soon as practicable, but in any event not later than 16 months after the end of the Company’s current fiscal year, an earnings statement (which need not be audited) covering a 12-month period that shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.

 

(jj) Periodic Reporting Obligations. During the Prospectus Delivery Period, the Company shall file, on a timely basis, with the Commission all reports and documents required to be filed under the Exchange Act. Additionally, the Company shall report the use of proceeds from the issuance of the Firm Shares as may be required under Rule 463 under the Securities Act.

 

(kk) Foreign Tax Compliance. Except as otherwise disclosed in the Disclosure Package and the Prospectus, no transaction, stamp, capital or other issuance, registration, transaction, transfer or withholding taxes or duties are payable in Malaysia or Hong Kong to any Hong Kong or Malaysia taxing authority in connection with the issuance, sale and delivery of the Offered Securities, and the delivery of the Offered Securities to or for the account of the Underwriters.

 

(ll) D&O Questionnaires. To the Company’s knowledge, all information contained in the questionnaires (the “Questionnaires”) completed by each of the Company’s directors and officers prior to the Offering (the “Insiders”) as well as in the Lock-Up Agreement in the form attached hereto as Exhibit A provided to the Representative is true and correct in all respects and the Company has not become aware of any information which would cause the information disclosed in the Questionnaires completed by each Insider to become inaccurate and incorrect.

 

Any certificate signed by an officer of the Company and delivered to the Representative or to counsel for the Representative shall be deemed to be a representation and warranty by the Company to the Underwriters as to the matters set forth therein. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section 5 hereof, counsel to the Company, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.

 

(mm) Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Offered Securities hereunder, the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, are sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). Except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. The Registration Statement and the Prospectus set forth as of [●] all outstanding secured and unsecured Indebtedness of the Company, each Subsidiary and Consolidated Affiliated Entity, or for which the Company, any Subsidiary or Consolidated Affiliated Entity has commitments. For the purposes of this Agreement, “Indebtedness” means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with U.S. GAAP. Except as set forth in the Registration Statement and the Prospectus, neither the Company nor any Subsidiary or Consolidated Affiliated Entity is in default with respect to any Indebtedness.

 

9

 

 

(nn) Regulation M Compliance. The Company has not, and to its knowledge no one authorized to act on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Offered Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Offered Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Underwriters in connection with the Offering.

 

(oo) Testing the Waters Communications. The Company (a) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Underwriters with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (b) has not authorized anyone other than the Underwriters to engage in Testing-the-Waters Communications. The Company reconfirms that the Underwriters have been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications.

 

(pp) Margin Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the Offered Securities to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

 

(qq) Integration. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under the Securities Act.

 

SECTION 2. Firm Shares; Additional Shares; Representative Warrants.

 

(a) Purchase of Firm Shares. On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell to the Underwriters the Firm Shares at a purchase price (net of discounts)1 of (i) $[●] per share with respect to investors introduced to the Company by the Underwriters or (ii) $[●] per share with respect to investors introduced by the Company. The Underwriters agree to purchase from the Company the Firm Shares in such amounts as set forth opposite their respective names on Schedule A attached hereto and made a part hereof.

 

 

1 8% or 6%, as applicable

 

10

 

 

(b) Delivery of and Payment for Firm Shares. Delivery of and payment for the Firm Shares shall be made at 10:00 A.M., Eastern time, on the third (3rd) Business Day following the Applicable Time, or at such time as shall be agreed upon by the Representative and the Company, at the offices of the Representative’s counsel or at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Representative and the Company. The hour and date of delivery of and payment for the Firm Shares is called the “Closing Date.” The closing of the payment of the purchase price for is referred to herein as the “Closing.” Payment for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds upon delivery to the Underwriters of certificates (in form and substance reasonably satisfactory to the Underwriters) representing the Firm Shares (or if uncertificated through the full fast transfer facilities of the Depository Trust Company (the “DTC”)) for the account of the Underwriters. The Firm Shares shall be registered in such names and in such denominations as the Underwriters may request in writing at least two Business Days prior to the Closing Date. If certificated, the Company will permit the Underwriters to examine and package the Firm Shares for delivery at least one full Business Day prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender of payment by the Underwriters for all the Firm Shares.

 

(c) Additional Shares. The Company hereby grants to the Underwriters an option (the “Over-allotment Option”), exercisable for 45 days from the date of the Prospectus, to purchase up to an additional [●] 2 shares of Common Stock (the “Additional Shares”), in each case solely for the purpose of covering over-allotments of such securities, if any. The Over-allotment Option is, at the Representative’s sole discretion, for Additional Shares.

 

(d) Exercise of Over-allotment Option. The Over-allotment Option granted pursuant to Section 2(c) hereof may be exercised by the Representative on or within 45 days after the Closing Date. The purchase price to be paid per Additional Shares shall be equal to the price per Firm Share in Section 2(a). The Underwriters shall not be under any obligation to purchase any Additional Shares prior to the exercise of the Over-allotment Option. The Over-allotment Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which shall be confirmed in writing via overnight mail or facsimile or other electronic transmission, setting forth the number of Additional Shares to be purchased and the date and time for delivery of and payment for the Additional Shares (the “Option Closing Date”), which shall not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by the Company and the Representative, at the offices of the Representative’s counsel or at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Additional Shares does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the Additional Shares, subject to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Additional Shares specified in such notice and (ii) the Underwriters shall purchase that portion of the total number of Additional Shares.

 

(e) Delivery and Payment of Additional Shares. Payment for the Additional Shares shall be made on the Option Closing Date by wire transfer in Federal (same day) funds, upon delivery to the Representative of certificates (in form and substance satisfactory to the Representative) representing the Additional Shares (or through the facilities of DTC) for the account of the Underwriters. The Additional Shares shall be registered in such name or names and in such authorized denominations as the Representative may request in writing at least two (2) full Business Days prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Additional Shares except upon tender of payment by the Underwriters for applicable Additional Shares. The Option Closing Date may be simultaneous with, but not earlier than, the Closing Date; and in the event that such time and date are simultaneous with the Closing Date, the term “Closing Date” shall refer to the time and date of delivery of the Firm Shares and Additional Shares.

 

(f) Underwriting Discount. In consideration of the services to be provided for hereunder, the Company shall pay to the Underwriters, with respect to any Offered Securities sold to investors in this Offering, (i) an eight percent (8%) underwriting discount for investors introduced to the Company by the Underwriters or (ii) a six percent (6%) discount for investors introduced by the Company.

 

 

2 15% of the Firm Shares

 

11

 

 

(g)            Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of shares of common stock, representing seven percent (7%) of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the one hundred eightieth (180th) days after the commencement of sales of the Offering and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is equal to 110% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the shares of Common Stock issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days after the commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

 

(i)            Delivery of the Representative Warrants. Delivery of the Representative’s Warrants shall be made on the Closing Date, and shall be issued in the name or names and in such authorized denominations as the Representative may request.

 

SECTION 3. Covenants of the Company.

 

The Company covenants and agrees with the Underwriters as follows:

 

(a) Underwriters’ Review of Proposed Amendments and Supplements. During the period beginning at the Applicable Time and ending on the later of the Closing Date or such date as, in the opinion of counsel for the Representative, the Prospectus is no longer required by law to be delivered in connection with sales by the Underwriters or selected dealers, including under circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act (the “Prospectus Delivery Period”), prior to amending or supplementing the Registration Statement or the Prospectus, including any amendment or supplement through incorporation by reference of any report filed under the Exchange Act, the Company shall furnish to the Underwriters for review a copy of each such proposed amendment or supplement, and the Company shall not file any such proposed amendment or supplement to which the Underwriters reasonably objects.

 

(b) Securities Act Compliance. After the date of this Agreement, during the Prospectus Delivery Period, the Company shall promptly advise the Underwriters in writing (i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (ii) of the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Pricing Prospectus or the Prospectus, (iii) of the time and date that any post-effective amendment to the Registration Statement becomes effective and (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or of any order or notice preventing or suspending the use of the Registration Statement, the Pricing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Offered Securities from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order or order or notice of prevention or suspension at any time, the Company will use commercially reasonable efforts to obtain the lifting of such order at the earliest possible moment or will file a new registration statement and use commercially reasonable efforts to have such new registration statement declared effective as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b) and 430A, as applicable, under the Securities Act, including with respect to the timely filing of documents thereunder and will confirm that any filings made by the Company under such Rule 424(b) were received in a timely manner by the Commission.

 

12

 

 

(c) Exchange Act Compliance. During the Prospectus Delivery Period, to the extent the Company becomes subject to reporting obligation under the Exchange Act, the Company will file all documents required to be filed with the Commission pursuant to Sections 13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act.

 

(d) Amendments and Supplements to the Registration Statement, Prospectus and Other Securities Act Matters. If, during the Prospectus Delivery Period, any event or development shall occur or condition exist as a result of which the Disclosure Package or the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made, as the case may be, not misleading, or if it shall be necessary to amend or supplement the Disclosure Package or the Prospectus, in order to make the statements therein, in the light of the circumstances under which they were made, as the case may be, not misleading, or if in the opinion of the Underwriters it is otherwise necessary to amend or supplement the Registration Statement, the Disclosure Package or the Prospectus, or to file a new registration statement containing the Prospectus, in order to comply with law, including in connection with the delivery of the Prospectus, the Company agrees to (i) notify the Underwriters of any such event or condition (unless such event or condition was previously brought to the Company’s attention by the Underwriters during the Prospectus Delivery Period) and (ii) promptly prepare (subject to Section 3(a) and Section 3(f) hereof), file with the Commission (and use its commercially reasonable efforts to have any amendment to the Registration Statement or any new registration statement to be declared effective) and furnish at its own expense to the Underwriters and to dealers, amendments or supplements to the Registration Statement, the Disclosure Package or the Prospectus, or any new registration statement, necessary in order to make the statements in the Disclosure Package or the Prospectus as so amended or supplemented, in the light of the circumstances under which they were made, as the case may be, not misleading or so that the Registration Statement, the Disclosure Package or the Prospectus, as amended or supplemented, will comply with law.

 

(e) Permitted Free Writing Prospectuses. The Company represents that it has not made, and agrees that, unless it obtains the prior written consent of the Underwriters, it will not make, any offer relating to the Offered Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus” (as defined in Rule 405 under the Securities Act) required to be filed by the Company with the Commission or retained by the Company under Rule 433 under the Securities Act; provided that the prior written consent of the Underwriters hereto shall be deemed to have been given in respect of each free writing prospectuses listed on Schedule B hereto. Any such free writing prospectus consented to by the Underwriters is hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company agrees that (i) it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, and (ii) has complied and will comply, as the case may be, with the requirements of Rules 164 and 433 under the Securities Act applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the Commission, legending and record keeping.

 

(f) Copies of any Amendments and Supplements to the Prospectus. The Company agrees to furnish the Underwriters, without charge, during the Prospectus Delivery Period, as many copies of each of the preliminary prospectuses, the Prospectus and the Disclosure Package and any amendments and supplements thereto (including any documents incorporated or deemed incorporated by reference therein) as the Underwriters may reasonably request.

 

(g) Use of Proceeds. The Company shall apply the net proceeds from the Offering in the manner consistent with the application thereof described under the caption “Use of Proceeds” in the Disclosure Package and the Prospectus.

 

(h) Transfer Agent. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Offered Securities.

 

13

 

 

(i) Internal Controls. The Company will maintain a system of internal accounting controls designed to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance with U.S. GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The internal controls, upon consummation of the Offering, will be, overseen by the Audit Committee (the “Audit Committee”) of the Board in accordance with the rules of the Nasdaq Stock Market (“Nasdaq”).

 

(j) Exchange Listing. The shares of Common Stock has been duly authorized for listing on the Nasdaq Capital Market, subject to official notice of issuance. The Company is in material compliance with the provisions of the rules and regulations promulgated by Nasdaq and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements (to the extent applicable to the Company as of the date hereof, the Closing Date or the Option Closing Date, if any; and subject to all exemptions and exceptions from the requirements thereof as are set forth therein, to the extent applicable to the Company). Without limiting the generality of the foregoing and subject to the qualifications above: (i) all members of the Company’s board of directors who are required to be “independent” (as that term is defined under applicable laws, rules and regulations), including, without limitation, all members of each of the audit committee, compensation committee and nominating committee of the Company’s board of directors, meet the qualifications of independence as set forth under such laws, rules and regulations, (ii) the audit committee of the Company’s board of directors has at least one member who is an “audit committee financial expert” (as that term is defined under such laws, rules and regulations), and (iii) that, based on discussions with Nasdaq, the Company meets all requirements for listing on the Nasdaq Capital Market.

 

(k) Future Reports to the Underwriters. For one year after the date of this Agreement, the Company will furnish, if not otherwise available on EDGAR, to the Representative at 590 Madison Avenue 39th Floor, New York, NY, 10022 Attn: Joseph Rallo (i) as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders’ equity and cash flows for the year then ended and the opinion thereon of the Company’s independent public or certified public accountants; (ii) as soon as practicable after the filing thereof, copies of each proxy statement, annual report on Form 10-K, quarterly report on From 10-Q, or other report filed by the Company with the Commission; and (iii) as soon as available, copies of any report or communication of the Company mailed generally to holders of its capital stock.

 

(l) No Manipulation of Price. The Company will not take, directly or indirectly, any action designed to cause or result in, or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities of the Company.

 

(m) Existing Lock-Up Agreements. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, there are no existing agreements between the Company and its security holders that prohibit the sale, transfer, assignment, pledge or hypothecation of any of the Company’s securities. The Company will direct the transfer agent to place stop transfer restrictions upon the securities of the Company that are bound by such “lock-up” agreements for the duration of the periods contemplated therein.

 

14

 

 

(n) Company Lock-Up.

 

(i) The Company will not, without the prior written consent of the Representative, from the date of execution of this Agreement and continuing for a period of 180 days from Applicable Time (the “Lock-Up Period”), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, enter into any “at-the-market” or continuous equity, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock of the Company or any securities convertible into or exercisable or exchangeable for shares of Common Stock of the Company; (ii) file or caused to be filed any registration statement with the Commission relating to the offering of any shares of Common Stock of the Company or any securities convertible into or exercisable or exchangeable for shares of Common Stock of the Company other than registration statements on Form S-8 filed with the SEC after the Closing Date; or (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of shares of Common Stock of the Company, whether any such transaction described in clause (i), (ii), or (iii) above is to be settled by delivery of shares of Common Stock or such other securities of the Company, in cash or otherwise. The Company agrees not to accelerate the vesting of any option or warrant or the lapse of any repurchase right prior to the expiration of the Lock-Up Period.

 

(ii) The restrictions contained in Section 3(n)(i) hereof shall not apply to: (A) the Offered Securities, (C) any shares of Common Stock issued under a company stock plan or warrants issued by the Company, in each case, described as outstanding in the Registration Statement, the Disclosure Package or the Prospectus, (D) any options and other awards granted under a company stock plan or shares of Common Stock issued pursuant to an employee stock purchase plan, and (E) shares of Common Stock or other securities issued in connection with a transaction with an unaffiliated third party that includes a bona fide commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company; provided that the recipient of any such shares of Common Stock or other securities issued or granted pursuant to clause (E) during the Lock-Up Period shall enter into an agreement substantially in the form of Exhibit A hereto for the remaining term of the Lock-Up Period.

 

SECTION 4. Payment of Fees and Expenses. The Company has agreed to pay the reasonable and documented out-of-pocket accountable expenses of the Representative in total up to $204,500.

 

Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, the Company agrees to pay all reasonable, actual and accountable costs, fees and expenses incurred in connection with the transactions contemplated hereby, including without limitation (i) all filing fees and expenses relating to the registration of the Offered Securities with the Commission; (ii) all fees and expenses relating to the listing of the Common Stock on a national estrange, if applicable; (iii) all filing fees, attorneys’ fees and expenses incurred by the Company, or the Representative, in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Securities for offer and sale under the state securities or blue sky laws, and, if requested by the Representative, preparing and printing a “Blue Sky Survey” or memorandum, and any supplements thereto, advising the Representative of such qualifications, registrations and exemptions; (iv) all fees, expenses and disbursements relating to the registration, qualification or exemption of the Offered Securities under the securities laws of such foreign jurisdictions as Representative may reasonably designate; (v) the costs of all mailing and printing of the Offering documents; (vi) transfer and/or stamp taxes, if any, payable upon the transfer of Offered Securities from the Company to Representative; (vii) the fees and expenses of the Company’s accountants; (viii) all filing fees and communication expenses associated with the review of the Offering by FINRA; (ix) up to $20,000 of Representative’s actual accountable road show expenses for the Offering; (x) the $29,500 cost associated with Representative’s use of Ipreo’s book building, prospectus tracking and compliance software for the offering; (xi) the costs associated with bound volumes of the Offering materials as well as commemorative mementos and lucite tombstones in an aggregate amount not to exceed $5,000; and (xii) the fees for Representative’s legal counsel, in an amount not to exceed $150,000. For the sake of clarity, it is understood and agreed that the Company shall be responsible for Representative’s external counsel legal costs detailed in this Section irrespective of whether the Offering is consummated or not, subject to a cap of $50,000 in total expenses in the event that there is not a Closing. The Company has advanced $50,000 to the Representative to cover its out-of-pocket expenses. The advance will be returned to the Company to the extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA Rule 5110(g). In addition, the Company agrees to pay to the Representative at the Closing or Option Closing, as applicable, a non-accountable expense allowance equal to one percent (1%) of the gross proceeds raised at the Closing and at the Option Closing, as applicable.

 

15

 

 

SECTION 5. Conditions of the Obligations of the Underwriters. The obligations of the Underwriters to purchase the Offered Securities as provided herein on the Closing Date or the Option Closing Date shall be subject to (1) the accuracy of the representations and warranties on the part of the Company set forth in Section 1 hereof as of the date hereof and as of the Closing Date or the Option Closing Date, if any, as though then made; (2) the timely performance by the Company of its covenants and other obligations hereunder; and (3) each of the following additional conditions:

 

(a) Accountants’ Comfort Letters. On the date hereof, the Representative shall have received from each of the Accountants, a letter dated the date hereof addressed to the Representative, in form and substance satisfactory to the Representative, containing statements and information of the type ordinarily included in accountants’ “comfort letters” to Representative, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial information contained in the Registration Statement and the Prospectus.

 

(b) Effectiveness of Registration Statement; Compliance with Registration Requirements; No Stop Order. During the period from and after the execution of this Agreement to and including the Closing Date or the Option Closing Date, as applicable:

 

(i) the Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information required by such Rule 430A, and such post-effective amendment shall have become effective; and

 

(ii) no stop order suspending the effectiveness of the Registration Statement, or any post-effective amendment to the Registration Statement, shall be in effect and no proceedings for such purpose shall have been instituted or threatened by the Commission.

 

(c) No Material Adverse Change. For the period from and after the date of this Agreement to and including the Closing Date or the Option Closing Date, if any, in the reasonable judgment of the Representative there shall not have occurred any Material Adverse Change.

 

(d) CFO Certificate. On the Closing Date and/or the Option Closing Date, the Representative shall have received a written certificate executed by the Chief Financial Officer of the Company, dated as of such date, on behalf of the Company, with respect to certain financial data contained in the Registration Statement, Disclosure Package and the Prospectus, providing “management comfort” with respect to such information, in form and substance reasonably satisfactory to the Representative.

 

(e) Officers’ Certificate. On the Closing Date and the Option Closing Date, as applicable, the Representative shall have received a written certificate executed by the Chief Executive Officer and the Chief Financial Officer of the Company, dated as of such date, to the effect that the signers of such certificate have reviewed the Registration Statement, the Disclosure Package and the Prospectus and any amendment or supplement thereto, each Issuer Free Writing Prospectus, if any and this Agreement, to the effect that, to the knowledge of such individual:

 

(i) The representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such Closing Date or Option Closing Date, if applicable, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to such Closing Date or Option Closing Date, if applicable;

 

(ii) No stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus has been issued and no proceedings for that purpose have been instituted or are pending or, to the Company’s knowledge, threatened under the Securities Act; no order having the effect of ceasing or suspending the distribution of the Offered Securities or any other securities of the Company has been issued by any securities commission, securities regulatory authority or stock exchange in the United States and no proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange in the United States; and

 

16

 

 

(iii) Subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus, there has not been: (a) any Material Adverse Change; (b) any transaction that is material to the Company, the Subsidiaries and the Consolidated Affiliated Entities taken as a whole, except transactions entered into in the ordinary course of business; (c) any obligation, direct or contingent, that is material to the Company, the Subsidiaries and the Consolidated Affiliated Entities taken as a whole, incurred by the Company, any Subsidiary or Consolidated Affiliated Entity, except obligations incurred in the ordinary course of business; (d) any material change in the capital stock (except changes thereto resulting from the exercise of outstanding options or warrants or conversion of outstanding indebtedness into shares of Common Stock of the Company) or outstanding indebtedness of the Company, any Subsidiary or Consolidated Affiliated Entity (except for the conversion of such indebtedness into shares of Common Stock of the Company); (e) any dividend or distribution of any kind declared, paid or made on shares of Common Stock of the Company; or (f) any loss or damage (whether or not insured) to the property of the Company, any Subsidiary or Consolidated Affiliated Entity which has been sustained or will have been sustained which has a Material Adverse Effect.

 

(f) Secretary’s Certificate. On the Closing Date and/or the Option Closing Date, the Representative shall have received a certificate of the Company signed by the Secretary of the Company, dated such Closing Date, certifying: (i) that the Company’s articles of incorporation attached to such certificate is true and complete, has not been modified and is in full force and effect; (ii) that each of the Subsidiaries’ and Consolidated Affiliated Entities’ articles of association, memorandum of association or charter documents attached to such certificate is true and complete, has not been modified and is in full force and effect; (iii) that the resolutions of the Company’s Board of Directors relating to the Offering attached to such certificate are in full force and effect and have not been modified; and (iv) the good standing of the Company and each of the Subsidiaries and Consolidated Affiliated Entities (except in such jurisdictions where the concept of good standing is not applicable). The documents referred to in such certificate shall be attached to such certificate.

 

(g) Bring-down Comfort Letters. On the Closing Date and/or the Option Closing Date, the Representative shall have received from each of the Accountants, a letter dated such date, in form and substance satisfactory to the Representative, to the effect that the Accountants reaffirm the statements made in the letter furnished by them pursuant to subsection (a) of this Section 5, except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the Closing Date and/or the Option Closing Date.

 

(h) Lock-Up Agreement from Certain Security holders of the Company. On or prior to the date hereof, the Company shall have furnished to the Representative an agreement substantially in the form of Exhibit A hereto from each of the Company’s officers, directors, all security holders of the Company’s shares of Common Stock or securities convertible into or exercisable for the Company’s shares of Common Stock listed on Schedule D hereto.

 

(i) Exchange Listing. The Offered Securities to be delivered on the Closing Date and/or the Option Closing Date shall have been approved for listing on the Nasdaq Capital Market, subject to official notice of issuance.

 

(j) Company Counsel Opinions. On the Closing Date and/or the Option Closing Date, the Representative shall have received:

 

(i) the favorable opinion of Loeb & Loeb, LLP, U.S. securities counsel to the Company, dated as of such date, addressed to the Representative, including a negative assurance letter, in form and substance reasonably satisfactory to the Representative.

 

(ii) the favorable opinion of Lee & Poh Partnership, Malaysia counsel to the Company, in form and substance reasonably satisfactory to the Representative.

 

17

 

 

The Underwriters shall rely on the opinions of (i) Loeb & Loeb, LLP, filed as Exhibit 5.1 to the Registration Statement, as to the due incorporation, validity of the Offered Securities and the Underlying Shares and due authorization, execution and delivery of the Agreement.

 

(k) FINRA shall have confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and arrangements.

 

(l) Additional Documents. On or before the Closing Date and/or the Option Closing Date, as applicable, the Representative and counsel for the Representative shall have received such information, documents and opinions as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of the Offered Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained.

 

If any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representative by written notice to the Company at any time on or prior to the Closing Date and/or the Option Closing Date, as applicable, which termination shall be without liability on the part of any party to any other party, except that Section 4 (with respect to the reimbursement of reasonable out-of-pocket accountable, bona fide expenses actually incurred by the Representative) and Section 7 shall at all times be effective and shall survive such termination.

 

SECTION 6. Effectiveness of this Agreement. This Agreement shall not become effective until the later of (i) the execution of this Agreement by the parties hereto and (ii) notification (including by way of oral notification from the reviewer at the Commission) by the Commission to the Company of the effectiveness of the Registration Statement under the Securities Act.

 

SECTION 7. Indemnification.

 

(a) Indemnification by the Company. The Company shall indemnify and hold harmless the Underwriters, their respective affiliates and each of its respective directors, officers, members, employees and agents and each person, if any, who controls such Underwriters within the meaning of Section 15 of the Securities Act of or Section 20 of the Exchange Act (collectively the “Underwriters Indemnified Parties,” and each a “Underwriters Indemnified Party”) from and against any losses, claims, damages or liabilities (including in settlement of any litigation if such settlement is effected with the prior written consent of the Company) arising out of (i) an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including the information deemed to be a part of the Registration Statement at the time of effectiveness and at any subsequent time pursuant to Rules 430A and 430B of the Securities Act Regulations, or arise out of or are based upon the omission from the Registration Statement, or alleged omission to state therein, a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; or (ii) an untrue statement or alleged untrue statement of a material fact contained in the Prospectus, or any amendment or supplement thereto, or in any other materials used in connection with the Offering, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and shall reimburse such Underwriters Indemnified Party for any legal or other expenses reasonably incurred by it in connection with evaluating, investigating or defending against such loss, claim, damage, liability or action; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement in, or omission from any preliminary prospectus, the Registration Statement or the Prospectus, or any such amendment or supplement thereto, or any Issuer Free Writing Prospectus or in any other materials used in connection with the Offering made in reliance upon and in conformity with the Underwriters Information. The indemnification obligations under this Section 7(a) are not exclusive and will be in addition to any liability, which the Underwriters might otherwise have and shall not limit any rights or remedies which may otherwise be available at law or in equity to each Underwriters Indemnified Party.

 

18

 

 

(b) Indemnification by the Underwriters. The Underwriters shall indemnify and hold harmless the Company and the Company’s affiliates and each of their respective directors, officers, employees, agents and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the “Company Indemnified Parties” and each a “Company Indemnified Party”) from and against any losses, claims, damages or liabilities (including in settlement of any litigation if such settlement is effected with the prior written consent of the Underwriters) arising out (i) any untrue statement of a material fact contained in any preliminary prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement or the Prospectus, or in any amendment or supplement thereto, or (ii) the omission to state in any preliminary prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement or the Prospectus, or in any amendment or supplement thereto, a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, but in each case only to the extent that the untrue statement or omission was made in reliance upon and in conformity with the Underwriters Information and shall reimburse the Company for any legal or other expenses reasonably incurred by such party in connection with investigating or preparing to defend or defending against or appearing as third party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as such fees and expenses are incurred. Notwithstanding the provisions of this Section 7(b), in no event shall any indemnity by the Underwriters under this Section 7(b) exceed the total discounts received by the Underwriters in connection with the Offering. The indemnification obligations under this Section 7(b) are not exclusive and will be in addition to any liability, which the Company might otherwise have and shall not limit any rights or remedies which may otherwise be available at law or in equity to each Company Indemnified Party.

 

(c) Procedure. Promptly after receipt by an indemnified party under this Section 7 of notice of the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section 7, notify such indemnifying party in writing of the commencement of that action; provided, however, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this Section 7 except to the extent it has been materially adversely prejudiced by such failure; and, provided, further, that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this Section 7. If any such action shall be brought against an indemnified party, and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such action with counsel reasonably satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party, be counsel to the indemnifying party). After notice from the indemnifying party to the indemnified party of its election to assume the defense of such action, except as provided herein, the indemnifying party shall not be liable to the indemnified party under Section 7(a) or 7(b), as applicable, for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense of such action other than reasonable costs of investigation; provided, however, that any indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense of such action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified party unless (i) the employment thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification under Section 7(a), (ii) such indemnified party shall have been advised by its counsel that there may be one or more legal defenses available to it which are different from or additional to those available to the indemnifying party, or (iii) the indemnifying party has failed to assume the defense of such action and employ counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice of the commencement of the action or the indemnifying party does not diligently defend the action after assumption of the defense, in which case, if such indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure to diligently defend the action after assumption of the defense, to continue to defend) such action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently incurred by such indemnified party in connection with the defense of such action; provided, however, that the indemnifying party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys at any time any such indemnified party (in addition to any local counsel), which firm shall be designated in writing by the Underwriters if the indemnified party under this Section 7 is an Underwriters Indemnified Party or by the Company if an indemnified party under this Section 7 is a Company Indemnified Party. Subject to this Section 7(c), the amount payable by an indemnifying party under Section 7 shall include, but not be limited to, (x) reasonable legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or preparing to defend or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any action, investigation, proceeding or claim, and (y) all amounts paid in settlement of any of the foregoing. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of judgment with respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this Section 7 (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the following sentence, no indemnifying party shall be liable for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with its written consent, if its consent has been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability by reason of such settlement or judgment. In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated herein effected without its written consent if (i) such settlement is entered into more than forty-five (45) days after receipt by such indemnifying party of the request for reimbursement, (ii) such indemnifying party shall have received notice of the terms of such settlement at least thirty (30) days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.

 

19

 

 

(d) Contribution. If the indemnification provided for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under Section 7(a) or Section 7(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the indemnifying party or parties on the one hand and the indemnified parry or parties on the other hand from the Offering, or (ii) if the allocation provided by clause (i) of this Section 7(d) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) of this Section 7(d) but also the relative fault of the indemnifying party or parties on the one hand and the indemnified party or parties on the other with respect to the statements, omissions, acts or failures to act which resulted in such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant equitable considerations as determined in a final judgment by a court of competent jurisdiction. The relative benefits received by the Company on the one hand and the Underwriters on the other with respect to the Offering shall be deemed to be in the same proportion as the total proceeds from the Offering (before deducting expenses) received by the Company bear to the total underwriting discounts received by the Underwriters in connection with the Offering, in each case as set forth in the table on the cover page of the Prospectus. The relative fault of the Company on the one hand and the Underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission, act or failure to act; provided that the parties hereto agree that the written information furnished to the Company by the Underwriters for use in any preliminary prospectus, the Registration Statement or the Prospectus, or in any amendment or supplement thereto, consists solely of the Underwriters Information. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this Section 7(d) be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to above in this Section 7(d) shall be deemed to include, for purposes of this Section 7(d), any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section 7(d), the Underwriters shall not be required to contribute any amount in excess of the total discounts received in cash by the Underwriters in connection with the Offering less the amount of any damages that the Underwriters have otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

 

20

 

 

SECTION 8. Termination of this Agreement. Prior to the Closing Date, whether before or after notification by the Commission to the Company of the effectiveness of the Registration Statement under the Securities Act, this Agreement may be terminated by the Representative by written notice given to the Company if at any time (i) trading or quotation in the Company’s Common Stock shall have been suspended or limited by the Commission or by Nasdaq; (ii) a general banking moratorium shall have been declared by any U.S. federal or Malaysia authorities; (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States’ or international political, financial or economic conditions that, in the reasonable judgment of the Representative, is material and adverse and makes it impracticable to market the Offered Securities in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of the Offered Securities; or (iv) regulatory approval (including but not limited to NASDAQ approval) for the Offering is denied, conditioned or modified and as a result it makes it impracticable for the Representative to proceed with the offering, sale and/or delivery of the Offered Securities or to enforce contracts for the sale of the Offered Securities.. Except as otherwise stated in this section, the Agreement may not be terminated by the Company prior to the Closing Date, other than for “Cause.”

 

Any termination pursuant to this Section 8 shall be without liability on the part of (a) the Company to any of the Underwriters, except that the Company shall be, subject to demand by the Underwriters, obligated to reimburse the Representative for only those out-of-pocket expenses (including the reasonable fees and expenses of its counsel, and expenses associated with a due diligence report), actually incurred and documented by the Representative in connection herewith as allowed under FINRA Rule 5110, less any amounts previously paid by the Company; provided, however, that all such expenses shall not exceed $50,000 in the aggregate, (b) the Underwriters to the Company, or (c) of any party hereto to any other party except that the provisions of Section 4 (with respect to the reimbursement of out-of-pocket accountable, bona fide expenses actually incurred by the Representative) and Section 7 shall at all times be effective and shall survive such termination.

 

Upon termination or expiration of this Agreement, unless the Company terminates this Agreement for “Cause” as defined below or the Representative’s material failure to provide the underwriting services contemplated by this Agreement, if the Company subsequently completes any public or private financing with any investors introduced to the Company by the Representative at any time during the twelve (12) months after such termination, then the Representative shall be entitled to receive the compensation as set forth in this Agreement. “Cause,” for the purpose of this Agreement, shall mean, as an uncured material breach of the Agreement by the Representative or a material failure by the Representative to provide the underwriting services contemplated hereunder. In the event that the Company believes that the Representative has engaged conduct constituting Cause, it must first notify Representative in writing of the facts and circumstances supporting such an assertion(s) and allow Representative twenty (20) days to cure such alleged conduct.

 

21

 

 

SECTION 9. No Advisory or Fiduciary Responsibility. The Company hereby acknowledges that the Underwriters are acting solely as Underwriters in connection with the Offering. The Company further acknowledges that the Underwriters are acting pursuant to a contractual relationship created solely by this Agreement entered into on an arm’s-length basis and in no event do the parties intend that the Underwriters act or be responsible as a fiduciary to the Company, its management, shareholders, creditors or any other person in connection with any activity that the Underwriters may undertake or have undertaken in furtherance of the Offering, either before or after the date hereof. The Underwriters hereby expressly disclaim any fiduciary or similar obligations to the Company, either in connection with the transactions contemplated by this Agreement or any matters leading up to such transactions, and the Company hereby confirms its understanding and agreement to that effect. The Company hereby further confirms its understanding that no Underwriter has assumed an advisory or fiduciary responsibility in favor of the Company with respect to the Offering contemplated hereby or the process leading thereto, including, without limitation, any negotiation related to the pricing of the Offered Securities; and the Company has consulted its own legal and financial advisors to the extent it has deemed appropriate in connection with this Agreement and the Offering. The Company and the Underwriters agree that they are each responsible for making their own independent judgments with respect to any such transactions, and that any opinions or views expressed by the Underwriters to the Company regarding such transactions, including but not limited to any opinions or views with respect to the price or market for the Company’s securities, do not constitute advice or recommendations to the Company. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any breach or alleged breach of any fiduciary or similar duty to the Company in connection with the transactions contemplated by this Agreement or any matters leading up to such transactions.

 

SECTION 10. Representations and Indemnities to Survive Delivery. The respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers, and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Underwriters or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and will survive delivery of and payment for the Offered Securities sold hereunder and any termination of this Agreement.

 

Section 11. Right of First Refusal; Tail Financing.

 

(a) Right of First Refusal. The Company agrees that it shall provide the Representative an irrevocable right of first refusal (“Right of First Refusal”) until 12 months after the date the Offering is completed to act as sole investment banker, sole book-runner, and/or sole placement agent, at the Representative’s sole discretion, for each and every future public and private equity and debt offering, including all equity linked financings of the Company, or any successor to or any current or future subsidiary of the Company (collectively, “Future Services”). The Representative shall have the sole right to determine whether or not any other broker dealer shall have the right to participate in the Future Services and the economic terms of such participation. For the avoidance of doubt, the Company shall not retain, engage, or solicit any additional investment banker, book-runner, financial advisor, underwriter and/or placement agent for Future Services without the express written consent of the Representative. In the event the Company notifies the Representative of its intention to pursue an activity that would enable the Representative to exercise its Right of First Refusal to provide Future Services, the Representative shall notify the Company of its election to provide such Future Services, including notification of the compensation and other terms to which the Representative claims to be entitled, within fifteen (15) days of written notice by the Company. In the event the Company engages the Representative to provide such Future Services, the Representative will be compensated as mutually agreed by the Company and the Representative. To the extent this Agreement is terminated by the Company for Cause, the Right of Refusal granted hereunder will terminate.

 

(b) Tail Financing. The Representative shall be entitled to a cash fee equal to eight percent (8.0%) of the gross proceeds received by the Company from the sale of any equity, debt and/or equity derivative instruments to any investor actually introduced by the Representative to the Company during the period (the “Engagement Period”) beginning October 3, 2022 and ending on the earlier of (i) October 2, 2023, or (ii) the final closing, if any, of the Offering (excluding any existing investor of the Company or its subsidiaries or affiliates), in connection with any public or private financing or capital raise (each a “Tail Financing”), and such Tail Financing is consummated within the twelve (12) month period following the expiration or termination of the Engagement Period (the “Tail Period”), provided that such Tail Financing is by a party actually introduced to the Company by the Representative in an offering in which the Company has direct knowledge of such party’s participation.

 

22

 

 

SECTION 12. Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered or emailed to the parties hereto as follows:

 

If to the Representative:

 

EF Hutton,

division of Benchmark Investments, LLC

590 Madison Avenue, 39th Floor

New York, NY 10022

Attn: Joseph Rallo

Email: jrallo@efhuttongroup.com

 

With a copy (which shall not constitute notice) to:

 

Hunter Taubman Fischer & Li LLC

950 Third Avenue, 19th Floor

New York, NY 10022

Attn.: Louis Taubman, Esq.; Guillaume de Sampigny, Esq.

Email: ltaubman@htflawyers.com; gdesampigny@htflawyers.com

 

If to the Company:

 

AGAPE ATP CORPORATION

1705 - 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia,

Taman Desa, Kuala Lumpur, Malaysia (Postal Code: 58100)

Attn: How Kok Choong

Email: corporate@agapeatp.com

 

With a copy (which shall not constitute notice) to:

 

Loeb & Loeb LLP

2206-19 Jardine House

1 Connaught Place Central

Attn: Lawrence S. Venick, Esq.

Email: lvenick@loeb.com

 

Any party hereto may change the address for receipt of communications by giving written notice to the others.

 

SECTION 13. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto and to the benefit of the employees, officers and directors and controlling persons referred to in Section 7, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term “successors” shall not include any purchaser of the Offered Securities as such merely by reason of such purchase.

 

SECTION 14. Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

 

SECTION 15. Governing Law Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, without giving effect to conflict of laws principles thereof.

 

SECTION 16. Consent to Jurisdiction. No legal suit, action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby (each, a “Related Proceeding”) may be commenced, prosecuted or continued in any court other than the courts of the State of New York located in the City and County of New York or in the United States District Court for the Southern District of New York, which courts (collectively, the “Specified Courts”) shall have jurisdiction over the adjudication of any Related Proceeding, and the parties to this Agreement hereby irrevocably consent to the exclusive jurisdiction the Specified Courts and personal service of process with respect thereto. The parties to this Agreement hereby irrevocably waive any objection to the laying of venue of any Related Proceeding in the Specified Courts and irrevocably waive and agree not to plead or claim in any Specified Court that any Related Proceeding brought in any Specified Court has been brought in an inconvenient forum.

 

SECTION 17. General Provisions. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the Offering. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.

 

[Signature Page Follows]

 

23

 

 

If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.

 

  Very truly yours,
   
  AGAPE ATP CORPORATION
     
  By:  
  Name: How Kok Choong
  Title: Chief Executive Officer, Chief Operating Officer, Director, Chairman of the Board of Directors and Secretary

 

The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representative as of the date first above written.

 

EF HUTTON,  
DIVISION OF BENCHMARK INVESTMENTS, LLC  
     
By:    
Name: Sam Fleischmann  
 Title: Supervisory Principal  

 

24

 

 

SCHEDULE A

 

Underwriters   

Number

of Firm

Shares

 
EF Hutton, division of Benchmark Investments, LLC   [●] 
Total   [●] 

 

25

 

 

SCHEDULE B

 

Issuer Free Writing Prospectus(es)

 

[●]

 

26

 

 

SCHEDULE C

 

Pricing Information

 

Number of Firm Shares: [●]

 

Number of Additional Shares: [●]

 

Public Offering Price per one Share: [●]

 

Underwriting Discount per one Share: [●]

 

Proceeds to Company per one Share (before expenses): [●]

 

27

 

 

SCHEDULE D

 

Lock-Up Parties

 

How Kok Choong

Mohd Shaharuddin Bin Abdullah

Lee Kam Fan Andrew

Ramesh Ruben Louis

Professor Dr. John Hing Vong

Chee Aik Chin

HKC Talent Limited

SeokTin Khor

Yuen Foong Hew

Kock Yong Siew

Chuen Mun Sew

Sing Yin Gan

Wai Choo Sew

Harn Yi Hu

Jen Jiang Teo

Pek Ching Leong

Yap Foo Ching @ Steve Yap

 

28

 

 

SCHEDULE E

 

Subsidiaries and Consolidated Affiliated Entities

 

Subsidiaries  

Jurisdiction of

Formation

Agape ATP Corporation   Malaysia
Agape ATP International Holding Limited   Hong Kong
Agape Superior Living Sdn. Bhd.   Malaysia
DSY Wellness International Sdn Bhd.   Malaysia
Wellness ATP International Holdings Sdn, Bhd   Malaysia

 

Consolidated Affiliated Entity  

Jurisdiction of

Formation

Agape S.E.A. Sdn. Bhd.   Malaysia

 

29

 

 

 

EXHIBIT A

 

Form of Lock-Up Agreement

 

[●], 2023

 

EF Hutton,

Division of Benchmark Investments, LLC

590 Madison Avenue, 39th Floor

New York, NY 10022

 

Ladies and Gentlemen:

 

This Lock-Up Agreement (this “Agreement”) is being delivered to EF Hutton, division of Benchmark Investments, LLC (the “Representative”) in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between AGAPE ATP CORPORATION, a Nevada corporation (the “Company”), and the Representative, relating to the proposed public offering (the “Offering”) of shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. Initial capitalized terms not otherwise defined herein shall have the meaning given to those terms in the Underwriting Agreement.

 

In order to induce the Underwriters (as defined in the Underwriting Agreement) to continue their efforts in connection with the Offering, and in light of the benefits that the Offering will confer upon the undersigned in its capacity as a shareholder and/or an officer or director of the Company, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Representative that, during the period beginning on and including the date of this Agreement through and including the date that is 180 days from the date of this Agreement (the “Lock-Up Period”), the undersigned will not, without the prior written consent of the Representative, directly or indirectly, (i) offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of Common Stock now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (including, without limitation, shares of Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations promulgated under the Securities Act of 1933, as amended, and as the same may be amended or supplemented on or after the date hereof from time to time (the “Securities Act”)) (such shares, the “Beneficially Owned Shares”) or securities convertible into or exercisable or exchangeable for shares of Common Stock, (ii) enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part, the economic risk of ownership of the Beneficially Owned Shares or securities convertible into or exercisable or exchangeable for shares of Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition, or (iii) engage in any short selling of the shares of Common Stock.

 

The restrictions set forth in the immediately preceding paragraph shall not apply to:

 

(1) if the undersigned is a natural person, any transfers made by the undersigned (a) as a bona fide gift to any member of the immediate family (as defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned or members of the undersigned’s immediate family, (b) by will or intestate succession upon the death of the undersigned, (c) as a bona fide gift to a charity or educational institution, (d) any transfer pursuant to a qualified domestic relations order or in connection with a divorce; or (e) if the undersigned is or was an officer or director of the Company, to the Company pursuant to the Company’s right of repurchase upon termination of the undersigned’s service with the Company;

 

(2) if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfers to any shareholder, partner or member of, or owner of a similar equity interest in, the undersigned, as the case may be, if, in any such case, such transfer is not for value;

 

(3) if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer made by the undersigned (a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned’s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the undersigned’s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this Agreement or (b) to another corporation, partnership, limited liability company or other business entity so long as the transferee is an affiliate (as defined below) of the undersigned and such transfer is not for value;

 

30

 

 

(4) (a) exercises of stock options or equity awards granted pursuant to an equity incentive or other plan or warrants to purchase shares of Common Stock or other securities (including by cashless exercise to the extent permitted by the instruments representing such stock options or warrants so long as such cashless exercise is effected solely by the surrender of outstanding stock options or warrants to the Company and the Company’s cancellation of all or a portion thereof to pay the exercise price), provided that in any such case the securities issued upon exercise shall remain subject to the provisions of this Agreement (as defined below); (b) transfers of shares of Common Stock or other securities to the Company in connection with the vesting or exercise of any equity awards granted pursuant to an equity incentive or other plan and held by the undersigned to the extent, but only to the extent, as may be necessary to satisfy tax withholding obligations pursuant to the Company’s equity incentive or other plans;

 

(5) the exercise by the undersigned of any warrant(s) issued by the Company prior to the date of this Agreement, including any exercise effected by the delivery of shares of Common Stock of the Company held by the undersigned; provided, that, the shares of Common Stock received upon such exercise shall remain subject to the restrictions provided for in this Agreement;

 

(6) the occurrence after the date hereof of any of (a) an acquisition by an individual or legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of 100% of the voting securities of the Company, (b) the Company merges into or consolidates with any other entity, or any entity merges into or consolidates with the Company, (c) the Company sells or transfers all or substantially all of its assets to another person, or (d) provided, that, the shares of Common Stock received upon any of the events set forth in clauses (a) through (c) above shall remain subject to the restrictions provided for in this Agreement;

 

(7) the Offering;

 

(8) transfers consented to, in writing by the Representative;

 

(9) transactions relating to shares of Common Stock acquired in open market transactions after the completion of the Offering; provided that, no filing by any party under the Exchange Act or other public announcement shall be required or shall be voluntarily made in connection with such transactions;

 

provided however, that in the case of any transfer described in clauses (1), (2) or (3) above, it shall be a condition to the transfer that the transferee executes and delivers to the Representative, acting on behalf of the Underwriters, not later than one business day prior to such transfer, a written agreement, in substantially the form of this Agreement (it being understood that any references to “immediate family” in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and not to the immediate family of the transferee) and otherwise satisfactory in form and substance to the Representative. Furthermore, notwithstanding the foregoing, the undersigned may transfer the Beneficially Owned Securities in a transaction not involving a public offering or public resale; provided that (x) the transferee agrees in writing with the Representative to be bound by the terms of this Agreement, and (y) no filing by any party under Section 16(a) of the Exchange Act shall be required or shall be made voluntarily in connection with such transfer.

 

In addition, the restrictions set forth herein shall not prevent the undersigned from entering into a sales plan pursuant to Rule 10b5-1 under the Exchange Act after the date hereof, provided that (i) a copy of such plan is provided to the Representative promptly upon entering into the same and (ii) no sales or transfers may be made under such plan until the Lock-Up Period ends or this Agreement is terminated in accordance with its terms. For purposes of this paragraph, “immediate family” shall mean any relationship by blood, marriage or adoption, nor more remote than first cousin; and “affiliate” shall have the meaning set forth in Rule 405 under the Securities Act.

 

31

 

 

If (i) during the last 17 days of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating to the Company occurs, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results or becomes aware that material news or a material event will occur during the 16-day period beginning on the last day of the Lock-Up Period, the restrictions imposed by this Agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of such material news or material event, as applicable, unless the Representative waives, in writing, such extension.

 

If the undersigned is an officer or director of the Company, (i) the Representative agrees that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, the Representative will notify the Company of the impending release or waiver. Any release or waiver granted by the Representative hereunder to any such officer or director shall only be effective two business days after the publication date of such press release; provided, that such press release is not a condition to the release of the aforementioned lock-up provisions due to the expiration of the Lock-Up Period. The provisions of this paragraph will also not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this Agreement to the extent and for the duration that such terms remain in effect at the time of such transfer.

 

In furtherance of the foregoing, (1) the undersigned also agrees and consents to the entry of stop transfer instructions with any duly appointed transfer agent for the registration or transfer of the securities described herein against the transfer of any such securities except in compliance with the foregoing restrictions, and (2) the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Agreement.

 

The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement and that this Agreement has been duly authorized (if the undersigned is not a natural person), executed and delivered by the undersigned and is a valid and binding agreement of the undersigned. This Agreement and all authority herein conferred are irrevocable and shall survive the death or incapacity of the undersigned (if a natural person) and shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned for the term of the Lock-Up Period.

 

This Agreement shall automatically terminate upon the earliest to occur, if any, of (1) either the Representative, on the one hand, or the Company, on the other hand, advising the other in writing, they have determined not to proceed with the Offering, (2) termination of the Underwriting Agreement before the sale of shares of Common Stock, or (3) the withdrawal of the Registration Statement.

 

This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, without regard to the conflict of laws principles thereof.

 

[Signature Page Follows]

 

32

 

 

  Very truly yours,
  (Name - Please Print)
  (Signature)
  (Name of Signatory, in the case of entities - Please Print)
  (Title of Signatory, in the case of entities - Please Print)
  Address:  
 

# of shares of Common Stock Held by

Signatory:

 

 

33

 

 

Exhibit 4.2

 

THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT, OR ANY OF THE UNDERLYING SECURITIES, EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT, OR ANY OF THE UNDERLYING SECURITIES, FOR A PERIOD ENDING ON, AND INCLUDING, THE DATE THAT IS ONE HUNDRED EIGHTY (180) DAYS BEGINNING ON THE DATE OF COMMENCEMENT OF SALES OF THE OFFERING TO ANYONE OTHER THAN (I) EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC, OR A REPRESENTATIVE OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC, OR OF ANY SUCH UNDERWRITERS OR SELECTED DEALER.

 

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [●]. VOID AFTER 5:00 P.M., EASTERN TIME, [●].

 

UNDERWRITER’S WARRANT

 

FOR THE PURCHASE OF [●] SHARES OF COMMON STOCK

 

OF

 

AGAPE ATP CORPORATION

 

1. Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between AGAPE ATP CORPORATION, a Nevada corporation (the “Company”), on one hand, and EF Hutton, division of Benchmark Investments, LLC (the “Holder”), on the other hand, dated [●] (the “Underwriting Agreement”), the Holder, as registered owner of this underwriter’s warrant (this “Purchase Warrant”), is entitled, at any time or from time to time from [●] (the “Exercise Date”), and at or before 5:00 p.m., Eastern Time, on [●] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of Common Stock of the Company, par value $0.0001 per share (“Common Stock”) (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●] per share (110% of the price of the shares of Common Stock sold in the Offering); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per share and the number of shares of Common Stock to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price of this Purchase Warrant as set forth above or the adjusted exercise price as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

 

2. Exercise.

 

2.1 Exercise Form. In order to exercise this Purchase Warrant, the exercise form attached hereto as Exhibit A must be duly executed and completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the shares of Common Stock being purchased payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern Time, on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and expire.

 

 

2.2 Cashless Exercise. The Holder may elect to receive the number of shares of Common Stock equal to the value of this Purchase Warrant (or the portion thereof being exercised), by surrender of this Purchase Warrant to the Company, together with the exercise form attached hereto, in which event the Company shall issue to Holder, Shares in accordance with the following formula:

 

X = Y(A-B)    
A    
       
Where, X = The number of shares of Common Stock to be issued to Holder;
  Y = The number of shares of Common Stock for which the Purchase Warrant is being exercised;
  A = The fair market value of one share of Common Stock; and
  B = The Exercise Price.

 

For purposes of this Section 2.2, the “fair market value” of a share of Common Stock is defined as follows:

 

  (i) if the shares of Common Stock are traded on a national securities exchange, the value shall be deemed to be the weighted average closing price on such exchange for the five consecutive trading days ending on the trading day immediately prior to the exercise form being submitted in connection with the exercise of the Purchase Warrant; or

 

  (ii) if the shares of Common Stock are actively traded over-the-counter, the value shall be deemed to be the weighted average closing bid price of the shares of Common Stock for the five consecutive trading days ending on the trading day immediately prior to the exercise form being submitted in connection with the exercise of the Purchase Warrant; or

 

  (iii) if there is no market for the shares of Common Stock, the value shall be the fair market value thereof, as determined in good faith by the Board.

 

2.3 Legend. Each certificate for the securities purchased under this Purchase Warrant shall bear the following legends unless such securities have been registered under the Securities Act of 1933, as amended (the “Act”), or are exempt from registration under the Act:

 

(i) “THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD ENDING ON, AND INCLUDING, THE DATE THAT IS ONE HUNDRED AND EIGHTY (180) DAYS BEGINNING ON THE DATE OF COMMENCEMENT OF SALES OF THE OFFERING PURSUANT TO THE REGISTRATION STATEMENT OF THE COMPANY’S SECURITIES (FILE NO. 333-239951) AND MAY NOT BE (A) SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED TO ANYONE OTHER THAN EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC, OR BONA FIDE OFFICERS OR PARTNERS OF EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC, OR (B) CAUSED TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THE SECURITIES HEREUNDER, EXCEPT AS PROVIDED FOR IN FINRA RULE 5110(E)(2).”

 

 

 

 

(ii) Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by a certificate, instrument, or book entry so legended.

 

3. Transfer.

 

3.1 General Restrictions. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant or any of the Shares exercisable hereunder for a period ending on, and including, the date that is one hundred eighty (180) days beginning on the date of commencement of sales of the Offering (the “Initial Transfer Date”) to anyone other than: (i) the Underwriter or a selected dealer participating in the Offering, or (ii) a bona fide officer or partner of the Underwriter or of any such selected dealer, in each case in accordance with FINRA Rule 5110(e)(2)(B), or (b) cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(e)(2). On and after the Initial Transfer Date, transfers to others may be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto as Exhibit B duly executed and completed, together with this Purchase Warrant and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Business Days transfer this Purchase Warrant on the books of the Company and shall execute and deliver a new warrant or warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of shares of Common Stock purchasable hereunder or such portion of such number as shall be contemplated by any such assignment.

 

3.2 Restrictions Imposed by the Act. The securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) the Company has received the opinion of counsel for the Company that the securities may be transferred pursuant to an exemption from registration under the Act and applicable state securities laws, the availability of which is established to the reasonable satisfaction of the Company, (ii) a registration statement or a post-effective amendment to the Registration Statement relating to the offer and sale of such securities that has been declared effective by the Commission and includes a current prospectus or (iii) a registration statement, pursuant to which the Holder has exercised its registration rights pursuant to Sections 4.1 and 4.2 herein, relating to the offer and sale of such securities has been filed and declared effective by the Commission and compliance with applicable state securities law has been established.

 

4. Registration Rights. The Company shall be required to keep a registration statement effective on Form S-1 until such date that is the earlier of the date when all of the shares of Common Stock underlying this Purchase Warrant have been publicly sold by the Holder or such time as Rule 144 or another similar exemption under the Securities Act, is available for the sale of all of such Holder’s Shares underlying this Purchase Warrant without registration.

 

5. New Purchase Warrants to be Issued.

 

5.1 Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised pursuant to Section 2.1 hereof, the Company shall cause to be delivered to the Holder without charge a new warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of shares of Common Stock purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.

 

5.2 Lost Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new warrant of like tenor and date. Any such new warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.

 

6. Adjustments.

 

6.1 Adjustments to Exercise Price and Number of Shares of Common Stock. The Exercise Price and the number of Shares of Common Stock underlying this Purchase Warrant shall be subject to adjustment from time to time as hereinafter set forth:

 

6.1.1 Share Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock or by a split up of shares of Common Stock or other similar event, then, on the effective day thereof, the number of shares of Common Stock purchasable hereunder shall be increased in proportion to such increase in outstanding shares of Common Stock, and the Exercise Price shall be proportionately decreased.

 

6.1.2 Aggregation of Shares of Common Stock. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding shares of Common Stock is decreased by a consolidation, combination or reclassification of shares of Common Stock or other similar event, then, on the effective date thereof, the number of shares of Common Stock purchasable hereunder shall be decreased in proportion to such decrease in outstanding shares, and the Exercise Price shall be proportionately increased.

 

2

 

 

6.1.3 Replacement of shares of Common Stock upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding shares of Common Stock other than a change covered by Section 6.1.1 or Section 6.1.2 hereof or that solely affects the par value of such shares of Common Stock, or in the case of any share reconstruction or amalgamation or consolidation of the Company with or into another corporation (other than a consolidation or share reconstruction or amalgamation in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of the outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the kind and amount of shares of Common Stock or other securities or property (including cash) receivable upon such reclassification, reorganization, share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by a Holder of the number of shares of Common Stock of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results in a change in shares of Common Stock covered by Section 6.1.1 or Section 6.1.2, then such adjustment shall be made pursuant to Section 6.1.1, Section 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications, reorganizations, share reconstructions or amalgamations, or consolidations, sales or other transfers.

 

6.1.4 Fundamental Transaction. If, at any time while this Purchase Warrant is outstanding, the Company enters into the following transactions with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with, the other Persons making or party to such stock or share purchase agreement or other business combination): (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any direct or indirect purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of shares of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spinoff or scheme of arrangement) with another Person or group of Persons (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Purchase Warrant, the Holder shall have the right to receive, for each Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional or alternative consideration (the “Alternative Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Purchase Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternative Consideration based on the amount of Alternative Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternative Consideration in a reasonable manner reflecting the relative value of any different components of the Alternative Consideration. If holders of shares of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternative Consideration it receives upon any exercise of this Purchase Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Purchase Warrant, and to deliver to the Holder in exchange for this Purchase Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Purchase Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Purchase Warrant immediately prior to such Fundamental Transaction, and with an exercise price which applies the Exercise Price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction, the value of such shares of capital stock, the number of shares of such capital stock and the exercise price for such shares of capital stock for the purpose of protecting the economic value of this Purchase Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Purchase Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of, the Company and shall assume all of the obligations of the Company, under this Purchase Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

3

 

 

6.1.5 Changes in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1, and any warrants issued after such change, in exchange or replacement of this Purchase Warrant may state the same Exercise Price and the same number of shares of Common Stock as are stated in the Purchase Warrant initially issued pursuant to this Purchase Warrant. The acceptance by any Holder of the issuance of a new warrant reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the date hereof or the computation thereof.

 

6.2 Substitute Purchase Warrant. Except as otherwise provided in Section 6.1.5, in case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification or change of the outstanding shares of Common Stock ), the corporation formed by such consolidation or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental warrant providing that the holder of this Purchase Warrant shall have the right thereafter (until the stated expiration of this Purchase Warrant) to receive, upon exercise of such supplemental warrant, the kind and amount of shares of common stock and other securities and property receivable upon such consolidation or share reconstruction or amalgamation, by a holder of the number of shares of Common Stock of the Company for which this Purchase Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental warrant shall provide for adjustments which shall be substantially the same to the adjustments provided for in this Section 6. The above provisions of this Section 6 shall similarly apply to successive consolidations or share reconstructions or amalgamations.

 

6.3 Elimination of Fractional Interests. The Company shall not be required to issue certificates representing fractions of shares of Common Stock upon the exercise of this Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to the nearest whole number of shares of Common Stock or other securities, properties or rights.

 

7. Reservation and Listing. The Company shall at all times reserve and keep available out of its authorized shares of Common Stock, solely for the purpose of issuance upon exercise of this Purchase Warrant, such number of shares of Common Stock or other securities, properties or rights as shall be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of this Purchase Warrant and payment of the Exercise Price therefor, unless this Purchase Warrant is exercised pursuant to a cashless exercise, as provided in Section 2.2 hereof, in accordance with the terms hereby, all shares of Common Stock and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. The Company further covenants and agrees that upon exercise of this Purchase Warrant and payment of the exercise price therefor, unless this Purchase Warrant is exercised pursuant to a cashless exercise, as provided in Section 2.2 hereof, all shares of Common Stock and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. As long as this Purchase Warrant shall be outstanding, the Company shall use its commercially reasonable efforts to cause all shares of Common Stock issuable upon exercise of this Purchase Warrant to be listed (subject to official notice of issuance) on all national securities exchanges (or, if applicable, on the OTCQB Market or any successor quotation system) on which the shares of Common Stock are then listed and/or quoted (if at all).

 

4

 

 

8. Certain Notice Requirements.

 

8.1 Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holder the right to vote or consent or to receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company. If, however, at any time prior to the expiration of this Purchase Warrant and the exercise thereof, any of the events described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen days prior to the date fixed as a record date or the date of closing the transfer books (the “Notice Date”) for the determination of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to the Holder a copy of each notice given to the other shareholders of the Company at the same time and in the same manner that such notice is given to the shareholders.

 

8.2 Events Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of the following events: (i) if the Company shall take a record of the holders of its shares of Common Stock for the purpose of entitling them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall offer to all the holders of its shares of Common Stock any additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution, liquidation or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a sale of all or substantially all of its property, assets and business shall be proposed.

 

8.3 Notice of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section 6 hereof, send notice to the Holder of such event and change (“Price Notice”). The Price Notice shall describe the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company’s Chief Financial Officer.

 

8.4 Transmittal of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall be deemed to have been duly made if made in accordance with the notice provisions of the Underwriting Agreement to the addresses and contact information set forth below:

 

If to the Holder, then to:

 

EF Hutton,

division of Benchmark Investments, LLC

590 Madison Avenue, 39th Floor

New York, NY 10022

Attn: Joseph Rallo

Email: jrallo@efhuttongroup.com

 

With a copy to:

 

Hunter Taubman Fischer & Li LLC

48 Wall Street, Suite 2800

New York, NY 1100
Attn: Louis Taubman, Esq.; Guillaume de Sampigny, Esq.

Email: ltaubman@htflawyers.com; gdesampigny@htflawyers.com

 

5

 

 

If to the Company:

 

AGAPE ATP CORPORATION

1705 - 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia,

Taman Desa, Kuala Lumpur, Malaysia (Postal Code: 58100)

Attn: How Kok Choong

Email: corporate@agapeatp.com

 

With a copy to:

 

Loeb & Loeb LLP

2206-19 Jardine House

1 Connaught Place Central

Attn: Lawrence S. Venick, Esq.

Email: lvenick@loeb.com

 

9. Miscellaneous.

 

9.1 Amendments. The Company and the Underwriter may from time to time supplement or amend this Purchase Warrant without the approval of the Holder in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company and the Underwriter may deem necessary or desirable and that the Company and the Underwriter deem shall not adversely affect the interest of the Holder. All other modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the modification or amendment is sought.

 

9.2 Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant.

 

9.3 Entire Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

9.4 Binding Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained.

 

9.5 Governing Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

 

6

 

 

9.6 Waiver, etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

 

9.7 Holder Not Deemed a Shareholder. Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder of this Purchase Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Purchase Warrant be construed to confer upon the Holder, solely in its capacity as a holder of this Purchase Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of shares, reclassification of shares, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Shares which it is then entitled to receive upon the due exercise of this Purchase Warrant. In addition, nothing contained in this Purchase Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Purchase Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

9.8 Restrictions. The Holder acknowledges that the Shares acquired upon the exercise of this Purchase Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

9.9 Severability. Wherever possible, each provision of this Purchase Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Purchase Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Purchase Warrant.

 

[Signature Page Follows]

 

7

 

 

IN WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of the [●]th day of _______, 2022.

 

  AGAPE ATP CORPORATION
     
  By:  
  Name: How Kok Choong
  Title: Chief Executive Officer, Chief Operating Officer,
  Director, Chairman of the Board of Directors and Secretary

 

8

 

 

EXHIBIT A

 

Exercise Notice

 

Form to be used to exercise Purchase Warrant:

 

Date: __________, 202_

 

The undersigned hereby elects irrevocably to exercise the Purchase Warrant for ______ shares of Common Stock of AGAPE ATP CORPORATION, a Nevada corporation (the “Company”), and hereby makes payment of $____ (at the rate of $____ per share) in payment of the Exercise Price pursuant thereto. Please issue the shares of Common Stock as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of shares of Common Stock for which this Purchase Warrant has not been exercised.

 

or

 

The undersigned hereby elects irrevocably to convert its right to purchase ___ shares of Common Stock under the Purchase Warrant for ______ shares of Common Stock, as determined in accordance with the following formula:

 

  X = Y(A-B)  
  A  
Where, X = The number of shares of Common Stock to be issued to Holder;
  Y = The number of shares of Common Stock for which the Purchase Warrant is being exercised;
  A = The fair market value (as defined in Section 2.2 of this Purchase Warrant) of one share of Common Stock which is equal to $_____; and
  B = The Exercise Price which is equal to $______ per share

 

The undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect to the calculation shall be resolved by the Company in its sole discretion.

 

Please issue the shares of Common Stock as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of shares of Common Stock for which this Purchase Warrant has not been converted.

 

Signature

 

Signature Guaranteed

 

INSTRUCTIONS FOR REGISTRATION OF SECURITIES

 

Name:

(Print in Block Letters)

Address:

 

NOTICE: The signature to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange.

 

 

 

 

EXHIBIT B

 

Assignment Notice

 

Form to be used to assign Purchase Warrant:

 

ASSIGNMENT

 

(To be executed by the registered Holder to effect a transfer of the within Purchase Warrant):

 

FOR VALUE RECEIVED, does hereby sell, assign and transfer unto the right to purchase shares of Common Stock of AGAPE ATP CORPORATION, a Nevada corporation (the “Company”), evidenced by the Purchase Warrant and does hereby authorize the Company to transfer such right on the books of the Company.

 

Dated: , 202

 

Signature

 

Signature Guaranteed

 

NOTICE: The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange.

 

 

 

 

Exhibit 10.3

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 
 

 

 

 

 
 

 

 

 

 
 

 

 

 

 
 

 

 

 

 
 

 

 

 

 
 

 

 

 

 
 

 

 

 

 
 

 

   

 

 

Exhibit 10.4

   

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

 

Exhibit 10.5

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

 

Exhibit 10.6

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

 

 

Exhibit 10.7

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

   

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 
 

 

 

 

 
 

  

 

 

 

 

Exhibit 10.8

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

   

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

 

 

Exhibit 10.9

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

 

Exhibit 10.11

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

 

Exhibit 10.14

 

INDEPENDENT DIRECTOR AGREEMENT

 

This INDEPENDENT DIRECTOR AGREEMENT (the “Agreement”) is made and entered into as of this __12th__ day of September 2022, by and between Agape ATP Corporation, a Nevada corporation (the “Company”), and Dr. John Hing Vong (Australia Passport No.: PB2689742) (the “Independent Director”) and shall become effective on the closing date of the Company’s initial public offering on the Nasdaq Stock Market/ The New York Stock Exchange (the “Effective Date”).

 

WHEREAS, the Company desires to engage the Independent Director, and the Independent Director desires to serve, as a non-employee director of the Company, subject to the terms and conditions contained in this Agreement.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the receipt of which is hereby acknowledged, the Company and the Independent Director, intending to be legally bound, hereby agree as follows:

 

1. DEFINITIONS.

 

(a) “Corporate Status” describes the capacity of the Independent Director with respect to the Company and the services performed by the Independent Director in that capacity.

 

(b) “Entity” shall mean any corporation, partnership, limited liability company, joint venture, trust, foundation, association, organization or other legal entity.

 

I “Proceeding” shall mean any threatened, pending or completed claim, action, suit, arbitration, alternate dispute resolution process, investigation, administrative hearing, appeal, or any other proceeding, whether civil, criminal, administrative or investigative, whether formal or informal, including a proceeding initiated by the Independent Director pursuant to Section 12 of this Agreement to enforce the Independent Director’s rights hereunder.

 

(d) “Expenses” shall mean all reasonable fees, costs and expenses, approved in writing by the Company in advance and reasonably incurred in connection with any Proceeding, including, without limitation, attorneys’ fees, disbursements and retainers, fees and disbursements of expert witnesses, private investigators, professional advisors (including, without limitation, accountants and investment bankers), court costs, transcript costs, fees of experts, travel expenses, duplicating, printing and binding costs, telephone and fax transmission charges, postage, delivery services, secretarial services, and other disbursements and expenseI(e) “Liabilities” shall mean judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement.

 

(f) “Parent” shall mean any corporation or other entity (other than the Company) in any unbroken chain of corporations or other entities ending with the Company, if each of the corporations or entities, other than the Company, owns stock or other interests possessing 50% or more of the economic interest or the total combined voting power of all classes of stock or other interests in one of the other corporations or entities in the chain.

 

 

 

 

(g) “Subsidiary” shall mean any corporation or other entity (other than the Company) in any unbroken chain of corporations or other entities beginning with the Company, if each of the corporations or entities, other than the last corporation or entity in the unbroken chain, owns stock or other interests possessing 50% or more of the economic interest or the total combined voting power of all classes of stock or other interests in one of the other corporations or entities in the chain.

 

2. DUTIES OF INDEPENDENT DIRECTOR.While this Agreement is in effect, the Independent Director shall serve as an independent director and/or a member of the committess of the Board, and shall perform duties, responsibilities and obligations consistent and customarily assigned to individuals serving in the positions of the foregoing, be compensated for such and be reimbursed expenses in accordance with the Schedule A attached to this Agreement, subject to the following:

 

(a) The Independent Director shall exercise all powers in good faith and in the best interests of the Company, including but not limited to the following:

 

(i) CONFLICTS OF INTEREST/APPLICABLE LAW. In the event that the Independent Director has a direct or indirect financial or personal interest in a contract or transaction to which the Company is a party, or the Independent Director is contemplating entering into a transaction that involves use of corporate assets or competition against the Company, the Independent Director shall promptly disclose such potential conflict to the applicable Board committee or the Board and proceed as directed by such committee or the Board, as applicable. The Director acknowledges the duty of loyalty and the duty of care owed to the Company pursuant to applicable law and agrees to act in all cases in accordance with applicable law.

 

(ii) CORPORATE OPPORTUNITIES. Whenever the Independent Director becomes aware of a business opportunity related to the Company’s business, which one could reasonably expect the Director to make available to the Company, the Independent Director shall promptly disclose such opportunity to the applicable Board committee or the Board and proceed as directed by such committee or the Board, as applicable.

 

2

 

 

(iii) CONFIDENTIALITY. The Independent Director agrees and acknowledges that, by reason of the nature of the Independent Director duties on the Board, the Independent Director will have or may have access to and become informed of proprietary, confidential and secret information which is a competitive asset of the Company (“Confidential Information”), including, without limitation, any lists of customers or suppliers, distributors, financial statistics, research data or any other statistics and plans or operation plans or other trade secrets of the Company and any of the foregoing which belong to any person or company but to which the Independent Director has had access by reason of the Independent Director’s relationship with the Company. The term “Confidential Information” shall not include information which: (i) is or becomes generally available to the public other than as a result of a disclosure by the Independent Director or the Independent Director’s representatives; or (ii) is required to be disclosed by the Independent Director due to governmental regulatory or judicial process. The Independent Director agrees faithfully to keep in strict confidence, and not, either directly or indirectly, to make known, divulge, reveal, furnish, make available or use (except for use in the regular course of employment duties) any such Confidential Information. The Independent Director acknowledges that all manuals, instruction books, price lists, information and records and other information and aids relating to the Company’s business, and any and all other documents containing Confidential Information furnished to the Independent Director by the Company or otherwise acquired or developed by the Director, shall at all times be the property of the Company. Upon termination of the Director’s services hereunder, the Independent Director shall return to the Company any such property or documents which are in the Director’s possession, custody or control, but this obligation of confidentiality shall survive such termination until and unless any such Confidential Information shall have become, through no fault of the Independent Director, generally known to the public. The obligations of the Director under this subsection are in addition to, and not in limitation or preemption of, all other obligations of confidentiality which the Independent Director may have to the Company under general legal or equitable principles.

 

(iv) Code of Business Conduct and Ethics. The Independent Director agrees to abide by and follow all such procedures set forth in the Company’s code of business conduct and ethics, as may be in existence now or at any time during the term of this Agreement, and any other policy, code or document governing the conduct of directors of the Company as may be in existence now or at any time during the term of this Agreement.

 

(b) The Independent Director is solely responsible for taxes arising out of any compensation paid by the Company to the Independent Director under this Agreement. The Independent Director acknowledges and agrees that because he/she is not an employee of the Company, the Company will not withhold any amounts for taxes from any of his/her payments under the AgreeIt.

 

3

 

 

(c) The Company may offset any and all monies payable to the Independent Director to the extent of any monies owing to the Company from the Independent Director.

 

(d) The rules and regulations of the Company notified to the Independent Director, from time to time, apply to the Independent Director. Such rules and regulations are subject to change by the Company in its sole discretion. Notwithstanding the foregoing, in the event of any conflict or inconsistency between the terms and conditions of this Agreement and rules and regulations of the Company, the terms of this Agreement shall control.

 

3. REQUIREMENTS OF INDEPENDENT DIRECTOR. During the term of the Independent Director’s services to the Company hereunder, Independent Director shall observe all applicable laws and regulations relating to independent directors of a public company as promulgated from time to time and the Company’s policy, and shall not: (1) be an employee of the Company or any Parent or Subsidiary; (2) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the Company other than asexpressly provided in this Agreement ; (3) be an affiliated person of the Company or any Parent or Subsidiary, as the term “affiliate” is defined in 17 CFR 240.10A-3(e)(1), other than in his capacity as a director and/or a member of a committee of the Board; (4) possess an interest in any transaction with the Company or any Parent or Subsidiary, for which disclosure would be required pursuant to 17 CFR 229.404(a), other than in his capacity as a director and/or a member of a committee of the Board committees; (5) be engaged in a business relationship with the Company or any Parent or Subsidiary, for which disclosure would be required pursuant to 17 CFR 229.404(b), except that the required beneficial interest therein shall be modified to be 5% hereby.

 

4. REPORT OBLIGATION. While this Agreement is in effect, the Independent Director shall immediately report to the Company in the event: (1) the Independent Director knows or has reason to know or should have known that any of the requirements specified in Section 3 hereof is not satisfied or is not going to be satisfied; and (2) the Independent Director simultaneously serves on an audit committee of any other public company.

 

5. TERM AND TERMINATION. This Agreement hereunder shall commence on the date hereof and the Independent Director’s services shall commence on the Effective Date and terminate upon the earlier of the following:

 

(a) Removal of the Independent Director as a director of the Company, upon proper Board or stockholder action in accordance with the By-Laws of the Company and applicable law;

 

(b) Resignation of the Independent Director as a director of the Company upon 14 days written notice to the Board of Directors of the CIany;

 

(c) Disqualification of the Independent Director as a director of the Company in accordance with the By-Laws of the Company;

 

(d) Termination of this Agreement by the Company upon 14 days written notice, in the event of breach of Section 2 hereof or any of the requirements specified in Section 3 hereof is not satisfied, as determined by the Company in its sole discrIon; or

 

4

 

 

(e) Failure of the stockholders of the Company to re-elect the Independent Director at the Company’s annual shareholders’ meeting.

 

6. LIMITATION OF LIABILITY. In no event shall the Independent Director be individually liable to the Company or its shareholders for any damages for breach of fiduciary duty as an independent director of the Company, unless the Independent Director’s act or failure to act involves intentional misconduct, fraud, dishonesty, negligence or a knowing violation of law.

 

7. AGREEMENT OF INDEMNITY. The Company agrees to indemnify the Independent Director as follows:

 

(a) Subject to the exceptions contained in Section 8(a)below, if the Independent Director was or is a party or is threatened to be made a party to any proceeding (other than an action by or in the right of the Company) by reason of the Independent Director’s Corporate Status (a “Proceeding”), the Independent Director shall be indemnified by the Company against all expenses and liabilities incurred or paid by the Independent Director in connection with such Proceeding (referred to herein as “INDEMNIFIABLE EXPENSES” and “INDEMNIFIABLE LIABILITIES,” respectively, and collectively as “INDEMNIFIABLE AMOUNTS”).

 

(b) Subject to the exceptions contained in Section 8(b) below, if the Independent Director was or is a party or is threatened to be made a party to any Proceeding by or in the right of the Company, to procure a judgment in its favor by reason of the Independent Director’s Corporate Status, the Independent Director shall be indemnified by the Company against all IndemnifiabIe Expenses.

 

(c) For purposes of this Agreement, the Independent Director shall be deemed to have acted in good faith in conducting the Company’s affairs as an independent director of the Company and/or a member of a committee of the Board of the Company, if the Independent Director: (i) exercised or used the same degree of diligence, care, and skill as an ordinarily prudent man would have exercised or used under the circumstances in the conduct of his/her own affairs; or (ii) took, or omitted to take, an action in reliance upon advise of counsels or other professional advisors for the Company, or upon statements made or information furnished by other directors, officers or employees of the Company, or upon a financial statement of the Company provided by a person in charge of its accounts or certified by a public accountant or a firm of public accountants, which the Independent Director had reasonable grounds to believe to be true.

 

(d) In the event the Company is obligated under this Agreement to advance or bear any expenses for any Proceeding, the Company shall be entitled to assume the defense, settlement or appeal of such Proceeding with the assistance and cooperation of the Independent Director, with counsel approved by Independent Director, upon delivery to the Independent Director of its election to do so. After delivery of such notice, approval of such counsel by Independent Director and the retention of such counsel by the Company, the Company shall not be liable to Independent Director under this Agreement for any fees of counsel subsequently incurred by Independent Director with respect to the same Proceeding, unless (i) the employment of counsel by Independent Director has been authorized by the Company, (ii) Independent Director shall have reasonably concluded, based on written advice of counsel, that there may be a conflict of interest of such counsel retained by the Company between the Company and Independent Director in the conduct of any such defense, or (iii) the Company ceases or terminates the employment of such counsel with respect to the defense of such Proceeding, in any of which events the fees and expenses of Independent Director’s counsel shall be at the expense of the Company.

 

5

 

 

8. EXCEPTIONS TO INDEMNIFICATION. Director shall be entitled to indemnification under Sections 7(a) and 7(b) above in all circumstances other than the following:

 

(a) If indemnification is requested under Section 7(a) and it has been adjudicated finally by a court or arbitral body of competent jurisdiction that, in connection with the subject of the Proceeding out of which the claim for indemnification has arisen, (i) the Independent Director failed to act in good faith and in a manner the Independent Director reasonably believed to be in or not opposed to the best interests of the Company, (ii) the Independent Director had reasonable cause to believe that the Independent Director’s conduct was unlawful, or (iii) the Independent Director’s conduct constituted willful misconduct, fraud, dishonesty or knowing violation of law, then the Independent Director shall not be entitled to payment of Indemnifiable Amounts hereunder.

 

(b) If indemnification is requested under Section 7(b) and

 

(i) it has been adjudicated finally by a court or arbitral body of competent jurisdiction that, in connection with the subject of the Proceeding out of which the claim for indemnification has arisen, the Independent Director failed to act in good faith and in a manner the Independent Director reasonably believed to be in or not opposed to the best interests of the Company, including without limitation, the breach of Section 4 hereof by the Independent Director, the Independent Director shall not be entitled to payment of Indemnifiable Expenses hereunder; or

 

(ii) it has been adjudicated finally by a court or arbitral body of competent jurisdiction that the Independent Director is liable to the Company with respect to any claim, issue or matter involved in the Proceeding out of which the claim for indemnification has arisen, including, without limitation, a claim that the Independent Director received an improper benefit or improperly took advantage of a corporate opportunity, the Independent Director shall not be entitled to payment of Indemnifiable Expenses hereunder with respect to such claim, issue or matter.

 

9. WHOLLY OR PARTLY SUCCESSFUL. Notwithstanding any other provision of this Agreement, and without limiting any such provision, to the extent that the Independent Director is, by reason of the Independent Director’s Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, the Independent Director shall be indemnified against all Indemnifiable Expenses in connection therewith. If the Independent Director is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify the Independent Director against those Indemnifiable Expenses reasonably incurred by the Independent Director or on the Independent Director’s behalf in connection with each successfully resolved claim, issue or matter. For purposes of this section, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

6

 

 

10. ADVANCES AND INTERIM EXPENSES. The Company may, on its sole discretion, pay to the Independent Director all Indemnifiable Expenses incurred by the Independent Director in connection with any Proceeding, including a Proceeding by or in the right of the Company, in advance of the final disposition of such Proceeding, if the Independent Director furnishes the Company with a written undertaking, to the satisfaction of the Company, to repay the amount of such Indemnifiable Expenses advanced to the Independent Director in the event it is finally determined by a court or arbitral body of competent jurisdiction that the Independent Director is not entitled under this Agreement to indemnification with respect to such Indemnifiable Expenses.

 

11. PROCEDURE FOR PAYMENT OF INDEMNIFIABLE AMOUNTS. The Independent Director shall submit to the Company a written request specifying the Indemnifiable Amounts, for which the Independent Director seeks payment under Section 7 hereof and the Proceeding of which has been previously notified to the Company and approved by the Company for indemnification hereunder. At the request of the Company, the Independent Director shall furnish such documentation and information as are reasonably available to the Independent Director and necessary to establish that the Independent Director is entitled to indemnification hereunder. The Company, on receipt of documentation acceptable to it, shall pay such Indemnifiable Amounts within thirty (30) days of receipt of all required documents.

 

12. REMEDIES OF INDEPENDENT DIRECTOR.

 

(a) RIGHT TO PETITION COURT. In the event that the Independent Director makes a request for payment of Indemnifiable Amounts under Sections 7, 9-11 above, and the Company fails to make such payment or advancement in a timely manner pursuant to the terms of this Agreement, the Independent Director may petition the appropriate judicial authority to enforce the Company’s obligations under this Agreement.

 

(b) BURDEN OF PROOF. In any judicialProceeding brought under Section 12 (a) above, the Company shall have the burden of proving that the Independent Director is not entitled to payment of Indemnifiable AInts hereunder.

 

(c) EXPENSES. The Company agrees to reimburse the Independent Director in full for any Expenses incurred by the Independent Director in connection with investigating, preparing for, litigating, defending or settling any action brought by the Independent Director under Section 12 (a) above, or in connection with any claim or counterclaim brought by the Company in coIction therewith.

 

(e) FAILURE TO ACT NOT A DEFENSE. The failure of the Company (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of the payment of Indemnifiable Amounts or the advancement of Indemnifiable Expenses under this Agreement shall not be a defense in any action brought under Section 12 (a) above.

 

7

 

 

13. PROCEEDINGS AGAINST COMPANY. Except as otherwise provided in this Agreement, the Independent Director shall not be entitled to payment of Indemnifiable Amounts or advancement of Indemnifiable Expenses with respect to any Proceeding brought by the Independent Director against the Company, any Entity which it controls, any director or officer thereof, or any third party, unless the Company has consented to the initiation of such Proceeding. This section shall not apply to counterclaims or affirmative defenses asserted by the Independent Director in an action brought against the Independent Director.

 

15. SUBROGATION. In the event of any payment of Indemnifiable Amounts under this Agreement, the Company, as the case may be, shall be subrogated to the extent of such payment to all of the rights of contribution or recovery of the Independent Director against other persons, and the Independent Director shall take, at the request of the Company, all reasonable action necessary to secure such rights, including the execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

16. AUTHORITY. Each party has all necessary power and authority to enter into, and be bound by the terms of, this Agreement, and the execution, delivery and performance of the undertakings contemplated by this Agreement have been duly authorized by each party hereto:

 

17. SUCCESSORS AND ASSIGNMENT. This Agreement shall (a) be binding upon and inure to the benefit of all successors and assigns of the Company (including any transferee of all or a substantial portion of the business, stock and/or assets of the Company and any direct or indirect successor by merger or consolidation or otherwise by operation of law), and (b) be binding on and shall inure to the benefit of the heirs, personal representatives, executors and administrators of the Independent Director. The Independent Director has no power to assign this Agreement or any rights and obligations hereunder.

 

18. CHANGE IN LAW. To the extent that a change in applicable law (whether by statute or judicial decision) shall mandate broader or narrower indemnification than is provided hereunder, the Independent Director shall be subject to such broader or narrower indemnification and this Agreement shall be deemed to be amended to such extent.

 

19. SEVERABILITY. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement, or any clause thereof, shall be determined by a court of competent jurisdiction to be illegal, invalid or unenforceable, in whole or in part, such provision or clause shall be limited or modified in its application to the minimum extent necessary to make such provision or clause valid, legal and enforceable, and the remaining provisions and clauses of this Agreement shall remain fully enforceable and binding on the parties.

 

20. MODIFICATIONS AND WAIVER. Except as provided in Section 18 hereof with respect to changes in applicable law which broaden or narrow the right of the Independent Director to be indemnified by the Company, no supplement, modification or amendment of this Agreement shall be binding unless executed in writing by each of the parties hereto. No delay in exercise or non-exercise by the Company of any right under this Agreement shall operate as a current or future waiver by it as to its same or different rights under this Agreement or otherwise.

 

8

 

 

21. NOTICES. All notices, requests, demands and other communications hereunder shall be in writing in English and shall be deemed to have been duly given (a) when delivered by hand, (b) when transmitted by facsimile and receipt is acknowledged, (c) if mailed by express mail with delivery confirmation with postage prepaid, on the 5th business day after the date on which it is so mailed, and (d) when transmitted by email and receipt is acknowledged:

 

If to Independent Director, to: 71 Ubi Road 1, #05-41, Oxley BizHub, Singapore 408732, email: [John.Vong@outlook.com ].

 

If to the Company, to: 1705 – 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia, Taman Desa, Kuala Lumpur, Malaysia (Post Code: 58100), email: [ir@agapeatp.com].

 

Or to such other address as may have been furnished in the same manner by any party to the others.

 

22. GOVERNING LAW. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Nevada.

 

23. AGREEMENT GOVERNS. This Agreement is to be deemed consistent wherever possible with relevant provisions of the By-Laws of the Company; however, in the event of a conflict between this Agreement and such provisions, the provisions of this Agreement shall control.

 

24. INDEPENDENT CONTRACTOR. The parties understand, acknowledge and agree that the Independent Director’s relationship with the Company is that of an independent contractor and nothing in this Agreement is intended to or should be construed to create a relationship other than that of independent contractor. Nothing in this Agreement shall be construed as a contract of employment/engagement between the Independent Director and the Company or as a commitment on the part of the Company to retain the Independent Director in any capacity, for any period of time or under any specific terms or conditions, or to continue the Independent Director’s service to the Company beyond any period.

 

25. ENTIRE AGREEMENT. This Agreement, including its schedules and any documents executed by the parties simultaneously herewith or pursuant thereto, constitutes the entire agreement between the Company and the Independent Director with respect to the subject matter hereof, and supersedes all prior understandings and agreements with respect to such subject matter.

 

26. SURVIVAL. The provision of this Agreement which are capable of having effect after the expiration or termination of the Agreement shall remain in full force and effect following the expiration or termination of this Agreement.

 

27. SCHEDULES. The schedules attached to this Agreement form an integral part of this Agreement for all purposes of it.

 

[SIGNATURE PAGE FOLLOWS]

 

9

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Independent Director Agreement as of the day and year first above written.

 

Company   Independent Director
     
     
Agape ATP Corporation   Name: Dr. John Hing Vong
Name: How Kok Choong      
Title: Chief Executive Officer      
         
In the presence of :  

In the presence of:

     
     
Name:     Name :  
Title:     Title:  

 

10

 

 

SCHEDULE A

 

I POSITION:

 

INDEPENDENT DIRECTOR.

 

II. COMPENSATION:

 

FEES. For all services rendered by the Independent Director after the Effective Date pursuant to this Agreement, both during and outside of normal working hours, including but not limited to, attending all required meetings of the Board or applicable committees thereof, executive sessions of the independent directors, reviewing filing reports and other corporate documents as requested by the Company, providing comments and opinions as to business matters as requested by the Company, the Company agrees to pay to the Independent Director fees in accordance with the schedule set forth below:

 

US$[21,600] per annum payable by four (4) quarterly monthly installments of approximately US$[5,400] (or a pro rata amount for an incomplete month) and will be paid in United States Dollars.

 

EXPENSES. During the term of the Independent Director’s service as a director of the Company, the Company shall promptly reimburse the Independent Director for all expenses approved by the Company in advance and incurred by her in connection with attending (a) all meetings of the Board or applicable committees thereof, (b) executive sessions of the independent directors, and (c) stockholder meetings, as a director or a member of any committee of the Board, which are approved by the Company in advance. In addition, the Independent Director shall rely on the Company to arrange for all hotel accommodations in connection with any such meetings the Independent Director must attend. The amount of such expenses eligible for reimbursement by the Company during a calendar year shall not affect such expenses eligible for reimbursement by the Company in any other calendar year, and the reimbursement of any such eligible expenses shall be made promptly, usually within 10 business days, after the expense report and original receipts are submitted.NO OTHER BENEFITS OR COMPENSATION. The Independent Director acknowledges and agrees that he/she is not granted and is not entitled to any other benefits or compensation from the Company for the services provided under this Agreement except expressly provided for in this Schedule A or as determined from time to time by the Company in its sole discretion.

 

[SIGNATURE PAGE FOLLOWS]

 

11

 

 

Company   Independent Director
     
     
Agape ATP Corporation   Name: Dr. John Hing Vong
Name: How Kok Choong      
Title: Chief Executive Officer      

 

12

 

 

Exhibit 10.15

 

INDEPENDENT DIRECTOR AGREEMENT

 

This INDEPENDENT DIRECTOR AGREEMENT (the “Agreement”) is made and entered into as of this ___30th_ day of November 2022, by and between Agape ATP Corporation, a Nevada corporation (the “Company”), and Chee Chin Aik (Malaysia Passport No. A54740909) (the “Independent Director”) and shall become effective on the closing date of the Company’s initial public offering on the Nasdaq Stock Market (the “Effective Date”).

 

WHEREAS, the Company desires to engage the Independent Director, and the Independent Director desires to serve, as a non-employee director of the Company, subject to the terms and conditions contained in this Agreement.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the receipt of which is hereby acknowledged, the Company and the Independent Director, intending to be legally bound, hereby agree as follows:

 

1. DEFINITIONS.

 

(a) “Corporate Status” describes the capacity of the Independent Director with respect to the Company and the services performed by the Independent Director in that capacity.

 

(b) “Entity” shall mean any corporation, partnership, limited liability company, joint venture, trust, foundation, association, organization or other legal entity.

 

(c) “Proceeding” shall mean any threatened, pending or completed claim, action, suit, arbitration, alternate dispute resolution process, investigation, administrative hearing, appeal, or any other proceeding, whether civil, criminal, administrative or investigative, whether formal or informal, including a proceeding initiated by the Independent Director pursuant to Section 12 of this Agreement to enforce the Independent Director’s rights hereunder.

 

(d) “Expenses” shall mean all reasonable fees, costs and expenses, approved in writing by the Company in advance and reasonably incurred in connection with any Proceeding, including, without limitation, attorneys’ fees, disbursements and retainers, fees and disbursements of expert witnesses, private investigators, professional advisors (including, without limitation, accountants and investment bankers), court costs, transcript costs, fees of experts, travel expenses, duplicating, printing and binding costs, telephone and fax transmission charges, postage, delivery services, secretarial services, and other disbursements and expenses.

 

(e) “Liabilities” shall mean judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement.

 

(f) “Parent” shall mean any corporation or other entity (other than the Company) in any unbroken chain of corporations or other entities ending with the Company, if each of the corporations or entities, other than the Company, owns stock or other interests possessing 50% or more of the economic interest or the total combined voting power of all classes of stock or other interests in one of the other corporations or entities in the chain.

 

 

 

 

(g) “Subsidiary” shall mean any corporation or other entity (other than the Company) in any unbroken chain of corporations or other entities beginning with the Company, if each of the corporations or entities, other than the last corporation or entity in the unbroken chain, owns stock or other interests possessing 50% or more of the economic interest or the total combined voting power of all classes of stock or other interests in one of the other corporations or entities in the chain.

 

2. DUTIES OF INDEPENDENT DIRECTOR.While this Agreement is in effect, the Independent Director shall serve as an independent director and/or a member of the committess of the Board, and shall perform duties, responsibilities and obligations consistent and customarily assigned to individuals serving in the positions of the foregoing, be compensated for such and be reimbursed expenses in accordance with the Schedule A attached to this Agreement, subject to the following:

 

(a) The Independent Director shall exercise all powers in good faith and in the best interests of the Company, including but not limited to the following:

 

(i) CONFLICTS OF INTEREST/APPLICABLE LAW. In the event that the Independent Director has a direct or indirect financial or personal interest in a contract or transaction to which the Company is a party, or the Independent Director is contemplating entering into a transaction that involves use of corporate assets or competition against the Company, the Independent Director shall promptly disclose such potential conflict to the applicable Board committee or the Board and proceed as directed by such committee or the Board, as applicable. The Director acknowledges the duty of loyalty and the duty of care owed to the Company pursuant to applicable law and agrees to act in all cases in accordance with applicable law.

 

(ii) CORPORATE OPPORTUNITIES. Whenever the Independent Director becomes aware of a business opportunity related to the Company’s business, which one could reasonably expect the Director to make available to the Company, the Independent Director shall promptly disclose such opportunity to the applicable Board committee or the Board and proceed as directed by such committee or the Board, as applicable.

 

2

 

 

(iii) CONFIDENTIALITY. The Independent Director agrees and acknowledges that, by reason of the nature of the Independent Director duties on the Board, the Independent Director will have or may have access to and become informed of proprietary, confidential and secret information which is a competitive asset of the Company (“Confidential Information”), including, without limitation, any lists of customers or suppliers, distributors, financial statistics, research data or any other statistics and plans or operation plans or other trade secrets of the Company and any of the foregoing which belong to any person or company but to which the Independent Director has had access by reason of the Independent Director’s relationship with the Company. The term “Confidential Information” shall not include information which: (i) is or becomes generally available to the public other than as a result of a disclosure by the Independent Director or the Independent Director’s representatives; or (ii) is required to be disclosed by the Independent Director due to governmental regulatory or judicial process. The Independent Director agrees faithfully to keep in strict confidence, and not, either directly or indirectly, to make known, divulge, reveal, furnish, make available or use (except for use in the regular course of employment duties) any such Confidential Information. The Independent Director acknowledges that all manuals, instruction books, price lists, information and records and other information and aids relating to the Company’s business, and any and all other documents containing Confidential Information furnished to the Independent Director by the Company or otherwise acquired or developed by the Director, shall at all times be the property of the Company. Upon termination of the Director’s services hereunder, the Independent Director shall return to the Company any such property or documents which are in the Director’s possession, custody or control, but this obligation of confidentiality shall survive such termination until and unless any such Confidential Information shall have become, through no fault of the Independent Director, generally known to the public. The obligations of the Director under this subsection are in addition to, and not in limitation or preemption of, all other obligations of confidentiality which the Independent Director may have to the Company under general legal or equitable principles.

 

(iv) Code of Business Conduct and Ethics. The Independent Director agrees to abide by and follow all such procedures set forth in the Company’s code of business conduct and ethics, as may be in existence now or at any time during the term of this Agreement, and any other policy, code or document governing the conduct of directors of the Company as may be in existence now or at any time during the term of this Agreement.

 

(b) The Independent Director is solely responsible for taxes arising out of any compensation paid by the Company to the Independent Director under this Agreement. The Independent Director acknowledges and agrees that because he/she is not an employee of the Company, the Company will not withhold any amounts for taxes from any of his/her payments under the Agreement.

 

3

 

 

(c) The Company may offset any and all monies payable to the Independent Director to the extent of any monies owing to the Company from the Independent Director.

 

(d) The rules and regulations of the Company notified to the Independent Director, from time to time, apply to the Independent Director. Such rules and regulations are subject to change by the Company in its sole discretion. Notwithstanding the foregoing, in the event of any conflict or inconsistency between the terms and conditions of this Agreement and rules and regulations of the Company, the terms of this Agreement shall control.

 

3. REQUIREMENTS OF INDEPENDENT DIRECTOR. During the term of the Independent Director’s services to the Company hereunder, Independent Director shall observe all applicable laws and regulations relating to independent directors of a public company as promulgated from time to time and the Company’s policy, and shall not: (1) be an employee of the Company or any Parent or Subsidiary; (2) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the Company other than asexpressly provided in this Agreement ; (3) be an affiliated person of the Company or any Parent or Subsidiary, as the term “affiliate” is defined in 17 CFR 240.10A-3(e)(1), other than in his capacity as a director and/or a member of a committee of the Board; (4) possess an interest in any transaction with the Company or any Parent or Subsidiary, for which disclosure would be required pursuant to 17 CFR 229.404(a), other than in his capacity as a director and/or a member of a committee of the Board committees; (5) be engaged in a business relationship with the Company or any Parent or Subsidiary, for which disclosure would be required pursuant to 17 CFR 229.404(b), except that the required beneficial interest therein shall be modified to be 5% hereby.

 

4. REPORT OBLIGATION. While this Agreement is in effect, the Independent Director shall immediately report to the Company in the event: (1) the Independent Director knows or has reason to know or should have known that any of the requirements specified in Section 3 hereof is not satisfied or is not going to be satisfied; and (2) the Independent Director simultaneously serves on an audit committee of any other public company.

 

5. TERM AND TERMINATION. This Agreement hereunder shall commence on the date hereof and the Independent Director’s services shall commence on the Effective Date and terminate upon the earlier of the following:

 

(a) Removal of the Independent Director as a director of the Company, upon proper Board or stockholder action in accordance with the By-Laws of the Company and applicable law;

 

(b) Resignation of the Independent Director as a director of the Company upon 14 days written notice to the Board of Directors of the Company;

 

(c) Disqualification of the Independent Director as a director of the Company in accordance with the By-Laws of the Company;

 

(d) Termination of this Agreement by the Company upon 14 days written notice, in the event of breach of Section 2 hereof or any of the requirements specified in Section 3 hereof is not satisfied, as determined by the Company in its sole discretion; or

 

4

 

 

(e) Failure of the stockholders of the Company to re-elect the Independent Director at the Company’s annual shareholders’ meeting.

 

6. LIMITATION OF LIABILITY. In no event shall the Independent Director be individually liable to the Company or its shareholders for any damages for breach of fiduciary duty as an independent director of the Company, unless the Independent Director’s act or failure to act involves intentional misconduct, fraud, dishonesty, negligence or a knowing violation of law.

 

7. AGREEMENT OF INDEMNITY. The Company agrees to indemnify the Independent Director as follows:

 

(a) Subject to the exceptions contained in Section 8(a)below, if the Independent Director was or is a party or is threatened to be made a party to any proceeding (other than an action by or in the right of the Company) by reason of the Independent Director’s Corporate Status (a “Proceeding”), the Independent Director shall be indemnified by the Company against all expenses and liabilities incurred or paid by the Independent Director in connection with such Proceeding (referred to herein as “INDEMNIFIABLE EXPENSES” and “INDEMNIFIABLE LIABILITIES,” respectively, and collectively as “INDEMNIFIABLE AMOUNTS”).

 

(b) Subject to the exceptions contained in Section 8(b) below, if the Independent Director was or is a party or is threatened to be made a party to any Proceeding by or in the right of the Company, to procure a judgment in its favor by reason of the Independent Director’s Corporate Status, the Independent Director shall be indemnified by the Company against all Indemnifiable Expenses.

 

(c) For purposes of this Agreement, the Independent Director shall be deemed to have acted in good faith in conducting the Company’s affairs as an independent director of the Company and/or a member of a committee of the Board of the Company, if the Independent Director: (i) exercised or used the same degree of diligence, care, and skill as an ordinarily prudent man would have exercised or used under the circumstances in the conduct of his/her own affairs; or (ii) took, or omitted to take, an action in reliance upon advise of counsels or other professional advisors for the Company, or upon statements made or information furnished by other directors, officers or employees of the Company, or upon a financial statement of the Company provided by a person in charge of its accounts or certified by a public accountant or a firm of public accountants, which the Independent Director had reasonable grounds to believe to be true.

 

(d) In the event the Company is obligated under this Agreement to advance or bear any expenses for any Proceeding, the Company shall be entitled to assume the defense, settlement or appeal of such Proceeding with the assistance and cooperation of the Independent Director, with counsel approved by Independent Director, upon delivery to the Independent Director of its election to do so. After delivery of such notice, approval of such counsel by Independent Director and the retention of such counsel by the Company, the Company shall not be liable to Independent Director under this Agreement for any fees of counsel subsequently incurred by Independent Director with respect to the same Proceeding, unless (i) the employment of counsel by Independent Director has been authorized by the Company, (ii) Independent Director shall have reasonably concluded, based on written advice of counsel, that there may be a conflict of interest of such counsel retained by the Company between the Company and Independent Director in the conduct of any such defense, or (iii) the Company ceases or terminates the employment of such counsel with respect to the defense of such Proceeding, in any of which events the fees and expenses of Independent Director’s counsel shall be at the expense of the Company.

 

5

 

 

8. EXCEPTIONS TO INDEMNIFICATION. Director shall be entitled to indemnification under Sections 7(a) and 7(b) above in all circumstances other than the following:

 

(a) If indemnification is requested under Section 7(a) and it has been adjudicated finally by a court or arbitral body of competent jurisdiction that, in connection with the subject of the Proceeding out of which the claim for indemnification has arisen, (i) the Independent Director failed to act in good faith and in a manner the Independent Director reasonably believed to be in or not opposed to the best interests of the Company, (ii) the Independent Director had reasonable cause to believe that the Independent Director’s conduct was unlawful, or (iii) the Independent Director’s conduct constituted willful misconduct, fraud, dishonesty or knowing violation of law, then the Independent Director shall not be entitled to payment of Indemnifiable Amounts hereunder.

 

(b) If indemnification is requested under Section 7(b) and

 

(i) it has been adjudicated finally by a court or arbitral body of competent jurisdiction that, in connection with the subject of the Proceeding out of which the claim for indemnification has arisen, the Independent Director failed to act in good faith and in a manner the Independent Director reasonably believed to be in or not opposed to the best interests of the Company, including without limitation, the breach of Section 4 hereof by the Independent Director, the Independent Director shall not be entitled to payment of Indemnifiable Expenses hereunder; or

 

(ii) it has been adjudicated finally by a court or arbitral body of competent jurisdiction that the Independent Director is liable to the Company with respect to any claim, issue or matter involved in the Proceeding out of which the claim for indemnification has arisen, including, without limitation, a claim that the Independent Director received an improper benefit or improperly took advantage of a corporate opportunity, the Independent Director shall not be entitled to payment of Indemnifiable Expenses hereunder with respect to such claim, issue or matter.

 

9. WHOLLY OR PARTLY SUCCESSFUL. Notwithstanding any other provision of this Agreement, and without limiting any such provision, to the extent that the Independent Director is, by reason of the Independent Director’s Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, the Independent Director shall be indemnified against all Indemnifiable Expenses in connection therewith. If the Independent Director is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify the Independent Director against those Indemnifiable Expenses reasonably incurred by the Independent Director or on the Independent Director’s behalf in connection with each successfully resolved claim, issue or matter. For purposes of this section, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

6

 

 

10. ADVANCES AND INTERIM EXPENSES. The Company may, on its sole discretion, pay to the Independent Director all Indemnifiable Expenses incurred by the Independent Director in connection with any Proceeding, including a Proceeding by or in the right of the Company, in advance of the final disposition of such Proceeding, if the Independent Director furnishes the Company with a written undertaking, to the satisfaction of the Company, to repay the amount of such Indemnifiable Expenses advanced to the Independent Director in the event it is finally determined by a court or arbitral body of competent jurisdiction that the Independent Director is not entitled under this Agreement to indemnification with respect to such Indemnifiable Expenses.

 

11. PROCEDURE FOR PAYMENT OF INDEMNIFIABLE AMOUNTS. The Independent Director shall submit to the Company a written request specifying the Indemnifiable Amounts, for which the Independent Director seeks payment under Section 7 hereof and the Proceeding of which has been previously notified to the Company and approved by the Company for indemnification hereunder. At the request of the Company, the Independent Director shall furnish such documentation and information as are reasonably available to the Independent Director and necessary to establish that the Independent Director is entitled to indemnification hereunder. The Company, on receipt of documentation acceptable to it, shall pay such Indemnifiable Amounts within thirty (30) days of receipt of all required documents.

 

12. REMEDIES OF INDEPENDENT DIRECTOR.

 

(a) RIGHT TO PETITION COURT. In the event that the Independent Director makes a request for payment of Indemnifiable Amounts under Sections 7, 9-11 above, and the Company fails to make such payment or advancement in a timely manner pursuant to the terms of this Agreement, the Independent Director may petition the appropriate judicial authority to enforce the Company’s obligations under this Agreement.

 

(b) BURDEN OF PROOF. In any judicial Proceeding brought under Section 12 (a) above, the Company shall have the burden of proving that the Independent Director is not entitled to payment of Indemnifiable Amounts hereunder.

 

(c) EXPENSES. The Company agrees to reimburse the Independent Director in full for any Expenses incurred by the Independent Director in connection with investigating, preparing for, litigating, defending or settling any action brought by the Independent Director under Section 12 (a) above, or in connection with any claim or counterclaim brought by the Company in connection therewith.

 

(e) FAILURE TO ACT NOT A DEFENSE. The failure of the Company (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of the payment of Indemnifiable Amounts or the advancement of Indemnifiable Expenses under this Agreement shall not be a defense in any action brought under Section 12 (a) above.

 

7

 

 

13. PROCEEDINGS AGAINST COMPANY. Except as otherwise provided in this Agreement, the Independent Director shall not be entitled to payment of Indemnifiable Amounts or advancement of Indemnifiable Expenses with respect to any Proceeding brought by the Independent Director against the Company, any Entity which it controls, any director or officer thereof, or any third party, unless the Company has consented to the initiation of such Proceeding. This section shall not apply to counterclaims or affirmative defenses asserted by the Independent Director in an action brought against the Independent Director.

 

15. SUBROGATION. In the event of any payment of Indemnifiable Amounts under this Agreement, the Company, as the case may be, shall be subrogated to the extent of such payment to all of the rights of contribution or recovery of the Independent Director against other persons, and the Independent Director shall take, at the request of the Company, all reasonable action necessary to secure such rights, including the execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

16. AUTHORITY. Each party has all necessary power and authority to enter into, and be bound by the terms of, this Agreement, and the execution, delivery and performance of the undertakings contemplated by this Agreement have been duly authorized by each party hereto:

 

17. SUCCESSORS AND ASSIGNMENT. This Agreement shall (a) be binding upon and inure to the benefit of all successors and assigns of the Company (including any transferee of all or a substantial portion of the business, stock and/or assets of the Company and any direct or indirect successor by merger or consolidation or otherwise by operation of law), and (b) be binding on and shall inure to the benefit of the heirs, personal representatives, executors and administrators of the Independent Director. The Independent Director has no power to assign this Agreement or any rights and obligations hereunder.

 

18. CHANGE IN LAW. To the extent that a change in applicable law (whether by statute or judicial decision) shall mandate broader or narrower indemnification than is provided hereunder, the Independent Director shall be subject to such broader or narrower indemnification and this Agreement shall be deemed to be amended to such extent.

 

19. SEVERABILITY. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement, or any clause thereof, shall be determined by a court of competent jurisdiction to be illegal, invalid or unenforceable, in whole or in part, such provision or clause shall be limited or modified in its application to the minimum extent necessary to make such provision or clause valid, legal and enforceable, and the remaining provisions and clauses of this Agreement shall remain fully enforceable and binding on the parties.

 

20. MODIFICATIONS AND WAIVER. Except as provided in Section 18 hereof with respect to changes in applicable law which broaden or narrow the right of the Independent Director to be indemnified by the Company, no supplement, modification or amendment of this Agreement shall be binding unless executed in writing by each of the parties hereto. No delay in exercise or non-exercise by the Company of any right under this Agreement shall operate as a current or future waiver by it as to its same or different rights under this Agreement or otherwise.

 

8

 

 

21. NOTICES. All notices, requests, demands and other communications hereunder shall be in writing in English and shall be deemed to have been duly given (a) when delivered by hand, (b) when transmitted by facsimile and receipt is acknowledged, (c) if mailed by express mail with delivery confirmation with postage prepaid, on the 5th business day after the date on which it is so mailed, and (d) when transmitted by email and receipt is acknowledged:

 

If to Independent Director, to: 12B Cairnhill Rise, #08-10, 229745 Singapore, email: chinaik@gmail.com.

 

If to the Company, to: 1705 – 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia, Taman Desa, Kuala Lumpur, Malaysia (Post Code: 58100), email: ir@agapeatp.com.

 

Or to such other address as may have been furnished in the same manner by any party to the others.

 

22. GOVERNING LAW. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Nevada.

 

23. AGREEMENT GOVERNS. This Agreement is to be deemed consistent wherever possible with relevant provisions of the By-Laws of the Company; however, in the event of a conflict between this Agreement and such provisions, the provisions of this Agreement shall control.

 

24. INDEPENDENT CONTRACTOR. The parties understand, acknowledge and agree that the Independent Director’s relationship with the Company is that of an independent contractor and nothing in this Agreement is intended to or should be construed to create a relationship other than that of independent contractor. Nothing in this Agreement shall be construed as a contract of employment/engagement between the Independent Director and the Company or as a commitment on the part of the Company to retain the Independent Director in any capacity, for any period of time or under any specific terms or conditions, or to continue the Independent Director’s service to the Company beyond any period.

 

25. ENTIRE AGREEMENT. This Agreement, including its schedules and any documents executed by the parties simultaneously herewith or pursuant thereto, constitutes the entire agreement between the Company and the Independent Director with respect to the subject matter hereof, and supersedes all prior understandings and agreements with respect to such subject matter.

 

26. SURVIVAL. The provision of this Agreement which are capable of having effect after the expiration or termination of the Agreement shall remain in full force and effect following the expiration or termination of this Agreement.

 

27. SCHEDULES. The schedules attached to this Agreement form an integral part of this Agreement for all purposes of it.

 

[SIGNATURE PAGE FOLLOWS]

 

9

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Independent Director Agreement as of the day and year first above written.

 

Company   Independent Director
     
     
Agape ATP Corporation   Name: Chee Chin Aik
Name: How Kok Choong      
Title: Chief Executive Officer      
         
In the presence of :   In the presence of:
     
     
Name:     Name :  
Title:     Title:  

 

10

 

 

SCHEDULE A

 

I POSITION:

 

INDEPENDENT DIRECTOR.

 

II. COMPENSATION:

 

FEES. For all services rendered by the Independent Director after the Effective Date pursuant to this Agreement, both during and outside of normal working hours, including but not limited to, attending all required meetings of the Board or applicable committees thereof, executive sessions of the independent directors, reviewing filing reports and other corporate documents as requested by the Company, providing comments and opinions as to business matters as requested by the Company, the Company agrees to pay to the Independent Director fees in accordance with the schedule set forth below:

 

US$21,600 per annum payable by four (4) quarterly monthly installments of approximately US$5,400 (or a pro rata amount for an incomplete month) and will be paid in United States Dollars.

 

EXPENSES. During the term of the Independent Director’s service as a director of the Company, the Company shall promptly reimburse the Independent Director for all expenses approved by the Company in advance and incurred by her in connection with attending (a) all meetings of the Board or applicable committees thereof, (b) executive sessions of the independent directors, and (c) stockholder meetings, as a director or a member of any committee of the Board, which are approved by the Company in advance. In addition, the Independent Director shall rely on the Company to arrange for all hotel accommodations in connection with any such meetings the Independent Director must attend. The amount of such expenses eligible for reimbursement by the Company during a calendar year shall not affect such expenses eligible for reimbursement by the Company in any other calendar year, and the reimbursement of any such eligible expenses shall be made promptly, usually within 10 business days, after the expense report and original receipts are submitted.NO OTHER BENEFITS OR COMPENSATION. The Independent Director acknowledges and agrees that he/she is not granted and is not entitled to any other benefits or compensation from the Company for the services provided under this Agreement except expressly provided for in this Schedule A or as determined from time to time by the Company in its sole discretion.

 

[SIGNATURE PAGE FOLLOWS]

 

11

 

 

Company   Independent Director
     
     
Agape ATP Corporation   Name: Chee Chin Aik
Name: How Kok Choong      
Title: Chief Executive Officer      

 

12

 

 

 

 

Exhibit 23.1

 

 

Independent Registered Public Accounting Firm’s Consent

 

We consent to the inclusion in this Registration Statement of Agape ATP Corporation of the Amendment No. 5 to Form S-1 [FILE NO. 333-239951] of our report dated March 31, 2023, with respect to our audit of the consolidated financial statements of Agape ATP Corporation as of December 31, 2022 and for the year ended December 31, 2022, appearing in the Prospectus, and being part of this Registration Statement. We also consent to the reference to our firm under the heading “Experts” in the Prospectus, which is part of this Registration Statement.

 

/s/ Marcum Asia CPAs LLP

 

Marcum Asia CPAs LLP

 

New York, New York

April 14, 2023

 

NEW YORK OFFICE • 7 Penn Plaza • Suite 830 • New York, New York • 10001

Phone 646.442.4845 • Fax 646.349.5200 • www.marcumasia.com

 

 

 

 

Exhibit 23.2

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the inclusion in this Registration Statement on Form S-1 (Amendment No. 5) of our report dated March 28, 2022, with respect to our audit of the consolidated financial statements of Agape ATP Corporation for the year ended December 31, 2021, which report appears in the Prospectus, and part of this Registration Statement. We also consent to the reference to our firm under the heading “Experts” in such Registration Statement. We were dismissed as auditors on October 20, 2022 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements incorporated by reference for the periods after the date of our dismissal.

 

/s/ Friedman LLP

 

New York, New York

April 14, 2023

 

 

 

 

 

 

Exhibit 107

 

Filing Fee Table

 

S-1

(Form Type)

 

AGAPE ATP CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

   Security Type  Security Class Title  Fee Calculation or Carry Forward Rule  Amount Registered   Proposed Maximum Offering Price Per Share(4)   Proposed Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee 
Newly Registered Securities
Fees to be Paid 

Equity

 

Common Stock, par value US$0.0001 per share(1)

 

Rule 457(o)

   

690,000

   $6.50  $

4,485,000

    

0.0001102

   $

494.25

 
  Equity  Common Stock, par value US$0.0001 per share (2)  Rule 457(c)    30,269,516    $6.50   $ 196,751854      0.0000927     

$

18,238,90  
  

Equity

 

Underwriter’s

Warrants(3)(5)

 

Rule 457(g)

   -    -    -    -     
  Equity  Common Stock underlying Underwriter Warrants (3)  Rule 457(g)    48,300     

$

7.15   $ 345,345     0.0000927   $ 32.01  
   Total Offering Amounts   $ 18,765.16  
   Total Fees Previously Paid   $31,746.62 

(6)

   Net Fee Due    - 

 

  (1) The registration fee for securities is based on an estimate of the proposed maximum offering price of the securities, and such estimate is solely for the purpose of calculating the registration fee pursuant to Rule 457(o).
     
  (2) This Registration Statement also covers the resale under a separate resale prospectus (the “Resale Prospectus”) by selling stockholders of the Registrant of up to 30,269,516 shares of common stock previously issued to the selling stockholders as named in the Resale Prospectus. Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, using the maximum proposed offerings price of the Registrant’s common stock being offered under this prospectus at $6.50 per share.
     
  (3)

We have agreed to grant to the Underwriter a warrant covering a number of shares of common stock equal to 7% of the shares of common stock sold by the Underwriter in this public offering, including as a result of the over-allotment option (the “Underwriter Warrant”). The Underwriter Warrant will be exercisable, commencing six (6) months from the effective date of offering and will expire on the fifth anniversary of the commencement of sales of this offering. The Underwriter Warrant will be exercisable at a price equal to 110% of the initial public offering price. The Underwriter Warrant shall not be redeemable or cancellable. We will register the shares underlying the Underwriter Warrant and file all necessary undertakings in connection therewith. The Underwriter Warrant may not be exercised, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days beginning on the date of commencement of sales of the offering (in accordance with FINRA Rule 5110), except that they may be assigned, in whole or in part, to any officer or partner of the Underwriter, and to members of the syndicate or selling group and their respective officers or partners. The Underwriter Warrants may be exercised as to all or a lesser number of shares, will provide for cashless exercise and will contain provisions for one demand registration right and unlimited “piggyback” registration rights at our expense with a duration of more than five years and seven years, respectively, from the commencement of sales of the offering. We have registered the Underwriter Warrant and the shares underlying the Underwriter Warrant in this offering.

     
  (4) Estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(a) under the Securities Act of 1933.
     
  (5) No separate registration fee required pursuant to Rule 457(g) under the Securities Act.
     
  (6) $31,746.62 of the registration fee was calculated based on the previous filing fee rate, 0.000923, previously issued by the Securities and Exchange Commission effective until September 30, 2022, and $494.25 of the registration fee was calculated based on the updated filing fee rate, 0.00011020, issued by the Securities and Exchange Commission effective from October 1, 2022.